<SEC-DOCUMENT>0001683168-22-004940.txt : 20220713
<SEC-HEADER>0001683168-22-004940.hdr.sgml : 20220713
<ACCEPTANCE-DATETIME>20220713161537
ACCESSION NUMBER:		0001683168-22-004940
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220713
DATE AS OF CHANGE:		20220713

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sonoma Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001367083
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				680423298
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33216
		FILM NUMBER:		221081212

	BUSINESS ADDRESS:	
		STREET 1:		645 MOLLY LANE, SUITE 150
		CITY:			WOODSTOCK
		STATE:			GA
		ZIP:			30189
		BUSINESS PHONE:		800-759-9305

	MAIL ADDRESS:	
		STREET 1:		645 MOLLY LANE, SUITE 150
		CITY:			WOODSTOCK
		STATE:			GA
		ZIP:			30189

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oculus Innovative Sciences, Inc.
		DATE OF NAME CHANGE:	20060622
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sonoma_i10k-033122.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:SNOA="http://sonomapharma.com/20220331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_SNOA_sonomapharma.com_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20210401_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001367083 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityCentralIndexKey">0001367083</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0224" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0281" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0349" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedWithConversionOfCShares" contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedWithConversionOfCShares" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedWithConversionOfCShares" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedWithConversionOfCShares" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedWithConversionOfCShares" contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:SharesIssuedWithConversionOfCShares" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0437" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="snoa-20220331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-04-01to2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:FirstCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:SecondCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:ThirdCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:FirstCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:SecondCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:ThirdCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:FirstCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:SecondCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:ThirdCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_NetRevenuesMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:FirstCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_NetRevenuesMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:SecondCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ShippingAndHandlingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_ShippingAndHandlingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_CommonStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_CommonStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-24_custom_MicromedLabsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">SNOA:MicromedLabsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-24_custom_MicromedLabsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">SNOA:MicromedLabsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-31_custom_InsurancePremiums1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-252021-01-31_custom_InsurancePremiums1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-25</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-10-01_custom_InsurancePremiums1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-31_custom_InsurancePremiums2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-252022-01-31_custom_InsurancePremiums2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-25</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-012023-12-31_custom_InsurancePremiums2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-252020-05-01_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SNOA:PaycheckProtectionProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:StatesBankInAtlantaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-25</xbrli:startDate>
        <xbrli:endDate>2020-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SNOA:PaycheckProtectionProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:StatesBankInAtlantaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_TromblyBusinessLawMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:TromblyBusinessLawMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_TromblyBusinessLawMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:TromblyBusinessLawMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_SeriesCPreferredStockMember44329203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_Plan2006Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2006Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-09-12_custom_Plan2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-09-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-012019-03-31_custom_Plan2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_Plan2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_Plan2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-02_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-012019-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_Plan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_Plan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_StockOptionMember44329593">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_Plan2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_custom_HumanCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_ProductMember_custom_HumanCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_custom_AnimalCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_ProductMember_custom_AnimalCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_ServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000765" toRefs="Footnote000772"></ix:relationship>
  <ix:relationship fromRefs="Fact000767" toRefs="Footnote000772"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="#a_001"><span style="font-size: 7pt">Table of Contents</span></a></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Form&#160;<span id="xdx_906_edei--DocumentType_c20210401__20220331_zwckftFzjdOf"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(Mark One)</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--DocumentAnnualReport_c20210401__20220331_zLLSLRkMmkme"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="width: 95%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
    EXCHANGE ACT OF 1934</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><b>For the fiscal year ended <span id="xdx_90E_edei--DocumentPeriodEndDate_c20210401__20220331_zj4CXNi9Qr6e"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_905_edei--CurrentFiscalYearEndDate_c20210401__20220331_zSBqHcJU0Rxf"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">March 31</ix:nonNumeric></span>, 2022</ix:nonNumeric></span></b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--DocumentTransitionReport_c20210401__20220331_zsSWlNwNBNOe"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="width: 95%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: 0.5in">&#160;&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"><b>For transition period from _________________ to _________________</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission File Number: <span id="xdx_90C_edei--EntityFileNumber_c20210401__20220331_z1ZTGlJ8kGeb"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityFileNumber">001-33216</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b><span id="xdx_909_edei--EntityRegistrantName_c20210401__20220331_zWc8J31MHAS6"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityRegistrantName">SONOMA PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Exact name of registrant as specified in its
charter)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20210401__20220331_zITb59VIlM2i"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; font-size: 10pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20210401__20220331_zAS65XMn0Ifh"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityTaxIdentificationNumber">68-0423298</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><i>(State or other jurisdiction of incorporation or organization)</i></span></td>
    <td style="font-size: 10pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><i>(I.R.S. Employer Identification No.)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20210401__20220331_zZyxVygsrfz4"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityAddressAddressLine1">645 Molly Lane</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20210401__20220331_zFG1uU6DKDJ7"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityAddressAddressLine2">Suite 150</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20210401__20220331_zyLQB55enYci"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityAddressCityOrTown">Woodstock</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20210401__20220331_zEXGTKOtFcHf"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Georgia</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20210401__20220331_zIxThowxBGm"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityAddressPostalZipCode">30189</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Address of principal executive offices) (Zip
Code)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--CityAreaCode_c20210401__20220331_zeprg69mzx0f"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:CityAreaCode">(800)</ix:nonNumeric></span>&#160;<span id="xdx_904_edei--LocalPhoneNumber_c20210401__20220331_zUNHoJHdcVll"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:LocalPhoneNumber">759-9305</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Registrant&#8217;s telephone number, including
area code)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section&#160;12(b)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20210401__20220331_zJsNmtLaBsL"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:Security12bTitle">Common Stock, $0.0001 par value</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20210401__20220331_zSrAaZpQuypk"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:TradingSymbol">SNOA</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt">The <span id="xdx_90D_edei--SecurityExchangeName_c20210401__20220331_z48BEIGsVt47"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock&#160;Market LLC</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Title of Each Class)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Trading Symbol(s))</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Name of Each Exchange on Which Registered)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section&#160;12(g)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<span id="xdx_906_edei--EntityWellKnownSeasonedIssuer_c20210401__20220331_zg4Ch7NeMGWd"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark if
the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<span id="xdx_90A_edei--EntityVoluntaryFilers_c20210401__20220331_zzSixIquOgul"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has
been subject to such filing requirements for the past 90&#160;days. <span id="xdx_902_edei--EntityCurrentReportingStatus_c20210401__20220331_zaNO2bcMIgUa"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>
No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T
(&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit
such files). <span id="xdx_909_edei--EntityInteractiveDataCurrent_c20210401__20220331_zNQRKO2tZwpe"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 62%"><span style="font-size: 10pt">Large accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td>
    <td style="width: 38%"><span style="font-size: 10pt">Accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td></tr>
  <tr>
    <td><span style="font-size: 10pt"><span id="xdx_90E_edei--EntityFilerCategory_c20210401__20220331_zxNbl9RuLKKg"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></span></td>
    <td><span style="font-size: 10pt">Smaller reporting company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_edei--EntitySmallBusiness_c20210401__20220331_zHREZ2DcSSmg"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20210401__20220331_zleGbcsm91V"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<span id="xdx_909_edei--EntityShellCompany_c20210401__20220331_zNCKhFzQl48k"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The aggregate market value
of the voting&#160;and non-voting common stock held by non-affiliates of the registrant on September 30, 2021, was $<span id="xdx_90B_edei--EntityPublicFloat_iI_pp0p0_c20210930_z1qEangS7HX8" title="Entity public float"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,658,750</ix:nonFraction></span> based on
a total of 2,985,439 non-affiliate shares of the registrant&#8217;s common stock held by non-affiliates on September 30, 2021, at the
closing price of $5.58&#160;per share, as reported on the Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There were <span id="xdx_90B_edei--EntityCommonStockSharesOutstanding_iI_c20220711_zKx4zJNKyeia" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-07-11" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,100,937</ix:nonFraction></span> shares
of the registrant&#8217;s common stock issued and outstanding on July 11, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>DOCUMENTS INCORPORATED BY
REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Items&#160;10 (as to directors
and Section&#160;16(a) Beneficial Ownership Reporting Compliance), 11, 12, 13 and 14 of Part&#160;III will incorporate by reference information
from the registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation
of proxies for the registrant&#8217;s 2021 annual meeting of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_001"></span>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%">&#160;</td>
    <td style="width: 80%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 10%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><a href="#a_002"><span style="font-size: 10pt"><b>PART&#160;I</b></span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 1.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_003">Business</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 1A.</span></td>
    <td style="vertical-align: top"><a href="#a_004"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">21</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 2.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_005">Properties</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">36</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 3.</span></td>
    <td style="vertical-align: top"><a href="#a_006"><span style="font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">ITEM 4.</span></td>
    <td><span style="font-size: 10pt"><a href="#a_007">Mine Safety Disclosures (Not applicable.)</a></span></td>
    <td style="text-align: center"><span style="font-size: 10pt">36</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><a href="#a_008"><span style="font-size: 10pt"><b>PART&#160;II</b></span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 5.</span></td>
    <td style="vertical-align: top"><a href="#a_009"><span style="font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">37</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 6.</span></td>
    <td style="vertical-align: top"><a href="#a_010"><span style="font-size: 10pt">Selected Financial Data</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">37</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 7.</span></td>
    <td style="vertical-align: top"><a href="#a_011"><span style="font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">37</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 7A.</span></td>
    <td style="vertical-align: top"><a href="#a_012"><span style="font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">43</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 8.</span></td>
    <td style="vertical-align: top"><a href="#a_013"><span style="font-size: 10pt">Consolidated Financial Statements and Supplementary Data</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">44</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 9.</span></td>
    <td style="vertical-align: top"><a href="#a_021"><span style="font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">45</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 9A.</span></td>
    <td style="vertical-align: top"><a href="#a_022"><span style="font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="vertical-align: bottom; text-align: center">45</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 9B.</span></td>
    <td style="vertical-align: top"><a href="#a_023"><span style="font-size: 10pt">Other Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center">46</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><a href="#a_024"><span style="font-size: 10pt"><b>PART&#160;III</b></span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 10.</span></td>
    <td style="vertical-align: top"><a href="#a_025"><span style="font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">47</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 11.</span></td>
    <td style="vertical-align: top"><a href="#a_026"><span style="font-size: 10pt">Executive&#160;Compensation</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">48</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 12.</span></td>
    <td style="vertical-align: top"><a href="#a_027"><span style="font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">48</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 13.</span></td>
    <td style="vertical-align: top"><a href="#a_028"><span style="font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">48</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 14.</span></td>
    <td style="vertical-align: top"><a href="#a_029"><span style="font-size: 10pt">Principal Accounting Fees and Services</span></a></td>
    <td style="vertical-align: bottom; text-align: center">48</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><a href="#a_030"><span style="font-size: 10pt"><b>PART IV</b></span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 15.</span></td>
    <td style="vertical-align: top"><a href="#a_031"><span style="font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">49</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">ITEM 16.</span></td>
    <td style="vertical-align: top"><a href="#a_032"><span style="font-size: 10pt">Form 10-K Summary</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">52</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_033">Signatures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">53</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_002"></span>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>This report includes &#8220;forward-looking
statements.&#8221; The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
&#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;aim,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;likely,&#8221;
and similar expressions as they relate to us or our management are intended to identify these forward-looking statements. All statements
by Sonoma regarding expected financial position, revenues, cash flows and other operating results, business strategy, legal proceedings
and similar matters are forward-looking statements. Our expectations expressed or implied in these forward-looking statements may not
turn out to be correct. Our results could be materially different from our expectations because of various risks, including the risks
discussed in this report under &#8220;Part&#160;I&#160;&#8212; Item&#160;1A&#160;&#8212; Risk Factors.&#8221; Any forward-looking statement
speaks only as of the date as of which such statement is made, and, except as required by law, we undertake no obligation to update any
forward-looking statement to reflect events or circumstances, including unanticipated events, after the date as of which such statement
was made.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_003"></span>ITEM&#160;1.&#160;Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We originally incorporated as Micromed Laboratories,
Inc. in 1999 under the laws of the State of California. We changed our name to Oculus Innovative Sciences, Inc. in 2001. In December 2006
we reincorporated under the laws of the State of Delaware, and in December 2016 we changed our name to Sonoma Pharmaceuticals, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2020, we relocated our principal executive
offices from 1129 N. McDowell Blvd., Petaluma, California, 94954 to 645 Molly Lane, Suite 150, Woodstock, Georgia, 30189. We have two
active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A. de C.V., and Sonoma Pharmaceuticals Netherlands, B.V. Our fiscal
year end is March 31. Our corporate telephone number is (800) 759-9305. Our websites are www.sonomapharma.com and www.sonomapharma.eu.
The websites and any information contained therein or connected thereto is not intended to be incorporated into this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a global healthcare leader for developing
and producing stabilized hypochlorous acid, or HOCl, products for a wide range of applications, including wound care, animal health care,
eye care, oral care and dermatological conditions. Our products reduce infections, itch, pain, scarring and harmful inflammatory responses
in a safe and effective manner. In-vitro and clinical studies of HOCl show it to have impressive antipruritic, antimicrobial, antiviral
and anti-inflammatory properties. Our stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does
not sting or irritate skin and oxygenates the cells in the area treated, assisting the body in its natural healing process. We sell our
products either directly or via partners in 54 countries worldwide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Update</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After two years of restructuring the Company,
we are now focused on growing our revenues while maintaining costs. During 2021, we built out our Boulder, Colorado office with new sales
and marketing staff. We are beginning to see growth in the U.S. market with new customer and distributor relationships while concurrently
building on organic growth from existing customers. We have also focused on introducing new products into multiple markets around the
world and increasing our regulatory reach by seeking new approvals and clearances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our recent business updates
include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">In January 2022, Sonoma partnered with Anlicare International to seek regulatory clearance for oral and
dental products in China. Anlicare will bear the costs of the regulatory process. The regulatory clearance is expected in 2024.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">On March 20, 2022, Sonoma launched Microdox&#174;, a urinary tract infection, catheter, and bladder
                                                                                                             rinse. This new indication for Microdox&#174; based on Sonoma&#8217;s patented Microcyn&#174; Technology is intended to treat and
                                                                                                             prevent infections in the urinary tract and bladder and is currently available for immediate use through Sonoma&#8217;s partners, Te
                                                                                                             Arai BioFarma in New Zealand and Australia, and NuAngle in South Africa.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">In spring 2022, our animal healthcare partner Manna Pro, began selling
our HOCl-products through Cabela&#8217;s and Bass Pro Shops introducing new customers to our Microcyn&#174; technology.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">On May 3, 2022, Sonoma expanded its successful partnership with MicroSafe Group DMCC with the announcement
of the EPA Approval for Nanocyn&#174; Hospital-Grade Disinfectant in the United States. The EPA approval process was a coordinated effort
by Sonoma and MicroSafe Group. MicroSafe Group managed and financed the regulatory process with the EPA in exchange for non-exclusive
rights to distribute Nanocyn in the United States. Sonoma provided expertise and manufactured the required product samples.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">In June 2022, Sonoma Pharmaceuticals and MicroSafe Group DMCC announced
Nanocyn&#174; hospital grade disinfectant has been added to the list of COVID-19 disinfectants maintained by the U.S. Environmental Protection
Agency&#8217;s List N. The addition to the COVID-19 disinfectant list represents an extension of the EPA approval for this product. Also
in June, the EPA added Nanocyn&#174; to List-Q as a disinfectant for Emerging Viral Pathogens, including Monkeypox.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to invest in research and development,
both in the U.S. and internationally, for our core performance-stabilized hypochlorous acid, or HOCl, technology. We have an active pipeline
of products and are engaged in on-going studies either independently or with partners to increase applications of our technology. Additionally,
we continue to seek new regulatory clearances to expand potential markets we can sell our products into.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The COVID-19 pandemic still affects our business
and presents new challenges. Whereas in the beginning of the pandemic, we had to manage closures and shelter-in-place orders, we now face
higher shipping costs, shipping delays and higher labor costs driven by inflation and a surplus of opportunities for job seekers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we move into our new fiscal year, our path
forward will consist of looking for U.S. and international distribution partners, developing new products to bring to market and expanding
further into U.S. over-the-counter markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Channels</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our core market differentiation is based on
being the leading developer and producer of stabilized hypochlorous acid, or HOCl, solutions. Unlike many of our competitors, we
have been in business for over 20 years, and in that time we have developed significant scientific knowledge of how best to develop
and manufacture HOCl products backed by decades of studies and data collection. HOCl is known to be among the safest and
most-effective ways to relieve itch, inflammation and burns while stimulating natural healing through increased oxygenation and
eliminating persistent microorganisms and biofilms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell our products into many markets both in
the U.S. and internationally. In international markets, we ship products to 54 countries. Our core strategy is to work with partners both
in the United States and around the world to market and distribute our products. In some cases, we market and sell our own products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dermatology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sonoma Dermatology has developed unique, differentiated,
prescription-strength and safe dermatologic products that support paths to healing among various key dermatologic conditions. Our products
are primarily targeted at the treatment of acne, the management of scars and atopic dermatitis. We are strategically focused on introducing
innovative new products that are supported by human clinical data with applications that address specific dermatological procedures currently
in demand. In addition, we look for markets where we can provide effective product line extensions and pricing to new product families.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, we partner with EMC Pharma,
LLC to sell our prescription products for an initial term of five years, subject to meeting minimum purchase and other requirements. Pursuant
to our agreement with EMC Pharma, we manufacture products for EMC Pharma and EMC Pharma markets, sells and distributes them to patients
and customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On September
28, 2021, we launched a new over-the-counter product, Regenacyn&#174; Advanced Scar Gel, which is clinically proven to improve the overall
appearance of scars while reducing pain, itch, redness, and inflammation. Additionally, on the same day, we launched Regenacyn&#174; Plus,
a prescription-strength scar gel which is available as an office-dispense product through physician offices. Our consumer products are
available through Amazon.com, our website and U.S.-based distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell dermatology products in Europe, Asia,
and Brazil through a distributor network. In these international markets, we have a network of partners, ranging from country specific
distributors to large pharmaceutical companies to full-service sales and marketing companies. We work with our international partners
to create products they can market in their home country. Some products we develop and manufacture are private label while others use
branding we have already developed. We have created or co-developed a wide range of products for international markets using our core
HOCl technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>First Aid and Wound Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our HOCl-based wound care products are intended
for the treatment of acute and chronic wounds as well as first- and second-degree burns. They work by first removing foreign material and
debris from the skin surface and moistening the skin, thereby improving wound healing. Second, our HOCl products assist in the wound healing
process through their antimicrobial properties by removing microorganisms. Since HOCl is an important constituent of our innate immune
system and is formed and released by the macrophages during phagocytosis, it is advantageous to other wound-irrigation and antiseptic
solutions as highly organized cell structures such as human tissue can tolerate the action of our wound care solution while single-celled
microorganisms cannot. Due to its unique chemistry, our wound treatment solution is much more stable than similar products on the market
and therefore maintains much higher levels of hypochlorous acid over its shelf life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, we sell our wound care products
directly to hospitals, physicians, nurses, and other healthcare practitioners and indirectly through several non-exclusive distribution
arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To respond to market demand for our HOCl technology-based
products, we launched our first direct to consumer over-the-counter product in the United States in February 2021. Microcyn&#174; OTC Wound
and Skin Cleanser is formulated for home use without prescription to help manage and cleanse wounds, minor cuts, and burns, including
sunburns and other skin irritations. Microcyn&#174; OTC Wound and Skin Cleanser is available without prescription through Sonoma&#8217;s
online store.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In Europe, we rely on agreements with country-specific
distributors for the sale of our wound care products under a variety of brand names into 27 countries, including Austria, Belgium, Croatia,
Italy, the Netherlands, Germany, Greece, Hungary, the Czech Republic, Spain, Norway, Switzerland, Poland, Portugal, Slovenia, the Slovak
Republic, Finland, Denmark, Montenegro and Serbia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2021, we received approval to market
and use our HOCl products as biocides under Article 95 of the European Biocidal Products Regulation in France, Germany and Portugal. The
approval applies to our products MucoClyns&#8482; for human hygiene to be marketed and commercialized by us, MicrocynAH&#174; for animal
heath marketed and commercialized through our partner, Petagon Limited, and MicroSafe for disinfectant use to be marketed and commercialized
through our partner, MicroSafe Group Dubai.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Eye Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our prescription product
Acuicyn&#8482; is an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes
and helps manage red, itchy, crusty and inflamed eyes. It is strong enough to kill the bacteria that causes discomfort, fast enough to
provide near instant relief, and gentle enough to use as often as needed. In the United States, our partner EMC Pharma is selling our
prescription-based eye care product through its distribution network.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 28, 2021,
we launched Ocucyn Eyelid &amp; Eyelash Cleanser, which is sold directly to consumers on Amazon.com.&#160;<span style="background-color: white">Ocucyn
Eyelid &amp; Eyelash Cleanser, designed for everyday use, is a safe, gentle, and effective solution for good eyelid &amp; eyelash hygiene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In international markets
we rely on a network of distribution partners to sell our eye products. On May 19, 2020, we entered into an expanded license and distribution
agreement with our existing partner, Brill International S.L. for our Microdacyn60&#174; Eye Care HOCl-based product. Under the license
and distribution agreement, Brill has the right to market and distribute our eye care product under the private label Ocudox&#8482; in
Italy, Germany, Spain, Portugal, France, and the United Kingdom for a period of 10 years, subject to meeting annual minimum sales quantities.
In return, Brill will pay us a one-time fee, and the agreed upon supply prices. In parts of Asia, Dyamed Biotech markets our eye product
under the private label Ocucyn.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Oral, Dental and Nasal Care </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">We sell
a variety of oral, dental, and nasal products around the world.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In late 2020 we launched two HOCl-based products
in the dental, head and neck markets and launched Endocyn&#174;, a biocompatible root canal irrigant. In August 2021, we launched OroGenix
Oral Hygiene Rinse. In the U.S., we sell our dental products through U.S.-based distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Internationally, our product Microdacyn60&#174;
Oral Care treats mouth and throat infections and thrush. Microdacyn60 solution assists in reducing inflammation, pain, soothing cough
relief and does not contain any harmful chemicals. It does not stain teeth, is non-irritating, non-sensitizing, has no contraindications
and is ready for use with no mixing or dilution. In New Zealand and Australia, our partner Te Arai BioFarma Ltd. markets our oral product
under their label Oracyn&#174; Oral Care. Our partner, Dyamed Biotech, expects to launch Oracyn&#174; Oral Care in parts of Asia this year.
On January 18, 2022, we partnered with Anlicare International to seek regulatory clearances for our dental and oral products in China
and Macau.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our international nasal care product Sinudox&#8482;
based on our HOCl technology is a solution intended for nasal irrigation. Sinudox Hypotonic Nasal Hygiene clears and cleans a blocked
nose, stuffy nose and sinuses by ancillary ingredients that may have a local antimicrobial effect. Sinudox is sold through Amazon in Europe.
In New Zealand and Australia, our partner Te Arai markets our nasal product under their label Nasocyn&#174; Nasal Care.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Animal Health Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MicrocynAH&#174; is a HOCl-based topical product
that cleans, debrides and treats a wide spectrum of animal wounds and infections. It is intended for the safe and rapid treatment of a
variety of animal afflictions including cuts, burns, lacerations, rashes, hot spots, rain rot, post-surgical sites, pink eye symptoms
and wounds to the outer ear of any animal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For our animal health products sold in the U.S.
and Canada, we partnered with Manna Pro Products, LLC to bring relief to pets and peace of mind to their owners. Manna Pro distributes
non-prescription products to national pet-store retail chains, farm animal specialty stores, in the United States and Canada, such as
Chewy.com, PetSmart, Tractor Supply, Cabela&#8217;s, PetExpress, and Bass Pro Shops. Additionally, we recently expanded our animal health
product offerings by adding a MicrocynAH line for felines at PetSmart.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For the
Asian and European markets, on May 20, 2019, we partnered with Petagon, Limited, an international importer and distributor of quality
pet food and products for an initial term of five years. We supply Petagon with all MicrocynAH products sold by Petagon. On August 3,
2020, Petagon received a license from the People&#8217;s Republic of China for the import of veterinary drug products manufactured by
us. This is the highest classification Petagon and Sonoma can receive for animal health products in China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Surface Disinfectants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In-vitro and clinical studies of HOCl show it
to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. HOCl has been formulated as a disinfectant
and sanitizer solution for our partner MicroSafe Group, Dubai, and is sold in numerous countries. It is designed to be used to spray in
aerosol format to areas and environments which are suspected to serve as a breeding ground for the spread of infectious disease, likely
to result in epidemics or pandemics. The medical-grade surface disinfectant solution is used in hospitals worldwide to keep doctors and
patients protected and safe. In May 2020, Nanocyn&#174; Disinfectant &amp; Sanitizer, received approval to be entered into the Australian
Register of Therapeutic Goods, or ARTG, as well as in Canada, for use against the coronavirus SARS-CoV-2, or COVID-19. Nanocyn has also
met the stringent environmental health and social/ethical criteria of Good Environmental Choice Australia, or GECA, becoming one of the
very few eco-certified, all-natural disinfectant solutions in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through our partner MicroSafe Group DMCC, Dubai,
we sell hard surface disinfectant products into the U.S., Europe, the Middle East and Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2021, we granted MicroSafe the non-exclusive
right to sell and distribute Nanocyn in the United States provided that MicroSafe secure U.S. EPA approval. In April of 2022, MicroSafe
secured the EPA approval for Nanocyn&#174; Disinfectant &amp; Sanitizer, meaning that it can now be sold in the United States as a surface
disinfectant, and it was subsequently added to the EPA&#8217;s list N for use against COVID-19. We intend to build upon this ground-breaking
approval by securing further approvals of this nature. Nanocyn&#174; is a hospital-grade disinfectant and manufactured by us using our
patented HOCl technology. Nanocyn&#174; is currently sold by MicroSafe in Europe, the Middle East and Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of July 11, 2022, we employed
a total of 11 full-time employees in the United States, and one full-time employee in the Netherlands.
Additionally, we had 165 employees in Mexico, all of which were contracted through an employment agency. We are not a party to any
collective bargaining agreements. We believe relations with employees are very good.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Products</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our products are all classified as medical devices and categorized
as prescription products, over-the-counter, or OTC, and office dispense. Below are some of our key products that we either sell through
our own efforts or through partnership agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Dermatology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States our prescription product
offerings are Epicyn&#8482; Antimicrobial Facial Cleanser, Levicyn&#8482; Antimicrobial Dermal Spray, Levicyn&#8482; Antipruritic Gel,
Levicyn&#8482; Antipruritic Spray Gel, Celacyn&#8482; Scar Management Gel and Sebuderm&#8482; Topical Gel. We also have our office dispense
products Lasercyn&#8482; Dermal Spray, Lasercyn&#8482; Post Procedure Gel and Regenacyn&#8482; Advanced Scar Management. We also offer
Regenacyn Advanced Scar Gel for OTC purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Internationally, we offer GramaDerm&#8482; Hydrogel and Solution Combo
Pack to assist in the treatment of topical mild to moderate acne, Epicyn&#8482; Scar Management Hydrogel and Pediacyn&#8482; Atopic Dermatitis
Hydrogel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Celacyn&#174; Scar Management Gel</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 20%"><img src="a1.jpg" alt="" /></td>
    <td style="width: 1%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&#160;</p></td>
    <td style="width: 79%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">Celacyn&#174; offers scar management by protecting and moisturizing
    wound and scar sites to promote lighter, flatter, less prominent scarring.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">Celacyn&#174;, is a HOCl-based topical
    prescription product indicated to promote efficient healing through the management of new and old scars resulting from surgical procedures
    and trauma wounds or burns.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">&#160;</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 20%"><img src="a2.jpg" alt="" /></td>
    <td style="width: 1%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 79%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Epicyn&#8482; relieves the common symptoms of irritated skin and dermal
    lesions. Epicyn<sup>&#8482;</sup> Antimicrobial Facial cleanser is intended for the cleansing, irrigation, moistening, debridement and
    removal of foreign material and debris from acute and chronic dermal lesions.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Levicyn&#8482; Antipruritic Dermal Spray, Antipruritic Spray Gel, and
Antipruritic Gel</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 16%"><img src="a3.jpg" alt="" /></td>
    <td style="width: 1%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 83%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Levicyn&#8482; offers fast itch relief. Levicyn&#8482; is a HOCl-based
    topical prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lasercyn&#8482;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 16%"><img src="a4.jpg" alt="" /></td>
    <td style="width: 1%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 83%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lasercyn&#8482; Post Procedure Gel is intended for the management of
    post non ablative laser therapy procedures, post microdermabrasion therapy and following superficial chemical peels. Lasercyn&#8482; Procedure
    Gel may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Wound Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the United States we offer Microcyn&#174; wound and skin care both
as an OTC, and prescription product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<img src="a5.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Microcyn&#174; Wound Care Management</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 23%"><img src="a6.jpg" alt="" /></td>
    <td style="width: 1%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 76%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Microcyn&#174; offers enhanced healing properties.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Microcyn&#174; is a HOCl-based topical line of products designed to
    stimulate expedited healing by targeting a wide range of pathogens including viruses, fungi, spores and bacteria, including antibiotic-resistant
    strains that slow the natural healing of wounds.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Eye, Nasal and Oral Care </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acuicyn&#8482; Eyelid and Eyelash Hygiene</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26%; font-size: 10pt"><span style="font-size: 10pt"><img src="image_001.jpg" alt="" style="height: 170px; width: 170px" /></span></td>
    <td style="width: 1%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 37%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acuicyn&#8482; offers safe and effective eyelid and eyelash hygiene.
    Acuicyn&#8482; is a HOCl-based topical prescription product indicated to relieve itch and inflammation while helping to keep areas around
    the eye clean. We also offer Ocucyn&#174; Eyelid and Eyelash Cleanser as an OTC version for purchase.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ocudox&#8482; is substantially the same eye care product marketed by
    Brill in Europe.</p></td>
    <td style="width: 36%; font-size: 10pt"><span style="font-size: 10pt"><img src="image_002.jpg" alt="" style="height: 188px; width: 146px" /></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Microdacyn60&#174; Oral Care</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24%; font-size: 10pt"><span style="font-size: 10pt"><img src="image_004.jpg" alt="" style="height: 200px; width: 165px" /></span></td>
    <td style="width: 1%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 3%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 71%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Microdacyn60 Oral Care with patented technology supports the treatment
    of mouth and throat infections and the debridement and moistening of mouth lesions and thrush.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This adjuvant solution assists in reducing inflammation, pain, soothing
    cough relief and does not contain any harmful chemicals. It does not stain teeth, is non-irritating, non-sensitizing, has no contraindications
    and is ready for use with no mixing or dilution.</p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Animal Health Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States and internationally, our HOCl-based MicrocynAH&#174;
line offers topical solutions designed to relieve the common symptoms of hot spots, scratches, skin rashes post-surgical sites and irritated
animal skin and promote expedited healing for all animals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<img src="a10.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Surface Disinfectants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through our partner MicroSafe DMCC, Dubai, we sell Nanocyn&#174;. Nanocyn
is a hospital-grade disinfectant indicated to sterilize hard surfaces by spraying directly onto the surface, for medical devices by submerging
the device in Nanocyn, and also for fumigation into the air.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When fumigated, Nanocyn has demonstrated the ability to kill a wide
range of airborne pathogens and significantly reduce the spread of infectious disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<img src="a11.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expense consists primarily
of expenses for clinical studies, personnel, regulatory services and supplies. For the years ended March 31, 2022 and 2021, research and
development expense amounted to $125,000 and $555,000, respectively. A small percentage of these expenses were borne by our customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing and Packaging</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through June 23, 2020, we manufactured products
at facilities in Petaluma, California and Zapopan, Mexico. On June 24, 2020, we transitioned all of our manufacturing to Zapopan, Mexico
and closed our Petaluma facility. We have developed a manufacturing process and conduct quality assurance testing on each production batch
in accordance with current U.S., Mexican and international Current Good Manufacturing Practices. Both facilities are required to meet
and maintain regulatory standards applicable to the manufacture of pharmaceutical and medical device products. Our Mexican facilities
are certified and comply with U.S. Current Good Manufacturing Practices, Quality Systems Regulations for medical devices, and International
Organization for Standardization, or ISO, guidelines. Our Mexican facility has been approved by the Ministry of Health and is also ISO
13485 certified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our machines are tested regularly, which is part
of a validation protocol mandated by U.S., Mexican and international Current Good Manufacturing Practices, Quality Systems Regulation,
and ISO requirements. This validation is designed to ensure that the final product is consistently manufactured in accordance with product
specifications at all manufacturing sites. Certain materials and components used in manufacturing are proprietary to Sonoma. All other
raw materials and supplies utilized in the manufacturing process of our products are available from various third-party suppliers in quantities
adequate to meet our needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe we own a sufficient factory space and
equipment to produce an adequate amount of product to meet anticipated future requirements for at least the next two years. With expansion
into new geographic markets, we may establish additional manufacturing facilities to better serve those new markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. Regulatory Approvals and Clearances</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have obtained 21 U.S. Food and Drug
Administration, or FDA, clearances permitting the sale of products as medical devices for Section 510(k) of the Federal Food, Drug and
Cosmetic Act in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outside the United States, we sell products for
dermatological and advanced tissue care with a European Conformity marking, Conformit&#233; Europ&#233;enne, or CE. On April 9, 2020,
we received an updated EC certificate covering 39 products in 54 countries with various approvals in Brazil, China, Southeast Asia, South
Korea, India, Australia, New Zealand, and the Middle East.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table summarizes
our current material regulatory approvals and clearances by brand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 35%; text-align: center"><span style="font-size: 10pt"><b>Brand</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Approval Type</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 51%; text-align: center"><span style="font-size: 10pt"><b>Summary Indication</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>HOCl-based Products:</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Lasercyn&#8482; Gel, Levicyn&#8482; Gel</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">U.S. 510(k)<br />
<br />
EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Prescription and OTC product, intended for use to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns, such as sunburn. As a prescription product it is also intended for sores, injuries, ulcers of dermal tissue and exuding wounds.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Sebuderm&#8482;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. 510(k)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EU CE Mark</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Prescription-only product, manages and relieves the burning, itching, erythema, scaling, and pain experienced with seborrhea and seborrheic dermatitis. It also helps to relieve dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Celacyn&#174; Scar Management Gel,</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Prescription and OTC product, for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures and trauma wounds.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Levicyn&#8482; SG</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">U.S. 510(k)<br />
<br />
EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Prescription and OTC product, for the management and relief of burning and itching associated with many common types of skin irritation, lacerations, abrasions and minor burns. As a prescription product it also relieves burning and itching and pain associated with various types of dermatoses, including radiation dermatitis and atopic dermatitis.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Epicyn&#8482; Antimicrobial Facial Cleanser</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">U.S. 510(k)<br />
<br />
EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Prescription and OTC product, management of skin abrasions, lacerations, minor irritations, cuts and intact skin. As a prescription product it is intended for the cleansing, irrigation, moistening, debridement and removal of foreign material and debris from exudating wounds, first- and second-degree burns and other skin irritations.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Lasercyn&#8482; Gel</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Prescription and OTC product, intended for the management of minor skin irritations following post non ablative laser therapy procedures, post microdermabrasion therapy and following superficial chemical peels, and to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Levicyn&#8482; Dermal Spray, Lasercyn&#8482; Dermal Spray</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Prescription and OTC product, for the management of skin abrasions, lacerations, minor irritations, cuts and intact skin. As a prescription product it is intended for the cleansing, irrigation, moistening, debridement and removal of foreign material including microorganisms and debris from exudating wounds, acute and chronic dermal lesions, burns, and other skin irritations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 35%"><span style="font-size: 10pt">Acuicyn Antimicrobial Eyelid &amp; Eyelash Hygiene</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 12%"><span style="font-size: 10pt">U.S. 510(k) </span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 51%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prescription product, Under the supervision of
    a healthcare professional, Acuicyn Antimicrobial Eyelid &amp; Eyelash Hygiene is intended for the cleansing, irrigation, moistening, debridement
    and removal of foreign material and debris from exudating wounds, acute and chronic dermal lesions including stage I-IV pressure ulcers,
    stasis ulcers, diabetic ulcers, post-surgical wounds, first- and second-degree burns, abrasions, minor irritations of the skin, diabetic
    foot ulcers, ingrown toe nails, grafted/donor sites and exit sites. It is also intended for use to moisten and lubricate wound dressings
    and for use with devices intended to irrigate wounds.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OTC product, Ocucyn Antimicrobial Eyelid &amp; Eyelash Hygiene is intended
for OTC use in the management of skin abrasions, lacerations, minor irritations, cuts, and intact skin.</p></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Endocyn Root Canal Irrigation Solution</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">U.S.510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Endocyn Root Canal Irrigation Solution is intended to irrigate, cleanse, and debride root canal systems including the removal of foreign material and debris during root canal therapy. It is also intended to provide for lubrication and irrigation during root canal instrumentation.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Gramaderm&#174;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Various product formulations for the topical treatment of mild to moderate acne.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Microdacyn60&#174;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Various product formulations for the management of itching, burning and other skin irritations.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">MucoClyns&#8482;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Indicated for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns and body surfaces for the treatment immediately after an unexpected exposure to infection risk, and professional medical attention.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Sinudox&#8482;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Solution intended for nasal irrigation, including the moistening of cuts, abrasions and lacerations located in the nasal cavity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Significant Customers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on certain key customers for a
significant portion of revenues. In the U.S., our key customers are EMC Pharma, LLC with which we partnered in March 2021 to sell
our prescription dermatology and eye care products and Manna Pro, our partner for our animal health care products. Our wound
care products are purchased by hospitals, physicians, nurses, and other healthcare practitioners from us directly. At March 31,
2022, one customer represented 20% of our net accounts receivable balance, one customer represented 15% of our net accounts
receivable balance, and one customer represented 14% of our net accounts receivable balance. At March 31, 2021, one customer
represented 17% of our net accounts receivable balance, one customer represented 16% of our net accounts receivable balance, and one
customer represented 14% of our net accounts receivable balance. For the year ended March 31, 2022, one customer represented 10%,
one customer represented 17%, and one customer represented 21% of net revenues. For the year ended March 31, 2021, one customer
represented 32%, and one customer represented 15% of net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends in part on an ability to obtain
and maintain proprietary protection for product technology and know-how, to operate without infringing proprietary rights of others, and
to prevent others from infringing on our proprietary rights. We seek to protect a proprietary position by, among other methods, filing,
when possible, U.S. and foreign patent applications relating to our technology, inventions and improvements that are important to the
business. We have patented certain aspects of our HOCl technology in the United States and worldwide. We also rely on trade secrets, know-how,
continuing technological innovation, and in-licensing opportunities to develop and maintain a proprietary position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we work diligently to protect proprietary
technology, there are no assurances that any patent will be issued from currently pending patent applications or from future patent applications.
The scope of any patent protection may not exclude competitors or provide competitive advantages, and any patent may not be held valid
if subsequently challenged, and others may claim rights in or ownership of patents and proprietary rights. Furthermore, others may develop
products similar to ours and may duplicate any of the products or design around patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have also filed for trademark protection for
marks used with products in each of the following regions: United States, Europe, Canada, certain countries in Central and South America,
including Mexico and Brazil, certain countries in the Middle East and certain countries in Asia, including Japan, China, Hong Kong, the
Republic of Korea, India and Australia. In addition to patents and trademarks, we rely on trade secret and other intellectual property
laws, nondisclosure agreements and other measures to protect intellectual property rights. We believe that in order to have a competitive
advantage, we must develop and maintain the proprietary aspects of technologies. Employees, consultants and advisors are required to execute
confidentiality agreements in connection with their employment, consulting or advisory relationships. Employees, consultants and advisors
with whom we expect to work with are also required to disclose and assign to us all inventions made in the course of a working relationship
with them, while using intellectual property or which relate to our business. Despite any measures taken to protect our intellectual property,
unauthorized parties may attempt to copy aspects of the products or to wrongfully obtain or use information that regarded as proprietary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We compete globally across five main channels:
dermatology, eye, nasal and oral care, wound and acute care, animal health and surface disinfectants with our HOCl technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dermatology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our dermatology products are at the forefront
of HOCl-based solutions, a safe and highly effective active ingredient designed to relieve itching, burning and inflammation and acts
as a highly effective antimicrobial agent. We believe no other solutions on the market provide the same patient benefits at the levels
of safety and cost. Our HOCl-based solutions face significant competition in the United States from prescription products including corticosteroids,
topical steroids and topical antibiotics. Our opportunity as an adjunct to these steroids is based on the insight that many doctors and
patients limit steroid and antibiotic use due to potential side effects. These side effects include bacterial resistance, stinging, burning
and inflammation for topical antibiotics and stretch marks, easy bruising, tearing of the skin and, to a lesser extent, enlarged of blood
vessels for topical steroids. Our HOCl-based products are safe, non-toxic and have shown few side effects in clinical studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Wound and Acute Care Markets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Similar to our dermatology products, our HOCl-based
wound and acute care solutions provide improved efficacy at lower costs than traditional acute care products. Our HOCl-based solutions
compete with topical anti-infectives and antibiotics, as well as some advanced wound technologies, such as skin substitutes, growth factors
and delayed release silver-based dressings. Our opportunity in this space relative to antibiotics is based on the insight that competing
antibiotic solutions may have resistance-building properties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Factors Affecting Competitive Position</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While some other companies are able to produce
small molecule, HOCl-based formulations, based on our research, their products may become unstable after a relatively short period of
time or have large ranges of effectiveness. We believe our HOCl-based solutions are among the most stable therapeutics available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our competitors in the dermatology, wound
care, eye, nasal and oral care, animal health care and surface disinfectant markets enjoy several competitive advantages. These include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">greater name recognition;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">established relationships with healthcare professionals, patients and third-party payors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">established distribution networks;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">additional product lines and the ability to offer rebates or bundle products to offer discounts or incentives;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">experience in conducting research and development, manufacturing, obtaining regulatory approval for products and marketing; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">financial and human resources for product development, sales and marketing and patient support.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Government authorities in the United States, at
the federal, state and local levels, and foreign countries extensively regulate, among other things, the research, development, testing,
manufacture, labeling, promotion, advertising, distribution, sampling, marketing, and import and export of pharmaceutical products, biologics
and medical devices. All of our products in development will require regulatory approval or clearance by government agencies prior to
commercialization. In particular, human therapeutic products are subject to rigorous pre-clinical and clinical trials and other approval
procedures of the FDA and similar regulatory authorities in foreign countries. Various federal, state, local and foreign statutes and
regulations also govern testing, manufacturing, safety, labeling, storage, distribution and record-keeping related to such products and
their marketing. The process of obtaining these approvals and clearances, and the subsequent process of maintaining substantial compliance
with appropriate federal, state, local, and foreign statutes and regulations, require the expenditure of substantial time and financial
resources. In addition, statutes, rules, regulations and policies may change and new legislation or regulations may be issued that could
delay such approvals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Medical Device Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have received 21 510(k) clearances
for use of products as medical devices in tissue care management, such as cleaning, debridement, lubricating, moistening and dressing,
including for acute and chronic wounds, and in dermatology applications. Any future product candidates or new applications classified
as medical devices will require clearance by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medical devices are subject to FDA clearance and
extensive regulation under the Federal Food Drug and Cosmetic Act. Under the Federal Food Drug and Cosmetic Act, medical devices are classified
into one of three classes: Class I, Class II or Class III. The classification of a device into one of these three classes generally depends
on the degree of risk associated with the medical device and the extent of control needed to ensure safety and effectiveness. Devices
may also be designated unclassified. Unclassified devices are legally marketed pre-amendment devices for which a classification regulation
has yet to be finalized and for which a pre-market approval is not required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Class I devices are devices for which safety and
effectiveness can be assured by adherence to a set of general controls. These general controls include compliance with the applicable
portions of the FDA&#8217;s Quality System Regulation, which sets forth good manufacturing practice requirements; facility registration,
device listing and product reporting of adverse medical events; truthful and non-misleading labeling; and promotion of the device only
for its cleared or approved intended uses. Class&#160;II devices are also subject to these general controls, and any other special controls
as deemed necessary by the FDA to ensure the safety and effectiveness of the device. Review and clearance by the FDA for these devices
is typically accomplished through the 510(k) pre-market notification procedure. When 510(k) clearance is sought, a sponsor must submit
a pre-market notification demonstrating that the proposed device is substantially equivalent to a legally marketed device. If the FDA
agrees that the proposed device is substantially equivalent to the predicate device, then 510(k) clearance to market will be granted.
After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would
constitute a major change in its intended use, requires a new 510(k) clearance or could require a pre-market approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials are almost always required to
support a pre-market approval application and are sometimes required for a 510(k) pre-market notification. These trials generally require
submission of an application for an investigational device exemption. An investigational device exemption must be supported by pre-clinical
data, such as animal and laboratory testing results, which show that the device is safe to test in humans and that the study protocols
are scientifically sound. The FDA must approve an investigational device exemption, in advance, for a specified number of patients, unless
the product is deemed a non-significant risk device and is eligible for more abbreviated investigational device exemption requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both before and after a medical device is commercially
distributed, manufacturers and marketers of the device have ongoing responsibilities under FDA regulations. The FDA reviews design and
manufacturing practices, labeling and record keeping, and manufacturers&#8217; required reports of adverse experiences and other information
to identify potential problems with marketed medical devices. Device manufacturers are subject to periodic and unannounced inspection
by the FDA for compliance with the Quality System Regulation, which sets forth the Current Good Manufacturing Practice requirements that
govern the methods used in, and the facilities and controls used for the design, manufacture, packaging, servicing, labeling, storage,
installation and distribution of all finished medical devices intended for human use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FDA regulations prohibit the advertising and promotion
of a medical device for any use outside the scope of a 510(k) clearance or pre-market approval or for unsupported safety or effectiveness
claims. Although the FDA does not regulate physicians&#8217; practice of medicine, the FDA does regulate manufacturer communications with
respect to off-label use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the FDA finds that a manufacturer has failed
to comply with FDA laws and regulations or that a medical device is ineffective or poses an unreasonable health risk, it can institute
or seek a wide variety of enforcement actions and remedies, ranging from a public warning letter to more severe actions such as:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">imposing fines, injunctions and civil penalties</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">requiring a recall or seizure of products</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">implementing operating restrictions, which can include a partial suspension or total shutdown of production</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refusing requests for 510(k) clearance or pre-market approval of new products</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">withdrawing 510(k) clearance or pre-market approval approvals already granted</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">criminal prosecution</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA also has the authority to require a company
to repair, replace, or refund the cost of any medical device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA also administers certain controls over
the export of medical devices from the United States, as international sales of medical devices that have not received FDA clearance are
subject to FDA export requirements. Additionally, each foreign country subjects such medical devices to its own regulatory requirements.
In the European Union, there is a single regulatory approval process and approval is represented by the presence of a CE marking.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Regulation in the United States</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The Physician Payments Sunshine Act</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Physician Payments Sunshine Act signed into
law in 2010 as part of the Affordable Care Act requires manufacturers of medical devices, drugs, biologicals, and medical supplies to
track and report certain payments made to and transfers of value provided to physicians and teaching hospitals as well as to report certain
ownership and investment interests held by physicians and their immediate family members. These manufacturers must report annually to
the Center for Medicare &amp; Medicaid Services any direct or indirect payments and transfers of value of $10 or more, or annual aggregate
of $100 or more, made to physicians or to a third party at the request of or on behalf of a physician, including dentists. Payment includes:
consulting fees, compensation for services other than consulting, honoraria, gifts, entertainment, food, travel (including the specified
destinations), education, research, charitable contribution, royalty or license, current or prospective ownership or investment interest,
direct compensation for serving as faculty or as a speaker for a medical education program, grants, any other nature of the payment, or
other transfer of value. Manufacturers face monetary penalties for non-compliance. Certain payments related to research must be reported
separately. Product samples intended for patient use need not be reported.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Health Care Coverage and Reimbursement by Third-Party
Payors</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commercial success in marketing and selling products
depends, in part, on the availability of adequate coverage and reimbursement from third-party health care payors, such as government and
private health insurers and managed care organizations. Third-party payors are increasingly challenging the pricing of medical products
and services. Government and private sector initiatives to limit the growth of health care costs, including price regulation, competitive
pricing, and managed-care arrangements, are continuing in many countries where we do business, including the United States. These changes
are causing the marketplace to be more cost-conscious and focused on the delivery of more cost-effective medical products. Government
programs, including Medicare and Medicaid, private health care insurance companies, and managed-care plans control costs by limiting coverage
and the amount of reimbursement for particular procedures or treatments. This has created an increasing level of price sensitivity among
customers for our products. Some third-party payors also require that a favorable coverage determination be made for new or innovative
medical devices or therapies before they will provide reimbursement of those medical devices or therapies. Even though a new medical product
may have been cleared or approved for commercial distribution, we may find limited demand for the product until adequate coverage and
reimbursement have been obtained from governmental and other third-party payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fraud and Abuse Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, we are subject to various
federal and state laws pertaining to healthcare fraud and abuse, which, among other things, prohibit the offer or acceptance of remuneration
intended to induce or in exchange for the purchase of products or services reimbursed under a federal healthcare program and the submission
of false or fraudulent claims with the government. These laws include the federal Anti-Kickback Statute, the False Claims Act and comparable
state laws. These laws regulate the activities of entities involved in the healthcare industry, such as Sonoma, by limiting the kinds
of financial arrangements such entities may have with healthcare providers who use or recommend the use of medical products, including,
for example, sales and marketing programs, advisory boards and research and educational grants. In addition, in order to ensure that healthcare
entities comply with healthcare laws, the Office of Inspector General of the U.S.&#160;Department of Health and Human Services recommends
that healthcare entities institute effective compliance programs. To assist in the development of effective compliance programs, the Office
of Inspector General has issued model Compliance Program Guidance, materials for a variety of healthcare entities which, among other things,
identify practices to avoid that may implicate the federal Anti-Kickback Statute and other relevant laws and describes elements of an
effective compliance program. While compliance with the Compliance Program Guidance materials is voluntary, a California law requires
pharmaceutical and devices manufacturers to initiate compliance programs that incorporate the Compliance Program Guidance and the July
2002 Pharmaceuticals Research and Manufacturers of America Code on Interactions with Healthcare Professionals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the scope and breadth of the provisions
of some of these laws, it is possible that some of our practices might be challenged by the government under one or more of these laws
in the future. Violations of these laws, which are discussed more fully below, can lead to civil and criminal penalties, damages, imprisonment,
fines, exclusion from participation in Medicare, Medicaid and other federal health care programs, and the curtailment or restructuring
of operations. Any such violations could have a material adverse effect on our business, financial condition, results of operations or
cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Anti-Kickback Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations are subject to federal and state
anti-kickback laws. The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or
providing remuneration directly or indirectly to induce either the referral of an individual for a good or service reimbursed under a
federal healthcare program, or the furnishing, recommending, or arranging of a good or service, for which payment may be made under a
federal healthcare program, such as Medicare or Medicaid. The definition of &#8220;remuneration&#8221; has been broadly interpreted to
include anything of value, including such items as gifts, discounts, the furnishing of supplies or equipment, waiver of co-payments, and
providing anything at less than its fair market value. Because the Anti-Kickback Statute makes illegal a wide variety of common, even
beneficial, business arrangements, the Office of Inspector General was tasked with issuing regulations, commonly known as &#8220;safe
harbors,&#8221; that describe arrangements where the risk of illegal remuneration is minimal. As long as all of the requirements of a
particular safe harbor are strictly met, the entity engaging in that activity will not be prosecuted under the federal Anti-Kickback Statute.
The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal
or that prosecution will be pursued. However, business arrangements that do not fully satisfy an applicable safe harbor may result in
increased scrutiny by government enforcement authorities, such as the Office of Inspector General. Our agreements to pay compensation
to our advisory board members and physicians who provide other services for we may be subject to challenge to the extent they do not fall
within relevant safe harbors under state and federal anti-kickback laws. In addition, many states have adopted laws similar to the federal
Anti-Kickback Statute, which apply to the referral of patients for health care services reimbursed by Medicaid, and some have adopted
such laws with respect to private insurance. Violations of the Anti-Kickback Statute are subject to significant fines and penalties and
may lead to a company being excluded from participating in federal health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>False Claims Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The federal False Claims Act prohibits knowingly
filing a false claim, knowingly causing the filing of a false claim, or knowingly using false statements to obtain payment from the federal
government. Certain violations of the Anti-Kickback Statute constitute per se violations of the False Claims Act. Under the False Claims
Act, such suits are known as &#8220;qui tam&#8221; actions. Individuals may file suit on behalf of the government and share in any amounts
received by the government pursuant to a settlement. In addition, certain states have enacted laws modeled after the federal False Claims
Act under the Deficit Reduction Act of 2005, where the federal government created financial incentives for states to enact false claims
laws consistent with the federal False Claims Act. As more states enact such laws, we expect the number of qui tam lawsuits to increase.
Qui tam actions have increased significantly in recent years, causing greater numbers of healthcare companies to have to defend false
claims actions, pay fines or be excluded from Medicare, Medicaid or other federal or state government healthcare programs as a result
of investigations arising out of such actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>HIPAA</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Two federal crimes were created under the Health
Insurance Portability and Accountability Act of 1996, or HIPAA: healthcare fraud and false statements relating to healthcare matters.
The healthcare fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including
private payors. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or
making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits,
items or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Health Information Privacy and Security</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Individually, identifiable health information
is subject to an array of federal and state regulation. Federal rules promulgated pursuant to HIPAA regulate the use and disclosure of
health information by &#8220;covered entities.&#8221; Covered entities include individual and institutional health care providers from
which we may receive individually identifiable health information. These regulations govern, among other things, the use and disclosure
of health information for research purposes, and require the covered entity to obtain the written authorization of the individual before
using or disclosing health information for research. Failure of the covered entity to obtain such authorization could subject the covered
entity to civil and criminal penalties. We may experience delays and complex negotiations in dealing with each entity&#8217;s differing
interpretation of the regulations and what is required for compliance. Also, where our customers or contractors are covered entities,
including hospitals, universities, physicians or clinics, we may be required by the HIPAA regulations to enter into &#8220;business associate&#8221;
agreements that subject the company to certain privacy and security requirements. In addition, many states have laws that apply to the
use and disclosure of health information, and these laws could also affect the manner in which we conduct research and other aspects of
business. Such state laws are not preempted by the federal privacy law when such laws afford greater privacy protection to the individual
than the federal law. While activities to assure compliance with health information privacy laws are a routine business practice, we are
unable to predict the extent to which resources may be diverted in the event of an investigation or enforcement action with respect to
such laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether or not we obtain FDA approval for a product,
approval of a product by the applicable regulatory authorities of foreign countries must be obtained before clinical trials or marketing
of the product in those countries can begin. The approval process varies from country to country, and the time may be longer or shorter
than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement
also vary greatly from country to country. Although governed by the applicable country, clinical trials conducted outside of the United
States typically are administered under a three-phase sequential process similar to that discussed above for medical devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>European Union Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Medical Device Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our products are classified as medical devices
in the European Union. In order to sell medical device products within the European Union, we are required to comply with the requirements
of the Medical Devices Directive, and its national implementations, including affixing CE markings on products. The CE marking indicates
a product&#8217;s compliance with EU legislation and so enables the sale of products throughout the European Economic Area, or the EEA,
comprising the 28 Member States of the EU and European Free Trade Association, or EFTA, countries Iceland, Norway, and Liechtenstein.
In order to comply with the Medical Devices Directive, we must meet certain requirements relating to the safety and performance of products
and, prior to marketing products, we must successfully undergo verification of products&#8217; regulatory compliance, or conformity assessment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2017, the new Medical Devices Directive
became effective in the EEA, becoming fully applicable after a transition period of three years, on May 26, 2020. Under the new Medical
Devices Directive, certain devices will be classified in higher classes, new devices will become classified, and certain new obligations
are imposed on manufacturers and distributors. Manufacturers will be required to engage a medical device expert and carry insurance for
possible liability claims. In addition, the pre-market approval and post-market surveillance requirements were enhanced. The European
Database for Medical Devices, or Eudamed, will hold and publish information on medical devices collected from the European Commission
and the national authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medical devices are divided into three regulatory
classes: Class&#160;I, Class&#160;IIB and Class&#160;III. The nature of the conformity assessment procedures depends on the regulatory
class of the product. In order to comply with the examination, we completed, among other things, a risk analysis and presented clinical
data, which demonstrated that our products met the performance specifications claimed by us, provided sufficient evidence of adequate
assessment of unwanted side effects and demonstrated that the benefits to the patient outweigh the risks associated with the device. We
are subject to continued supervision and are required to report any serious adverse incidents to the appropriate authorities. We are also
required to comply with additional national requirements that are beyond the scope of the Medical Devices Directive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We received a CE certificate for 39 of our Class
IIB medical devices, which allows us to affix CE markings on these products and sell them in Europe. We may not be able to maintain the
requirements established for CE markings for any or all of our products or be able to produce these products in a timely and profitable
manner while complying with the requirements of the Medical Devices Directive and other regulatory requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>European Good Manufacturing Process</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the European Union, the manufacture of pharmaceutical
products and clinical trial supplies is subject to good manufacturing practice as set forth in the relevant laws and guidelines. Compliance
with good manufacturing practice is generally assessed by the competent regulatory authorities. They may conduct inspections of relevant
facilities, and review manufacturing procedures, operating systems and personnel qualifications. In addition to obtaining approval for
each product, in many cases each drug manufacturing facility must be approved. Further inspections may occur over the life of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mexican Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Ministry of Health is the authority in charge
of sanitary controls in Mexico. Sanitary controls are a group of practices related to the orientation, education, testing, verification
and application of security measures and sanctions exercised by the Ministry of Health. The Ministry of Health is responsible for the
issuance of Official Mexican Standards and specifications for drugs subject to the provisions of the General Health Law, which govern
the process and specifications of drugs, including the obtaining, preparing, manufacturing, maintaining, mixing, conditioning, packaging,
handling, transporting, distributing, storing and supplying of products to the public at large. In addition, a medical device is defined
as a device that may contain antiseptics or germicides used in surgical practice or in the treatment of continuity solutions, skin injuries
or its attachments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the General Health Law, a business that
manufactures drugs is either required to obtain a &#8220;Sanitary Authorization&#8221; or to file an &#8220;Operating Notice.&#8221; Our
Mexican subsidiary, Oculus Technologies of Mexico, S.A. de C.V., is considered a business that manufactures medical devices and therefore
is not subject to a Sanitary Authorization, but rather only required to file an Operating Notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to its Operating Notice, our Mexico
subsidiary has obtained a &#8220;Good Processing Practices Certificate&#8221; issued by Mexican Federal Commission for the Protection
against Sanitary Risks, which demonstrates that the manufacturing at our facility located in Zapopan, Mexico, operates in accordance with
the applicable official standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, regulatory approval of prices is
required in most countries other than the United States, which could result in lengthy negotiations delaying our ability to commercialize
products. We face the risk that the prices which result from the regulatory approval process would be insufficient to generate an acceptable
return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Available Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We make available on sonomapharma.com, free of
charge, copies of our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments
to these reports, as soon as reasonably practicable after electronically filing or furnishing such materials to the Securities and Exchange
Commission, or SEC. Sonomapharma.com and the information contained therein or connected thereto are not intended to be incorporated into
this annual report on Form&#160;10-K. The SEC maintains an Internet site that contains reports, proxy and information statements, and
other information regarding issuers that file electronically with the SEC at www.sec.gov.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_004"></span>ITEM&#160;1A. Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a history of losses, we expect to
continue to incur losses and we may never achieve profitability and our March 31, 2022 audited consolidated financial statements included
disclosure that casts substantial doubt regarding our ability to continue as a going concern.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reported a loss from continuing operations
of $5,086,000 and $4,615,000 for the years ended March 31, 2022 and 2021, respectively. At March 31, 2022 and 2021, our accumulated deficit
amounted to $184,363,000 and $179,277,000, respectively. We had working capital of $10,611,000 and $8,905,000 as of March 31, 2022 and
2021, respectively. During the years ended March 31, 2022 and 2021, net cash used in operating activities amounted to $4,248,000 and $3,378,000,
respectively. As of March 31, 2022, we had cash and cash equivalents of $7,396,000. We spent the most recent two fiscal years working
to reduce our losses and have made significant progress. However, we expect to continue incurring losses for the foreseeable future. We
may never achieve or sustain profitability. We must raise additional capital to pursue our product development initiatives, penetrate
markets for the sale of our products and continue as a going concern. We cannot provide any assurance that we will raise additional capital.
We believe that we have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations,
or other means. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives
and take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations.
These measures could cause significant delays in our efforts to further commercialize our products, which are critical to the realization
of our business plan and to our future operations. These matters raise substantial doubt about our ability to continue as a going concern
or become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We derived a significant amount of revenue from our contract
with Invekra during the fiscal years ended March 31, 2022 and 2021, and our revenues from Invekra will decline following the transition
of Invekra towards their own manufacturing.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our revenues from our Latin American business
that we sold to Invekra on October 27, 2016 were $2,095,000 and $5,876,000 for the years ended March 31, 2022 and 2021, respectively.
Most of the revenues from fiscal year 2021 were from orders prior to the ending of our transition agreement with Invekra on October, 27,
2020. Our arrangement with Invekra required us to supply product at close to our cost until October 2020 while Invekra built their own
manufacturing. Since then, our revenues related to Invekra declined because we only process overflow orders for Invekra. We may continue
to manufacture for Invekra at prices commensurate with the market. We expect that our overall revenues from Invekra will decrease while
our margins, if any, will increase. If we are unable to increase our sales to replace the outgoing Invekra revenues, our results of operations
and financial condition may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend on third party distributors and
intend to continue to license or collaborate with third parties in various potential markets, and events involving these strategic partners
or any future collaboration could delay or prevent us from developing or commercializing products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business strategy and our short- and long-term
operating results depend in part on our ability to execute on existing strategic collaborations and to license or partner with new strategic
partners. We believe collaborations allow us to leverage our resources and technologies and to access markets that are compatible with
our own core areas of expertise while avoiding the cost of establishing or maintaining a direct sales force in each market. We may incur
significant costs in the use of third parties to identify and assist in establishing relationships with potential collaborators. We currently
use distributors for most of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have limited control over the amount and timing
of resources that our current partners or any future collaborators devote to our collaborations or potential products. These partners
may breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully and in a timely
manner. Further, our partners may not develop or commercialize products that arise out of our collaborative arrangements or devote sufficient
resources to the development, manufacture, marketing or sale of these products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To penetrate our target markets, we may need to
enter into additional collaborative agreements to assist in the development and commercialization of products. Establishing strategic
collaborations is difficult and time-consuming. Potential collaborators may reject collaborations based upon their assessment of our financial,
regulatory or intellectual property position and our internal capabilities. Our discussions with potential collaborators may not lead
to the establishment of new collaborations on favorable terms and may have the potential to provide collaborators with access to our key
intellectual property filings and next generation formations. By entering into collaboration, we may preclude opportunities to collaborate
with other third parties who do not wish to associate with our existing third-party strategic partners. Moreover, in the event of termination
of a collaboration agreement, termination negotiations may result in less favorable terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mexican tax law prevents us from deducting intercompany interest
expense incurred by our Mexico subsidiary Oculus Technologies of Mexico, S.A. de C.V and requires withholding tax on payments remitted
to the US. At the same time, we are unable to recognize tax benefits for foreign tax credits for U.S. tax purposes.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Since 2004, we loaned
substantial amounts to our Mexico subsidiary Oculus Technologies of Mexico, S.A. de C.V. at various interest rates to fund their operations.
As of March 31, 2022, our Mexico subsidiary owes approximately $11.2 million in principal, $7.3 million in technical assistance payments
and $18.3 million in accrued interest. The intercompany loans mature in 2027. There is no guarantee that our Mexican subsidiary will be
able to pay any or all of the amounts due. If we were to forgive the debt or if we were to convert the debt to equity, it would be subject
to Mexico income tax at 30%, or approximately $11.0 million, as well as Mexican withholding tax of 15%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mexico&#8217;s thin capitalization
rules also require taxpayers to maintain a debt-to-equity ratio of 3:1. Any interest paid to foreign related parties that results in indebtedness
exceeding a ratio of 3:1 to their stockholder&#8217;s equity is not deductible for Mexican corporate income tax purposes and we did not
meet that condition. Therefore, we have not been able to deduct the intercompany interest on our Mexico tax returns since 2004. It has
prevented our Mexico subsidiary from accruing net operating losses in Mexico to offset potential future profits. At the same time the
intercompany interest income in the United States decreases our U.S. net operating losses and reduces our ability to apply these carryforwards
to offset future taxable income in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, any interest
paid to a foreign lender is subject to Mexico withholding tax of 15%. We also have interest owed on our intercompany technical assistance
agreement and royalty withholding of 10% on our technical assistance agreement. This would amount to approximately $3.9 million in Mexico
withholding tax at March 31, 2022, if all of the interest and technical assistance were to be repaid to us. In general, the foreign related
party parent can then claim a credit for these withholding taxes on their U.S. income tax return. However, because of our substantial
U.S. net operating losses, we are prevented from claiming any credit on any withholding tax for U.S. income tax purposes. Any such failure
to pay intercompany debt, inability to deduct income taxes or apply credits, or liability for tax payments could have a material adverse
effect on our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A majority of our business is conducted
outside of the United States, exposing us to additional risks that may not exist in the United States, which in turn could cause our business
and operating results to suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have material international operations in Mexico,
Asia and Europe. During the years ended March 31, 2022 and 2021, approximately 70% and 71% of our total revenue, respectively, were generated
from sales outside of the United States. Our business is highly regulated for the use, marketing and manufacturing of our HOC1-based products
both domestically and internationally. Our international operations are subject to risks, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">local political or economic instability;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">continuing restrictions related to the Covid-19 pandemic;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">changes in exchange rates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">changes in governmental regulation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">changes in import/export duties;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">trade restrictions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">lack of experience in foreign markets;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">difficulties and costs of staffing and managing operations in certain foreign countries;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">work stoppages or other changes in labor conditions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">difficulties in collecting accounts receivables on a timely basis or, at all; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">adverse tax consequences or overlapping tax structures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to continue to market and sell our products
internationally to respond to customer requirements and market opportunities. We currently have manufacturing facilities in Mexico. Establishing
operations in any foreign country or region presents risks such as those described above as well as risks specific to the particular country
or region. In addition, until a payment history is established over time with customers in a new geographic area or region, the likelihood
of collecting receivables generated by such operations could be less than our expectations. As a result, there is a greater risk that
the reserves set with respect to the collection of such receivables may be inadequate. If our operations in any foreign country are unsuccessful,
we could incur significant losses and we may not achieve profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, changes in policies or laws of the
United States or foreign governments resulting in, among other things, changes in regulations and the approval process, higher taxation,
currency conversion limitations, restrictions on fund transfers or the expropriation of private enterprises, could reduce the anticipated
benefits of our international expansion. If we fail to realize the anticipated revenue growth of our future international operations,
our business and operating results could suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to generate revenue will be
diminished if we or our partners are unable to obtain acceptable prices or an adequate level of reimbursement from third-party payors,
or our partners may face pricing pressure from private third-party payers, including customers, from rebates and restrictive reimbursement
practices.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, none of our products are reimbursed
by federal healthcare programs, such as Medicare and Medicaid, and we do not anticipate that they will be reimbursed by such programs
in the future. Our partner&#8217;s ability to commercialize our products successfully will depend in part on the extent to which appropriate
coverage and reimbursement levels for the cost of our products and related treatment are obtained from governmental authorities, private
health insurers and other organizations, such as health maintenance organizations, or HMOs. In the United States, governmental and private
payors have limited the growth of health care costs through price regulation or controls, competitive pricing programs and drug rebate
programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is significant uncertainty concerning third-party
coverage and reimbursement of newly approved medical products. Third-party payors are increasingly challenging the prices charged for
medical products and services. Also, the trend toward managed healthcare in the United States and the concurrent growth of organizations
such as HMOs, as well as the &#8220;Affordable Care Act,&#8221; or any new healthcare laws may result in lower prices for or rejection
of our products. The cost containment measures that health care payors and providers are instituting and the effect of any healthcare
reform or changes to managed healthcare could materially and adversely affect our ability to generate revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States and some foreign jurisdictions,
there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our partner&#8217;s
abilities to sell our products profitably, and thus lead to decreased demand for our products and revenues for us. We were able to negotiate
minimum purchase requirements in certain of our third-party distributor agreements. However, we have limited control over purchases by
our distributors, to meet the minimum purchase thresholds or above the minimum purchase thresholds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Increasingly, private health insurance companies
and self-insured employers have been raising co-payments required from beneficiaries and looking for other ways to shift more of the cost
burden to manufacturers and patients. This cost shifting has given consumers greater control of medication choices, as they pay for a
larger portion of their prescription costs and may cause consumers to favor lower cost generic alternatives to branded pharmaceuticals.
Additionally, patients continue to face cost reduction pressures that may cause them to curtail their use of, or seek reimbursement for,
our products, to negotiate reduced fees or other concessions or to delay payment. Third-party payors may reduce or limit reimbursement
for our products in the future, such as by withdrawing their coverage policies, canceling any future contracts, reviewing and adjusting
the rate of reimbursement, or imposing limitations on coverage. Any such changes could negatively impact the sales of our products by
our partners, and therefore, have a material adverse effect on our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to generate revenue will be
diminished if we or our partners are unable to manage customer product substitutions for our prescription products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Similar to other pharmaceutical companies, patients
are increasingly seeking lower-cost substitutes to our products. Even if our patients have a prescription for our product, the pharmacist
may recommend a less expensive product even if that product is less effective or designed for conditions different from what the patient
is seeking to treat. As a result, the patient may choose to abandon purchasing our prescribed product for a less expensive alternative
product resulting in a lost sale for our partners. If the number of consumers substituting our products increases, it could have a material
adverse effect on sales of our products by our partners, and therefore, our revenues, financial position, cash flows and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to obtain, or experience significant
delays in obtaining, additional regulatory clearances or approvals to market our current or future products, we may be unable to commercialize
these products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The developing, testing, manufacturing, marketing
and selling of medical technology products is subject to extensive regulation by numerous governmental authorities in the United States
and other countries. The process of obtaining regulatory clearance and approval of medical technology products is costly and time consuming.
Even though their underlying product formulations may be the same or similar, our products are subject to different regulations and approval
processes depending upon their intended use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA generally clears marketing of a medical
device through the 510(k) pre-market clearance process if it is demonstrated the new product has the same intended use and the same or
similar technological characteristics as another legally marketed Class&#160;II device, such as a device already cleared by the FDA through
the 510(k) premarket notification process, and otherwise meets the FDA&#8217;s requirements. Product modifications, including labeling
the product for a new intended use, may require the submission of a new 510(k) clearance and FDA approval before the modified product
can be marketed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we do not know whether the necessary
approvals or clearances will be granted or delayed for future products. The FDA could request additional information, changes to product
formulation(s) or clinical testing that could adversely affect the time to market and sale of products as drugs. If we do not obtain the
requisite regulatory clearances and approvals, we will be unable to commercialize our products and may never recover any of the substantial
costs we have invested in the development of HOCl.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Distribution of our products outside the United
States is subject to extensive government regulation. These regulations, including the requirements for approvals or clearance to market,
the time required for regulatory review and the sanctions imposed for violations, vary from country to country. We do not know whether
we will obtain regulatory approvals in such countries or that we will not be required to incur significant costs in obtaining or maintaining
these regulatory approvals. In addition, the export by us of certain of our products that have not yet been cleared for domestic commercial
distribution may be subject to FDA export restrictions. Failure to obtain necessary regulatory approvals, the restriction, suspension
or revocation of existing approvals or any other failure to comply with regulatory requirements would have a material adverse effect on
our future business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our products do not gain market acceptance,
our business will suffer because we might not be able to fund future operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A number of factors may affect the market acceptance
of our products or any other products we develop or acquire, including, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">the price of our products relative to other products for the same or similar treatments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">the perception by patients, physicians and other members of the healthcare community of the effectiveness and safety of our products for their indicated applications and treatments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">changes in practice guidelines and the standard of care for the targeted indication;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">our ability to fund our sales and marketing efforts; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">the effectiveness of our sales and marketing efforts or our partners&#8217; sales and marketing efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to effectively promote and sell any
approved products will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive price
and our ability to obtain sufficient third-party coverage or reimbursement, if any. In addition, our efforts to educate the medical community
on the benefits of our product candidates may require significant resources, may be constrained by FDA rules and policies on product promotion,
and may never be successful. If our products do not gain market acceptance, we may not be able to fund future operations, including developing,
testing and obtaining regulatory approval for new product candidates and expanding our sales and marketing efforts for our approved products,
which would cause our business to suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our competitors develop products with
similar characteristics to HOCl, we may need to modify or alter our business strategy, which may delay the achievement of our goals.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competitors have and may continue to develop products
with similar characteristics to HOCl. Such similar products marketed by larger competitors can hinder our or our partners&#8217; efforts
to penetrate the market. As a result, we may be forced to modify or alter our business and regulatory strategy and sales and marketing
plans, as a response to changes in the market, competition and technology limitations, among others. Such modifications may pose additional
delays in achieving our goals.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on a number of key customers who
may not consistently purchase our products in the future and if we lose any one of these customers, our revenues may decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we have a significant number of customers
in each of the geographic markets that we operate in, we rely on certain key customers for a significant portion of our revenues. For
the year ended March 31, 2022 one customer represented 21%, one customer represented 17%, and one customer represented 10% of net revenues.
For the year ended March 31, 2021, one customer represented 32%, and one customer represented 15% of net revenues. In the future, a small
number of customers may continue to represent a significant portion of our total revenues in any given period. These customers may not
consistently purchase our products at a particular rate over any subsequent period. The loss of any of these customers could adversely
affect our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Negative economic conditions increase the
risk that we could suffer unrecoverable losses on our customers&#8217; accounts receivable which would adversely affect our financial
results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We grant credit to our business customers, which
are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. We maintain
allowances for potential credit losses. At March 31, 2022, one customer represented 20% of the Company&#8217;s net accounts receivable
balance, one customer represented 15% of the Company&#8217;s net accounts receivable balance, and one customer represented 14% of the
Company&#8217;s net accounts receivable balance. At March 31, 2021, three customers each and individually represented more than 10% of
net accounts receivable balance. While we believe we have a varied customer base and have experienced strong collections in the past,
if current economic conditions disproportionately impact any one of our key customers, including reductions in their purchasing commitments
to us or their ability to pay their obligations, it could have a material adverse effect on our revenues and liquidity. We have not purchased
insurance on our accounts receivable balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with ongoing regulatory
requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal
from the market.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory approvals or clearances that we currently
have and that we may receive in the future are subject to limitations on the indicated uses for which the products may be marketed, and
any future approvals could contain requirements for potentially costly post-marketing follow-up studies. If the FDA determines that our
promotional materials or activities constitute promotion of an unapproved use or we otherwise fail to comply with FDA regulations, we
may be subject to regulatory enforcement actions, including warning letters, injunctions, seizures, civil fines or criminal penalties.
In addition, the manufacturing, labeling, packaging, adverse event reporting, storing, advertising, promoting, distributing and record-keeping
for approved products are subject to extensive regulation. We are subject to continued supervision by European regulatory agencies relating
to our CE markings and are required to report any serious adverse incidents to the appropriate authorities. Our manufacturing facilities,
processes and specifications are subject to periodic inspection by the FDA, Mexican and other regulatory authorities and, from time to
time, we may receive notices of deficiencies from these agencies as a result of such inspections. Our failure to continue to meet regulatory
standards or to remedy any deficiencies could result in restrictions being imposed on our products or manufacturing processes, fines,
suspension or loss of regulatory approvals or clearances, product recalls, termination of distribution, product seizures or the need to
invest substantial resources to comply with various existing and new requirements. In the more egregious cases, criminal sanctions, civil
penalties, disgorgement of profits or closure of our manufacturing facilities are possible. The subsequent discovery of previously unknown
problems with HOC1, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of our
products, and could include voluntary or mandatory recall or withdrawal of products from the market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New government regulations may be enacted and
changes in FDA policies and regulations and, their interpretation and enforcement, could prevent or delay regulatory approval of our products.
We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative
action, either in the United States or abroad. Therefore, we do not know whether we will be able to continue to comply with any regulations
or that the costs of such compliance will not have a material adverse effect on our future business, financial condition, and results
of operations. If we are not able to maintain regulatory compliance, we will not be permitted to market our products and our business
would suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may experience difficulties in manufacturing
our products, which could prevent us from commercializing one or more of our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The machines used to manufacture our products
are complex, use complicated software and must be monitored by highly trained engineers. Slight deviations anywhere in our manufacturing
process, including quality control, labeling, and packaging, could lead to a failure to meet the specifications required by the FDA, the
Environmental Protection Agency, European notified bodies, Mexican regulatory agencies and other foreign regulatory bodies, which may
result in lot failures or product recalls. If we are unable to obtain quality internal and external components, mechanical and electrical
parts, if our software contains defects or is corrupted, or if we are unable to attract and retain qualified technicians to manufacture
our products, our manufacturing output of HOC1, or any other product candidate based on our platform that we may develop, could fail to
meet required standards, our regulatory approvals could be delayed, denied or revoked, and commercialization of one or more of our products
may be delayed or foregone. Manufacturing processes that are used to produce the smaller quantities of HOC1-based products needed for
clinical tests and current commercial sales may not be successfully scaled up to allow production of significant commercial quantities.
Any failure to manufacture our products to required standards on a commercial scale could result in reduced revenues, delays in generating
revenue and increased costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our competitive position depends on our
ability to protect our intellectual property and our proprietary technologies.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to compete and to achieve and maintain
profitability depends on our ability to protect our intellectual property and proprietary technologies. We currently rely on a combination
of patents, patent applications, trademarks, trade secret laws, confidentiality agreements, license agreements and invention assignment
agreements to protect our intellectual property rights. We also rely upon unpatented know-how and continuing technological innovation
to develop and maintain our competitive position. These measures may not be adequate to safeguard our HOC1 technology. If we do not protect
our rights adequately, third parties could use our technology, and our ability to compete in the market would be reduced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our pending patent applications and any patent
applications we may file in the future may not result in issued patents, and we do not know whether any of our in-licensed patents or
any additional patents that might ultimately be issued by the U.S.&#160;Patent and Trademark Office or foreign regulatory body will protect
our HOC1 technology. Any claims that are issued may not be sufficiently broad to prevent third parties from producing competing substitutes
and may be infringed, designed around, or invalidated by third parties. Even issued patents may later be found to be invalid or may be
modified or revoked in proceedings instituted by third parties before various patent offices or in courts. For example, our European patent
that was initially issued on May 30, 2007 was revoked by the Opposition Division of the European Patent Office in December 2009 following
opposition proceedings instituted by a competitor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The degree of future protection for our proprietary
rights is more uncertain in part because legal means afford only limited protection and may not adequately protect our rights, and we
will not be able to ensure that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">we were the first to invent the inventions described in patent applications;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">we were the first to file patent applications for inventions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">others will not independently develop similar or alternative technologies or duplicate our products without infringing our intellectual property rights;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">any patents licensed or issued to us will provide us with any competitive advantages;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">we will develop proprietary technologies that are patentable; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">the patents of others will not have an adverse effect on our ability to do business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The policies we use to protect our trade secrets
may not be effective in preventing misappropriation of our trade secrets by others. In addition, confidentiality and invention assignment
agreements executed by our employees, consultants and advisors may not be enforceable or may not provide meaningful protection for our
trade secrets or other proprietary information in the event of unauthorized use or disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that the steps we have taken
will prevent the misappropriation and use of our intellectual property in the United States, or in foreign countries where the laws may
not protect our proprietary rights as fully as in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may face intellectual property infringement
claims that could be time-consuming, costly to defend and could result in our loss of significant rights and, in the case of patent infringement
claims, the assessment of treble damages.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On occasion, we may receive notices of claims
of infringement, misappropriation, or misuse of other parties&#8217; proprietary rights. We may have disputes regarding intellectual property
rights with the parties that have licensed those rights to us. We may also initiate claims to defend our intellectual property. Intellectual
property litigation, regardless of its outcome, is expensive and time-consuming, and could divert management&#8217;s attention from our
business and have a material negative effect on our business, operating results, or financial condition. In addition, the outcome of such
litigation may be unpredictable. If there is a successful claim of infringement against us, we may be required to pay substantial damages,
including treble damages if we were to be found to have willfully infringed a third party&#8217;s patent, to the party claiming infringement,
develop non-infringing technology, stop selling our products or using technology that contains the allegedly infringing intellectual property
or enter into royalty or license agreements that may not be available on acceptable or commercially practical terms, if at all. Our failure
to develop non-infringing technologies or license the proprietary rights on a timely basis could harm our business. In addition, modifying
our products to exclude infringing technologies could require us to seek re-approval or clearance from various regulatory bodies for our
products, which would be costly and time consuming. Also, we may be unaware of pending patent applications that relate to our technology.
Parties making infringement claims on future issued patents may be able to obtain an injunction that would prevent us from selling our
products or using technology that contains the allegedly infringing intellectual property, which could harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We could be required to indemnify third
parties for alleged intellectual property infringement, which could cause us to incur significant costs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our distribution agreements contain commitments
to indemnify our distributors against liability arising from infringement of third-party intellectual property, such as patents. We may
be required to indemnify our customers for claims made against them or to contribute to license fees they are required to pay. If we are
forced to indemnify for claims or to pay license fees, our business and financial condition could be substantially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our international operations are subject
to trade policies and trade agreements and unfavorable changes could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have significant international operations in
Mexico and Europe, and we manufacture products for export in Mexico. There may be changes to existing trade agreements, like the, the
USMCA, which went to effect on July 1, 2020, greater restrictions on free trade generally, and significant increases in tariffs on goods
imported into the United States, particularly tariffs on products manufactured in Mexico, among other possible changes. Any changes to
USMCA (or subsequent trade agreements) could impact our operations in countries where we manufacture or sell products or source components,
or materials, which could adversely affect our operating results and our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our sales in international markets subject
us to foreign currency exchange and other risks and costs which could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A substantial portion of our revenues are derived
from outside the United States, primarily from Mexico and Europe. We anticipate that revenues from international customers will continue
to represent a substantial portion of our revenues for the foreseeable future. Because we generate revenues in foreign currencies, we
are subject to the effects of exchange rate fluctuations. The functional currency of our Mexican subsidiary is the Mexican Peso and the
functional currency of our Netherlands subsidiary is the Euro. For the preparation of our consolidated financial statements, the financial
results of our foreign subsidiaries are translated into U.S.&#160;dollars using average exchange rates during the applicable period. If
the U.S.&#160;dollar appreciates against the Mexican Peso or the Euro, as applicable, the revenues we recognize from sales by our subsidiaries
will be adversely impacted. Foreign exchange gains or losses as a result of exchange rate fluctuations in any given period could harm
our operating results and negatively impact our revenues. Additionally, if the effective price of our products were to increase as a result
of fluctuations in foreign currency exchange rates, demand for our products could decline and adversely affect our results of operations
and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The markets in which we operate are highly
competitive and subject to rapid technological change. If our competitors are better able to develop and market products that are less
expensive or more effective than any products that we may develop, our commercial opportunity may be reduced or eliminated.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends, in part, upon our ability
to stay at the forefront of technological change and to maintain a competitive position. We compete with large healthcare, pharmaceutical
and biotechnology companies, along with smaller or early-stage companies that have collaborative arrangements with larger pharmaceutical
companies, academic institutions, government agencies and other public and private research organizations. Many of our competitors have
significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical
trials, obtaining regulatory approvals and marketing approved products than we do. Our competitors may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">develop and patent processes or products earlier than we will;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">develop and commercialize products that are less expensive or more efficient than any products that we may develop;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">obtain regulatory approvals for competing products more rapidly than we will; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">improve upon existing technological approaches or develop new or different approaches that render our technology or products obsolete or non-competitive.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, we may not be able to successfully
commercialize any future products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The success of our research and development
efforts may depend on our ability to find suitable collaborators to fully exploit our capabilities. If we are unable to establish collaborations
or if these future collaborations are unsuccessful, our research and development efforts may be unsuccessful, which could adversely affect
our results of operations and financial condition.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An important element of our business strategy
is to enter into collaborative or license arrangements under which we license our HOC1 technology to other parties for development and
commercialization. We expect to seek collaborators for our potential products because of the expense, effort and expertise required to
conduct clinical trials and further develop those potential product candidates. Because collaboration arrangements are complex to negotiate,
we may not be successful in our attempts to establish these arrangements. If we need third party assistance in identifying and negotiating
one or more acceptable arrangements, it might be costly. Also, we may not have products that are desirable to other parties, or we may
be unwilling to license a potential product because the party interested in it is a competitor. The terms of any arrangements that we
establish may not be favorable to us. Alternatively, potential collaborators may decide against entering into an agreement with us because
of our financial, regulatory or intellectual property position or for scientific, commercial or other reasons. If we are unable to establish
collaborative agreements, we may not be able to develop and commercialize new products, which would adversely affect our business and
our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for any of these collaboration or license
arrangements to be successful, we must first identify potential collaborators or licensees whose capabilities complement and integrate
well with ours. We may rely on these arrangements for not only financial resources, but also for expertise or economies of scale that
we expect to need in the future relating to clinical trials, manufacturing, sales and marketing, and for licensing technology rights.
However, it is likely that we will not be able to control the amount and timing or resources that our collaborators or licensees devote
to our programs or potential products. If our collaborators or licensees prove difficult to work with, are less skilled than we originally
expected, or do not devote adequate resources to the program, the relationship will not be successful. If a business combination involving
a collaborator or licensee and a third party were to occur, the effect could be to diminish, terminate or cause delays in development
of a potential product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to comply with broad and
complex federal and state fraud and abuse laws, including state and federal anti-kickback laws, we could face substantial penalties and
our products could be excluded from government healthcare programs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to various federal and state laws
pertaining to healthcare fraud and abuse, which include, among other things, &#8220;anti-kickback&#8221; laws that prohibit payments to
induce the referral of products and services, and &#8220;false claims&#8221; statutes that prohibit the fraudulent billing of federal
healthcare programs. Our operations are subject to the Federal Anti-Kickback Statute, a criminal statute that, subject to certain statutory
exceptions, prohibits any person from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly,
to induce or reward a person either (i)&#160;for referring an individual for the furnishing of items or services for which payment may
be made in whole or in part by a government healthcare program such as Medicare or Medicaid, or (ii)&#160;for purchasing, leasing, ordering
or arranging for or recommending the purchasing, leasing or ordering of an item or service for which payment may be made under a government
healthcare program. Because of the breadth of the Federal Anti-Kickback Statute, the Office of Inspector General of the U.S.&#160;Department
of Health and Human Services, was authorized to adopt regulations setting forth additional exceptions to the prohibitions of the statute
commonly known as &#8220;safe harbors.&#8221; If all of the elements of an applicable safe harbor are fully satisfied, an arrangement
will not be subject to prosecution under the Federal Anti-Kickback Statute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, if there is a change in law, regulation
or administrative or judicial interpretations of these laws, we may have to change our business practices or our existing business practices
could be challenged as unlawful, which could have a negative effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Healthcare fraud and abuse laws are complex, and
even minor, inadvertent irregularities can potentially give rise to claims that a statute or regulation has been violated. The frequency
of suits to enforce these laws has increased significantly in recent years and has increased the risk that a healthcare company will have
to defend a false claim action, pay fines or be excluded from the Medicare, Medicaid or other federal and state healthcare programs as
a result of an investigation arising out of such action. We cannot guarantee that we will not become subject to such litigation. Any violations
of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could harm our reputation,
be costly to defend and divert management&#8217;s attention from other aspects of our business. Similarly, if the physicians or other
providers or entities with which we do business are found to have violated abuse laws, they may be subject to sanctions, which could also
have a negative impact on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to maintain sufficient
product liability insurance to cover claims against us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product liability insurance for the healthcare
industry is generally expensive to the extent it is available at all. We may not be able to maintain such insurance on acceptable terms
or be able to secure increased coverage if the commercialization of our products progresses, nor can we be sure that existing or future
claims against us will be covered by our product liability insurance. Moreover, the existing coverage of our insurance policy or any rights
of indemnification and contribution that we may have may not be sufficient to offset existing or future claims. A successful claim against
us with respect to uninsured liabilities or in excess of insurance coverage and not subject to any indemnification or contribution could
have a material adverse effect on our future business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If any of our third-party
contractors fail to perform their responsibilities to comply with FDA rules and regulations, the manufacture, marketing and sales of our
products could be delayed, which could decrease our revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Supplying the market
with our HOC1 technology products requires us to manage relationships with an increasing number of collaborative partners, suppliers and
third-party contractors. As a result, our success depends partially on the success of these third parties in performing their responsibilities
to comply with FDA rules and regulations. Although we pre-qualify our contractors and we believe that they are fully capable of performing
their contractual obligations, we cannot directly control the adequacy and timeliness of the resources and expertise that they apply to
these activities. For example, we and our suppliers are required to comply with the FDA&#8217;s quality system regulations, which cover
the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping
of our products. The FDA enforces the quality system regulation through inspections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If any of our partners
or contractors fail to perform their obligations in an adequate and timely manner or fail to comply with the FDA&#8217;s rules and regulations,
including failure to comply with quality systems regulations or a corrective action submitted to the FDA after notification by the FDA
of a deficiency is deemed insufficient, then the manufacture, marketing and sales of our products could be delayed. Our products could
be detained or seized, the FDA could order a recall, or require our partner to replace or offer refunds for our products. The FDA could
also require our partner, and depending on our agreement with our partner, us, to notify healthcare professionals and others that the
products present unreasonable risks of substantial harm to the public health. If any of these events occur, the manufacture, marketing
and sales of our products could be delayed which could decrease our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If we fail to comply
with the FDA&#8217;s rules and regulations and are subject to an FDA recall as part of an FDA enforcement action, the associated costs
could have a material adverse effect on our business, financial position, results of operations and cash flows.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our Company, our products,
the manufacturing facilities for our products, the distribution of our products, and our promotion and marketing materials are subject
to strict and continual review and periodic inspection by the FDA and other regulatory agencies for compliance with pre-approval and post-approval
regulatory requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If we fail to comply
with the FDA&#8217;s rules and regulations, we could be subject to an enforcement action by the FDA. The FDA could undertake regulatory
actions, including seeking a consent decree, recalling or seizing our products, ordering a total or partial shutdown of production, delaying
future marketing clearances or approvals, and withdrawing or suspending certain of our current products from the market. A product recall,
restriction, or withdrawal could result in substantial and unexpected expenditures, destruction of product inventory, and lost revenues
due to the unavailability of one or more of our products for a period of time, which could reduce profitability and cash flow. In addition,
a product recall or withdrawal could divert significant management attention and financial resources. If any of our products are subject
to an FDA recall, we could incur significant costs and suffer economic losses. Production of our products could be suspended and we could
be required to establish inventory reserves to cover estimated inventory losses for all work-in-process and finished goods related to
products we, or our third-party contractors, manufacture. A recall of a material amount of our products could have a significant, unfavorable
impact on our future gross margins.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>If our products
fail to comply with FDA and other governmental regulations, or our products are deemed defective, we may be required to recall our products
and we could suffer adverse public relations that could adversely impact our sales, operating results, and reputation which would adversely
affect our business operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We may be exposed to
product recalls, including voluntary recalls or withdrawals, and adverse public relations if our products are alleged to cause injury
or illness, or if we are alleged to have mislabeled or misbranded our products or otherwise violated governmental regulations. Governmental
authorities can also require product recalls or impose restrictions for product design, manufacturing, labeling, clearance, or other issues.
For the same reasons, we may also voluntarily elect to recall, restrict the use of a product or withdraw products that we consider below
our standards, whether for quality, packaging, appearance or otherwise, in order to protect our brand reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Product recalls, product
liability claims, even if unmerited or unsuccessful, or any other events that cause consumers to no longer associate our brand with high
quality and safe products may also result in adverse publicity, hurt the value of our brand, harm our reputation among our customers and
other healthcare professionals who use or recommend the products, lead to a decline in consumer confidence in and demand for our products,
and lead to increased scrutiny by federal and state regulatory agencies of our operations, any of which could have a material adverse
effect on our brand, business, performance, prospects, value, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our inability to raise additional capital
on acceptable terms in the future may cause us to curtail certain operational activities, including regulatory trials, sales and marketing,
and international operations, in order to reduce costs and sustain the business, and such inability would have a material adverse effect
on our business and financial condition.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect capital outlays and operating expenditures
to increase over the next several years as we work to expand our sales force, conduct regulatory trials, commercialize our products and
expand our infrastructure. We may need to raise additional capital in order to, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">increase our sales and marketing efforts to drive market adoption and address competitive developments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">sustain commercialization of our current products or new products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">acquire or license technologies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">develop new products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">expand our manufacturing capabilities; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">finance capital expenditures and our general and administrative expenses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our present and future funding requirements will
depend on many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">the level of research and development investment required to maintain and improve our technology position;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">our efforts to acquire or license complementary technologies or acquire complementary businesses;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">changes in product development plans needed to address any difficulties in commercialization;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">competing technological and market developments;&#160;and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">changes in regulatory policies or laws that affect our operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we raise additional funds by issuing equity
securities, it will result in dilution to our stockholders. Any equity securities issued also may provide for rights, preferences or privileges
senior to those of holders of our common stock. If we raise additional funds by issuing debt securities, these debt securities would have
rights, preferences and privileges senior to those of holders of our common stock, and the terms of the debt securities issued could impose
significant restrictions on our operations. If we raise additional funds through collaborations or licensing arrangements, we might be
required to relinquish significant rights to our technologies or products, or grant licenses on terms that are not favorable to us. A
failure to obtain adequate funds may cause us to curtail certain operational activities, including regulatory trials, sales and marketing,
and international operations, in order to reduce costs and sustain our business, and would have a material adverse effect on our business
and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our information technology and infrastructure
may be breached or attacked.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of our business, we collect
and store a limited amount of sensitive data, including intellectual property, our proprietary business information and that of our customers,
suppliers, business partners, and personally identifiable information of our customers and employees, in our data centers and on our networks.
The secure processing, maintenance, and transmission of this information is critical to our operations and business strategy. Despite
our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee
error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed,
publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings,
liability under laws that protect the privacy of personal information, and regulatory penalties, disrupt our operations and the services
we provide to customers, and damage our reputation, and cause a loss of confidence in our products and services, which could adversely
affect our business, revenues and competitive position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our common stock may
be volatile, and the value of your investment could decline significantly.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading price for our common stock has been,
and we expect it to continue to be, volatile. The price at which our common stock trades depends upon a number of factors, including our
historical and anticipated operating results, our financial situation, announcements of new products by us or our competitors, our ability
or inability to raise the additional capital we may need and the terms on which we raise it, and general market and economic conditions.
Some of these factors are beyond our control. Broad market fluctuations may lower the market price of our common stock and affect the
volume of trading in our stock, regardless of our financial condition, results of operations, business or prospects. It is impossible
to assure you that the market price of our shares of common stock will not fall in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our operating results may fluctuate, which
could cause our stock price to decrease.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fluctuations in our operating results may lead
to fluctuations, including declines, in our share price. Our operating results and our share price may fluctuate from period to period
due to a variety of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">demand by physicians, other medical staff and patients for our HOC1-based products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">reimbursement decisions by third-party payors and announcements of those decisions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">clinical trial results published by others in our industry and publication of results in peer-reviewed journals or the presentation at medical conferences;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">the inclusion or exclusion of our HOC1-based products in large clinical trials conducted by others;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">actual and anticipated fluctuations in our quarterly financial and operating results;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">developments or disputes concerning our intellectual property or other proprietary rights;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">issues in manufacturing our product candidates or products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">new or less expensive products and services or new technology introduced or offered by our competitors or by us;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">the development and commercialization of product enhancements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">changes in the regulatory environment;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">delays in establishing our sales force or new strategic relationships;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">costs associated with collaborations and new product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">introduction of technological innovations or new commercial products by us or our competitors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">litigation or public concern about the safety of our product candidates or products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">changes in recommendations of securities analysts or lack of analyst coverage;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">failure to meet analyst expectations regarding our operating results;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">additions or departures of key personnel; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">general market conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Variations in the timing of our future revenues
and expenses could also cause significant fluctuations in our operating results from period to period and may result in unanticipated
earning shortfalls or losses. In addition, The Nasdaq Capital Market, in general, and the market for life sciences companies, in particular,
have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance
of those companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Anti-takeover provisions in our certificate
of incorporation and bylaws and under Delaware law may make it more difficult for stockholders to change our management and may also make
a takeover difficult.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate documents and Delaware law contain
provisions that limit the ability of stockholders to change our management and may also enable our management to resist a takeover. These
provisions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">the ability of our Board of Directors to issue and designate, without stockholder approval, the rights of up to 714,286 shares of convertible preferred stock, which rights could be senior to those of common stock;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">limitations on persons authorized to call a special meeting of stockholders; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">advance notice procedures required for stockholders to make nominations of candidates for election as directors or to bring matters before meetings of stockholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to Section 203 of the Delaware
General Corporation Law, which, subject to certain exceptions, prohibits &#8220;business combinations&#8221; between a publicly-held Delaware
corporation and an &#8220;interested stockholder,&#8221; which is generally defined as a stockholder who became a beneficial owner of
15% or more of a Delaware corporation&#8217;s voting stock for a three-year period following the date that such stockholder became an
interested stockholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These provisions might discourage, delay or prevent
a change of control in our management. These provisions could also discourage proxy contests and make it more difficult for you and other
stockholders to elect directors and cause us to take other corporate actions. In addition, the existence of these provisions, together
with Delaware law, might hinder or delay an attempted takeover other than through negotiations with our Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our stockholders may experience substantial
dilution in the value of their investment if we issue additional shares of our capital stock or other securities convertible into common
stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Restated Certificate of Incorporation, as
amended, allows us to issue up to 24,000,000 shares of our common stock and to issue and designate, without stockholder approval, the
rights of up to 714,286 shares of preferred stock. In the event we issue additional shares of our capital stock, dilution to our stockholders
could result. In addition, if we issue and designate a class of convertible preferred stock, these securities may provide for rights,
preferences or privileges senior to those of holders of our common stock. Additionally, if we issue preferred stock, it may convert into
common stock at a ratio of 1:1 or greater because our Restated Certificate of Incorporation, as amended, allows us to designate a conversion
ratio without limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shares issuable upon the conversion of warrants
or preferred stock or the exercise of outstanding options may substantially increase the number of shares available for sale in the public
market and depress the price of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, we had outstanding warrants
exercisable for an aggregate of 108,000 shares of our common stock at a weighted average exercise price of approximately $10.33 per share.
We also had units convertible into 46,000 shares of common stock at an exercise price of $11.25 per unit. In addition, as of March 31,
2022, options to purchase an aggregate of 466,000 shares of our common stock were outstanding at a weighted average exercise price of
$12.09 per share and a weighted average contractual term of 8.89 years. In addition, 982,000 shares of our common stock were available
on March 31, 2022 for future option grants under our 2016 Equity Incentive Plan and our 2021 Equity Incentive Plan. To the extent any
of these warrants or options are exercised and any additional options are granted and exercised, there will be further dilution to stockholders
and investors. Until the options and warrants expire, these holders will have an opportunity to profit from any increase in the market
price of our common stock without assuming the risks of ownership. Holders of options and warrants may convert or exercise these securities
at a time when we could obtain additional capital on terms more favorable than those provided by the options or warrants. The exercise
of the options and warrants will dilute the voting interest of the owners of presently outstanding shares by adding a substantial number
of additional shares of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed several registration statements
with the SEC, so that substantially all of the shares of our common stock which are issuable upon the exercise of outstanding warrants
and options may be sold in the public market. The sale of our common stock issued or issuable upon the exercise of the warrants and options
described above, or the perception that such sales could occur, may adversely affect the market price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160; <b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_005"></span>ITEM&#160;2.&#160;Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022, we have a corporate
office in Woodstock, Georgia, an office in Boulder, Colorado for our sales and marketing team, and our manufacturing facility in
Zapopan, Mexico. We currently lease the following material properties:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 61%"><span style="font-size: 10pt"><b>Location</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 12%"><span style="font-size: 10pt"><b>Rent per month</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left; vertical-align: bottom; width: 25%"><span style="font-size: 10pt"><b>Purpose</b></span></td></tr>
  <tr style="background-color: #EEEEEE">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">360 Molly Lane, Suite 150, Woodstock, GA &#160;&#160;&#160;&#160;30189</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">USD 5,507</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Principal executive office</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">5445 Conestoga Court, Unit 150, Boulder, CO 80301</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">USD 3,680</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Offices</span></td></tr>
  <tr style="vertical-align: top; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Industria Vidriera 81, &amp; 87 Zapopan Industrial Norte, Zapopan, Jalisco, 45135, Mexico</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">MXN 173,063</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Office, manufacturing</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Industria Maderera 124, 106, 115 &amp; 815 Zapopan Industrial Norte, Zapopan, Jalisco, 45135, Mexico</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">MXN 191,036</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Warehouse</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that our properties will be adequate
to meet our needs for at least the next 12 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_006"></span>ITEM&#160;3.&#160;Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be involved in legal matters arising in
the ordinary course of our business including matters involving proprietary technology. While management believes that such matters are
currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may
have a material adverse effect on our business, financial condition or results of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_007"></span>ITEM&#160;4.&#160;Mine Safety Disclosures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_008"></span>PART&#160;II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_009"></span>ITEM&#160;5.&#160;Market for Registrant&#8217;s Common Equity, Related
Stockholder Matters and Issuer Purchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Market Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is traded on The Nasdaq Capital
Market under the symbol &#8220;SNOA.&#8221; Previously, it traded under the symbol &#8220;OCLS&#8221; until December 6, 2016. Our common
stock has been trading since our initial public offering on January&#160;25, 2007.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of July 11, 2022, we had approximately 298
holders of record of our common stock. Holders of record include nominees who may hold shares on behalf of multiple owners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any cash dividends
on our common stock. We currently anticipate that we will retain all future earnings for the operation of our business and we do not currently
intend to pay any cash dividends on our common stock in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Securities Authorized for Issuance Under Equity
Compensation Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information required to be disclosed by Item
201(d) of Regulation S-K, &#8220;Securities Authorized for Issuance Under Equity Compensation Plans,&#8221; is incorporated herein by
reference. Refer to Item 12 of Part III of this annual report on Form 10-K for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Sales of Unregistered Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We did not issue any unregistered securities
during the year ended March 31, 2022 and through July 11, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_010"></span>ITEM&#160;6.&#160;Selected Financial Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a smaller reporting company, as defined by
Rule&#160;12b-2 of the Exchange Act and in Item&#160;10(f)(1) of Regulation&#160;S-K, we are electing scaled disclosure reporting obligations
and therefore are not required to provide the information requested by this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_011"></span>ITEM 7. &#160;Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of our consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America requires management to exercise
its judgment. We exercise considerable judgment with respect to establishing sound accounting policies and in making estimates and assumptions
that affect the reported amounts of our assets and liabilities, our recognition of revenues and expenses, and disclosure of commitments
and contingencies at the date of the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On an ongoing basis, we evaluate our estimates
and judgments. Areas in which we exercise significant judgment include, but are not necessarily limited to, our valuation of accounts
receivable, inventory, income taxes, equity transactions (compensatory and financing) and contingencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We base our estimates and judgments on a variety
of factors including our historical experience, knowledge of our business and industry, current and expected economic conditions, the
attributes of our products, the regulatory environment, and in certain cases, the results of outside appraisals. We periodically re-evaluate
our estimates and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are
necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we believe that the factors we evaluate
provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will
always be accurate. Since the determination of these estimates requires the exercise of judgment, actual results could differ from such
estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a Summary of Critical Accounting Policies,
please refer to Notes to Consolidated Financial Statements, Note 3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Continuing Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of the Year Ended March 31, 2022
and 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows our consolidated total
revenue and revenue by geographic region for the year ended March 31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Years Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 44%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,807</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,419</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,612</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(30%</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,095</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,976</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,881</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(65%</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Europe and Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,726</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,234</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(508</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7%</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,628</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,629</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,001</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(32%</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The decrease in United States revenues for the
year ended March 31, 2022 compared to the same period in the prior year of $1.6 million, is primarily the result of our transition from
a direct sales force to a distributor model for our dermatology and eye care prescription products in the United States. Under the old
direct sales model, our revenues were higher due to higher retail pricing than what we agreed to with the distributors. However, our operating
expenses are also much lower under this new arrangement as we do not have to manage a sales force, provide patient rebates or manage product
substitutions. Revenue for our animal health products declined slightly. Revenue for wound care products increased 19% from the prior
year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the asset purchase agreement and
arrangement we entered into on October 27, 2016 with Invekra,with our assistance Invekra built up their own manufacturing of HOCl products
and we manufactured products for Invekra at cost during the transition time. Invekra began their own manufacturing in November 2020. As
we previously disclosed, we expected our revenues to decline following the transition of Invekra towards their own manufacturing. Since
November 2020, we continue to process overflow orders for Invekra but we do so at market prices and at lower volumes. As a result of the
foregoing, Latin America revenue declined by $3.9 million during the year ended March 31, 2022 compared to the year ended March 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The decrease in Europe and Rest of the World revenues
for the year ended March 31, 2022 compared to the prior year was primarily the result of decreases in disinfectant sales in the Middle
East due to the pandemic receding and to a lesser extent a slight decline in European sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenue and Gross Profit</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of revenue and gross profit metrics are
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><i>(In thousands, except for percentages)</i></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Change</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>% Change</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 44%"><span style="font-size: 10pt">Cost of Revenue</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">8,635</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">12,070</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">(3,435</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)&#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">(28)%&#160;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Cost of Revenue as a % of Revenue</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">68%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">65%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3%&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Gross Profit</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">3,993</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">6,559</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(2,566</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(39)%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Gross Profit as a % of Revenue</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">32%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">35%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(3)%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross margin decrease of 3% for the year ended
March 31, 2022 compared to the year ended March 31, 2021 is a result of product mix and higher sales to distributors versus sales through
our direct sales force.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The research and development metrics are as follows:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><i>(In thousands, except for percentages)</i></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Change</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>% Change</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 44%"><span style="font-size: 10pt">Research and Development Expense</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">125</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">555</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">(430</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">(77)%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-size: 10pt">Research and Development Expense as a % of Revenue</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(2)%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended March 31, 2022, research and
development expenses decreased as a result the closure of our research and development facility in Seattle, Washington and its relocation
to our facility in Mexico.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selling, General and Administrative Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling, general and administrative expense
metrics are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><i>(In thousands, except for percentages)</i></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Change</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>% Change</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 44%"><span style="font-size: 10pt">Selling, General and Administrative Expense</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">9,755</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">9,453</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">302</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span style="font-size: 10pt">3%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-size: 10pt">Selling, General and Administrative Expense as a % of Revenue</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">77%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">50%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">27%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The increase in Selling, General and Administrative
expense for the year ended March 31, 2022 was primarily the result of an increase in our insurance premiums.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Interest (Expense) Income, net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest (expense) income, net was $(10,000) and
$4,000, respectively, for the years ended March 31, 2022 and March 31, 2021.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Forgiveness of PPP loan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On May 1,
2020, we received loan proceeds in the amount of $1,310,000&#160;under the Paycheck Protection Program (&#8220;PPP&#8221;), from Coastal
States Bank in Atlanta, Georgia. We used the loan amount for eligible purposes, such as payroll expenses. For the year ended March 31,
2022, we received approval for loan forgiveness in the amount of $723,000.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Expense, net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other expense, net for the year ended March 31,
2022 and 2021, was $394,000 and $594,000, respectively. The decrease in other expense, net relates primarily to a reduction in foreign
exchange losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gain on Sale of Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended March 31, 2022, we sold equipment
for a gain of $150,000. Gain on the sale of assets for the year ended March 31, 2021 was $137,000. We sold fixed assets no longer needed
after closing our Petaluma manufacturing facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Tax Benefit (Expense)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income tax benefit (expense) for the year ended
March 31, 2022 was $332,000 compared to $(713,000) for the year ended March 31, 2021. The increase in income tax benefit is the result
of the reversal of the valuation allowance for Mexico as the result of three years of taxable income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss from Continuing Operations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss from continuing operations for the year
ended March 31, 2022 and 2021, was $5,086,000 and $4,615,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Discontinued Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of Year ended March 31, 2022 and 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 24, 2020, we closed on an asset purchase
agreement with Infinity Labs SD, Inc. We decided to divest our Micromed business, resulting in a strategic shift that had a major effect
on our operations and financial results. Therefore, the divested Micromed operations meet the criteria to be reported as discontinued
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The related assets, liabilities, results of operations
and cash flows for our Micromed business are classified as discontinued operations for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The operations of the Micromed business included in discontinued operations
is summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: justify">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">214,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Selling general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">38,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Income from discontinued operations before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Gain on disposal of discontinued operations before income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">770,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Total income from discontinued operating, before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">893,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Income Tax benefit (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(228,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt">Income from discontinued operations, net of tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">665,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gain on disposal of discontinued operations for
the year ended March 31, 2021, includes $770,000 of gain primarily from the value of the customer base of Micromed partially offset by
a working capital adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides the net loss for
each period along with the computation of basic and diluted net income per share:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">Loss from continuing operations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(5,086</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,615</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Income from discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">665</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,086</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,950</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,653</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,996</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Loss per share from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.92</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.31</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Income per share from discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.33</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.92</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.97</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reported a net loss of $5,086,000 and $3,950,000
for the years ended March 31, 2022 and 2021, respectively. At March 31, 2022 and 2021, our accumulated deficit amounted to $184,363,000
and $179,277,000, respectively. As of March 31, 2022, we had cash and cash equivalents of $7,396,000 compared to $4,220,000 on March 31,
2021. Since our inception, substantially all of our operations have been financed through sales of equity securities. Other sources of
financing that we have used to date include our revenues, as well as various loans and the sale of certain assets to Invekra, Petagon,
MicroSafe and Infinity Labs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since April 1, 2021, substantially all of our
operations have been financed through the following transactions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-size: 10pt">Proceeds of $7,554,000 from sales on the ATM facility with HC Wainwright; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Proceeds of $217,000 from the exercise of stock options and warrants</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents a summary of our
consolidated cash flows for operating, investing and financing activities for the year ended March 31, 2022 and 2021 as well balances
of cash and cash equivalents and working capital:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Net cash provided by (used in):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: justify">Operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,248</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(3,378</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(99</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,308</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Effect of exchange rates on cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">127</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">211</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,176</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">529</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Cash and cash equivalents, beginning of the period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,220</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,691</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Cash and cash equivalents, end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,396</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 10pt">Working capital <sup>(1)</sup>, end of period</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,611</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,905</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Defined as current assets minus current liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, we had cash and cash equivalents
of $7,396,000 compared to $4,220,000 as of March 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities during the
year ended March 31, 2022 was $4,248,000, primarily due to a net loss of $5,086,000 and partially offset by an increase from accounts
receivable net provision for write-offs and returns and an increase of $900,000 from deferred revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities during the
year ended March 31, 2021 was $3,378,000, primarily due to a net loss of $3,950,000 for the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in investing activities for the
year ended March 31, 2022 was $99,000, primarily related to the purchase of property and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by investing activities for
the year ended March 31, 2021 was $388,000, primarily related to the proceeds from the sale of our Micromed division of $610,000 partially
offset by the purchase of equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities for
the year ended March 31, 2022 was $7,396,000 primarily related to proceeds of $7,554,000 from the sale of common stock on our At-the-Market
facility with HC Wainwright, proceeds of $216,000 from the exercise of stock options and warrants, partially offset by the payments on
PPP loan and long term debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities for
the year ended March 31, 2021 was $3,308,000, primarily related to proceeds from the exercise of stock options and warrants of $2,287,000,
and PPP loans of $1,310,000 partially offset by payments on long term debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect revenues to fluctuate and may incur
losses in the foreseeable future and may need to raise additional capital to pursue our product development initiatives, to penetrate
markets for the sale of our products and continue as a going concern. We cannot provide any assurances that we will be able to raise additional
capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that we have access to capital
resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, we cannot
provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the economic climate in the
U.S. deteriorates, our ability to raise additional capital could be negatively impacted. If we are unable to secure additional capital,
we may be required to take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations
and meet our obligations. These measures could cause significant delays in our continued efforts to commercialize our products, which
is critical to the realization of our business plan and our future operations. These matters raise substantial doubt about our ability
to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Capital Expenditures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently forecast capital expenditures in
order to execute on our business plan and maintain growth; however, the actual amount and timing of such capital expenditures will ultimately
be determined by the volume of business. We currently do not anticipate that a material amount will be purchased for the year ended March
31, 2023. If we purchase capital equipment, we expect to pay cash for those expenditures or to finance them through equipment leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Material Trends and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are exposed to risk from decline in foreign
currency for both the Euro and the Mexico Peso versus the US dollar. Most recently there has been a sharp decline in the Euro versus the
US Dollar which has impacted our financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As we have previously
discussed in our annual report on Form 10-K filed with the SEC on July 14, 2021, we face a substantial Mexico tax liability, intercompany
debt, unpaid technical assistance charges and accrued interest. These amounts are not due until 2027. At this time, management believes
there are sufficient assets on the balance sheet to more than cover any tax obligation without interrupting the Company&#8217;s operations
or business. We have engaged tax professionals to review all options to limit our exposure to these amounts and to proceed in a manner
that is most advantageous to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As the pandemic continues
to impact economies worldwide, we are closely watching inflation, increased volatility within financial markets, shipping costs, supply
chain issues and labor costs. At this time, the overall impact of these issues has been minimal. The potential impact to our business
operations, customer demand and supply chain due to increased shipping costs may ultimately impact sales. We continue to evaluate our
end-to-end supply chain and assess opportunities to refine the impact on sales. Currently, most of our customers pay for shipping expenses,
including increased shipping costs, if any. We have not yet faced labor shortages however it is possible we may have difficulties retaining
and finding qualified employees in a tight labor market in the future. Furthermore, overall inflation tendencies may put pressure on our
product pricing and/or costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We also closely monitor
overall economic conditions and consumer sentiment and the prospect of a recession in the United States which may impact our financial
results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from
these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the recoverability
of long-lived assets, the valuation allowance related to our deferred tax assets, valuation of equity and derivative instruments, debt
discounts, valuation of investments and the estimated amortization periods of upfront product licensing fees received from customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Off-Balance Sheet Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no off-balance sheet arrangements
that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_012"></span>ITEM&#160;7A.&#160;Quantitative and Qualitative Disclosures About
Market Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a smaller reporting company as defined by Rule&#160;12b-2
of the Exchange Act and in Item&#160;10(f)(1) of Regulation&#160;S-K, we are electing scaled disclosure reporting obligations and therefore
are not required to provide the information requested by this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_013"></span>ITEM&#160;8.&#160;Consolidated Financial Statements and Supplementary
Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Sonoma Pharmaceuticals, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Index to Consolidated Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 94%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#a_015"><span style="font-size: 10pt">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB No. <span id="xdx_905_edei--AuditorFirmId_c20210401__20220331_zPfadan0VEIi"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AuditorFirmId">215</ix:nonNumeric></span>)</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#fs2">Report of Independent Registered Public Accounting Firm</a> (PCAOB No. <span id="xdx_908_edei--AuditorFirmId_c20200401__20210331_zubafROEDlMb"><ix:nonNumeric contextRef="From2020-04-012021-03-31" name="dei:AuditorFirmId">688</ix:nonNumeric></span>)</td>
    <td>&#160; </td>
    <td style="text-align: center">F-2</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#a_016"><span style="font-size: 10pt">Consolidated Balance Sheets as of March 31, 2022 and 2021</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#a_017"><span style="font-size: 10pt">Consolidated Statements of Comprehensive Loss for the Years Ended March 31, 2022 and 2021</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#a_018"><span style="font-size: 10pt">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years Ended March 31, 2022 and 2021</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#a_019"><span style="font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended March 31, 2022 and 2021</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-7</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#a_020"><span style="font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_015"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders and Board of Directors of Sonoma Pharmaceuticals,
Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Consolidated Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance sheet of Sonoma
Pharmaceuticals, Inc. and Subsidiaries (the &#34;Company&#34;) as of March 31, 2022, and the related consolidated statements of comprehensive
loss, changes in stockholders' equity and cash flows for the year ended March 31, 2022, and the related notes (collectively referred to
as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects,
the financial position of the Company as of March 31, 2022, and the results of their operations and cash flows for the year ended March
31, 2022, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Substantial Doubt About the Company&#8217;s Ability to Continue
as a Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred
significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial
doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These consolidated financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audit.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audit in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control
over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit
also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall
presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Critical audit matters are matters arising from the current period
audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that:
(1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging,
subjective, or complex judgments. We determined that there are no critical audit matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <span id="xdx_909_edei--AuditorName_c20210401__20220331_z8kSCsiP1bJ3"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AuditorName">Frazier &amp; Deeter</ix:nonNumeric></span>, LLC</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company's auditor since 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_907_edei--AuditorLocation_c20210401__20220331_zTiR1JmL4E42"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AuditorLocation">Atlanta, Georgia</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 13, 2022</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 47; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="fs2"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Shareholders and Board of Directors of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sonoma Pharmaceuticals, Inc<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheet of Sonoma Pharmaceuticals, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of March 31, 2021, the related consolidated
statements of comprehensive loss<b>,</b> changes in stockholders&#8217; equity and cash flow for the year ended March 31, 2021 , and the
related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly,
in all material respects, the financial position of the Company as of March 31, 2021, and the results of its operations and its cash flow
for the year ended March 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Explanatory Paragraph &#8211; Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred
significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial
doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in
Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#34;PCAOB&#34;) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The critical audit matters communicated below
are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to
the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion
on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions
on the critical audit matters or on the accounts or disclosures to which they relate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Revenue Recognition from Contracts with Customers - Measurement
of the Transaction Price, including the Constraint on Variable Consideration for Rebates And Discounts</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Critical Audit Matter Description </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed in Note 3 to the consolidated financial
statements, the Company offers sales incentives and other programs that they may make available to certain customers, which are considered
to be a form of variable consideration. The Company maintains estimated accruals and allowances using the expected value method. Revenue
recognized varies depending on whether a patient is covered by insurance or is not covered by insurance. In addition, the Company may
incur a revenue deductions related to the use of the Company&#8217;s rebate program.<span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The principal considerations for our determination
that performing procedures relating to the identification of contractual terms in customer arrangements to determine the transaction price
is a critical audit matter are there was significant judgment by management in identifying contractual terms due to the volume and customized
nature of the Company&#8217;s customer arrangements. This in turn led to significant effort in performing our audit procedures which were
designed to evaluate whether the contractual terms used in the determination of the transaction price and the timing of revenue recognition
were appropriately identified and determined by management and to evaluate the reasonableness of management&#8217;s estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Addressing the matter involved performing procedures
and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>How We Addressed the Matter in Our Audit</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit procedures included, amongst others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>Testing the completeness and accuracy of management&#8217;s identification of the contractual terms by examining customer arrangements
on a test basis</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>Testing management&#8217;s process for determining the appropriate amount and timing of revenue recognition based on the contractual
terms identified in the customer arrangements</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>We evaluated whether the assumptions used in the estimates were reasonable, including performing lookback analysis, considering actual
historical rebates and discount percentages utilized as well as actual collection patterns</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>We performed ratio and disaggregated revenue analysis for the Company&#8217;s product and customer types, comparing reserve balances
to gross to net sales</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>We confirmed balances due to third party for rebate claims, which are billed to the Company after end user customers submission, in
order to perform an analysis on rebates/discounts recorded compared to the Company&#8217;s revenue recognition</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <span style="font-variant: small-caps">llp</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_906_edei--AuditorName_c20200401__20210331_zIeafZKvCkBk"><ix:nonNumeric contextRef="From2020-04-012021-03-31" name="dei:AuditorName">Marcum llp</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are uncertain as to the year we began serving
consecutively as the auditor of the Company&#8217;s financial statements; however, we are aware that we have been the Company&#8217;s
auditor consecutively since at least 2006.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_909_edei--AuditorLocation_c20200401__20210331_zMfNWMy2FeH9"><ix:nonNumeric contextRef="From2020-04-012021-03-31" name="dei:AuditorLocation">New York, NY</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 14, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_016"></span>Consolidated Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands, except share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" id="xdx_303_111_pn3n3_zXTuj3DyNYA6" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td id="xdx_496_20220331" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_495_20210331" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2022</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31, </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td></tr>
  <tr id="xdx_400_eus-gaap--AssetsAbstract_iB_zHZW7TvwOOfl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt"><b>ASSETS</b></span></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_iB_zlWsWebjEdv7" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Current assets:</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_maCzOC1_zzgqnK0JjQMc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 67%"><span style="font-size: 10pt">Cash and cash equivalents</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="width: 14%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,396</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 14%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,220</ix:nonFraction></span></td></tr>
  <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_i01I_maCzOC1_zea9G0KC4dZ5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Accounts receivable, net</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,407</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,806</ix:nonFraction></span></td></tr>
  <tr id="xdx_408_eus-gaap--InventoryNet_i01I_maCzOC1_zQZlZ383l8I8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Inventories, net</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,663</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,530</ix:nonFraction></span></td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_maCzOC1_zynbgc2BzLRa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Prepaid expenses and other current assets</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,746</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,218</ix:nonFraction></span></td></tr>
  <tr id="xdx_40D_ecustom--DeferredConsiderationNetCurrent_i01I_maCzOC1_zk8ahraRZpG9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Current portion of deferred consideration, net of discount</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="SNOA:DeferredConsiderationNetCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="SNOA:DeferredConsiderationNetCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">209</ix:nonFraction></span></td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrent_i01TI_mtCzOC1_maCzV01_zH4iTqSFrxWg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">Total current assets</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,430</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,983</ix:nonFraction></span></td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzV01_zjLNoVgI2NUc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Property and equipment, net</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">320</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">360</ix:nonFraction></span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzV01_z2pjagqqR3qc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Operating lease, right of use assets</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">559</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">769</ix:nonFraction></span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxAssetsNet_i01I_d0_maCzV01_zyvmSZxSHH4f" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt">Deferred tax asset</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">829</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2021-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td></tr>
  <tr id="xdx_409_ecustom--DeferredConsiderationNetNoncurrent_i01I_maCzV01_zY1yGAwTSAOb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Deferred consideration, net of discount, less current portion</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="SNOA:DeferredConsiderationNetNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">630</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="SNOA:DeferredConsiderationNetNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">763</ix:nonFraction></span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherAssetsNoncurrent_i01I_maCzV01_zVLQV3jZRBk7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Other assets</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112</ix:nonFraction></span></td></tr>
  <tr id="xdx_401_eus-gaap--Assets_i01TI_mtCzV01_zpg4Lmk6szT5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">Total assets</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,845</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,987</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zSiChV836dBb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt"><b>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesCurrentAbstract_iB_zK8drpDIBLY9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Current liabilities:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccountsPayableCurrent_i01I_maCzZZK_zGgZ6qiEX765" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Accounts payable</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,641</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,769</ix:nonFraction></span></td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_i01I_maCzZZK_zKBwmXyv2Hdf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Accrued expenses and other current liabilities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,843</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,154</ix:nonFraction></span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredRevenueCurrent_i01I_maCzZZK_zFqAYIDaoIlg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Deferred revenue</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,223</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></span></td></tr>
  <tr id="xdx_402_ecustom--ContractWithCustomerLiabilityCurrentInvekra_i01I_maCzZZK_z9KiJNA9SfGc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Deferred revenue Invekra</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="SNOA:ContractWithCustomerLiabilityCurrentInvekra" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="SNOA:ContractWithCustomerLiabilityCurrentInvekra" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52</ix:nonFraction></span></td></tr>
  <tr id="xdx_40E_eus-gaap--NotesPayableCurrent_i01I_d0_maCzZZK_zouIRNljlGI6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Current portion of debt-PPP</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2021-03-31" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">-</ix:nonFraction></span></td></tr>
  <tr id="xdx_40E_eus-gaap--OtherLongTermDebtCurrent_i01I_maCzZZK_zxLYFRCM7NBb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Short-term debt</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherLongTermDebtCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">688</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OtherLongTermDebtCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">596</ix:nonFraction></span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maCzZZK_zROj4G7btIn7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Operating lease liabilities</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">240</ix:nonFraction></span></td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesCurrent_i01TI_mtCzZZK_maCzqSH_zLkPjikZt1yh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">Total current liabilities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,819</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,078</ix:nonFraction></span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredRevenueNoncurrent_i01I_maCzqSH_zdnSJuDNnB0l" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Long-term deferred revenue Invekra</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">182</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></span></td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtNoncurrent_i01I_d0_maCzqSH_zpqwXQkJG5jf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Long-term debt, less current portion &#8211; PPP</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2022-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,310</ix:nonFraction></span></td></tr>
  <tr id="xdx_40B_ecustom--WithholdingTaxPayable_i01I_maCzqSH_z5YWoI7R6Dw7" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Withholding Tax Payable</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="SNOA:WithholdingTaxPayable" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,838</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="SNOA:WithholdingTaxPayable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,478</ix:nonFraction></span></td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCzqSH_zGMqM5vJqlC" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Operating lease liabilities, less current portion</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">529</ix:nonFraction></span></td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i01TI_mtCzqSH_maCzlhp_zCmEiGzS8nnd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">Total liabilities</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">$&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,148</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,624</ix:nonFraction></span></td></tr>
  <tr id="xdx_402_eus-gaap--CommitmentsAndContingencies_i01I_zGPUNB3h6C41" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Commitments and Contingencies (Note 12)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquityAbstract_iB_zQx0tMEDmjTj" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Stockholders&#8217; Equity</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i01I_d0_maCzOGJ_zcAONE67uGea" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-size: 10pt">Convertible preferred stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zwgv9RHsgiC8" title="Convertible preferred stock par value"><span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20210331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zRvTKfS5CLF8" title="Convertible preferred stock par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z3NUCUkGAPV3" title="Convertible preferred stock shares authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20210331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zl5gUXYWZDUa" title="Convertible preferred stock shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">714,286</ix:nonFraction></ix:nonFraction></span></span> shares authorized at March 31, 2022 and 2021, respectively, <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zCnGIoZBRC38" title="Convertible preferred stock shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pip0_do_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zgsYrEge8Wme" title="Convertible preferred stock shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_c20210331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z3K60wwPIBQl" title="Convertible preferred stock shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pip0_do_c20210331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zEAkXOInNYv1" title="Convertible preferred stock shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at March 31, 2022 and 2021, respectively</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></span></td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i01I_maCzOGJ_zdOLlfVifBdj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-size: 10pt">Common stock, $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20220331_z0ETOoyRaDvd" title="Common stock par value"><span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20210331_zV1hvZGeqmO7" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20220331_z4qnoIFgAO16" title="Common stock shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20210331_zVInwnSKerz7" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">24,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized at March 31, 2022 and 2021, respectively, <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pip0_c20220331_zzoecWmNEkz9" title="Common stock shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20220331_zGBYNnC09PTa" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,100,937</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pip0_c20210331_zxdURwYDnV8h" title="Common stock shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20210331_zMxaSxYONHTj" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,092,909</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at March 31, 2022 and 2021, respectively (Note 13)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_maCzOGJ_zwohJRGGgn74" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Additional paid-in capital</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">197,370</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189,217</ix:nonFraction></span></td></tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzOGJ_zhkCW9pKkNag" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Accumulated deficit</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">184,363</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">179,277</ix:nonFraction>)</span></td></tr>
  <tr id="xdx_408_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maCzOGJ_zkjfl7p8JNJ1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt"><span style="font-size: 10pt">Accumulated other comprehensive loss</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,312</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,579</ix:nonFraction>)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_i01TI_mtCzOGJ_maCzlhp_zn6siwEmUqp9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">Total stockholders&#8217; equity</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,697</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,363</ix:nonFraction></span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCzlhp_zatJKD7JqaIj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt"><span style="font-size: 10pt">Total liabilities and stockholders&#8217; equity</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,845</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,987</ix:nonFraction></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC., AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_017"></span>Consolidated Statements of Comprehensive Income
(Loss)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands, except per share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_pn3n3_zXHupuyGvGs4" summary="xdx: Statement - Consolidated Statements of Comprehensive (Loss) Income" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20210401_20220331" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20200401_20210331" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_maCzNbV_zduvmfKKdoK1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,628</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,629</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_msCzNbV_zT9hcKeBvks1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,635</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,070</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_iT_mtCzNbV_maCzU2m_zW2r7My5y9w3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Gross profit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,993</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,559</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zvfT4j8FNc9i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_maCz5ub_zrSsFq5NAyq" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">555</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCz5ub_zi9ia5hY4hX2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,755</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,453</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_mtCz5ub_msCzU2m_z9e1VrqeH4E4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,880</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,008</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_i01T_mtCzU2m_maILFCOzUuH_zhPivLOCC0Le" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,887</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,449</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--InterestIncomeExpenseNet_i01_maILFCOzUuH_z6asdf59pVw" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Interest income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maILFCOzUuH_zOVdF1T8Rgc1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forgiveness of PPP Loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">723</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0224">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherOperatingIncomeExpenseNet_i01_maILFCOzUuH_zgOqBCY7Ttil" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">394</ix:nonFraction></td><td style="text-align: left">)&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">594</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--GainLossOnDispositionOfAssets_i01_maILFCOzUuH_zgIJ7pemInKa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gain on sale of assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">137</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtILFCOzUuH_maILFCOz9nj_zO9rQFp0XLci" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Loss from continuing operations before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,418</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,902</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_i01N_di_msILFCOz9nj_zSDBcod9BmIi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Income tax benefit (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">332</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">713</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_i01T_mtILFCOz9nj_maNILzgqh_zWCkHOE59z13" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Loss from continuing operations, net of tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,615</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_i01_d0_maNILzgqh_zJ6jYEJpDdU2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Income from discontinued operations, net of tax</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">665</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_i01T_mtNILzgqh_zmDT5bSv76oa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,950</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--EarningPerShareBasicAndDilutedAbstract_i01B_z0NRytL2sqF7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss per share: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IncomeLossFromContinuingOperationPerBasicAndDilutedShare_i02_pip0_z399gFi3WTMh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Continuing operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">1.92</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">2.31</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_i02_pip0_d0_zZUqPSbsl9cc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="INF" scale="0" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.33</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--EarningPerShareBasicAndDiluted_i02_pip0_zHODbAZPCQha" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="SNOA:EarningPerShareBasicAndDiluted" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">1.92</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="SNOA:EarningPerShareBasicAndDiluted" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">1.97</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_zCqsjJVBXcbc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted-average  shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,653</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,996</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossTaxAbstract_iB_zHJnMGYfBrZc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_i01_maOCILNzhjV_zXQHNM1iyTU4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,950</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_i01_maOCILNzhjV_zuFIIa4jRNuj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,031</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_i01T_mtOCILNzhjV_zAv0ju7yVRdi" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,819</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,919</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC., AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_018"></span>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217;
EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Years Ended March 31, 2022 and 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In thousands, except share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_114_pn3n3_zIvOR5tqymSa" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zjqYRKrcTCkj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z5D26UevRso8" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zvzViUM6cfF3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zIIhHKKAfqY9" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zlCcJGMtlnE3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BC_z22CpPGtAg25" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Series
    C Preferred Stock<br /> ($0.0001 par Value)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Common
    Stock<br /> ($0.0001 par Value)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Additional<br /> Paid
    in</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Accumulated</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Accumulated Other
    Comprehensive</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Loss</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_431_c20210401__20220331_eus-gaap--StockholdersEquity_iS_zTDJuOFNoH33" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; width: 14%"><span style="font-size: 8pt">Balance March 31, 2021</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pip0_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zkMiUDs3pIE4" title="Beginning balance, shares" style="width: 8%; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8211;</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8211;</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_987_eus-gaap--SharesOutstanding_iS_pip0_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zteQonmkIkWb" title="Beginning balance, shares" style="width: 8%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,092,909</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189,217</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">179,277</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,579</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,363</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueOther_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Shares issued in connection with ATM, net of transaction costs</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesOther_pip0_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zv2UVt3IxD56" title="Shares issued in connection with ATM, net of transaction costs, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">950,100</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,554</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,554</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_i_pn3n3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Shares issued in connection with exercise of stock options</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPWNkIqSYppf" title="Issuance of common stock due to options exercises, Shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">44,042</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">193</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">193</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Shares issued in connection with exercise of common stock warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_98B_ecustom--SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_pip0_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN1n8JXwdRSb" title="Shares issued in connection with exercise of common stock warrants, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">12,290</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0304">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_i_pn3n3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Employee stock-based compensation expense</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">372</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">372</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zdbbm8FqNzFk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Stock based compensation related to issuance of common stock restricted
    stock grants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pip0_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIM7bUkSyvHg" title="Stock based compensation related to common stock restricted stock grants, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,596</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_i_pn3n3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zbjAeM9vdHDg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr id="xdx_430_c20210401__20220331_eus-gaap--StockholdersEquity_iE_zvRH2s3TwbD8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Balance, March 31, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--SharesOutstanding_iE_pip0_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxMZJ2efVvOc" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0349">&#8211;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8211;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--SharesOutstanding_iE_pip0_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8CklWKTWt6f" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,100,937</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">197,370</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">184,363</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,312</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,697</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Series C Preferred Stock<br />
    ($0.0001 par Value)</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Common Stock<br />
    ($0.0001 par Value)</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Additional<br />
    Paid in</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Accumulated</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt"><b>Accumulated Other Comprehensive</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Shares</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Amount</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Shares</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Amount</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Capital</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Deficit</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Loss</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Total</b></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_43A_c20200401__20210331_eus-gaap--StockholdersEquity_iS_zxzF1MF1dWEc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; width: 14%"><span style="font-size: 8pt">Balance March 31, 2020</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pip0_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfrXSn8nBDE2" title="Beginning balance, shares" style="width: 8%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1.55</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8211;</span></span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_983_eus-gaap--SharesOutstanding_iS_pip0_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMM3iQgYrl77" title="Beginning balance, shares" style="width: 8%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,777,483</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">186,559</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">175,327</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 8pt">)</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,610</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 8pt">)</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 8pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,624</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_znZrOdrOR5N1" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Shares issued in connection with exercise of stock options</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z58zl2tTDhte" title="Shares issued in connection with exercise of stock options, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">93,301</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">511</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">511</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_iP3us-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_zPUrjipDWXH7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Shares issued in connection with vesting of restricted stock</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_iP3us-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pip0_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJeOdtOeS87g" title="Shares issued in connection with vesting of restricted stock, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,919</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_z2GIVQzwsxLd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Shares issued in connection with exercise of common stock warrants</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_98D_ecustom--SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_pip0_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwdzVixqH1Wa" title="Shares issued in connection with exercise of common stock warrants, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">200,984</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,776</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,776</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedWithConversionOfCShares_iP3custom--SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_z7EZs5er7cya" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Shares issued with conversion of C shares</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_981_ecustom--SharesIssuedWithConversionOfCSharesShares_iP3custom--SharesIssuedWithConversionOfCShares_pip0_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zV1nYHMpdKK6" title="Shares issued with conversion of C shares, shares" style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="SNOA:SharesIssuedWithConversionOfCSharesShares" contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="Shares">1.55</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">)</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_98C_ecustom--SharesIssuedWithConversionOfCSharesShares_pip0_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIzgpTHzWiNk" title="Shares issued with conversion of C shares, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="SNOA:SharesIssuedWithConversionOfCSharesShares" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">17,222</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zFG9fV5DYqh9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Employee stock-based compensation expense</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">332</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">332</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_z2v4wIPOVQB3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Stock based compensation related to issuance of common stock restricted stock grants</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_zWMI8lL84A5h" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Foreign currency translation adjustment</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#8211;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,031</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,031</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zpq6JAyRyOOj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Net loss</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 8pt">&#8211;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,950</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">)</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,950</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">)</span></td></tr>
  <tr id="xdx_436_c20200401__20210331_eus-gaap--StockholdersEquity_iE_zWk162xZFJT" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-size: 8pt">Balance, March 31, 2021</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_981_eus-gaap--SharesOutstanding_iE_pip0_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8ntvuutoegd" title="Ending balance, shares" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 8pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#8211;</span></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--SharesOutstanding_iE_pip0_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYDmelnbaOak" title="Ending balance, shares" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,092,909</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 8pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 8pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189,217</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 8pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">179,277</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">)</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 8pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,579</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">)</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 8pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,363</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC., AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_019"></span>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(In&#160;thousands)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_112_pn3n3_zhAv0bzpIMAh" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20210401__20220331_zCYhdgdbIfc" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20200401__20210331_z1CWAY3Yltd6" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zgVeQLKB2Co5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_maCzeUo_zTqBirWngAU3" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,950</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_zSiK4bhgehFi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DepreciationDepletionAndAmortization_i01_maCzeUo_zncOwFvKdMQi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">186</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">227</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProvisionForDoubtfulAccounts_i01_maCzeUo_zIceboRr7mad" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Recovery of doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">125</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">903</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns_i01_maCzeUo_zXm5oSDLnDhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision for (recovery of) discounts, rebates, distributor fees and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SNOA:ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,407</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">259</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i01_maCzeUo_zRwr5ykBysS9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">382</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">371</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ForgivenessOfPppLoan_i01N_di0_msCzeUo_zPoIop6COkN6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Forgiveness of PPP loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SNOA:ForgivenessOfPppLoan" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">723</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:ForgivenessOfPppLoan" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInDeferredIncomeTaxes_i01N_di_msCzeUo_zNSCj0egcoik" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Deferred income tax expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">829</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">&#8211;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i01N_di0_msCzeUo_zcWzVinDC1W6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i01N_di0_msCzeUo_zpZhFOw1KOEe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Gain on sale of assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">770</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_z4oiLHhkmuW5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsReceivable_i01N_di_msCzeUo_zIlxrj95bLU2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,971</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,608</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInInventories_i01N_di_msCzeUo_zlMIeBcoP9M3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInPrepaidExpense_i01N_di_msCzeUo_z6yPxTVwXBJj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">460</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--IncreaseDecreaseInDeferredConsiderationNetOfDiscount_i01_maCzeUo_z068P8fqvFP6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred consideration, net of discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">143</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_i01_maCzeUo_zoRZW2kEy07l" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">157</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">796</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i01_maCzeUo_zCob0NC8gpfk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">679</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">668</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--IncreaseDecreaseInWithholdingTaxPayable_i01_maCzeUo_zCFxUxai3M3h" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Withholding tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInWithholdingTaxPayable" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInWithholdingTaxPayable" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">397</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i01_maCzeUo_zpDFxF6a25t3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">222</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">215</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i01_maCzeUo_zXM4Yq6H107" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Deferred revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzeUo_maCz9zs_zCTAV9IygO2a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,248</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,378</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zUCgBDyQyOJd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzj4I_zB8KPoezrCTl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">137</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">179</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--IncreaseDecreaseInDeposits1_i01N_di_msCzj4I_z5W9CJ1P2tqa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInDeposits1" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SNOA:IncreaseDecreaseInDeposits1" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromSaleOfIntangibleAssets_i01_d0_maCzj4I_z8PM8WxNNgU4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from Micromed Transaction</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfIntangibleAssets" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">610</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzj4I_maCz9zs_zxQ4muQrzCt" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net cash (used in) provided by investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">99</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">388</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z1hRLCWvFXna" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_d0_maCzYqc_zIlWXX2ImYhi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,554</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--PaymentsOnPppLoan_i01N_di0_msCzYqc_zX0eH6l7UfH5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payments on PPP Loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SNOA:PaymentsOnPppLoan" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">467</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:PaymentsOnPppLoan" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromOtherEquity_i01_d0_maCzYqc_zex4xs5hLrLj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from PPP Loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,310</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzYqc_zf2ndmYXCHS4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from exercise of common stock options and purchase warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RepaymentsOfShortTermDebt_i01N_di_msCzYqc_zP2pyDF5zky9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Principal payments on short-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfShortTermDebt" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">)&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfShortTermDebt" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">481</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromShortTermDebt_i01_d0_maCzYqc_zsjQLhOZKh3b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds on short-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets_i01N_di0_msCzYqc_zeYD1k9eTNWh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Benefit from lease assumed less principal payments on ROU Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">192</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzYqc_maCz9zs_zpN6aHfgnzD5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,396</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,308</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01_maCz9zs_zmtL2fuwYY58" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Effect of exchange rate on cash and cash equivalents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">211</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_i01T_mtCz9zs_zJxVMMIJvj3k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,176</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">529</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01S_zdFSwhsUzBKe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Cash and cash equivalents, beginning of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,220</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,691</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01E_zXI7XjXSyMdh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,396</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zGQ1JfvgMX94" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestPaidNet_i01_zWgxi1fv7j0g" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxesPaidNet_i01_zFPSrldsKvhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash paid for taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">767</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">941</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zVdD1pd7W2N9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Non-cash operating and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--InsurancePremiumsFinanced_i01_zxKFGTWnxWji" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Insurance premiums financed</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:InsurancePremiumsFinanced" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">748</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:InsurancePremiumsFinanced" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">596</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><br />
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_020"></span>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zu6TsBwZut1i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;1&#160;&#8211; <span id="xdx_823_zwraHgvuJF72">Organization and Recent
Developments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sonoma Pharmaceuticals, Inc. (the &#8220;Company&#8221;)
was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware
in December 2006. The Company&#8217;s principal office was moved to Woodstock, Georgia from Petaluma, California in June 2020. The Company
is a global healthcare leader for developing and producing stabilized hypochlorous acid (&#8220;HOCl&#8221;) products for a wide range
of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company&#8217;s products
reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies
of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. The Company&#8217;s stabilized
HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells
in the area treated assisting the body in its natural healing process. The Company sells its products either directly or via partners
in 54 countries worldwide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_803_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zmKHvPxNB3wb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;2&#160;&#8211; <span id="xdx_82A_z8CQz0htyafe">Liquidity and Financial
Condition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reported a net loss of $<span id="xdx_900_eus-gaap--NetIncomeLoss_iN_di_c20210401__20220331_z9uOEU15ipfc" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,086,000</ix:nonFraction></span>
for the year ended March 31, 2022. At March 31, 2022 and 2021, the Company&#8217;s accumulated deficit amounted to $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20220331_z7QFEq9R169h" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">184,363,000</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20210331_zl2MGT0lkuy" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">179,277,000</ix:nonFraction></span>, respectively. The Company had working capital of $<span id="xdx_904_ecustom--WorkingCapital_c20220331_pp0p0" title="Working capital"><ix:nonFraction name="SNOA:WorkingCapital" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,611,000</ix:nonFraction></span> and $<span id="xdx_904_ecustom--WorkingCapital_iI_pp0p0_c20210331_zy7ELL6hSdm3" title="Working capital"><ix:nonFraction name="SNOA:WorkingCapital" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,905,000</ix:nonFraction></span> as of March 31, 2022 and 2021,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that the Company has access
to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other
means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms,
if needed. If the economic climate in the U.S. deteriorates, the Company&#8217;s ability to raise additional capital could be negatively
impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order
to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays
in the Company&#8217;s continued efforts to commercialize its products, which is critical to the realization of its business plan and
the future operations of the Company. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
The accompanying consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to
continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>COVID &#8211; 19</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 11, 2020 the
World Health Organization declared the novel strain of coronavirus (&#8220;COVID-19&#8221;) a global pandemic and recommended containment
and mitigation measures worldwide. In an effort to mitigate the continued spread of the virus, federal, state and local governments, as
well as certain private entities have mandated various restrictions, including travel restrictions, restrictions on public gatherings
and quarantining of people who may have been exposed to the virus. As a result of these restrictions, together with a general fear of
the impact on the global economy and financial markets, there is significant uncertainty surrounding the potential impact on the Company.
As events are rapidly changing, the Company is unable to accurately predict the impact that COVID-19 will have on its business due to
uncertainties including, but not limited to, the duration of quarantines and other travel restrictions within China, the U.S. and other
affected countries, the ultimate geographical spread of the virus, the severity of the disease, the duration of the outbreak and the public&#8217;s
response to the outbreak.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:exclude><p id="xdx_236_z9TjFUhimUk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zeQocnIaOWVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zEICh5TUIHx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 54; Value: 1 -->
    <div id="xdx_23F_zaLuxAgSWIOj" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td id="xdx_23B_zwFATZqzxTLf" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_z82G5OrBCAYc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_237_zjeaCEmbt5L7" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zGua9wY7QTEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zvBqxU4QvNPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;3&#160;&#8211; <span id="xdx_82D_zyMfraEQ5iu2">Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zdhJQAklOI82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zJrVB9o8qPaa">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#8220;Aquamed&#8221;), Oculus Technologies
of Mexico S.A. de C.V. (&#8220;OTM&#8221;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#8220;SP Europe&#8221;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#8220;U.S.&#8221;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6kTYYWEIm67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_869_zLEfOSLbmZUb">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated
financial statements have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission
(&#34;SEC&#34;) and are in conformity with U.S. generally accepted accounting principles (&#34;GAAP&#34;). The Company&#8217;s fiscal
year end is March 31. Unless otherwise stated, all years and dates refer to the fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMz1LixZSF48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86E_zUzki0mVVL08">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents
include cash on hand and all highly liquid investments with an original maturity of three months or less when purchased. The Company&#8217;s
cash equivalents are held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_840_eus-gaap--UseOfEstimates_z1rPJwv6qHzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_z3atnCgDmdz">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating
to the Company&#8217;s deferred tax assets, valuation of equity, fair value allocation of assets sold to Invekra, and the estimated amortization
periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zOfmMfmTTv2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_z78nGuyLyZK2">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2018, the Company adopted Accounting
Standards Update (&#34;ASU&#34;), &#34;Revenue from Contracts with Customers Topic 606&#8221; (&#8220;Topic 606&#8221;) using the modified
retrospective method. There was no material impact to the Company upon the adoption of Topic 606. Revenue is recognized when the Company
transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive
in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its
obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the promised goods or services in
the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are
distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zmvD4I1Vdzt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zv2Cv5UXJuf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zBj6W9DjhJGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 55; Value: 1 -->
    <div id="xdx_23D_z2fCyZKfFv9e" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zcTyVGLWpRW3" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td id="xdx_235_zCFG8xplYH1e" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zTYqDpcIHfY" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23C_zhVZNiroSI59" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zaRDC7lCcRUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company derives the majority of its revenue
through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including
hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license
its technology and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers customer purchase orders,
which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers
the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For all of its sales to non-consignment distribution
channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied),
which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on
the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers,
the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able
to estimate the amount of product that will be returned.&#160;&#160;Sales incentives and other programs that the Company may make available
to these customers are considered to be a form of variable consideration, and the Company maintains estimated accruals and allowances
using the expected value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the
Company&#8217;s rebate program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales to stocking distributors are made under
terms with fixed pricing and limited rights of return (known as &#8220;stock rotation&#8221;) of the Company&#8217;s products held in
their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assessed the promised goods and services
in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is
separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as
other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Service revenue from testing contracts is recognized
as tests are completed and a final report is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23C_z7nWmVOIryO8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_z997CiCrwOI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_234_z93MVOKQCE5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zpcGAt7sAVf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 56; Value: 1 -->
    <div id="xdx_235_zwqMe6Bc6aNh" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td id="xdx_23A_zmnmIhFyy7g" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zdwgMgs63U1b" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_230_zqthvfuCiiY2" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zjQCaCZuCo28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zQG8MWcuQMee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zZ7aTCwWRBjk">Concentration of Credit Risk and Major Customers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company grants credit to its business customers,
which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. The Company
maintains allowances for potential credit losses. At March 31, 2022, one customer represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZBZeds9Apq8" title="Significant customer concentration"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction>%</span> of our net accounts
receivable balance, one customer represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbmHbBQlzH1l"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction>%</span> of our net accounts receivable balance, and one customer represented
<span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvJLSXHG9ntb"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction>%</span> of our net accounts receivable balance. At March 31, 2021, one customer represented <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR4a2HzAazwk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>% of our net accounts receivable balance, one customer represented <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFiepuzigYl3"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>%
of our net accounts receivable balance, and one customer represented <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfGlF255Zn0c"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>% of our net accounts receivable balance. For the year ended March 31, 2022, one customer represented <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9ZQvKaieujk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%, one customer represented <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztnOOVa0t2Ni"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>%, and one customer represented
<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHbr1sCM4Di"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>% of net revenues. For the year ended March 31, 2021, one customer represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8l6YiasiR53"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-04-012021-03-31_custom_NetRevenuesMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32</ix:nonFraction></span>%, and one customer represented <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1E7AUHpoJq4"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-04-012021-03-31_custom_NetRevenuesMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% of net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ReceivablesPolicyTextBlock"><p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zuQPgL1h1zm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zspY2vT1pgK2">Accounts Receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are recorded net of
allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns
are based on analysis of contractual terms and historical trends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents
probable credit losses at March 31, 2022 and 2021 in the amounts of $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20220331_zVsbBVHGWjih" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20210331_zYEROlWyq70d" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span>, respectively. Additionally, at March 31, 2022 and
2021, the Company has allowances of $<span id="xdx_900_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20220331_zw7gjy1tGVMl" title="Allowance for sales discounts, rebates, distributor fees and returns"><ix:nonFraction name="SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,000</ix:nonFraction></span> and $<span id="xdx_909_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20210331_znQlQwN9KDLi" title="Allowance for sales discounts, rebates, distributor fees and returns"><ix:nonFraction name="SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,488,000</ix:nonFraction></span>, respectively, related to potential discounts, returns, distributor fees and
rebates. The allowances are included in Accounts Receivable, net in the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zBN59cHxSaZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_z1QVEANCPHbi">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision
to reduce the carrying amounts of inventories to their net realizable value in the amounts of <span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_c20220331_znPp91x7lir9" title="Inventory reserves">$<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,000</ix:nonFraction></span> and <span id="xdx_907_eus-gaap--InventoryValuationReserves_iI_c20210331_zvrHkh3kFRvj" title="Inventory reserves">$<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,000</ix:nonFraction></span> at March 31, 2022
and 2021, respectively, which is included in cost of revenues on the Company&#8217;s accompanying consolidated statements of comprehensive
(loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_zG9CkHQtY7t8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zLTvJHnQjrlf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_z5kJ7hpkyW3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 57; Value: 1 -->
    <div id="xdx_23E_zVMlUgK9pMG5" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zyGfQ4b5HgB7" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td id="xdx_235_zsdnlebeBJW5" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_z0BCgz3Wok1c" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_236_zVUPKxp1jNC6" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zvekwL0VmMjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zYOxwuVETy8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_zAUtJIXcoPw7">Financial Assets and Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, including cash and cash
equivalents, accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the
short-term nature of these instruments. The fair value of capital lease obligations and equipment loans approximates their carrying amounts
as a market rate of interest is attached to their repayment. The Company measures the fair value of financial assets and liabilities based
on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes
the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of
inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;1&#160;&#8211; quoted prices in active
markets for identical assets or liabilities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;2&#160;&#8211; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;3&#160;&#8211; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#8217;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#8217;s accounting and finance department
and are approved by the Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022 and 2021, there were <span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20210401__20220331_zOKiwZLZhKX6" title="Transfers in or out of Level 3"><span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20200401__20210331_z1CTkyNVUFY1" title="Transfers in or out of Level 3"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2021-04-01to2022-03-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2020-04-012021-03-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> transfers
in or out of Level 3 from other levels in the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_ziDHEVgeJb6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zlGufgVVqTze">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost less
accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the
estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over
the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification
is as follows:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_88E_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z27mgY7Q7NHa" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zdrkbAcSzJt7" style="display: none">Property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 85%"><span style="font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: center"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zxRRadcj8PJk" title="Useful asset life"><ix:nonNumeric contextRef="From2021-04-012022-03-31_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zR3oWDeVTsG5" title="Useful asset life"><ix:nonNumeric contextRef="From2021-04-012022-03-31_us-gaap_MachineryAndEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_znRvm3Gfvdp3" title="Useful asset life"><ix:nonNumeric contextRef="From2021-04-012022-03-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon retirement or sale, the cost and related
accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance
and repairs are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_zxVb5k2mRho3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zBoCSyuevycj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zxqz0MBX3yhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zwsYyquapMY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 58; Value: 1 -->
    <div id="xdx_233_zlQ816slHhl4" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td id="xdx_23E_zZZ6EQymFB0j" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zHL0Q8uNmHJ7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_238_zjzhXk1FkzZb" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_z3iDiRit3aJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1IwNgiIGVab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_znM5z7vIicDb">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company periodically reviews the carrying
values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying
values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of
impairment include, but are not necessarily limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a significant decrease in the fair value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a significant adverse change in legal factors or in the business climate that affects the value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When circumstances indicate that an impairment
may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows,
assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the
cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment
loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates
used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended March 31, 2022 and 2021,
the Company had noted <span id="xdx_909_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20210401__20220331_zMPvx9klZnHg" title="Asset impairment charges"><span id="xdx_90D_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20200401__20210331_zA5gdjLshMR6" title="Asset impairment charges"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2021-04-01to2022-03-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2020-04-012021-03-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> indicators of impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbYzOJfC1ib7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_z52U51uSXwr8">Research and Development</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses are charged
to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended
March 31, 2022 and 2021, research and development expense amounted to $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20210401__20220331_pn3p0" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">125,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20200401__20210331_pn3p0" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">555,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_zuiXNNC3aLNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_znaCXPH8z2Zj">Advertising Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising costs are charged to operations as
incurred. Advertising costs amounted to $<span id="xdx_907_eus-gaap--MarketingExpense_c20210401__20220331_z7FHj4x7970c" title="Advertising costs"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,000</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--MarketingExpense_c20200401__20210331_zPn8rcnKkOYk" title="Advertising costs"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,000</ix:nonFraction></span>, for the years ended March 31, 2022 and 2021, respectively. Advertising costs
are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="SNOA:ShippingAndHandlingCostsPolicyTextBlock"><p id="xdx_84C_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zwmlOy3BVSzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_869_zg6JsYKlEnyk">Shipping and Handling Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2022 and 2021, the Company recorded revenue related to shipping and
handling costs of $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_pp0p0" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ShippingAndHandlingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,000</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_pp0p0" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012021-03-31_us-gaap_ShippingAndHandlingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,000</ix:nonFraction></span>, respectively. These amounts are included in product revenues in the accompanying consolidated statements
of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_230_zgd7I8GgrNwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_z4O2csQeUWl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zEz6m1IZ4yVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 59; Value: 1 -->
    <div id="xdx_235_zzEo9T3ZMVq7" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_zjfDNcMfb9a6" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td id="xdx_23E_zex8HXtzDwKi" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zxJT0TiLtYO1" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23E_z0q4LFujJm5h" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zIWQ6xHVlmPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zv8lOk1b2B69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zz9h0XByutAe">Foreign Currency Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiary, OTM, uses the
local currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional
currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts
are translated at average exchange rates during the period. Resulting translation adjustments amounted to $<span id="xdx_90C_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20210401__20220331_zNm6o6YfPmu8" title="Foreign currency translation adjustment"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20200401__20210331_zD8llMX91eAl" title="Foreign currency translation adjustment"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,031,000</ix:nonFraction></span> for
the years ended March 31, 2022 and 2021, respectively. These amounts were recorded in other comprehensive loss in the accompanying consolidated
statements of comprehensive loss for the years ended March 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency transaction gains (losses) relate
primarily to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are
expected to be settled in the foreseeable future. The Company recorded foreign currency transaction losses of $<span id="xdx_905_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20210401__20220331_zGjcRd60GEe1" title="Foreign currency transaction loss"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">579,000</ix:nonFraction></span> for the year ended
March 31, 2022, and foreign currency transaction losses of $<span id="xdx_904_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20200401__20210331_zlsJxvRFYBEc" title="Foreign currency transaction loss"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">690,000</ix:nonFraction></span>, for the year ended March 31, 2021. The related amounts were recorded
in other expense in the accompanying consolidated statements of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zVxi6ReJV8M9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_zVyQqglG9Txg">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of an forfeitures for all stock
options as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zrSNgFEi4rea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zxcOkOQ22MM9">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tax benefits claimed or expected to be claimed
on a tax return are recorded in the Company&#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is
only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based
on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain
tax positions have had no impact on the Company&#8217;s consolidated financial condition, results of comprehensive (loss) income or cash
flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zcS8XeMQAjHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zJ1EihqTTxu6">Comprehensive Loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other comprehensive loss includes all changes
in stockholders&#8217; equity during a period from non-owner sources and is reported in the consolidated statement of changes in stockholders&#8217;
equity. To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other
comprehensive losses at March 31, 2022 and 2021 were $<span id="xdx_90C_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_di_c20220331_zJTmlaS86sF8" title="Accumulated other comprehensive loss"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,312,000</ix:nonFraction></span>, and $<span id="xdx_904_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_di_c20210331_zRGceQToe0Y1" title="Accumulated other comprehensive loss"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,579,000</ix:nonFraction></span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_z08iVpipoHsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_znoMRhEBR6x" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zWiG9Euw7rAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 60; Value: 1 -->
    <div id="xdx_231_zDGpLAoKm1b8" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_ztnQeVGqpA71" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td id="xdx_232_ztrWsRon0aw7" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zKsO90rSoZ9k" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_z13f9niMUZD7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zZIuD7ckLwr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_zwNsb8Rp0xj9">Net Income Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic net loss per share
by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period
and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution
that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#8220;treasury stock&#8221;
and/or &#8220;if converted&#8221; methods as applicable.</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zRsXO5wGZkFj" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span id="xdx_8B2_zpxwFLCCtP8l" style="display: none">Computation of earnings per share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20210401__20220331_zgB7s2aDRr86" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20200401__20210331_zmixmPzrIO54" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_zQP4TmgcF8gh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: justify">Loss from continuing operations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,615</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_pn3n3_d0_zBX7xn3gTW5b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Income  from discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">665</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_pn3n3_z5VgTLfopGV1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,086</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,950</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pin3_zYmPWPsI6bP3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average  shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">2,653</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">1,996</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeLossFromContinuingOperationPerBasicAndDilutedShare_pip0_z02qMOz8gKQ3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Loss per share from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">1.92</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">2.31</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_pip0_d0_zOMu6zBGKfAh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Income  per share from discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="INF" scale="0" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.33</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EarningPerShareBasicAndDiluted_pip0_zwbOIalyqXZg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="SNOA:EarningPerShareBasicAndDiluted" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">1.92</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="SNOA:EarningPerShareBasicAndDiluted" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">1.97</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The computation of basic loss per share for the
years ended March 31, 2022 and 2021 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_ztvvNLsaRsI5" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BF_z0EjdoIXDfP7" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Common stock to be issued upon vesting of restricted stock units</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zAp9FNVR20Fa" title="Antidilutive shares" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zQSnEapuGNGe" title="Antidilutive shares" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zGFCfY6Bzqba" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z9xIv4jNVfIh" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">268</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Common stock to be issued upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zALn25cy18v2" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-012022-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zq2rNd0ZLsZf" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012021-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">119</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon conversion of Series C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zpw5wzu3R7z7" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-012022-03-31_us-gaap_SeriesCPreferredStockMember" format="ixt:zerodash" decimals="-3" scale="3" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zImGLkNONzYa" title="Antidilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012021-03-31_us-gaap_SeriesCPreferredStockMember" format="ixt:zerodash" decimals="-3" scale="3" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon exercise of common stock units (1)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zfQ3iLmWAPAb" title="Antidilutive shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-012022-03-31_custom_CommonStockUnitsMember" id="Fact000765" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">46</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_z3MFiQjglZQ1" title="Antidilutive shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012021-03-31_custom_CommonStockUnitsMember" id="Fact000767" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">46</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331_z74sV2x6BNJc" title="Antidilutive shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">621</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331_zcYutqb7JmT5" title="Antidilutive shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">434</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%"><span id="xdx_F0B_z5FMj7xzgpCd" style="font-size: 10pt">(1)</span></td>
    <td style="width: 94%; text-align: justify"><span id="xdx_F12_zdUEYaIzOBF2" style="font-size: 10pt"><ix:footnote id="Footnote000772" xml:lang="en-US">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_zyDhTgPZH63i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_231_zwyravRXf7sh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zauuCegI2N72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_237_ztaD91UWZ6fj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zRw8FpfqxVw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 61; Value: 1 -->
    <div id="xdx_238_zGaI4GYysf47" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td id="xdx_238_zkGfqIYNB4zd" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zhTZ8AWPaVX" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zi3mQNAiiCx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_z3VfIE2uf0X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_865_zUk0jJiaGii2">Common Stock Purchase Warrants and Other
Derivative Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies common stock purchase warrants
and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement
or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).
The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if
an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net cash settlement or
settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability.
The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification
between assets and liabilities is required. The Company determined that its freestanding derivatives, which principally consist of warrants
to purchase common stock, satisfied the criteria for classification as equity instruments, other than certain warrants that contained
reset provisions and certain warrants that required net-cash settlement that the Company classified as derivative liabilities. The company
currently does not have any active derivative financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy"><p id="xdx_84C_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_z5xbRK3EYqgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zth03FqF3sud">Preferred Stock</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the accounting standards for
distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject
to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally
redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the
holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity.
At all other times, preferred shares are classified as stockholders' equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zwxMwRMLRIY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_zIo7djYjf1Jj">Subsequent Events</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated subsequent events or
transactions occurring through the date these consolidated financial statements were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcic2ZUgyW01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_z8VqGU08W4Bl">Recent Accounting Standards</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated all the recent accounting
standards and determined that none of them are material to it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"><p id="xdx_809_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zRcC4XJsVuA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span id="xdx_821_znALJJPmwWP9">Sale of Assets &#8211;
Discontinued Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Sale of Assets to Infinity Labs SD, Inc. and Discontinued Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 24, 2020, the Company closed on an asset
purchase agreement for the sale of its Micromed Laboratories division and testing facility, including all of Micromed&#8217;s assets,
such as testing equipment, certain office furniture and customer list, with Infinity Labs SD Inc. (&#8220;Infinity&#8221;) for an aggregate
purchase price of $850,000. On the closing date, the Company received $610,000 in cash from this sale which was adjusted for working capital,
a credit of $100,000 for future testing services from Infinity over the next two years in lieu of cash, and $60,000 held in escrow for
one year, subject to adjustment for certain indemnity claims or purchase price adjustments. The Company also retained its accounts receivables
outstanding on the date of closing in the amount of approximately $81,000 and an insignificant amount of liabilities. As part of the transaction,
Infinity also assumed the Petaluma lease for the office and lab space. The Company retained the warehouse space to store inventory and
assets until September 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23C_zz2spuKiay7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zt4QZYyIB3ed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zFPBACrrlOi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_238_zXN030qJdO7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 62; Value: 1 -->
    <div id="xdx_23E_z3GyvqFWsxx8" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td id="xdx_230_zDzuIpJlXxtg" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zZRzMh00NGyb" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zNDTjaKGzFZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Accounting for the disposition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For accounting purposes, the Company determined
that there was only one discrete component of the sale to Infinity. This component was the customer base and related services to be provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 20%"><span style="font-size: 10pt"><span style="text-decoration: underline">Component of Sale</span></span></td>
    <td style="width: 80%"><span style="font-size: 10pt"><span style="text-decoration: underline">Methodology to Estimate Selling Price</span></span></td></tr>
  <tr style="vertical-align: top; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Customer Base </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Based upon revenues expected from a market participant to provide technical services at expected service levels</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined an arm&#8217;s length selling
price for each component of the sale and then allocated the net proceeds received to the components on a relative selling price basis.
The Company estimated the selling prices of&#160;each component as described below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proceeds were allocated to the components of the sale based upon their
relative selling prices are as follows:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="SNOA:ScheduleOfAllocationOfSalePriceTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfAllocationOfSalePriceTableTextBlock_zDepiG3PBW4l" summary="xdx: Disclosure - Sale of Assets - Discontinued Operations (Details - Allocation of sale price)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span id="xdx_8BA_zVtlVTsr53b6" style="display: none">Schedule of allocation of sale price</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%; text-align: justify">Customer base</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_iI_pp0p0_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zMHZu6cLDip6" title="Customer base" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" contextRef="AsOf2020-06-24_custom_MicromedLabsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">850,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less:&#160;Funds remaining in escrow</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zA8OEhbffwTg" title="Less: Funds remaining in escrow" style="text-align: right">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" contextRef="AsOf2020-06-24_custom_MicromedLabsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Less:&#160;Services due from buyer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zmTnMXXkPGWg" title="Less: Services due from buyer" style="text-align: right">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" contextRef="AsOf2020-06-24_custom_MicromedLabsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Less: Working capital adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zXEXPzywP1Og" title="Less: Working capital adjustment" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" contextRef="AsOf2020-06-24_custom_MicromedLabsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total proceeds</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ProceedsFromDivestitureOfBusinesses_c20200401__20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_pp0p0" title="Proceeds from sale of business" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="From2020-04-012020-06-24_custom_MicromedLabsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">610,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Discontinued operations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 24, 2020, the Company determined that
the sale of its Micromed division to Infinity qualified as a sale of a component of its business and, as such, all such activity prior
to consummation of the sale is required to be included in discontinued operations on the Company&#8217;s statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no carrying value of the assets and liabilities of discontinued
operations on the consolidated balance sheets as of March 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The operations of the Micromed business included in discontinued operations
is summarized as follows:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zjpUZOSP1Ha4" summary="xdx: Disclosure - Sale of Assets - Discontinued Operations (Details - Discontinued Operations)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_z97pWsGLRhSa" style="display: none">Assets and liabilities of disposal group</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20210401__20220331_z4N6S8MWa0v3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20200401__20210331_zSfTP71LSpdi" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_d0_maDGIDOzviC_zxsTEjNmbal3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_d0_msDGIDOzviC_zCTPMLfSM4Na" style="vertical-align: bottom; background-color: White">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_d0_msDGIDOzviC_zcUZPLRTtrEf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Selling general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_iT_pp0p0_d0_mtDGIDOzviC_maDOILFzWBf_z1GKUibgaP37" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income from discontinued operations before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">123,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_d0_maDOILFzWBf_zEUoslj4DhDj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Gain on disposal of discontinued operations before income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">770,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_iT_pp0p0_d0_mtDOILFzWBf_maILFDOzvre_zcKXL6QfgXzj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total income from discontinued operations, before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">893,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_iN_pp0p0_di0_msILFDOzvre_znjlBqAWoor3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Income Tax benefit (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">228,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pp0p0_d0_mtILFDOzvre_zYRzpFjEDl01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income from discontinued operations, net of tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">665,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_230_zqVrWD7DqBOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_z2yb2x0x1JSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_z7kL8bUeUPbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 63; Value: 1 -->
    <div id="xdx_23A_zVp5PpNXKZq6" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zT5S8aPZIGC7" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td id="xdx_239_zTfNvzgUf9vl" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zXMRD2CtmBD3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zkiuKJchhr71" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p id="xdx_803_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zRvo8iavcMui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;5&#160;&#8211; <span id="xdx_820_zmdfGHaGPV1l">Accounts Receivable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable, net consists of the following:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zEDejifOY7j8" summary="xdx: Disclosure - Accounts Receivable (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B2_zJyLNvxQYP5e" style="display: none">Accounts receivable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20220331_z6bs1ZddSP3k" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20210331_z1GuUwyteqpk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCzGH6_z4OOc0u9TBM9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,488,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,419,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di0_msARNCzGH6_zxFa4KsYXg3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: allowance for doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2022-03-31" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--DiscountsRebatesDistributorFeesAndReturns_iNI_pp0p0_di_msARNCzGH6_z5XNRjHcRhw9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Less: discounts, rebates, distributor fees and returns</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:DiscountsRebatesDistributorFeesAndReturns" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:DiscountsRebatesDistributorFeesAndReturns" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,488,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzGH6_zbFmLeoq1e8i" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Accounts receivable, net&#160;</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,407,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,806,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zRbCQYuiEEh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;6&#160;&#8211; <span id="xdx_829_zahmYzWTk8ci">Inventories</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories consist of the following:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zRU3jnInaWY" summary="xdx: Disclosure - Inventories (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BC_zP06Hii7KMr1" style="display: none">Schedule of inventories</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20220331_zhycOw10rW87" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20210331_zBFAAsXszZ0c" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pp0p0_maINzPTc_zLXMYwxsNlW1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,626,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,670,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pp0p0_maINzPTc_zO9Qp0D4sUa2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,037,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">860,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryNet_iTI_pp0p0_mtINzPTc_z65dJ5Z0l1K4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Inventories, net</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,663,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,530,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_802_eus-gaap--OtherCurrentAssetsTextBlock_zaWjC6bCfQy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;7&#160;&#8211; <span id="xdx_822_zMV3U6agQGs1">Prepaid Expenses and
Other Current Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets consist
of the following:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zexLbkZ7Ij3" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B2_zIIRrMO3pgq6" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220331_zBpjz9EHFzDi" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20210331_zwrfO6O7sKB7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Prepaid insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">755,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">705,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidTaxes_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax prepaid to Mexican tax authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,371,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,850,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">620,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">663,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="color: rgb(238,238,238); padding-bottom: 2.5pt">&#160;Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,746,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,218,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:exclude><p id="xdx_239_zTnaVKvMr877" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zl38CoBoPIK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_z0oSa0ko1S02" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 -->
    <div id="xdx_234_z5X0VutUd7qd" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_znsIOTXVV01b" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td id="xdx_23F_zddLOYBrAyzl" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zAzJWa4rGT69" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zrOcKaejnbn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_806_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_ztRwaluJTAk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;8&#160;&#8211; <span id="xdx_827_zhOVDfNfSIR1">Property and Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment consists of the following:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--PropertyPlantAndEquipmentTextBlock_zW5jMmMkM8Ig" summary="xdx: Disclosure - Property and Equipment (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BE_zdb8YMwOM2Dg" style="display: none">Schedule of property and equipment</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220331_zf2bZXpoLYH3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20210331_zzKHeGMO06k9" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGzTcR_zRLtBPIUJok8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Manufacturing, lab, and other equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,281,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0p0_maPPAEGzTcR_zJNBwvfgBcv2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">139,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">109,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAEGzTcR_zqPximMIx3g7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">108,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">66,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LeaseholdImprovementsGross_iI_pp0p0_maPPAEGzTcR_zNwqMUhS56Li" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">503,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">486,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGzTcR_maPPAENzONv_z4KLBr1xciwl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: rgb(238,238,238)">Property and equipment, gross&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,031,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,831,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzONv_zEFHP6YBQpof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,711,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,471,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzONv_zFuVsqt4oxV7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: rgb(238,238,238); padding-bottom: 2.5pt">Property and equipment, net&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">320,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">360,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation and amortization expense amounted
to $<span id="xdx_90E_eus-gaap--DepreciationAndAmortization_c20210401__20220331_pp0p0" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">186,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--DepreciationAndAmortization_c20200401__20210331_pp0p0" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">227,000</ix:nonFraction></span> for the years ended March 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80C_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zkZcmG6SMIdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;9&#160;&#8211; <span id="xdx_825_zCW1jyqQtYac">Accrued Expenses and
Other Current Liabilities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses and other current liabilities
consist of the following:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zGDRfarYZHJ7" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BD_zIVGEqj7s9i4" style="display: none">Schedule of accrued expenses and other current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20220331_zgMgwi4W5bw7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20210331_zoXHv3sBp8da" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAz40k_zzEBlahCGuE1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Salaries and related costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,059,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">787,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAz40k_zS6K15J1Cfph" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">784,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">367,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pp0p0_mtAPAOAz40k_zEygzqqwz6ia" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Accrued expenses and other current liabilities</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,843,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,154,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_808_eus-gaap--LongTermDebtTextBlock_zQpb4v1Hd8gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;10&#160;&#8211; <span id="xdx_827_zpQMMfsd38kb">Debt</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Financing of Insurance Premiums</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 1, 2021, the Company entered into
a note agreement for $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zQJTq8bkAug"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-01-31_custom_InsurancePremiums1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">584,000</ix:nonFraction>
</span>with an interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210125__20210131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zbJAmrtAVsuj"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-01-252021-01-31_custom_InsurancePremiums1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.98</ix:nonFraction></span>%
per annum with final payment on October 1, 2021. This instrument was issued in connection with financing insurance premiums. The note
was payable in three quarterly installment payments of principal and interest of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20210401__20211001__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zovrkV3sSHa"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2021-04-012021-10-01_custom_InsurancePremiums1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">199,000</ix:nonFraction></span>,
with the first installment beginning April 1, 2021. These amounts were paid off during the year ended March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 1, 2022, the Company entered into
a note agreement for $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zJ0Q6KbxHNa9" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-01-31_custom_InsurancePremiums2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">748,000</ix:nonFraction></span> with an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220125__20220131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zTTlnUb02FRi" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2022-01-252022-01-31_custom_InsurancePremiums2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.68</ix:nonFraction></span>% per annum with final payment on January 1, 2023. This instrument was issued
in connection with financing insurance premiums. The note is payable in ten monthly installment payments of principal and interest of
$<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20220301__20231231__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zf4SeECarcg4" title="Principal payments made"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2022-03-012023-12-31_custom_InsurancePremiums2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,000</ix:nonFraction></span>, with the first installment beginning March 1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Paycheck Protection Program Loan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2020, the Company received loan proceeds
in the amount of $<span id="xdx_905_eus-gaap--ProceedsFromLoans_pp0p0_c20200425__20200501__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zpKGkoHG1rc5" title="Proceeds from loan"><ix:nonFraction name="us-gaap:ProceedsFromLoans" contextRef="From2020-04-252020-05-01_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,310,000</ix:nonFraction></span> under the Paycheck Protection Program (&#8220;PPP&#8221;), from Coastal States Bank in Atlanta, Georgia. The
PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, &#8220;CARES Act&#8221;, provides for loans to qualifying
businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest
are forgivable after eight or 24 weeks as long as the Company uses the loan proceeds for eligible purposes, including payroll, benefits,
rent and utilities, and maintains payroll levels. The amount of loan forgiveness will be reduced if the Company terminated employees or
reduced salaries during the applicable period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_237_z4MUVD0f98p3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zi9T0xObAQw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_ze6A5sWiCTf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 -->
    <div id="xdx_239_znCs5XBFuCN3" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zN10HMyGQNFg" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td id="xdx_234_zMuMuW6Yul61" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zrHlM5Hwbbn2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_233_zyebp1xXnXMj" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zmL50WDEKTR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unsecured loan, which is in the form of a
note dated April 29, 2020, matures on <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20210401__20220331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zPlH4lMypSK6" title="Debt maturity date"><ix:nonNumeric contextRef="From2021-04-012022-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">April 29, 2022</ix:nonNumeric></span> and bears interest at a rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210401__20220331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_z8fwqABcnZk3" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-04-012022-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% per annum, payable monthly commencing on May 1,
2021. The note may be prepaid at any time prior to maturity with no prepayment penalties. The Company has used the loan amount for eligible
purposes, such as payroll expenses. The Company met the conditions for $<span id="xdx_909_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20210401__20220331_zEOHeyAOrcpa" title="Approval for forgiveness"><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">723,000</ix:nonFraction></span> in forgiveness of the loan. At March 31, 2022 and  2021 the loan balance amounted to $<span id="xdx_903_eus-gaap--LoansPayable_iI_c20220331_zljo3x16dLC9" title="Loans payable"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--LoansPayable_iI_c20210331_z0a7IYXh7HIk"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,310,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zDbCO4iFaBc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;11&#160;&#8211; <span id="xdx_825_z20vjlEXVTyd">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating leases are comprised
primarily of facility leases. Balance sheet information related to the Company&#8217;s leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zHpv9Ch3nhA" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span id="xdx_8B5_zgjgIMzk1EKl" style="display: none">Lease cost information</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20220331_zUP5ouNOgUD5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20210331_zPHYAuYgSGL4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeasesOperatingAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Operating leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">559,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">769,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">240,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liabilities &#8211; non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">309,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">529,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other information related to leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31, 2022</b></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Year ended<br /> March 31, 2021</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Operating lease cost</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseCost_c20210401__20220331_pp0p0" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">367,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_eus-gaap--OperatingLeaseCost_pp0p0_c20200401__20210331_zG7hzOy5BJ3a" style="text-align: right; width: 13%"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">435,000</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">As of March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20210401__20220331_z35iuhcsLCIj" style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,000</ix:nonFraction></td><td style="text-align: left">)</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20200401__20210331_zURqMKrkpyW1" style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">215,000</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Weighted-average remaining lease term &#8211; operating leases (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220331_znLaPUYaszJ2" title="Weighted-average remaining lease term - operating leases (in months)"><ix:nonNumeric contextRef="AsOf2022-03-31" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">27.3</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20210331_zsNppxdqe5me"><ix:nonNumeric contextRef="AsOf2021-03-31" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">37.7</ix:nonNumeric></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220331_zS9Y4njkNw77" title="Weighted-average discount rate - operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.00</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20210331_zhoZjWPcAFc9"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.00</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zoukrhei48g3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 180.1pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2022, the annual future minimum lease payments of
the Company&#8217;s operating lease liabilities were as follows:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zqhCF8SPPeB9" summary="xdx: Disclosure - Leases (Details - Minimum operating lease liabilities)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B5_zy4v7mNQTqza" style="display: none">Schedule of minimum operating lease liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220331_zxGiy09tRUwh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">For Years Ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzgSf_zKNEfSx9HDL3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">297,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzgSf_z4i1UNi7T6ve" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">210,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzgSf_zRkCyd0nldLf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">106,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzgSf_zRPwdShP9MD2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzgSf_zWYrPtLzbS29" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">627,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zxP1sj7Y5o6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">559,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:exclude><p id="xdx_239_zYsJis0HGjxf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zobBNHGjVKP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zaaIF5wOpoe6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zJ5a6tEvjcV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 66; Value: 1 -->
    <div id="xdx_231_zmNMfmBMABdd" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td id="xdx_236_zVWtkD9RAlsj" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zauwjKAEJ9Vb" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zVVuXT9hBhnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zuG2q61SYw04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;12&#160;&#8211; <span id="xdx_823_z64C91qtLhjl">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legal Matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On occasion, the Company may be involved in legal
matters arising in the ordinary course of business including matters involving proprietary technology. While management believes that
such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become
involved in litigation may have a material adverse effect on its business and financial condition of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had employment
agreements in place with three of its key executives. These executive employment agreements provide, among other things, for the payment
of up to twelve months of severance compensation for terminations under certain circumstances. With respect to these agreements, at March
31, 2022, aggregated annual salaries would be $<span id="xdx_90C_eus-gaap--SalariesAndWages_c20210401__20220331_pp0p0" title="Annual salaries"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">775,000</ix:nonFraction></span> and potential severance payments to these key executives would be $<span id="xdx_908_eus-gaap--SeveranceCosts1_c20210401__20220331_pp0p0" title="Potential severance"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">775,000</ix:nonFraction></span> if triggered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Party Transactions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ms. Trombly was appointed the Chief Executive
Officer of the Company. Ms. Trombly is the owner of Trombly Business Law, PC which has been retained by the Company to advise on certain
corporate and securities law matters. During the years ending March 31, 2022 and  2021, the Company received $<span id="xdx_900_eus-gaap--LegalFees_c20210401__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_pp0p0" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2021-04-012022-03-31_custom_TromblyBusinessLawMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">170,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--LegalFees_pp0p0_c20200401__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_zwI4l1ctc8kf" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2020-04-012021-03-31_custom_TromblyBusinessLawMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">215,000</ix:nonFraction></span>,
respectively, in legal services from Trombly Business Law, PC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zZFHN06SH8xa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;13&#160;&#8211; <span id="xdx_826_zQLLTQi1rDCl">Stockholders&#8217;
Equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Authorized Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective September 13, 2018, the Company filed
a certificate of amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware
in order to affect an increase of the total number of shares of common stock, $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20220331_pdd" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value per share, authorized for issuance from
12,000,000 to a total of <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20220331_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,000,000</ix:nonFraction></span>. Additionally, the Company is authorized to issue <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">714,286</ix:nonFraction></span> shares of convertible preferred stock with
a par value of $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Preferred stock par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Description of Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of common stock has the right to one
vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Description of Series B Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18, 2016, the Company&#8217;s board
of directors approved, and the Company entered into, a Section 382 rights agreement, or the Rights Agreement, with Computershare Inc.,
or the Rights Agent. The Rights Agreement provides for a dividend of one preferred stock purchase right, or a Right, for each share of
common stock, par value $0.0001 per share, of the Company outstanding on November 1, 2016, or the Record Date. Each Right entitles the
holder to purchase from the Company one one-thousandth of a share of Series B Preferred Stock, par value $0.0001 per share, or the Preferred
Stock, for a purchase price of $10.00, subject to adjustment as provided in the Rights Agreement. The description and terms of the rights
are set forth in the Rights Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_235_zCeSdVfsTZ9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_ztrT26igOQb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 -->
    <div id="xdx_230_ziY7TDj1BpD9" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zDfs4YgBDkCi" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td id="xdx_23B_zQB9c5AX7Ijk" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zbCPpoPFcdpb" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_230_zcuf7ECl3qCf" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zlWvEcopevQ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zDh7xLOWKP3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the adoption of the Rights
Agreement, the Company&#8217;s board of directors adopted a Certificate of Designation of Series B Preferred Stock. The Certificate of
Designation was filed with the Secretary of State of the State of Delaware and became effective on October 18, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s board of directors adopted
the Rights Agreement to protect shareholder value by guarding against a potential limitation on the Company&#8217;s ability to use its
net operating loss carryforwards, or NOLs, and other tax benefits, which may be used to reduce potential future income tax obligations.
The Company has experienced and continue to experience substantial operating losses, and under the Internal Revenue Code of 1986, as amended,
and rules promulgated thereunder, the Company may &#8220;carry forward&#8221; these NOLs and other tax benefits in certain circumstances
to offset any current and future earnings and thus reduce our income tax liability, subject to certain requirements and restrictions.
To the extent that the NOLs and other tax benefits do not otherwise become limited, the Company believes that it will be able to carry
forward a significant amount of NOLs and other tax benefits, and therefore these NOLs and other tax benefits could be a substantial asset
to the Company. However, if the Company experiences an &#8220;ownership change,&#8221; as defined in Section 382 of the Code, its ability
to use its NOLs and other tax benefits will be substantially limited. Generally, an ownership change would occur if our shareholders who
own, or are deemed to own, 5% or more of the Company&#8217;s common stock increase their collective ownership in the Company by more than
50% over a rolling three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exercise of Series C Preferred Stock Units</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended March 31, 2021, investors
who participated in the November 21, 2018 offering exchanged <span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20210401__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z19ZFBopJyGd" title="Preferred stock converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2021-04-012022-03-31_us-gaap_SeriesCPreferredStockMember44329203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1.55</ix:nonFraction></span> shares of Series C into <span id="xdx_908_eus-gaap--ConversionOfStockSharesIssued1_c20210401__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Common stock issued upon conversion"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2021-04-012022-03-31_us-gaap_SeriesCPreferredStockMember44329203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,222</ix:nonFraction></span> shares of common stock. No further shares
of Series C are outstanding as of March 31, 2021 or 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zhP2zjcosJze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;14&#160;&#8211; <span id="xdx_82D_zqpuJvESPs7f">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2006 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board initially adopted the 2006 Stock Incentive
Plan on August 25, 2006. On December&#160;14, 2006, the stockholders approved the 2006 Stock Incentive Plan which became effective at
the close of the Company&#8217;s initial public offering. The 2006 Stock Incentive Plan was later amended and restated by a unanimous
board resolution on April&#160;26, 2007, and such amendments were subsequently approved by the stockholders. On September 10, 2009, the
Company&#8217;s shareholders approved a subsequent amendment to the 2006 Stock Incentive Plan. The 2006 Stock Incentive Plan, as amended
and restated, is hereafter referred to as the &#8220;2006 Plan.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2006 Plan provided for the granting of incentive
stock options to employees and the granting of non-statutory stock options to employees, non-employee directors, advisors and consultants.
The 2006 Plan also provided for grants of restricted stock, stock appreciation rights and stock unit awards to employees, non-employee
directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2006 Plan the stated exercise
price may not be less than 100% and 85% of the estimated fair market value of common stock on the date of grant for ISOs and NSOs, respectively,
as determined by the board of directors at the date of grant. With respect to any 10% stockholder, the exercise price of an ISO or NSO
shall not be less than 110% of the estimated fair market value per share on the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2006 Plan generally have
a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2021, there were <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_zcYztFQvJq4e" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-03-31_custom_Plan2006Member" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_236_zQaGq9zBCjA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zqPiqgeAFWrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zGWdHYPVek9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 68; Value: 1 -->
    <div id="xdx_236_zImYo5nqY6Kj" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_230_zAo6RHEmUIVd" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td id="xdx_23B_zF3CKBSFNWY6" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_z3VPYtLkfcs9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zssk9BL63b61" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zVi8dfGOmIq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2011 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2011, upon recommendation of
the board, the stockholders approved the Company&#8217;s 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;). The 2011 Plan is effective
as of June 21, 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2011 Plan provides for the grant of incentive
stock options as defined in Section 422 of the Internal Revenue Code to employees, and the grant of non-statutory stock options and stock
purchase rights to employees, non-employee directors, advisors and consultants. The 2011 Plan also permits the grant of stock appreciation
rights, stock units and restricted stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has initially authorized <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20110912__us-gaap--PlanNameAxis__custom--Plan2011Member_zySRVCm0C9L9" title="Shares initially authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2011-09-12_custom_Plan2011Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,508</ix:nonFraction></span> of the
Company&#8217;s common stock for issuance under the 2011 Plan, in addition to automatic increases provided for in the 2011 Plan through
April 1, 2021. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2011 Plan will automatically increase,
with no further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 15% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount approved by the Company&#8217;s
board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2011 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2011 Plan, the stated exercise
price of an employee incentive stock option shall not be less than 100% of the estimated fair market value of a share of common stock
on the date of grant, and the stated exercise price of an non-statutory option shall not be less 85% of the estimated fair market value
of a share of common stock on the date of grant, as determined by the board of directors. An employee who owns more than 10% of the total
combined voting power of all classes of outstanding stock of the Company shall not be eligible for the grant of an employee incentive
stock option unless such grant satisfies the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2011 Plan. No participant in the
2011 Plan can receive option grants, stock appreciation rights, restricted shares, or stock units for more than 2,381 shares in the aggregate
in any calendar year. As provided under the 2011 Plan, the aggregate number of shares authorized for issuance as awards under the 2011
Plan automatically increases on April 1 of each year by in an amount equal to the lesser of (i) 15% of the outstanding shares on the last
day of the immediately preceding year, or (ii) an amount determined by the board. During the year ended March 31, 2019, the board of directors
approved an increase of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2018-04-012019-03-31_custom_Plan2011Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">102,863</ix:nonFraction></span> shares authorized for issuance. During the year ended March 31, 2020, the board of directors approved
an increase of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20200401__20210331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2020-04-012021-03-31_custom_Plan2011Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">197,450</ix:nonFraction></span> shares authorized for issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan expired on September 12, 2021 in accordance
with its term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022, there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_zz8FD1I8w2Ef" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-03-31_custom_Plan2011Member" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2016 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2016, upon recommendation of the
board, the stockholders approved the Company&#8217;s 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;). The 2016 Plan is effective
as of September 2, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2016 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zWvcZA0onvvd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zcnrQZXHO8E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zQ0cjLDDsyl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 69; Value: 1 -->
    <div id="xdx_236_z2PNoNI2j04e" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_zp0bAbkQe852" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td id="xdx_237_zWmVfSHwrkw3" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_z2dicYovG5Cg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zYEH4OHfaMa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2016 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2016 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2016 Plan. No participant in the
2016 Plan can receive more than 11,112 option grants, or other awards with respect to more than 13,334 shares in the aggregate in any
calendar year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has authorized <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160902__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" title="Shares initially authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2016-09-02_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,445</ix:nonFraction></span> of the Company&#8217;s
common stock for issuance under the 2016 Plan, in addition to automatic increases provided for in the 2016 Plan through April 1, 2026.
The number of shares of the Company&#8217;s common stock reserved for issuance under the 2016 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 8% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#8217;s
board of directors. During the year ended March 31, 2019, the board of directors approved an increase of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2016Member_zr9jidES3M8g" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2018-04-012019-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,860</ix:nonFraction></span> shares authorized for issuance.
During the year ended March 31, 2020, the board of directors approved an increase of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2016Member_zM9WTHLlebV3" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2019-04-012020-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">105,306</ix:nonFraction></span> shares authorized for issuance. During the
year ended March 31, 2022, the board of directors approved an increase of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20210401__20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zgvz8PxehSyj" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-04-012022-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">167,432</ix:nonFraction></span> shares authorized for issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022 there were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zTgnKMlbDfF3" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">112,106</ix:nonFraction></span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2021 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 21, 2021, upon recommendation of
the board, the stockholders approved the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan is effective
as of September 21, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2021 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2021 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2021 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has authorized <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20200401__20210331__us-gaap--PlanNameAxis__custom--Plan2021Member_zhfQ8mlixOsd" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2020-04-012021-03-31_custom_Plan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of the
Company&#8217;s common stock for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022, there were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220331__us-gaap--PlanNameAxis__custom--Plan2021Member_z3G9lPD2j6Uc" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-03-31_custom_Plan2021Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">869,999</ix:nonFraction></span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_232_zgZJVsfdCIf7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_z2CrzzbJ11jj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zkaxZcU7tgN" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_zfH5PJM4xl01" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td id="xdx_239_zasAJOvBlcof" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_z56ETKhAPMj7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_ziAlLPbcMbq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues service, performance and market-based
stock options to employees and non-employees. The Company estimates the fair value of service and performance stock option awards using
the Black-Scholes option pricing model. The Company estimates the fair value of market-based stock option awards using a Monte-Carlo simulation.
Compensation expense for stock option awards is amortized on a straight-line basis over the awards&#8217; vesting period. Compensation
expense includes the impact of forfeitures as they are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expected term of the stock options represents
the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach
prescribed by&#160;the Securities&#160;and Exchange Commission's Staff Accounting Bulletin No.&#160;110 for &#8220;plain vanilla&#8221;
options. The expected stock price volatility for the Company&#8217;s stock options was determined by using an average of the historical
volatilities of the Company and its industry peers. The Company will continue to analyze the stock price volatility and expected term
assumptions as more data for the Company&#8217;s common stock and exercise patterns become available. The risk-free interest rate assumption
is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#8217;s stock options. The expected
dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimated the fair value of employee
and non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized
on a straight-line basis over the requisite service periods of the respective awards. The fair value of employee stock options was estimated
using the following weighted-average assumptions:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zx4slDOadTV1" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_zOwgBdab50ae" style="display: none">Weighted-average assumptions of fair value of employee stock options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Fair value of the Company&#8217;s common stock on date of grant</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331_pdd" title="Fair value of common stock on date of grant" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.60</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331_pdd" title="Fair value of common stock on date of grant" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.03</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331_zNTnFN5LZlkf" title="Expected term"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.00</ix:nonNumeric></span> yrs</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331_zIUDvpXnvw25" title="Expected term"><ix:nonNumeric contextRef="From2020-04-012021-03-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.00</ix:nonNumeric></span> yrs</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331_zpSQNOTt3tvh" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.60</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20210331_zs2PIM3k0umi" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.5800</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210401__20220331_z0385HWI6YS6" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200401__20210331_zOJxjyqx14cf" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331_zpGP0jQO90Ji" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">123.27</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20210331_zSP1gKMGh9Yh" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80.7</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of options granted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331_pdd" title="Fair value of options granted, per share" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.03</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200401__20210331_pdd" title="Fair value of options granted, per share" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share-based awards compensation expense is as follows:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqbYGhIavS6l" summary="xdx: Disclosure - Stock-Based Compensation (Details-Stock-based compensation)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B5_zqCTUmWFDUYi" style="display: none">Employee stock-based compensation expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%">Cost of revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zVSg8YnpOKR8" title="Total stock-based compensation" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012022-03-31_us-gaap_CostOfSalesMember" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_pp0p0" title="Total stock-based compensation" style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_CostOfSalesMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">27,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zb70l00hndJf" title="Total stock-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total stock-based compensation" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_pp0p0" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012022-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">382,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_pp0p0" title="Total stock-based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">372,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_c20210401__20220331_pn3p0" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">382,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_c20200401__20210331_pn3p0" title="Total stock-based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">371,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022, there were unrecognized compensation
costs of $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Unrecognized compensation costs"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,325,000</ix:nonFraction></span> related to stock options which is expected to be recognized over a weighted-average amortization period of <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zepHfdjzt6c6" title="Weighted average amortization period"><ix:nonNumeric contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.14</ix:nonNumeric></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A tax benefit of $<span id="xdx_90B_eus-gaap--UnrecognizedTaxBenefits_c20220331_pp0p0" title="Tax benefit"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,000</ix:nonFraction></span> has been recognized relating
to stock-based compensation as a result of non-qualified stock options and restricted stock exercised during the year ending March 31,
2022. In addition, the stock-based compensation deferred tax asset has been reduced by $<span id="xdx_901_eus-gaap--IncreaseDecreaseInDeferredCharges_c20210401__20220331_pp0p0" title="Decrease in stock based compensation deferred tax asset"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">309,000</ix:nonFraction></span> primarily related to the expiration of
stock compensation grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zXGeoPjQAMKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zNCaOdnDW1Ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zxwNKfCJM09k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 71; Value: 1 -->
    <div id="xdx_236_zRDZYL8eTyM3" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td id="xdx_236_zb6LpM8na4n5" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zI36mY3PQbge" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zqhFGStQ6qX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Award Activity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based awards outstanding at March 31, 2022
under the various plans are as follows:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zYhBjx8rFIT4" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B7_zN2yxi0bx2f" style="display: none">Schedule of stock-based awards outstanding by plan</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unvested</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restricted Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%">2006 Plan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_pdd" title="Options outstanding" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2006Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,787</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_zZvbDJbXFYMj" title="Restricted stock units outstanding" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2006Member" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_pdd" title="Total options and restricted stock units outstanding" style="width: 13%; text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2006Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,787</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>2011 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" title="Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2011Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,949</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_zDEx7OaHmGM6" title="Restricted stock units outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2011Member" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" title="Total options and restricted stock units outstanding" style="text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2011Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,949</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>2016 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" title="Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">221,497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zehALydc64Wb" title="Restricted stock units outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2016Member" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" title="Total options and restricted stock units outstanding" style="text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">221,497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">2021 Plan</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_pdd" title="Options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2017Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,001</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_zZhhEtnY9Wua" title="Restricted stock units outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2017Member" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_pdd" title="Total options and restricted stock units outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" contextRef="AsOf2022-03-31_custom_Plan2017Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,001</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331_pdd" title="Options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,234</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331_zNfWEZWyGVC1" title="Restricted stock units outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-03-31" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331_pdd" title="Total options and restricted stock units outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,234</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based awards available for grant as of March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20220331_pdd" title="Stock-based awards available for grant" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">982,105</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock options award activity is as follows:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zir3aMqibCs7" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B7_zIjDLy19hG2d" style="display: none">Schedule of option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br /> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br /> Average<br /> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br /> Average<br /> Contractual Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br /> Intrinsic<br /> Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 44%">Outstanding at April 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU9tM3PP1eza" title="Number of Shares Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">267,569</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVjk6YVhmDh9" title="Weighted- Average Exercise Price Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.16</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKVzXBFJQQyd" title="Number of Shares Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">272,958</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZwqf2Bm6Yo1" title="Weighted- Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxYAlx53fgYd" title="Number of Shares Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,042</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHZG9u7arrH5" title="Weighted- Average Exercise Price Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zt4hIQCJQ1Rb" title="Number of Shares Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUmM96xfRBCj" title="Weighted- Average Exercise Price Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2RUQku8FPt5" title="Number of Shares Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,001</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCggLX24sywa" title="Weighted- Average Exercise Price Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">84.83</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLldnrByxlI2" title="Number of Shares Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,234</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlAh44K59jq3" title="Weighted- Average Exercise Price Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.09</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zn27k069GNxl" title="Weighted- Average Contractual Term Outstanding at end of period"><ix:nonNumeric contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.89</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuN2ExoOhNle" title="Aggregate Intrinsic Value Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2LzLbNGgd85" title="Number of Shares Exercisable at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,144</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1uHcDyN8AU9" title="Weighted- Average Exercise Price Exercisable at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.56</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrpT3dYCyRs1" title="Weighted- Average Contractual Term Exercisable at end of period"><ix:nonNumeric contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.85</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zl7tfubcGOkb" title="Aggregate Intrinsic Value Exercisable at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of stock
options is calculated as the difference between the exercise price of the underlying stock options and the fair value of the
Company&#8217;s common stock, or $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Aggregate intrinsic value per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.01</ix:nonFraction></span>
and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20200401__20210331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCKFWRYes4oe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember44329593" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.43</ix:nonFraction></span> per share at March 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted stock award activity is as follows:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z0PMmUQt8vd6" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B3_zb8K18jPPAN1" style="display: none">Schedule of unvested restricted stock activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Average Award</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Date Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>per Share</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Unvested restricted stock awards outstanding at April 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOazG785cVV" title="Unvested restricted stock awards, beginning balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">833</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIQ6aS3cGMU2" title="Weighted average award date fair value per share, outstanding beginning balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.68</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock awards granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" title="Restricted stock awards granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" title="Weighted average award date fair value per share, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Restricted stock awards vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zH38ybfBvZJc" title="Restricted stock awards vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,429</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" title="Weighted average award date fair value per share, vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.70</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Unvested restricted stock awards outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpbGEFrRfWm1" title="Unvested restricted stock awards, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-03-31_us-gaap_RestrictedStockMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvtOTx7hV8tg" title="Weighted average award date fair value per share, outstanding ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-03-31_us-gaap_RestrictedStockMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><p id="xdx_236_zFGdKeGvUDA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zkMgkkfwByka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zcvhypgPP0E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 72; Value: 1 -->
    <div id="xdx_23A_zseArkapod2l" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td id="xdx_239_zalXKUtBo1Xh" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_z6GTzi1AuJC2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23F_z4Th3OEYcw3j" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zSDDA9mDE3ag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company did not capitalize any cost associated with stock-based
compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues new shares of common stock
upon exercise of stock options or release of restricted stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zEXF2n34RYcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;15&#160;&#8211; <span id="xdx_821_zQUxgDPvRiwj">Income Taxes</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has the following net deferred tax
assets:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zr6WYlqNMQPc" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BB_z06K2W0Eb5sj" style="display: none">Schedule of deferred tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20220331_zamRBdLxYHcl" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20210331_zqFMWYBOTg2i" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGz412_zTZs95gMXgbf" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,224,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,687,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGz412_zhyYh7LUfwsh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,850,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,850,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGz412_zKDHJZiXvmna" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">309,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,120,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0p0_maDTAGz412_zBsGGRNNH6Oe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Allowances and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,336,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">659,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pp0p0_d0_maDTAGz412_zjR6sJBCY3xh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" contextRef="AsOf2022-03-31" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">398,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pp0p0_maDTAGz412_znoCHGmqJkC7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGz412_maDTANzqCr_z0vmMTQhwtCj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Gross deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,782,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,792,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzqCr_zq8q7qO8gmi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Less valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,613,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,528,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzqCr_maDTALNzfiK_zGhqMg8J0Omf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,169,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">264,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pp0p0_di_maDITLzfJx_zriQ37QHmO33" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pp0p0_di_maDITLzfJx_zNQnYT6zKgwb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">186,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pp0p0_di_maDITLzfJx_zLuEU6vleCe3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Right of Use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pp0p0_di_mtDITLzfJx_msDTALNzfiK_zkPb5cIHAXMc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">340,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">264,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pp0p0_d0_mtDTALNzfiK_zbSiR7MSos8j" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">829,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2021-03-31" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision (benefit) is based on
the following loss before income taxes, which are from domestic sources and foreign loss before income taxes:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zseH5cht87fe" summary="xdx: Disclosure - Income Taxes (Details-Income source)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zPA5UDCgqzuk" style="display: none">Income tax provision domestic and foreign</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended March&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">Domestic</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ProfitLoss_pp0p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zo6vQ1YumKye" title="Income before income taxes" style="width: 13%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012022-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,516,000</ix:nonFraction>)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ProfitLoss_pp0p0_c20200401__20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zsw9EFiq2jLj" title="Income before income taxes" style="width: 13%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-04-012021-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,052,000</ix:nonFraction>)</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Foreign</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--ProfitLoss_pp0p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z8hs79iu2e7a" title="Income before income taxes" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012022-03-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,883,000</ix:nonFraction>)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--ProfitLoss_pp0p0_c20200401__20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zuStfLXjuOv" title="Income before income taxes" style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-04-012021-03-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,467,000</ix:nonFraction>)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331_z2D6HFIoFef2" title="Income before income taxes" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">5,399,000</ix:nonFraction>)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ProfitLoss_pn3p0_c20200401__20210331_zOzz6OEPJill" title="Income before income taxes" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">3,519,000</ix:nonFraction>)</span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:exclude><p id="xdx_239_zb2uFoQPDbcf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zaCiB3Y5X5Sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_239_zNdRUI2XjSX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zyFUFbC1efk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 73; Value: 1 -->
    <div id="xdx_236_zgULwTXmDnU7" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td id="xdx_234_zHD9rREBw6el" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zPAvnxfECRsb" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zNsXAUMavI1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s income tax expense/(benefits)
consist of the following:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_znsDd3EjIbs9" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_z6xcUQXl30sd" style="display: none">Schedule of income tax expense</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_491_20210401__20220331_z6ZgkUyyeA14" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_494_20200401__20210331_zBOqa0wIo839" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended March&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Current:</span></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">State</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CurrentForeignTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Foreign</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">469,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">941,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><b style="display: none">Current Income Tax Expense</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">942,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Deferred:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zjis4gxbRI36" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Federal</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zgHHC3PDfJ0l" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">State</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_d0_zpcAJAvJHRs3" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Foreign</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">809,000</ix:nonFraction>)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><b style="display: none">Total deferred income tax</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">332,000</ix:nonFraction>)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">942,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the statutory federal income
tax rate to the Company&#8217;s effective tax rate for continuing operations is as follows:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zV4x1gKKMBd4" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_z6uGOswNvCa4" style="display: none">Reconciliation of federal income tax rate to effective rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49F_20210401__20220331_zhL7miAKoiPl" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49E_20200401__20210331_zxHHbKsuXclk" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year&#160;Ended&#160;March&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zUEVliCEaalj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%"><span style="font-size: 10pt">Expected federal statutory rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction>%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction>%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_z60DI9aSzz71" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">State income taxes</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">5.7</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.1</ix:nonFraction>%</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zOLgQzc5D8hd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Foreign earnings taxed at different rates</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.7</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.6</ix:nonFraction>%</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_ecustom--ForeignTaxTrueup_dp0_zu1v1enA0JZ1" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Foreign tax true-up</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="SNOA:ForeignTaxTrueup" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="SNOA:ForeignTaxTrueup" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">12.4</ix:nonFraction>%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_dpi_zEb84tIE5CT3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Effect of permanent differences</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction>%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.5</ix:nonFraction>%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_zronOu5qGWgg" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Effect of intercompany interest permanent differences</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">12.3</ix:nonFraction>%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">17.9</ix:nonFraction>%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_ecustom--TrueupsOfStateDeferredAssets_dp_zCe8tbuXo4S6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">True-up of state deferred assets</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="SNOA:TrueupsOfStateDeferredAssets" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">25.6</ix:nonFraction>%</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="SNOA:TrueupsOfStateDeferredAssets" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">120.7</ix:nonFraction>%</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zwOCtkaa3pcl" style="vertical-align: bottom; background-color: White">
    <td><b style="display: none">Total effective rate</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.5</ix:nonFraction>%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">133.8</ix:nonFraction>%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zh0QHLE6lIAk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16.7</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">107.1</ix:nonFraction>%</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zsFrvUAF0th" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Totals</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">6.2</ix:nonFraction>%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">26.7</ix:nonFraction>%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had net
operating loss carryforwards for Federal, State and Foreign income tax purposes of approximately $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z4EZX4gPOWL" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">115.3</ix:nonFraction></span>
million, $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zR8tDfyI1y3l" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">44</ix:nonFraction></span>
million and $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pp0p0"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-03-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">541,000</ix:nonFraction></span>,
respectively. Due to the Tax Cuts and Job Act, Federal NOLs generated after March 31, 2018 have an indefinite life. Federal NOL
generated on and before March 31, 2017 will begin to expire 2024, if not utilized. State and Foreign NOLs will  begin to expire in
the year 2029 and 2024, respectively, if not utilized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had
Federal and California research credit carryforwards of approximately $<span id="xdx_90F_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zpTLy7WEMq5j" title="Research credit carryforwards"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1</ix:nonFraction></span>
million and $<span id="xdx_900_eus-gaap--TaxCreditCarryforwardAmount_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_pp0p0" title="Research credit carryforwards"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">790,000</ix:nonFraction></span>,
respectively. The Federal research credits will begin to expire in 2024 while the California research credits have no expiration
date. In addition, the Company has foreign tax credits of $<span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsForeign_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pp0p0" title="Foreign tax credit carryforward"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" contextRef="AsOf2022-03-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span>,
which begin to expire in the year 2023 if not utilized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 382 of the Internal Revenue Code limits
the use of the Federal net operating losses in certain situations where changes occur in stock ownership of a company. If the Company
should have an ownership change of more than 50% of the value of the Company's capital stock, utilization of the carryforwards could be
restricted. The Company is not aware of any changes in ownership that would result in a change in control under Internal Revenue Code
section 382.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_235_z5jmFr6Abbr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zuKmgGXeaj83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_z8lsh7SDfeo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 74; Value: 1 -->
    <div id="xdx_239_zBe1MhnyPSil" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zA33w3Kan5t4" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td id="xdx_23E_zVE3iv1V0wvk" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zYBaSeBZv262" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zfhFT7Voqtoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company released the valuation allowance recorded
against its Mexico deferred tax assets as of March 31, 2022. Given its recent history of earnings, current earnings and anticipated future
earnings, the Company concluded that there is sufficient positive evidence available to reach a conclusion that the valuation allowance
is no longer needed in Mexico. The release of the valuation allowance resulted in the recognition of deferred tax assets of $829,000.
The Company, after considering all available evidence, fully reserved against all deferred tax assets in the U.S. and Netherlands since
it is more likely than not such benefits will not be realized in future periods. The Company will continue to evaluate its deferred tax
assets to determine whether any changes in circumstances could affect the realization of their future benefit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has filed tax returns for federal,
state and foreign jurisdictions. The Company&#8217;s evaluation of uncertain tax matters was performed for tax years ended through March
31, 2022. Generally, the Company is subject to audit for the years ended March 31, 2021, 2020 and 2019. The Company has elected to retain
its existing accounting policy with respect to the treatment of interest and penalties attributable to income taxes and continues to reflect
interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit as
well as its outstanding income tax assets and liabilities. The Company believes that its income tax positions and deductions would be
sustained on audit and does not anticipate any adjustments to result in a material change to its financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock"><p id="xdx_80A_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zF95oKn7V0E3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;16&#160;&#8211; <span id="xdx_82C_zWyqM9mwUj89">Employee Benefit
Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a program to contribute and administer
a qualified 401(k) plan. Under the 401(k) plan, the Company matches employee contributions to the plan up to 4% of the employee&#8217;s
salary. Company contributions to the plan amounted to an aggregate of $<span id="xdx_900_eus-gaap--PensionAndOtherPostretirementBenefitContributions_c20210401__20220331_pp0p0" title="Company contributions to 401(k) plan"><ix:nonFraction name="us-gaap:PensionAndOtherPostretirementBenefitContributions" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,600</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--PensionAndOtherPostretirementBenefitContributions_c20200401__20210331_pp0p0" title="Company contributions to 401(k) plan"><ix:nonFraction name="us-gaap:PensionAndOtherPostretirementBenefitContributions" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,000</ix:nonFraction></span> for the years ended March 31, 2022 and 2021,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_z5lQfnB10xoa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;17 &#8211; <span id="xdx_82A_zJmtVf96s5Gc">Revenue Disaggregation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company generates product revenues from products
which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services
which are provided to medical device manufacturers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents the Company&#8217;s disaggregated revenues
by source:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--DisaggregationOfRevenueTableTextBlock_zf8ED1TsLjuc" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-align: left"><span id="xdx_8BC_zUH2QemuRLI9" style="display: none">Disaggregated Revenue by Source</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Product</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Human Care</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_pp0p0" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_custom_HumanCareMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,010,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_pp0p0" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012021-03-31_us-gaap_ProductMember_custom_HumanCareMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,317,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Animal Care</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_pp0p0" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_custom_AnimalCareMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,169,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_pp0p0" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012021-03-31_us-gaap_ProductMember_custom_AnimalCareMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,200,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Total Product Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3p0" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">12,179,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3p0" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012021-03-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">18,517,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Service/Royalty</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pn3p0" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ServiceMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">449,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pn3p0" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012021-03-31_us-gaap_ServiceMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">112,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331_pn3p0" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">12,628,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331_pn3p0" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">18,629,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the Company&#8217;s
revenues by geographic region:</p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zLFVfyGrcWfc" summary="xdx: Disclosure - Geographic Information (Details - Geographic regions)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B4_zU4cJrgRoiA2" style="display: none">Schedule of geographic sales</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_pp0p0" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,807,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_pp0p0" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,419,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_pp0p0" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,095,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_pp0p0" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,976,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Europe and Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_z9JI4GGjVUAl" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,726,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_pp0p0" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,234,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331_z3gxx56LAxPh" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,628,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200401__20210331_zmKl28Cg30Yk" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,629,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s service revenues in Latin
America amounted to $<span id="xdx_90C_eus-gaap--Revenues_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pp0p0" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-04-012022-03-31_us-gaap_ServiceMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">349,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--Revenues_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pp0p0" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-04-012021-03-31_us-gaap_ServiceMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">112,000</ix:nonFraction></span> for the years ended March 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_81F_zFXwNozuldXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_021"></span>ITEM&#160;9.&#160;Changes in and Disagreements
with Accountants on Accounting and Financial Disclosures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_022"></span>ITEM&#160;9A.&#160;Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain disclosure controls and procedures
that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is
recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information
is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate,
to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We carried out an evaluation, under the supervision
and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness
of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange
Act) as of the end of our most recent fiscal year. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures were not effective as of March 31, 2022. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the material weaknesses, management
believes the consolidated financial statements included in this Annual Report on Form 10-K present fairly, in all material respects, the
Company&#8217;s financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. generally
accepted accounting principles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s Annual Report on Internal
Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting, as such term is defined in the Exchange Act Rule&#160;13a-15(f) and
15d-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial
Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in the
<i>2013 Internal Control&#160;&#8212; Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on our evaluation, our management concluded that our internal control over financial reporting was not effective as of March 31,
2022. We concluded this because of the errors we found in the Form 10-Q filing from June 30, 2020 that were restated in our 10-Q/A that
was filed on November 17, 2020. We have determined that there were inadequate spreadsheet controls, a lack of separation of duties with
preparation and review of the reported numbers, and inadequate analysis of revenue reporting among other things. We also determined during
the quarter ended March 31, 2021 that there were errors related to income tax withholding accruals that required a revision in these financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s Remediation Measures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Management, with oversight
from the Audit Committee of the Board of Directors of the Company, is actively engaged in remediation efforts to address the material
weaknesses identified&#160;in the management&#8217;s evaluation of internal controls and procedures. Management has taken a number of
actions to remediate the material weaknesses described above, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 45; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt; background-color: white">&#183;</span></td>
    <td><span style="font-size: 10pt">Improved monitoring and risk assessment activities to address these control deficiencies.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt; background-color: white">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Hired a new full time Chief Financial Officer in September 2020 and a new corporate controller in October 2020 to replace the transitionary staff in place while we moved our corporate offices from Petaluma, CA to Woodstock, GA.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt; background-color: white">&#183;</span></td>
    <td><span style="font-size: 10pt">Separated the preparation of the financial reports from review of the financial reports.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt; background-color: white">&#183;</span></td>
    <td><span style="font-size: 10pt">Implemented additional process-level controls over revenue recognition of new contracts.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt; background-color: white">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Developed and delivered further internal controls training to individuals associated with these control deficiencies and enhance training provided to all personnel who have financial reporting or internal control responsibilities in these areas. The training will include a review of individual roles and responsibilities related to internal controls, proper oversight and reemphasize the importance of completing the control procedures.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt; background-color: white">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Did a detailed review of income taxes and our intercompany agreements which uncovered the fact that we should be accruing withholding taxes that will be paid to Mexico when intercompany interest and Technical Assistance payments are made to from Mexico to the United States that we will not be eligible for a tax credit in the United States because of our Net Operating Loss positions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These improvements are targeted at strengthening
the Company&#8217;s internal control over financial reporting and remediating the material weaknesses. We remain committed to an effective
internal control environment and management believes that these actions and the improvements management expects to achieve as a result,
will effectively remediate the material weaknesses. However, the material weaknesses in the Company&#8217;s internal control over financial
reporting will not be considered remediated until the controls operate for a sufficient period of time and management has concluded, through
testing that these controls operate effectively. As of the date of filing this Form 10-K, management is in the process of testing and
evaluating these additional controls to determine whether they are operating effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control over Financial
Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no changes in our internal control
over financial reporting during the year ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting. We have not finished our testing our remediated controls and sufficient time has not elapsed
to make the determination these controls are operating effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_023"></span>ITEM&#160;9B.&#160;Other Information&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_024"></span>PART&#160;III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_025"></span>ITEM&#160;10.&#160;Directors, Executive Officers and Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information required by this Item is incorporated
by reference to the definitive proxy statement for our 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange
Commission within 120&#160;days after the end of our fiscal year ended March 31, 2022 (the &#8220;2022 Proxy Statement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item&#160;405 of Regulation&#160;S-K requires
the disclosure of, based upon our review of the forms submitted to us during and with respect to our most recent fiscal year, any known
failure by any director, officer, or beneficial owner of more than ten percent of any class of our securities, or any other person subject
to Section 16 of the Exchange Act (&#8220;reporting person&#8221;) to file timely a report required by Section 16(a) of the Exchange Act.
This disclosure is contained in the section entitled &#8220;Section&#160;16(a) Beneficial Ownership Reporting Compliance&#8221; in the
2022 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Business Conduct</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted a Code of Business Conduct that
applies to all of our officers, directors, and employees, including our Chief Executive Officer, Chief Financial Officer, and other employees
who perform financial or accounting functions. The Code of Business Conduct sets forth the basic principles that guide the business conduct
of our employees. On January 17, 2017, our board of directors adopted changes to our Code of Business Conduct. The changes to the Code
of Business Conduct were made to update the code to current best practices. In addition to some clerical changes, the Code of Business
Conduct now explicitly requires employees, directors and officers to act honestly and ethically in dealing with customers, business partners
and others. Furthermore, the Code of Business Conduct now explicitly extends the confidentiality and conflicts of interest requirements
to directors and prohibits company loans. The Code of Business Conduct also updated the disclosure, reporting and enforcement provisions.
We filed our Code of Business Conduct with the Securities and Exchange Commission as exhibit 14.1 to the current report on Form 8-K on
January 23, 2017, and it is also available on our website at http://www.ir.sonomapharma.com/governance-documents. We will provide any
person, without charge, copies of our Code of Business Conduct and Ethics upon request. Such requests should be in writing and addressed
to: Sonoma Pharmaceuticals, Inc., Attention: Chief Financial Officer,645 Molly Lane, Suite 150, Woodstock, Georgia, 30189.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, there have been no waivers under our
Code of Business Conduct. We intend to disclose future amendments to certain provisions of our Code of Business Conduct or any waivers,
if and when granted, of our Code of Business Conduct on our website at http://www.sonomapharma.com within four business days following
the date of such amendment or waiver.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Procedures for Nominating Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no material changes to the procedures
by which stockholders may recommend nominees to our Board of Directors.&#160;The Board of Directors will consider candidates for director
positions that are recommended by any of our stockholders. Any such recommendation for a director nomination should be provided to our
Secretary. The recommended candidate should be submitted to us in writing and addressed to Sonoma Pharmaceuticals, Inc., Attention: Secretary,
645 Molly Lane, Suite 150, Woodstock, Georgia, 30189. The recommendation should include the following information: name of candidate;
address, phone and fax number of candidate; a statement signed by the candidate certifying that the candidate wishes to be considered
for nomination to our Board of Directors and stating why the candidate believes that he or she would be a valuable addition to our Board
of Directors; a summary of the candidate&#8217;s work experience for the prior five years and the number of shares of our stock beneficially
owned by the candidate.&#160;&#160;The Board will evaluate the recommended candidate and shall determine whether or not to proceed with
the candidate in accordance with our procedures. We reserve the right to change our procedures at any time to comply with the requirements
of applicable laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_026"></span>ITEM&#160;11.&#160;Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information required by this Item is incorporated by reference
to the 2022 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_027"></span>ITEM&#160;12.&#160;Security Ownership of Certain Beneficial Owners
and Management and Related Stockholder Matters.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information required by this Item is incorporated by reference
to the 2022 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information required to be disclosed by Item
201(d) of Regulation S-K, &#8220;Securities Authorized for Issuance Under Equity Compensation Plans,&#8221; appears under the caption
&#8220;Equity Compensation Plan Information&#8221; in the 2022 Proxy Statement and such information is incorporated by reference into
this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_028"></span>ITEM&#160;13.&#160;Certain Relationships, Related Transactions,
and Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information required by this Item is incorporated by reference
to the 2022 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_029"></span>ITEM&#160;14.&#160;Principal Accounting Fees and Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information required by this Item is incorporated by reference
to the 2022 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_030"></span>PART&#160;IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_031"></span>ITEM&#160;15.&#160;Exhibits, Financial Statement Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(a)&#160;Documents filed as part of this report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(1)&#160;&#160;&#160; <i>Financial Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reference is made to the Index to Consolidated
Financial Statements of Sonoma Pharmaceuticals, Inc. under Item&#160;8 of Part&#160;II hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(2)&#160;&#160;&#160; <i>Financial Statement
Schedules</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial statement schedules have been omitted that are not applicable
or not required or because the information is included elsewhere in the Consolidated Financial Statements or the Notes thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(b) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit&#160;Index</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Exhibit No.</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify"><b>Description</b></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="width: 10%; text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td style="width: 90%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013407013693/f31114exv3w1xiy.htm"><span style="font-size: 10pt">Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective January 30, 2006</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 of the Company&#8217;s Annual Report on Form 10-K filed June 20, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.2</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013408013005/f41943dedef14a.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective October 22, 2008</span></a> <span style="font-size: 10pt">(included as exhibit A in the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed July 21, 2008, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">3.4</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968713000950/oculus_8k-ex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective March 29, 2013</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed March 22, 2013, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.5</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968714004634/oculus_ex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective December 4, 2014</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed December 8, 2014, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">3.6</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968715003810/oculus_8k-ex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective October 22, 2015</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed October 27, 2015, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.7</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968716006784/oculus_8k-ex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective June 24, 2016</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 28, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">3.8</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000874/sonomaex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective December 6, 2016</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.9</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000874/sonomaex0302.htm"><span style="font-size: 10pt">Amended and Restated Bylaws, as amended, of Sonoma Pharmaceuticals, Inc., effective December 6, 2016</span></a> <span style="font-size: 10pt">(included as exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">3.10</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968712001481/oculus_8k-ex0402.htm"><span style="font-size: 10pt">Certificate of Designation of Preferences, Rights and Limitations of Series A 0% Convertible Preferred Stock, filed with the Delaware Secretary of State on April 24, 2012</span></a> <span style="font-size: 10pt">(included as exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K, filed April 25, 2012, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.11</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000348/oculus_8k-ex0301.htm"><span style="font-size: 10pt">Certificate of Designation of Series B Preferred Stock, effective October 18, 2016</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by references).</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">3.12</span></td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316819001947/sonoma_ex0301.htm"><span style="font-size: 10pt">Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective June 19, 2019</span></a> <span style="font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 19, 2019, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316817001670/sonoma_ex0401.htm"><span style="font-size: 10pt">Specimen Common Stock Certificate</span></a> <span style="font-size: 10pt">(included as exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K filed June 28, 2017, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">4.2</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000348/oculus_8k-ex0401.htm"><span style="font-size: 10pt">Section 382 Rights Agreement, dated as of October 18, 2016, between Oculus Innovative Sciences, Inc. and Computershare Inc., which includes the Form of Certificate of Designation of Series B Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Stock as Exhibit C</span></a> <span style="font-size: 10pt">(included as exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">4.3</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316818000600/sonoma_8k-ex0401.htm"><span style="font-size: 10pt">Form of Placement Agent Warrant granted to Dawson James Securities, Inc. and The Benchmark Company, LLC in connection with the March 2, 2018 public offering, dated March 6, 2018</span></a> <span style="font-size: 10pt">(included as exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed March 6, 2018, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">4.4</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316819003854/sonoma_8k-ex0401.htm"><span style="font-size: 10pt">Form of Placement Agent Warrant granted to Dawson James Securities, Inc. in connection with the November 2019 public offering</span></a> <span style="font-size: 10pt">(included as exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on November 29, 2019, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406017848/f21666a1exv10w1.htm"><span style="font-size: 10pt">Form of Indemnification Agreement between Oculus Innovative Sciences, Inc. and its officers and directors</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406012612/f21666orexv10w10.htm"><span style="font-size: 10pt">Office Lease Agreement, dated May 18, 2006, between Oculus Technologies of Mexico, S.A. de C.V. and Antonio Sergio Arturo Fernandez Valenzuela (translated from Spanish</span></a><span style="font-size: 10pt">) (included as exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406012612/f21666orexv10w11.htm"><span style="font-size: 10pt">Office Lease Agreement, dated July 2003, between Oculus Innovative Sciences, B.V. and Artikona Holding B.V. (translated from Dutch)</span></a> <span style="font-size: 10pt">(included as exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.4</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406012612/f21666orexv10w20.htm"><span style="font-size: 10pt">Form of Director Agreement</span></a> <span style="font-size: 10pt">(included as exhibit 10.20 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.5</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000089161807000277/f29846exv10w2.htm"><span style="font-size: 10pt">Amended and Restated Oculus Innovative Sciences, Inc. 2006 Stock Incentive Plan and related form stock option plan agreements</span></a> <span style="font-size: 10pt">(included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed May 2, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.6</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013408011240/f41055exv10w44.htm"><span style="font-size: 10pt">Amendment to Office Lease Agreement, effective February 15, 2008, by and between Oculus Innovative Sciences Netherlands B.V. and Artikona Holding B.V. (translated from Dutch)</span></a> <span style="font-size: 10pt">(included as exhibit 10.44 to the Company&#8217;s Annual Report on Form 10-K filed June 13, 2008, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.7</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000114420411042892/v230002_def14a.htm"><span style="font-size: 10pt">Oculus Innovative Sciences, Inc. 2011 Stock Incentive Plan</span></a> <span style="font-size: 10pt">(included as exhibit A in the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed July 29, 2011, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.8&#8224;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968716005552/oculus_8k-ex1001.htm"><span style="font-size: 10pt">Exclusive Sales and Distribution Agreement, dated November 6, 2015, by and between Oculus Innovative Sciences, Inc. and Manna Pro Products, LLC</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s 8-K filed March 23, 2016 and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.9&#8224;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000424/oculus_ex1001.htm"><span style="font-size: 10pt">Asset Purchase Agreement dated October 27, 2016, between Oculus Innovative Sciences, Inc. and Invekra, S.A.P.I de C.V.</span></a> <span style="font-size: 10pt">(included as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.10&#8224;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000424/oculus_ex1002.htm"><span style="font-size: 10pt">Amendment Agreement to Acquisition Option dated October 27, 2016, by and between More Pharma Corporation S. de R.L. de C.V. and Oculus Technologies of Mexico, S.A. de C.V.</span></a> <span style="font-size: 10pt">(included as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.11</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968716007052/oculus_def14a-072716.htm"><span style="font-size: 10pt">2016 Equity Incentive Plan</span></a> <span style="font-size: 10pt">(included as exhibit A in the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed July 29, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.12</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316818000600/sonoma_8k-ex1002.htm"><span style="font-size: 10pt">Securities Purchase Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and Montreux Equity Partners V, L.P., dated March 1, 2018</span></a> <span style="font-size: 10pt">(included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on March 6, 2018, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.13&#8224;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316818001589/sonoma_8k-ex1001.htm"><span style="font-size: 10pt">Exclusive License and Distribution Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and EMS.S.A., dated June 4, 2018</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on June 5, 2018, and incorporated herein by reference).</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.14</span></td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316818003538/sonoma_8k-ex1002.htm"><span style="font-size: 10pt">Warrant Agency Agreement entered into by and among Sonoma Pharmaceuticals, Inc., Computershare, Inc. and Computershare Trust Company, N.A., dated November 21, 2018</span></a> <span style="font-size: 10pt">(included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on November 21, 2018, and incorporated herein by reference). </span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.15&#11832;+</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316819001691/sonoma_8k-ex1001.htm"><span style="font-size: 10pt">Asset Purchase Agreement dated May 14, 2019, between Sonoma Pharmaceuticals, Inc. and Petagon, Ltd.</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 22, 2019, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.16&#11832;+</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820000599/sonoma_ex1001.htm"><span style="font-size: 10pt">Asset Purchase Agreement dated February 21, 2020, between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, DMCC</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 27, 2020, and incorporated herein by reference.)</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.17&#11832;+</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820001735/sonoma_8k-ex1001.htm"><span style="font-size: 10pt">License, Distribution and Supply Agreement by and between Sonoma Pharmaceuticals, Inc. and Brill International, S.L. dated May 19, 2020</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 26, 2020, and incorporated herein by reference.)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.18</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820001864/sonoma_ex1002.htm"><span style="font-size: 10pt">Consulting Agreement between the Company and Dr. Robert Northey, dated May 30, 2020.</span></a> <span style="font-size: 10pt">(included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on June 4, 2020, and incorporated herein by reference.)</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.19&#11832;+</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820002126/sonoma_ex1001.htm"><span style="font-size: 10pt">Asset Purchase Agreement between the Company and Infinity Labs SD, Inc., dated June 24, 2020</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on June 30, 2020, and incorporated herein by reference.)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.20+</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Woodstock Lease Agreement between the Company and Fowler Crossing Partners, LP, dated October 1, 2018.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.21&#11832;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820002539/sonoma_ex1001.htm"><span style="font-size: 10pt">Licensing Agreement between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, effective July 27, 2020</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on August 6, 2020, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.22&#11832;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820004342/sonoma_ex1001.htm"><span style="font-size: 10pt">Licensing and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Gabriel Science, LLC, effective December 14, 2020</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on December 17, 2020, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.23&#11832;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316821001155/sonoma_8k-ex1001.htm"><span style="font-size: 10pt">Exclusive Supply and Distribution Agreement between the Company and EMC Pharma, LLC, dated March 26, 2021</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on March 31, 2021, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.24</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316821002837/sonoma_ex1001.htm"><span style="font-size: 10pt">Employment Agreement by and between the Company and Amy Trombly, dated July 1, 2021</span></a> <span style="font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on July 6, 2021, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.25</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316821002837/sonoma_ex1002.htm"><span style="font-size: 10pt">Employment Agreement by and between the Company and Jerry Dvonch, dated July 1, 2021</span></a> <span style="font-size: 10pt">(included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on July 6, 2021, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.26</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316821002837/sonoma_ex1003.htm"><span style="font-size: 10pt">Employment Agreement by and between the Company and Bruce Thornton, dated July 1, 2021</span></a> <span style="font-size: 10pt">(included as exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on July 6, 2021, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.27</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316821003188/sonoma_8k-ex1001.htm">At-The-Market
    Offering Agreement, by and between the Company and H.C. Wainwright &amp; Co., LLC, dated July 30, 2021</a> (included as exhibit 10.1
    to the Company&#8217;s Current Report on Form 8-K filed on July 30, 2021, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.28</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2021
    Equity Incentive Plan (included as appendix on the Company&#8217;s proxy statement filed on July 29, 2021 and incorporated herein
    by reference).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.29+&#11832;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316821005361/snoa_ex1001.htm" style="-sec-extract: exhibit">Exclusive
    License and Distribution Agreement between the Company and Dyamed Biotech Pte Ltd., dated November 4, 2021</a>&#160;(included as exhibit
    10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 9, 2021, and incorporated herein by reference).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">10.30+&#11832;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316822000342/snoa_ex1001.htm">Non-Exclusive
    Distribution and Supply Agreement between the Company and Salus Medical, LLC dated January 19, 2022</a>&#160;(included as exhibit 10.1
    to the Company&#8217;s Current Report on Form 8-K filed on January 20, 2022, and incorporated herein by reference).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.31+&#11832;</span></td>
    <td style="width: 90%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316822000342/snoa_ex1002.htm">Exclusive License and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Anlicare International dated January 18, 2022</a>&#160;(included as exhibit 10.2 to the Company&#8217;s Current
    Report on Form 8-K filed on January 20, 2022, and incorporated herein by reference).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">14.1</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316817000150/sonoma_8k-ex1401.htm">Code of Business Conduct</a> (included as Exhibit 14.1 to the Company&#8217;s Current Report on Form 8-K filed on January 23, 2017, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">21.1</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316817001670/sonoma_ex-2101.htm">List of Subsidiaries</a> (included as Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K on June 28, 2017, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">23.1*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="sonoma_ex2301.htm">Consent of Frazier and Deeter independent registered public accounting firm.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">23.2*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="sonoma_ex2302.htm">Consent of Marcum LLP independent registered public accounting firm.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">31.1*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="sonoma_ex3101.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: center"><span style="font-size: 10pt">31.2*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="sonoma_ex3102.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">32.1*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="sonoma_ex3201.htm">Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: center"><span style="font-size: 10pt">101.INS*</span></td>
    <td style="width: 90%; text-align: justify"><span style="font-size: 10pt">XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">101.SCH*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Schema.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">101.CAL*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">101.DEF*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">101.LAB*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">101.PRE*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-size: 10pt">*</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#8224;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Confidential treatment has been granted with respect to certain portions of this agreement.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#11832;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;Certain portions of the exhibit have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">+</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The schedules to the exhibit have been omitted from this filing pursuant to Item 601(a)(5)&#160;of Regulation S-K.&#160; The Company will furnish copies of any such schedules to the SEC upon request.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Copies of above exhibits not contained herein
are available to any stockholder, upon payment of a reasonable per page fee, upon written request to: Chief Financial Officer, Sonoma
Pharmaceuticals, Inc., 645 Molly Lane, Suite 150, Woodstock, Georgia, 30189.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(c)&#160;Financial Statements and Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reference is made to Item&#160;15(a)(2) above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="a_032"></span>ITEM 16. Form 10-K Summary.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_033"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Section&#160;13
or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>SONOMA PHARMACEUTICALS, INC.</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 35%">&#160;</td>
    <td style="width: 10%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: July 13, 2022</span></td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">/s/ Amy Trombly</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">Amy Trombly</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">President and Chief Executive Officer,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(Principal Executive Officer)</p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: July 13, 2022</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">/s/ Jerome Dvonch</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Jerome Dvonch</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Principal Financial and</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Principal Accounting Officer</p></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and
on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 21%; text-align: center"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 56%; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 21%; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">/s/&#160;Amy Trombly</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">President, Chief Executive Officer </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 13, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Amy Trombly</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">/s/ Jerome Dvonch</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 13, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Jerome Dvonch</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Principal Financial and Principal Accounting Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">/s/&#160;Jay Edward Birnbaum</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 13,  2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Jay Edward Birnbaum</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">/s/&#160;Philippe Weigerstorfer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 13, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Philippe Weigerstorfer</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">/s/&#160;Jerry McLaughlin</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 13, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Jerry McLaughlin</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 84; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>sonoma_ex2301.htm
<DESCRIPTION>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM CONSENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; background-color: White"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference in
the Registration Statement of Sonoma Pharmaceuticals, Inc. on&nbsp;Form S-3 (File No. 333-221477), Form S-8 (333-262144), Form S-8 (File
No. 333-228898), Form S-8 (File No. 333-219058), Form S-8 (File No. 333-214760), Form S-8 (File No. 333-205171), Form S-8 (File No. 333-171412),
Form S-8 (File No. 333-182263), Form S-8 (File No. 333-195530), Form S-8 (File No. 333-194314), Form S-8 (File No. 333-163988) and Form
S-3 (File No. 333-250925) of our report dated July 13, 2022, which includes an explanatory paragraph as to the company&rsquo;s ability
to continue as a going concern with respect to our audit of the consolidated financial statements of Sonoma Pharmaceuticals, Inc. and
Subsidiaries as of March 31, 2022 and for the year then ended, which report is included in this Annual Report on Form 10-K of Sonoma Pharmaceuticals,
Inc. for the year ended March 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Frazier &amp; Deeter, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Atlanta, Georgia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 13, 2022</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>sonoma_ex2302.htm
<DESCRIPTION>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM CONSENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; background-color: White"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">We consent to the incorporation
by reference in the Registration Statement of Sonoma Pharmaceuticals, Inc. on Form S-3 (File No. 333-221477), Form S-8 (333-262144), Form
S-8 (File No. 333-228898), Form S-8 (File No. 333-219058), Form S-8 (File No. 333-214760), Form S-8 (File No. 333-205171), Form S-8 (File
No. 333-171412), Form S-8 (File No. 333-182263), Form S-8 (File No. 333-195530), Form S-8 (File No. 333-194314), Form S-8 (File No. 333-163988)
and Form S-3 (File No. 333-250925) of our report dated July 14, 2021, which includes an explanatory paragraph as to the company&rsquo;s
ability to continue as a going concern with respect to our audit of the consolidated financial statements of Sonoma Pharmaceuticals, Inc.
and Subsidiaries as of March 31, 2021 and for the year then ended, which report is included in this Annual Report on Form 10-K of Sonoma
Pharmaceuticals, Inc. for the year ended March 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">/s/ Marcum LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Marcum LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">New York, NY</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="background-color: white">July 13, 2022</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>sonoma_ex3101.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Amy Trombly, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on Form
10-K of Sonoma Pharmaceuticals, Inc. for the year ended March 31, 2022;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Disclosed in this report any change in the
registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">/<U>s/ Amy Trombly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="width: 8%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date: July 13, 2022</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amy Trombly</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>sonoma_ex3102.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Jerome Dvonch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on Form
10-K of Sonoma Pharmaceuticals, Inc. for the year ended March 31, 2022;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Disclosed in this report any change in the
registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>/s/ Jerome Dvonch&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="width: 8%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date: July 13, 2022</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Jerome Dvonch</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Financial Officer and Principal Accounting
    Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>sonoma_ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to section 906 of the Sarbanes-Oxley
Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officers of Sonoma
Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), do hereby certify, to such officers&rsquo; knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Annual Report on Form 10-K for the year ended
March 31, 2022 (the &ldquo;Form 10-K&rdquo;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition
and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: July 13, 2022</FONT></TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>/s/ Amy Trombly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="width: 8%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amy Trombly</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Executive Officer)</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date: July 13, 2022</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>/s/ Jerome Dvonch&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jerome Dvonch</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Financial Officer and Principal Accounting
    Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>a1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #$ #D# 2(  A$! Q$!_\0
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M10!6NKI;9>1O=NB5G?OGWS;/OU-JG_'U#_N/5:?[E &=?;)/X_+K+^RP[_\
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M-Q/K?]FIIB76_P"1+;?OV(GW$^?_ +[KUK3=5N?D2+1YHTW[/,^Y\E<OX?\
MX*[^R_U-=<*5;^<SE.'\AT_A?_CTG_ZZFMNL3PO_ ,>D_P#UU-;=:O<S.<\5
M?ZFU_P!]ZS4_U*5I^*_N6W_ _P"59B?ZE*J)!R/B:1(_DWIO?[D>_P"_7 3S
MPR/O29)$W_\ +-ZF^*&E:E(D]YJO]C7^G0N_D^98333HCO\ <^1_]A*\?U*.
M&>\_M)[/2;N>;?-YD>FWGSOO?_OC_?J"X'O?A^1)-FQ_,KO[+_4UXW\,K'4K
M2VLOWVF1Z1Y.](+&V=/G?Y_XZ]DLO]36\")'3^%_^/2?_KJ:VZQ/"_\ QZ3_
M /74UM9K I;'F7QF\6MX3T_3+A('F,MPR8239_ :X6#XV6WDIOL[Z/\ [X>M
MW]I88T'1O^OIO_0#7A'\-?C'$N?9C@,PE1P\_=/L,MR_#XG#<\XGH&L?%NSG
M^XE]_P!^4_\ BZXV?XFVTDW_ "]_]^4_^+KY^^/6I:EJ%U:Z=IMSK>ASP_:4
M^U6MMO@N=\.Q-C[_ .!W_P#B*\KNEUY[K4/-UW6Y(/.WS1R0W*)>?OM^R9T?
M]S\GR?N?[E>A@<TS"M1A6G6(JX3#PGR<A]V:5\5+.#9^YN_^^$KJ(/C3#'#\
MEG=R?\#1*^1?@UK,W^FZ;<?;I_.N9KR&>>%]D*?)^YWN[O\ [E>SP_=KY[,>
M(\SPL^2$SOP^7X2<.?D/J;X.^)6\6>'+N[>'R"MVR;-^_HB5WVSWKR;]F_CP
M5?'_ *?G_P#0$KU;SJ_6LGKRQ67T*]?XI(^,QD8T\1.,3QS]IC_D!Z/_ -?3
M?^@&O!_X:]Y_:6_Y &C?]?G_ +(:\&_AK\6XS_Y&TO\ MT^UR7_=CF_%6@:;
MKFS^T+"WOO)W[//3?LW_ 'ZX:3X>^&$=T3P]I\:/]_RX?OUZ!XBOK;2K.>\O
M9DM+6%/GGG?Y$KD+KQ'I4<VQ]2M(_DW_ .N2O-P52MR>X>A5A#G]\U/#.AZ;
MH<+PZ?86]A [[WC@39790_=KE]*D21$='21'^Y)'740_=KS,=-SG[YO2V/HS
M]F[_ )$N]_Z_G_\ 0$KUFO)OV;O^1+O?^OY__0$KUFOZ&R/_ )%6'_PH_.<=
M_O,_4^:_VUOBEH'PM\+>%KK7WN;>UO=2>!)H(MX1Q [?-^5>$Z5\6_!FL6R/
M;^)-/^=-_P"_?R7_ /'Z]@_X*"_".^^+/PHTR72;"34]2T'4/[02UB_UCIY;
MH^U/XSS7Y@7U]_9K/;7J/:3I]^.Z38__ (_7DYQPOALVQ'UF4Y1F>G@<PEA:
M7(?;'B#6-'UBS>&WUO3/G_Z;0S(__ *X>?1[:2:#?J6C^0GWXX[:'Y_GKY+D
MNH7_ +E$=U#_ +%>=A^%/8PY(5?_ "4[I9CS_9/MCPYJMGIM@D-[K&F2.G_/
M.9$1$_@2MN3XC>%=-3_2/$.G_P#7..;?_P"@5\+6M];1_P!RNAT?4O[5O(+:
MR1[N=WV)' F]ZPEP72K3YYU33^UN2!^M7[*^M6GB#X?WM[9.TEN]\^URFS^!
M*]IR/2O#?V0_!^J>"O@_:6^LVSVE[<S/<&WD^\N:]S_"OT7 X6&!P\,-'[)\
MGB*OMJTIC&C66/:ZAA[US'B#X<^%_%$.-7\/Z=J0_P"GJV63_P!"!HHKO,#@
M=0_9!^#FL-))=?#W1&;_ *9VJQ_^@@5S_P#PQ3\$=_\ R3S2_P Y/_BJ** -
MW2_V/?@UIS>9#\/=$W?]-+59/_0@:[SP[\-_"GA/_D#>'-+TS_KUM4C_ /00
/*** .M2-8^@I]%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>a2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #$ &D# 2(  A$! Q$!_\0
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M^$O6]:]B]8\-:=F]<G-RRYC&1TNE/_I47^\M?2%Y_P BX/\ =B_FM?-6E/\
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GJ^ -"_Y\(ZMV?A#1X?NV,0_X#110!KV]G#;IB*)8Q_LBIJ** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>a3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "H (P# 2(  A$! Q$!_\0
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MBBB@ HHHH **** "BBB@!COM7=7!>)]2@FL98%;8^YG^>NWOGV6KM7E6O?\
M+:@"WX5U*#36E667?N_N5Z-I=PMQ8PE?[BUX]9_)+_P*O5?#+?\ $MB_W/\
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M^&4_[?+C_OC[E>X>$GOIM&M'U.*"'4&B7SX;=M\2M_'L>N-L_P#CX%=[H_\
MJZ[=38[?PU_QZM_N_P#L[UQ&E::UY>:[JLC?O9Y=S._]U?N)_NI7::!_QXR_
M[O\ 5JP]'_Y VJJO_/6N:7Q!'X#SS_A<WA'[JZG(_P#N6KU,GQ=\*NO_ "$)
M/^_#U:TWX>^&OD_XD=C_ -^JY+1_$GAK6)[V*V^&6H7_ -EO/LL_V>P1/*^_
M\[[MG]S^#^_5RE0C*,>67]=^QY$O[0C[JJ4_Q.HMOB[X5AE1O[55$_BW0/\
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FH U;'P+H.FMNMM+MX6_V5K6AL8(?]7$J?\!HHH F\NGT44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>a4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #, $@# 2(  A$! Q$!_\0
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MS/Y*KM'S-TK-OGN8T=TN6W_\\XTK4FC\QTJ&[_X]I* //-<\3:KIKH\-^_\
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MIM]/_P!<TV5T-K8ZQX@1(98?L%EOWO'O^=Z]4ATFTM_]7 J_2K$=O'']U<4
..8VDZ5]AA1**VJ* /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>a5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #@ #@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
ML75(_MVHQVQF>--F_P"2N>O=.2&^>+[2[[?]N@#NZ*Y>PC_L_4H4BEEV.^QX
MY&S744 %%%% !1110!B2_P#(<?\ ZY+_ #K,U2-8]1F=>KO6NT?_ !.)W_V$
M2LC6/^/QZ )Y'_XFEE_UVKIZY63_ (_[5_\ ILE=50 4444 %,D;RT9J?4<W
M^I;Z4 9+3.MP\K)PU9>I1O=3._R;'K1G_P!9562@"&2?YT^3[CH]='8W7VVW
MW[=E<E)]X5TVB_\ 'G_P*J T:***D J.;_4M]*DK%OKI[I]B_)#_ .AT ,GJ
MK/(G]]/^^Z)-]021_P"PE$""K)(F_P"^G_?==)HF_P"S5S$D?S_<2KNGZ@^G
MM_?A_C2J&==14<<BR(K+RK45)1#?2;8MO][BL_RZNZA_!5:@"K/'Y=5'J]?2
M?)6=(]7 @9!!Y],D3RZ(Y_+WT>9YCUJ!NZ#-_H[PM_!14&@O_I$W^[17.6:5
M]_!4%3WW\%04 5+J,[>N:S)ZY*\USQ+)XFFL;6PN$^2;9<.G^BI\GR?^R5A1
MS_%WR84EA\(23[$WN_VGY_[[_P#H=<^'E5EI5I<OW?\ @6AA[6E6_A2/1XT\
MRG^6GI7*>"_^$SCU*?\ X26;1I++R?W/]FPNC[_]O>[UUTE>@:&AH'_'Q/\
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M6K$Z2">LZ2!_[CUXS^TI8W/BV2PT;R]=TI(1<)#J&FB'9<>=#LV?/(GR)O\
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C9VO^IMXT_P" U?,'*9/A6UN/WES-#Y"/]R.BNA^Y14%G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>a6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "T 4L# 2(  A$! Q$!_\0
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M[U?4YAPAF.68:6*K./+'S_X!Y&'SS"XJK&E&]Y'V51117Q)]$%%%% !1110
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M2V\C;F;:W]VIM8M?LZJW]ZL^U5O.5:[:9S2/7?#>KPZI9J!*6N%'[Q7^5O\
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M6W,WV5?F_=LO_H3;O_':X/0?#^H6%](RW6GK)-,LS-!IZQ[FV[?F^;^ZJ_\
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MU6_N_:H__BJV]G/^4YI8RC'_ )?1_KYG4^#/.75[%9Y%GF^RMYDBQ[59MO\
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M/VD@Y(GA_P 9OA"GC;5$O9=&M]9PNQ6;Y9(5_BV_]\UY%-^SC:^9_P B3/\
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "J *H# 2(  A$! Q$!_\0
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M***8@HHHH XCX@_Z^Q_W7_F*Y%>]==\0?^/BQ_W7_F*Y%>]>]@_X,3XW-/\
M>I_+\D!IIIQIIKI9YZ&2.(T9VSA1DX&36#,C3SRR)<2[&8MY9C8#!V\''/."
M/QKH.E57L()&8L'RQ).'(K"K!SV.S#5HTKMF/Y),; R.Q9"JYCDS%R>%]N>_
MI70VTPG4, 1@X.1CFJQTVW;&X2'' RYJY& NT 8 I4J<H%8BO"K:QZJMA:3(
M#+:P/QU:,&L77=/M;:V\RVTB&X?<!M2,9QZUT,61$, $XX!KCI#XIBMPC3Z;
M<./X]_WLDDD\#IE0/I7A.4FK79]>Z4&ME?T1%_9^'.-"LSSP?- _I71V6D6
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M9_%GGX\!:@?O3P#\ZE7X?W7\5Y$/HIKNZ*GZW6[EK*\*OL?B_P#,XE?A\_\
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EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "\ ),# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **SCKE@K%
M3*<@D'Y35:Y\4:9:.JRR2?,NX%4)KG>+H+>:^\U5"J]HLVJ*Y\>,M'_YZR?]
M^S2CQAHY_P"6TG_?LU/UW#_SK[ROJU;^5F_16$/%VDG_ ):O_P!^S2_\)9I/
M_/9_^^#3^N8?^=?>+ZO6_E9N45A_\)9I'_/PW_?!I?\ A*]('_+R?^^#1]<P
M_P#.OO#ZO6_E?W&W16+_ ,)7I'_/R?\ O@U=L-4M-2W_ &67?LQNXQC-7#$T
M9OEC)-DRHU(J\HM%VBBBMC,**** "BBB@ HHHH **** . 9HVGF(=>)''7N"
M<UGZZO\ QZD=T/\ .FZIHT]S<W;1O ^YY"%((/TST]N:FUE-EO8KCE8R#BOB
MJM.,6W%W_P"'/I(2UC_70Q<4H%0S^;]JM4CW[2S%]H.",=^/4^U6@/Q'M7.X
MM),Z+C02*?DYH I0M&HKC&PJEB< #)JA]L<H_P"_CRI R8S@>QK4"TX)QC''
MI5Q:6Z%<R4OBW'VB(G_KFPKT+P0FW[;]4_K7*A/8?E78^#UVQW7N5_K7HY;9
MXF+2[_D<>.?[AG3$A022 !W-1_:(#TFC/_ A5;45$OD1.,H[_,OK4%VZVJ_(
MN /X:^HN>%8TEFB=MJ2(Q] P-/KEA-$[&9(]DJ,"&'7K74TQ!1110 4444 %
M%%% 'F=ZD<>I7$C"-#YS'+!X\\]<C@U+K9#PV;J0596((].*NBV1K^Y?S #Y
MS';'(<'GHP/>H-;3]W:X[!OZ5\A65W+^NI[\9:Q_KH>>^,-1DLX[&U4SB*ZD
M(F,!Q(4&,JON<UB7-D_@Z6"Y@N+F6::?CY<1^5W23_;YZ=L5VNM6%M=60EN+
MEK0VK>='=*<&%AW]Q[5ROAG3M.OKUXFUR2^"R_:?LK1M&)''\9W?>_"O0PDX
MQP_DK\RMOVUL=2DK'7Z@ (%(-PIW@@P+N;OVJDH92FZ75#U('E#MV-:EZJ&$
M&5IE&X?-$2&!Y]*I+%9E@HN=0) W??;\JX*45RF?,1HDK8;S=57<2<%!\N/_
M -=6K>PE98I?MEZHX;RY,?D:C6.TPI\W4"%!7DMW_P *F@L;2ZF8I-?!@ 22
M[+[?G_C526G;Y!S&BL9]*Z[PF,17/U7^M<G:6*6BN(VE8,<X=]V/IZ5U_A==
ML=S]5_K6^6PMB%;S_(Y,;*])HT[X_P"D6O\ O$U3U/[E7KE-]U!GHH8_RJCJ
M/*XVY_'%?2'C&(K?N)R.PS7:#D"N,VX@G 7'R'^+-=C&<Q(?510@8ZBBBF(*
M*** "BBB@#@KQ%^USLRC'F-\S1Y'7^\O(_&C5E7R+/;RNTXY^E32NJW\K>2K
M,LA_U;8;KW!ZT_4K:6YCM3&G'S9)XQTKYETY2;25_P#ASV.9*S?]:'#^+;.:
MZ\/N((6F\N6.62%>LB*<D?Y]*SEO[7Q%XBTA]*M946R9I)YFBV!$QCR_>MCQ
M9#KFE0I>6.H6J1.T<"6[0[GDE9L  G@#_"F"U\2:9XBT>TU;5;22TOI&0F"
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M@?[X;'TJU-WK)N^AKV[GG6*KSVB%@%D^;@\"NATN]^VPL=FT(0HY[8KCI?\
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M_E6&%P*V_#[!(KDG^\/Y5E@E:JOF7B/X;-"8*&VG=N]AFL._N;6$D2/("/\
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MUW:QBP:") J(OR*.BXYK'DC7[*V\E4QR0,D<UP8B@HU/=6C-85G*.IZ;;_\
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4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #( *0# 2(  A$! Q$!_\0
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-10 ZBBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #. ?@# 2(  A$! Q$!_\0
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M/77_ &&C[#0!R']CT?V/77_8:/L- '(_V72?V/77_8:/L- '(?V/1_8]=?\
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MV-0W_P"^E6X_A#81N[_VE??^.5!J:&E>*M>G^_IMI'_VVKJ]*UR_D^_9P_\
M?=<]IOPUMH/D_M*^V5U>F^$4M]G^F7%0,V[759H_OHE:D>L/_<2JMKH:1_\
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M)M0GA3^^Z0I\E?,7B:UN?^%1>*_]#N-Z?%V&;R_)?[F_[_\ N5W/A'XA:/\
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M4G3^"2-*D@UR;0YGAN/WB)_RSK4TJU31]*@='\QW3SOWE<[?3_:KQYI43?4
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M(_#$_P#:MS<6FG[T\Z>U^^GSUYY/?>%?)M43Q;JT$%M9O^[C1]CIO=_.>KC
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M*GCDUC_GC8_]_G_^(KQNUU3PW)X,\2S?\+"U;6H+:V2:YGCWO/#^^WIY*?\
MCFRKNJZKHFF^'M+MM0\?WVR__P!-2>3?^^AFV(G\?_L_\;_)6?*![7:_VE_&
MEI_WV]:]I'>2.CO#:;T^Y)\]> :/8Z5]@>\_X61XAGTZP?\ TF.3>GR.^S[_
M /\ $5U%WX@T&?4DF?QSKEA!#9HCP>2Z03.GR;_[^]ZCD.@]UM?M/]R&KOES
M2??2&2O&+&^T2ZL_WOC/69-Z;/+D1]^S^/>B?[_S_P# *[SPYX<AU+PK:I::
M]?7>G3/]JMIY/OU'(!V4?G?\M=FS_IG16)X<\(_\(Y>75RFI7=W]I3]]'/\
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M'_B6Z//]H_T=W?\ CH(F58]G]M[_ ./?6W\3?^0;9/\ [=<A')_I^_\ V_\
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M][_/YB;ZR[KQ5>:I<P)=N]W=;/\ 40/L1/\ @%:0A[0PG,]HDC21-CHDB?\
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M7E\Z/%"\B(_^L_@KLM5NKFZAV);)_P!_JN!$SEX_^/BO2O#G_'FE>=QZ5?\
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MY$_YY[ZP=2@>-_\ CPM][_(GSU=NKZS_ .?#_P ?K%OM2L_G1[#[_P#MUR7
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M_?=9>N>)+F#_ )<W_P#'_P#XBN\Y>8M2/4D<E<-?>-+R"%'_ +-\S?\ [_\
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MWFQ*.81ZCH?_  D\=LF^S_?[_P#GSA3Y/^_U>A>'X];NH=DNRT?[_F26R?\
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M&WTVXW_\]'?97H5CL@LX-Z):?],]_P!RN7E]\VYCYZ\1R?\ %0ZI_P!?+_\
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M;_\ <KFO"O[/7C#QYX&TO6[K6/"?A=]5A2ZT>QU)YDNKF'[B/\GW$?\ V_\
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M33;]G\'W*]=F\:? &XT>ZTW1_$\6A?VE<I,]U'#,_P!C=/N.B;/_ !ROD_\
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5:MV^BLGQ1B_^?<1K(</_ ,_)'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $H 5H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK#ZY8>=_K'AF>']W_'LK[+^"&N:5X@^%WAN]T>^AU&P^QI")H7WC>GR.F?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN2/#>(G_ +3.7OG5+B'#<_U:$?</!/A7^T=XKU'QQIVFZ];6L]K>W_\ 9EQ
MB(EU87.S?]S^Y7KG[0&DPCPS:ZQ\L=U;3>2__39'JWIOPK\$^ -;G\57<S_V
MC\[_ &[4;G_4_P"Y7C?QH^*D?CN_M=.TK?\ V19OO\]_^6S_ -^OJ<EHXNB^
M>M,^:SVM@:T.2C ]Q_9O\5>&)_AW#HFMI%Y_VR9T>3^X]=9\6/@GX;U+P!JE
M_HCPQSOL=/+_ +]?&NF:M-I[)Y+^7MKM[7XMZK8Z/=0_:7\A_D\O?4XG!5EB
M/K-&?VC/!YIAIX?ZMB(?9/4OV*OB%=^$_BC<Z>'_ -"UBV?[3"_W$FA?[_\
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M4^;&S94__"47VU#YT7_?JO"Y6?0G<T5PW_"3:A_S\1?]^J8WB;4A_P OD/\
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M3^^B6R/O^F]!_MU Q/VGOA3XH^ _Q9C_ &A_A7827VT?\59H,/2Z@XWSA?\
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M>UFO++P_';W-LOG1.C'.Y/G'ZUDWVG)/IZ/*GF>2Z/7:7VH7UU"\,MY*Z/\
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MC/LN8DV>6_\ %7C_ .T]\+/#GQ(CT]?$#W]Q;JCF6QMKR;8^WE/W*/LW\O\
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MN?\ A /'\C_)X,U:/_IG)?PHF_[G_/:N=M?B-\4=*^34_"5C8/\ ]-_!B/\
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M1Y;_ -QJC\E_[CTP"39)]^JLEC;2??MH9/\ KHE3[*9Y= $']E6'\%G;Q_\
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M>33/(>K7VA/[Z?\ ?:4?:$_RZ58%+R7J/R'J]YGF?P5'YG^PU &=Y%,DM?\
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MK?Q Z(_\"56CGOX_XUKO;[0+#4)A-<6<,\W]YQ34\.Z='TMDK3G).(^UW_\
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MJBU8J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>snoa-20220331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOauHGaPty552mYkxvmR1fYlKvyQiwNcyny3UZVW2AYAN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:SNOA="http://sonomapharma.com/20220331" elementFormDefault="qualified" targetNamespace="http://sonomapharma.com/20220331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://sonomapharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome" id="StatementsOfComprehensiveLossIncome">
	  <link:definition>00000004 - Statement - Consolidated Statements of Comprehensive (Loss) Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" id="OrganizationAndRecentDevelopments">
	  <link:definition>00000007 - Disclosure - Organization and Recent Developments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" id="LiquidityAndFinancialCondition">
	  <link:definition>00000008 - Disclosure - Liquidity and Financial Condition</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperations" id="SaleOfAssetsDiscontinuedOperations">
	  <link:definition>00000010 - Disclosure - Sale of Assets &#8211; Discontinued Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccountsReceivable" id="AccountsReceivable">
	  <link:definition>00000011 - Disclosure - Accounts Receivable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Inventories" id="Inventories">
	  <link:definition>00000012 - Disclosure - Inventories</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
	  <link:definition>00000013 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000014 - Disclosure - Property and Equipment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
	  <link:definition>00000015 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Debt" id="Debt">
	  <link:definition>00000016 - Disclosure - Debt</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Leases" id="Leases">
	  <link:definition>00000017 - Disclosure - Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000018 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000019 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000020 - Disclosure - Stock-Based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000021 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
	  <link:definition>00000022 - Disclosure - Employee Benefit Plan</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregation" id="RevenueDisaggregation">
	  <link:definition>00000023 - Disclosure - Revenue Disaggregation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperationsTables" id="SaleOfAssetsDiscontinuedOperationsTables">
	  <link:definition>00000026 - Disclosure - Sale of Assets &#8211; Discontinued Operations (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccountsReceivableTables" id="AccountsReceivableTables">
	  <link:definition>00000027 - Disclosure - Accounts Receivable (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/InventoriesTables" id="InventoriesTables">
	  <link:definition>00000028 - Disclosure - Inventories (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
	  <link:definition>00000029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000030 - Disclosure - Property and Equipment (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
	  <link:definition>00000031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000032 - Disclosure - Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000033 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000034 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" id="RevenueDisaggregationTables">
	  <link:definition>00000035 - Disclosure - Revenue Disaggregation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" id="LiquidityAndFinancialConditionDetailsNarrative">
	  <link:definition>00000036 - Disclosure - Liquidity and Financial Condition (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" id="SummaryOfSignificantAccountingPoliciesDetails-usefulLives">
	  <link:definition>00000037 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" id="SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare">
	  <link:definition>00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" id="SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares">
	  <link:definition>00000039 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000040 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice" id="SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice">
	  <link:definition>00000041 - Disclosure - Sale of Assets - Discontinued Operations (Details - Allocation of sale price)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations" id="SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations">
	  <link:definition>00000042 - Disclosure - Sale of Assets - Discontinued Operations (Details - Discontinued Operations)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" id="AccountsReceivableDetails">
	  <link:definition>00000043 - Disclosure - Accounts Receivable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/InventoriesDetails" id="InventoriesDetails">
	  <link:definition>00000044 - Disclosure - Inventories (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsDetails">
	  <link:definition>00000045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
	  <link:definition>00000046 - Disclosure - Property and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
	  <link:definition>00000047 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesDetails">
	  <link:definition>00000048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
	  <link:definition>00000049 - Disclosure - Debt (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" id="LeasesDetails-BalanceSheetInformationRelatedToLeases">
	  <link:definition>00000050 - Disclosure - Leases (Details - Balance sheet information related to leases)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" id="LeasesDetails-MinimumOperatingLeaseLiabilities">
	  <link:definition>00000051 - Disclosure - Leases (Details - Minimum operating lease liabilities)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000052 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000053 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" id="Stock-basedCompensationDetails-assumptions">
	  <link:definition>00000054 - Disclosure - Stock-Based Compensation (Details-Assumptions)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" id="Stock-basedCompensationDetails-stock-basedCompensation">
	  <link:definition>00000055 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" id="Stock-basedCompensationDetails-plans">
	  <link:definition>00000056 - Disclosure - Stock-Based Compensation (Details-Plans)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" id="Stock-basedCompensationDetails-optionActivity">
	  <link:definition>00000057 - Disclosure - Stock-Based Compensation (Details-Option activity)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" id="Stock-basedCompensationDetails-restrictedStockActivity">
	  <link:definition>00000058 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000059 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" id="IncomeTaxesDetails-deferredTaxes">
	  <link:definition>00000060 - Disclosure - Income Taxes (Details-Deferred taxes)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" id="IncomeTaxesDetails-incomeSource">
	  <link:definition>00000061 - Disclosure - Income Taxes (Details-Income source)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" id="IncomeTaxesDetails-incomeTaxExpense">
	  <link:definition>00000062 - Disclosure - Income Taxes (Details-Income tax expense)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" id="IncomeTaxesDetails-reconciliationOfTaxRate">
	  <link:definition>00000063 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000064 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" id="EmployeeBenefitPlanDetailsNarrative">
	  <link:definition>00000065 - Disclosure - Employee Benefit Plan (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" id="RevenueDisaggregationDetails-DisaggregationOfRevenue">
	  <link:definition>00000066 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions" id="GeographicInformationDetails-GeographicRegions">
	  <link:definition>00000067 - Disclosure - Geographic Information (Details - Geographic regions)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" id="RevenueDisaggregationDetailsNarrative">
	  <link:definition>00000068 - Disclosure - Revenue Disaggregation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="snoa-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="snoa-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="snoa-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="snoa-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="SNOA_FirstCustomerMember" name="FirstCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_SecondCustomerMember" name="SecondCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ThirdCustomerMember" name="ThirdCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_NetRevenuesMember" name="NetRevenuesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CommonStockUnitsMember" name="CommonStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_MicromedLabsMember" name="MicromedLabsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_InsurancePremiums1Member" name="InsurancePremiums1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_InsurancePremiums2Member" name="InsurancePremiums2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PaycheckProtectionProgramMember" name="PaycheckProtectionProgramMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_StatesBankInAtlantaMember" name="StatesBankInAtlantaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_TromblyBusinessLawMember" name="TromblyBusinessLawMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2006Member" name="Plan2006Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2011Member" name="Plan2011Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2016Member" name="Plan2016Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2021Member" name="Plan2021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2017Member" name="Plan2017Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_HumanCareMember" name="HumanCareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_AnimalCareMember" name="AnimalCareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredConsiderationNetCurrent" name="DeferredConsiderationNetCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredConsiderationNetNoncurrent" name="DeferredConsiderationNetNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ContractWithCustomerLiabilityCurrentInvekra" name="ContractWithCustomerLiabilityCurrentInvekra" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_WithholdingTaxPayable" name="WithholdingTaxPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_EarningPerShareBasicAndDilutedAbstract" name="EarningPerShareBasicAndDilutedAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare" name="IncomeLossFromContinuingOperationPerBasicAndDilutedShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" name="IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_EarningPerShareBasicAndDiluted" name="EarningPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" name="SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" name="SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_SharesIssuedWithConversionOfCShares" name="SharesIssuedWithConversionOfCShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_SharesIssuedWithConversionOfCSharesShares" name="SharesIssuedWithConversionOfCSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" name="ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ForgivenessOfPppLoan" name="ForgivenessOfPppLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" name="IncreaseDecreaseInDeferredConsiderationNetOfDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_IncreaseDecreaseInWithholdingTaxPayable" name="IncreaseDecreaseInWithholdingTaxPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_IncreaseDecreaseInDeposits1" name="IncreaseDecreaseInDeposits1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PaymentsOnPppLoan" name="PaymentsOnPppLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" name="BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_InsurancePremiumsFinanced" name="InsurancePremiumsFinanced" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ShippingAndHandlingCostsPolicyTextBlock" name="ShippingAndHandlingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" name="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ScheduleOfAllocationOfSalePriceTableTextBlock" name="ScheduleOfAllocationOfSalePriceTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" name="ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" name="AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" name="DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DiscountsRebatesDistributorFeesAndReturns" name="DiscountsRebatesDistributorFeesAndReturns" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ForeignTaxTrueup" name="ForeignTaxTrueup" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_TrueupsOfStateDeferredAssets" name="TrueupsOfStateDeferredAssets" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PrepaidRebates" name="PrepaidRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_EffectOfStateOperatingLossExpiration" name="EffectOfStateOperatingLossExpiration" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>snoa-20220331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sonomapharma.com/role/Cover" xlink:href="snoa-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheets" xlink:href="snoa-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:href="snoa-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome" xlink:href="snoa-20220331.xsd#StatementsOfComprehensiveLossIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="snoa-20220331.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfCashFlows" xlink:href="snoa-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:href="snoa-20220331.xsd#OrganizationAndRecentDevelopments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:href="snoa-20220331.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperations" xlink:href="snoa-20220331.xsd#SaleOfAssetsDiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivable" xlink:href="snoa-20220331.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Inventories" xlink:href="snoa-20220331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="snoa-20220331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipment" xlink:href="snoa-20220331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="snoa-20220331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Debt" xlink:href="snoa-20220331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Leases" xlink:href="snoa-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:href="snoa-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquity" xlink:href="snoa-20220331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensation" xlink:href="snoa-20220331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxes" xlink:href="snoa-20220331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:href="snoa-20220331.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregation" xlink:href="snoa-20220331.xsd#RevenueDisaggregation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperationsTables" xlink:href="snoa-20220331.xsd#SaleOfAssetsDiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableTables" xlink:href="snoa-20220331.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesTables" xlink:href="snoa-20220331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="snoa-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:href="snoa-20220331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="snoa-20220331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesTables" xlink:href="snoa-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:href="snoa-20220331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesTables" xlink:href="snoa-20220331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:href="snoa-20220331.xsd#RevenueDisaggregationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:href="snoa-20220331.xsd#LiquidityAndFinancialConditionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice" xlink:href="snoa-20220331.xsd#SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations" xlink:href="snoa-20220331.xsd#SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:href="snoa-20220331.xsd#AccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesDetails" xlink:href="snoa-20220331.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="snoa-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:href="snoa-20220331.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="snoa-20220331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="snoa-20220331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:href="snoa-20220331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:href="snoa-20220331.xsd#LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:href="snoa-20220331.xsd#LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="snoa-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="snoa-20220331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-plans" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-optionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-restrictedStockActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-deferredTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-incomeSource" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-incomeTaxExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-reconciliationOfTaxRate" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="snoa-20220331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="snoa-20220331.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:href="snoa-20220331.xsd#RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions" xlink:href="snoa-20220331.xsd#GeographicInformationDetails-GeographicRegions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:href="snoa-20220331.xsd#RevenueDisaggregationDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredConsiderationNetCurrent" xlink:label="loc_SNOADeferredConsiderationNetCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_SNOADeferredConsiderationNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredConsiderationNetNoncurrent" xlink:label="loc_SNOADeferredConsiderationNetNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_SNOADeferredConsiderationNetNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ContractWithCustomerLiabilityCurrentInvekra" xlink:label="loc_SNOAContractWithCustomerLiabilityCurrentInvekra" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_SNOAContractWithCustomerLiabilityCurrentInvekra" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaapOtherLongTermDebtCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLongTermDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_WithholdingTaxPayable" xlink:label="loc_SNOAWithholdingTaxPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_SNOAWithholdingTaxPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive (Loss) Income">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOAChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SNOAChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ForgivenessOfPppLoan" xlink:label="loc_SNOAForgivenessOfPppLoan" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SNOAForgivenessOfPppLoan" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:label="loc_SNOAIncreaseDecreaseInDeferredConsiderationNetOfDiscount" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SNOAIncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:label="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncreaseDecreaseInDeposits1" xlink:label="loc_SNOAIncreaseDecreaseInDeposits1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_SNOAIncreaseDecreaseInDeposits1" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaapProceedsFromSaleOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_PaymentsOnPppLoan" xlink:label="loc_SNOAPaymentsOnPppLoan" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SNOAPaymentsOnPppLoan" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfShortTermDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfShortTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" xlink:label="loc_SNOABenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SNOABenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:title="00000007 - Disclosure - Organization and Recent Developments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:title="00000008 - Disclosure - Liquidity and Financial Condition" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperations" xlink:title="00000010 - Disclosure - Sale of Assets &#8211; Discontinued Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivable" xlink:title="00000011 - Disclosure - Accounts Receivable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Inventories" xlink:title="00000012 - Disclosure - Inventories" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipment" xlink:title="00000014 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000015 - Disclosure - Accrued Expenses and Other Current Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Debt" xlink:title="00000016 - Disclosure - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Leases" xlink:title="00000017 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensation" xlink:title="00000020 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxes" xlink:title="00000021 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:title="00000022 - Disclosure - Employee Benefit Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregation" xlink:title="00000023 - Disclosure - Revenue Disaggregation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperationsTables" xlink:title="00000026 - Disclosure - Sale of Assets &#8211; Discontinued Operations (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableTables" xlink:title="00000027 - Disclosure - Accounts Receivable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesTables" xlink:title="00000028 - Disclosure - Inventories (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:title="00000030 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesTables" xlink:title="00000032 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:title="00000033 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesTables" xlink:title="00000034 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:title="00000035 - Disclosure - Revenue Disaggregation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:title="00000036 - Disclosure - Liquidity and Financial Condition (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:title="00000037 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:title="00000039 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000040 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice" xlink:title="00000041 - Disclosure - Sale of Assets - Discontinued Operations (Details - Allocation of sale price)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations" xlink:title="00000042 - Disclosure - Sale of Assets - Discontinued Operations (Details - Discontinued Operations)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:title="00000043 - Disclosure - Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOADiscountsRebatesDistributorFeesAndReturns" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_SNOADiscountsRebatesDistributorFeesAndReturns" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesDetails" xlink:title="00000044 - Disclosure - Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsNetOfReserves" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterialsNetOfReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaapInventoryFinishedGoodsNetOfReserves" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoodsNetOfReserves" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:title="00000046 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000047 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:title="00000049 - Disclosure - Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:title="00000050 - Disclosure - Leases (Details - Balance sheet information related to leases)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:title="00000051 - Disclosure - Leases (Details - Minimum operating lease liabilities)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000052 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000053 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:title="00000054 - Disclosure - Stock-Based Compensation (Details-Assumptions)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:title="00000055 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:title="00000056 - Disclosure - Stock-Based Compensation (Details-Plans)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:title="00000057 - Disclosure - Stock-Based Compensation (Details-Option activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:title="00000058 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000059 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:title="00000060 - Disclosure - Income Taxes (Details-Deferred taxes)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredTaxAssetsLeaseLiability" xlink:label="loc_SNOADeferredTaxAssetsLeaseLiability" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_SNOADeferredTaxAssetsLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:title="00000061 - Disclosure - Income Taxes (Details-Income source)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:title="00000062 - Disclosure - Income Taxes (Details-Income tax expense)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:title="00000063 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000065 - Disclosure - Employee Benefit Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:title="00000066 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions" xlink:title="00000067 - Disclosure - Geographic Information (Details - Geographic regions)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:title="00000068 - Disclosure - Revenue Disaggregation (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>snoa-20220331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sonomapharma.com/role/Cover" xlink:href="snoa-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheets" xlink:href="snoa-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:href="snoa-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome" xlink:href="snoa-20220331.xsd#StatementsOfComprehensiveLossIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="snoa-20220331.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfCashFlows" xlink:href="snoa-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:href="snoa-20220331.xsd#OrganizationAndRecentDevelopments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:href="snoa-20220331.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperations" xlink:href="snoa-20220331.xsd#SaleOfAssetsDiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivable" xlink:href="snoa-20220331.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Inventories" xlink:href="snoa-20220331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="snoa-20220331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipment" xlink:href="snoa-20220331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="snoa-20220331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Debt" xlink:href="snoa-20220331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Leases" xlink:href="snoa-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:href="snoa-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquity" xlink:href="snoa-20220331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensation" xlink:href="snoa-20220331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxes" xlink:href="snoa-20220331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:href="snoa-20220331.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregation" xlink:href="snoa-20220331.xsd#RevenueDisaggregation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperationsTables" xlink:href="snoa-20220331.xsd#SaleOfAssetsDiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableTables" xlink:href="snoa-20220331.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesTables" xlink:href="snoa-20220331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="snoa-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:href="snoa-20220331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="snoa-20220331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesTables" xlink:href="snoa-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:href="snoa-20220331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesTables" xlink:href="snoa-20220331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:href="snoa-20220331.xsd#RevenueDisaggregationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:href="snoa-20220331.xsd#LiquidityAndFinancialConditionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice" xlink:href="snoa-20220331.xsd#SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations" xlink:href="snoa-20220331.xsd#SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:href="snoa-20220331.xsd#AccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesDetails" xlink:href="snoa-20220331.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="snoa-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:href="snoa-20220331.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="snoa-20220331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="snoa-20220331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:href="snoa-20220331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:href="snoa-20220331.xsd#LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:href="snoa-20220331.xsd#LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="snoa-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="snoa-20220331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-plans" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-optionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-restrictedStockActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-deferredTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-incomeSource" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-incomeTaxExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-reconciliationOfTaxRate" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="snoa-20220331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="snoa-20220331.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:href="snoa-20220331.xsd#RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions" xlink:href="snoa-20220331.xsd#GeographicInformationDetails-GeographicRegions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:href="snoa-20220331.xsd#RevenueDisaggregationDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive (Loss) Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" xlink:label="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" xlink:label="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedWithConversionOfCShares" xlink:label="loc_SNOASharesIssuedWithConversionOfCShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedWithConversionOfCShares_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedWithConversionOfCSharesShares" xlink:label="loc_SNOASharesIssuedWithConversionOfCSharesShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedWithConversionOfCSharesShares_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:title="00000007 - Disclosure - Organization and Recent Developments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:title="00000008 - Disclosure - Liquidity and Financial Condition" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperations" xlink:title="00000010 - Disclosure - Sale of Assets &#8211; Discontinued Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivable" xlink:title="00000011 - Disclosure - Accounts Receivable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Inventories" xlink:title="00000012 - Disclosure - Inventories" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipment" xlink:title="00000014 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000015 - Disclosure - Accrued Expenses and Other Current Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Debt" xlink:title="00000016 - Disclosure - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Leases" xlink:title="00000017 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensation" xlink:title="00000020 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxes" xlink:title="00000021 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:title="00000022 - Disclosure - Employee Benefit Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregation" xlink:title="00000023 - Disclosure - Revenue Disaggregation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperationsTables" xlink:title="00000026 - Disclosure - Sale of Assets &#8211; Discontinued Operations (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableTables" xlink:title="00000027 - Disclosure - Accounts Receivable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesTables" xlink:title="00000028 - Disclosure - Inventories (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:title="00000030 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesTables" xlink:title="00000032 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:title="00000033 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesTables" xlink:title="00000034 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:title="00000035 - Disclosure - Revenue Disaggregation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:title="00000036 - Disclosure - Liquidity and Financial Condition (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:title="00000037 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:title="00000039 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_CommonStockUnitsMember" xlink:label="loc_SNOACommonStockUnitsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SNOACommonStockUnitsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000040 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_NetRevenuesMember" xlink:label="loc_SNOANetRevenuesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_SNOANetRevenuesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_FirstCustomerMember" xlink:label="loc_SNOAFirstCustomerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOAFirstCustomerMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SecondCustomerMember" xlink:label="loc_SNOASecondCustomerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOASecondCustomerMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ThirdCustomerMember" xlink:label="loc_SNOAThirdCustomerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOAThirdCustomerMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaapShippingAndHandlingMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapShippingAndHandlingMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOAAllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_SNOAAllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryValuationReserves_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapMarketingExpense_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionLossBeforeTax_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionLossBeforeTax_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_180" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice" xlink:title="00000041 - Disclosure - Sale of Assets - Discontinued Operations (Details - Allocation of sale price)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_MicromedLabsMember" xlink:label="loc_SNOAMicromedLabsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_SNOAMicromedLabsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssets_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredRevenue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredRevenue_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" xlink:label="loc_SNOADisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_SNOADisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaapProceedsFromDivestitureOfBusinesses_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapProceedsFromDivestitureOfBusinesses_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations" xlink:title="00000042 - Disclosure - Sale of Assets - Discontinued Operations (Details - Discontinued Operations)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:title="00000043 - Disclosure - Accounts Receivable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesDetails" xlink:title="00000044 - Disclosure - Inventories (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:title="00000046 - Disclosure - Property and Equipment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000047 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:title="00000049 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_InsurancePremiums1Member" xlink:label="loc_SNOAInsurancePremiums1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_SNOAInsurancePremiums1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_InsurancePremiums2Member" xlink:label="loc_SNOAInsurancePremiums2Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_SNOAInsurancePremiums2Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_PaycheckProtectionProgramMember" xlink:label="loc_SNOAPaycheckProtectionProgramMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SNOAPaycheckProtectionProgramMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_StatesBankInAtlantaMember" xlink:label="loc_SNOAStatesBankInAtlantaMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SNOAStatesBankInAtlantaMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromLoans_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLoansPayable_120" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:title="00000050 - Disclosure - Leases (Details - Balance sheet information related to leases)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:title="00000051 - Disclosure - Leases (Details - Minimum operating lease liabilities)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000052 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_TromblyBusinessLawMember" xlink:label="loc_SNOATromblyBusinessLawMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SNOATromblyBusinessLawMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSalariesAndWages_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSeveranceCosts1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLegalFees_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000053 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:title="00000054 - Disclosure - Stock-Based Compensation (Details-Assumptions)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:title="00000055 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:title="00000056 - Disclosure - Stock-Based Compensation (Details-Plans)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2006Member" xlink:label="loc_SNOAPlan2006Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2006Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2011Member" xlink:label="loc_SNOAPlan2011Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2011Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2017Member" xlink:label="loc_SNOAPlan2017Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2017Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" xlink:label="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:title="00000057 - Disclosure - Stock-Based Compensation (Details-Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:title="00000058 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000059 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2006Member" xlink:label="loc_SNOAPlan2006Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2006Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2011Member" xlink:label="loc_SNOAPlan2011Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2011Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2021Member" xlink:label="loc_SNOAPlan2021Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2021Member_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCharges_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCharges_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_180" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:title="00000060 - Disclosure - Income Taxes (Details-Deferred taxes)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:title="00000061 - Disclosure - Income Taxes (Details-Income source)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:title="00000062 - Disclosure - Income Taxes (Details-Income tax expense)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:title="00000063 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsForeign_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsForeign_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000065 - Disclosure - Employee Benefit Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:title="00000066 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_HumanCareMember" xlink:label="loc_SNOAHumanCareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAHumanCareMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_AnimalCareMember" xlink:label="loc_SNOAAnimalCareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAAnimalCareMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions" xlink:title="00000067 - Disclosure - Geographic Information (Details - Geographic regions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueSegmentMember" xlink:label="loc_us-gaapSalesRevenueSegmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueSegmentMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember" xlink:label="loc_srtLatinAmericaMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtLatinAmericaMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:title="00000068 - Disclosure - Revenue Disaggregation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenues_30" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>snoa-20220331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_FirstCustomerMember" xlink:label="SNOA_FirstCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_FirstCustomerMember" xlink:to="SNOA_FirstCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_FirstCustomerMember_lbl" xml:lang="en-US">First Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SecondCustomerMember" xlink:label="SNOA_SecondCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_SecondCustomerMember" xlink:to="SNOA_SecondCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_SecondCustomerMember_lbl" xml:lang="en-US">Second Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ThirdCustomerMember" xlink:label="SNOA_ThirdCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ThirdCustomerMember" xlink:to="SNOA_ThirdCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ThirdCustomerMember_lbl" xml:lang="en-US">Third Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_NetRevenuesMember" xlink:label="SNOA_NetRevenuesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_NetRevenuesMember" xlink:to="SNOA_NetRevenuesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_NetRevenuesMember_lbl" xml:lang="en-US">Net Revenues [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="us-gaap_ShippingAndHandlingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingMember" xlink:to="us-gaap_ShippingAndHandlingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingMember_lbl" xml:lang="en-US">Shipping and Handling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_CommonStockUnitsMember" xlink:label="SNOA_CommonStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CommonStockUnitsMember" xlink:to="SNOA_CommonStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CommonStockUnitsMember_lbl" xml:lang="en-US">Common Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_MicromedLabsMember" xlink:label="SNOA_MicromedLabsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_MicromedLabsMember" xlink:to="SNOA_MicromedLabsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_MicromedLabsMember_lbl" xml:lang="en-US">Micromed Labs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_InsurancePremiums1Member" xlink:label="SNOA_InsurancePremiums1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_InsurancePremiums1Member" xlink:to="SNOA_InsurancePremiums1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_InsurancePremiums1Member_lbl" xml:lang="en-US">Insurance Premiums 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_InsurancePremiums2Member" xlink:label="SNOA_InsurancePremiums2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_InsurancePremiums2Member" xlink:to="SNOA_InsurancePremiums2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_InsurancePremiums2Member_lbl" xml:lang="en-US">Insurance Premiums 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_PaycheckProtectionProgramMember" xlink:label="SNOA_PaycheckProtectionProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PaycheckProtectionProgramMember" xlink:to="SNOA_PaycheckProtectionProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PaycheckProtectionProgramMember_lbl" xml:lang="en-US">Paycheck Protection Program [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_StatesBankInAtlantaMember" xlink:label="SNOA_StatesBankInAtlantaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_StatesBankInAtlantaMember" xlink:to="SNOA_StatesBankInAtlantaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_StatesBankInAtlantaMember_lbl" xml:lang="en-US">States Bank In Atlanta [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_TromblyBusinessLawMember" xlink:label="SNOA_TromblyBusinessLawMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_TromblyBusinessLawMember" xlink:to="SNOA_TromblyBusinessLawMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_TromblyBusinessLawMember_lbl" xml:lang="en-US">Trombly Business Law [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2006Member" xlink:label="SNOA_Plan2006Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2006Member" xlink:to="SNOA_Plan2006Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2006Member_lbl" xml:lang="en-US">2006 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2011Member" xlink:label="SNOA_Plan2011Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2011Member" xlink:to="SNOA_Plan2011Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2011Member_lbl" xml:lang="en-US">2011 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2016Member" xlink:label="SNOA_Plan2016Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2016Member" xlink:to="SNOA_Plan2016Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2016Member_lbl" xml:lang="en-US">2016 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2021Member" xlink:label="SNOA_Plan2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2021Member" xlink:to="SNOA_Plan2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2021Member_lbl" xml:lang="en-US">Plan 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2017Member" xlink:label="SNOA_Plan2017Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2017Member" xlink:to="SNOA_Plan2017Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2017Member_lbl" xml:lang="en-US">Plan 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_HumanCareMember" xlink:label="SNOA_HumanCareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_HumanCareMember" xlink:to="SNOA_HumanCareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_HumanCareMember_lbl" xml:lang="en-US">Human Care [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_AnimalCareMember" xlink:label="SNOA_AnimalCareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_AnimalCareMember" xlink:to="SNOA_AnimalCareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_AnimalCareMember_lbl" xml:lang="en-US">Animal Care [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueSegmentMember" xlink:label="us-gaap_SalesRevenueSegmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueSegmentMember" xlink:to="us-gaap_SalesRevenueSegmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueSegmentMember_lbl" xml:lang="en-US">Revenue, Segment Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember" xlink:label="srt_LatinAmericaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LatinAmericaMember" xlink:to="srt_LatinAmericaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LatinAmericaMember_lbl" xml:lang="en-US">Latin America [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity public float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredConsiderationNetCurrent" xlink:label="SNOA_DeferredConsiderationNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredConsiderationNetCurrent" xlink:to="SNOA_DeferredConsiderationNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredConsiderationNetCurrent_lbl" xml:lang="en-US">Current portion of deferred consideration, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease, right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredConsiderationNetNoncurrent" xlink:label="SNOA_DeferredConsiderationNetNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredConsiderationNetNoncurrent" xlink:to="SNOA_DeferredConsiderationNetNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredConsiderationNetNoncurrent_lbl" xml:lang="en-US">Deferred consideration, net of discount, less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ContractWithCustomerLiabilityCurrentInvekra" xlink:label="SNOA_ContractWithCustomerLiabilityCurrentInvekra" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ContractWithCustomerLiabilityCurrentInvekra" xlink:to="SNOA_ContractWithCustomerLiabilityCurrentInvekra_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ContractWithCustomerLiabilityCurrentInvekra_lbl" xml:lang="en-US">Deferred revenue Invekra</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Current portion of debt-PPP</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="us-gaap_OtherLongTermDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebtCurrent" xlink:to="us-gaap_OtherLongTermDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebtCurrent_lbl" xml:lang="en-US">Short-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Long-term deferred revenue Invekra</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt, less current portion &#8211; PPP</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_WithholdingTaxPayable" xlink:label="SNOA_WithholdingTaxPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_WithholdingTaxPayable" xlink:to="SNOA_WithholdingTaxPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_WithholdingTaxPayable_lbl" xml:lang="en-US">Withholding Tax Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2022 and 2021, respectively, no shares issued and outstanding at March 31, 2022 and 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 24,000,000 shares authorized at March 31, 2022 and 2021, respectively, 3,100,937 and 2,092,909 shares issued and outstanding at March 31, 2022 and 2021, respectively (Note 13)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible preferred stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Convertible preferred stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Convertible preferred stock shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Convertible preferred stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Forgiveness of PPP Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Gain on sale of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Loss from continuing operations, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Income from discontinued operations, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_EarningPerShareBasicAndDilutedAbstract" xlink:label="SNOA_EarningPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_EarningPerShareBasicAndDilutedAbstract" xlink:to="SNOA_EarningPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_EarningPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Loss per share: basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare" xlink:label="SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare" xlink:to="SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare_lbl" xml:lang="en-US">Continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:to="SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_lbl" xml:lang="en-US">Discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_EarningPerShareBasicAndDiluted" xlink:label="SNOA_EarningPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_EarningPerShareBasicAndDiluted" xlink:to="SNOA_EarningPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_EarningPerShareBasicAndDiluted_lbl" xml:lang="en-US">Total loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted-average shares outstanding: basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued in connection with ATM, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued in connection with ATM, net of transaction costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued in connection with exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares issued in connection with exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Shares issued in connection with vesting of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Shares issued in connection with vesting of restricted stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" xlink:label="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" xlink:to="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount_lbl" xml:lang="en-US">Shares issued in connection with exercise of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" xlink:label="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" xlink:to="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares_lbl" xml:lang="en-US">Shares issued in connection with exercise of common stock warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedWithConversionOfCShares" xlink:label="SNOA_SharesIssuedWithConversionOfCShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_SharesIssuedWithConversionOfCShares" xlink:to="SNOA_SharesIssuedWithConversionOfCShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_SharesIssuedWithConversionOfCShares_lbl" xml:lang="en-US">Shares issued with conversion of C shares</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedWithConversionOfCSharesShares" xlink:label="SNOA_SharesIssuedWithConversionOfCSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_SharesIssuedWithConversionOfCSharesShares" xlink:to="SNOA_SharesIssuedWithConversionOfCSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_SharesIssuedWithConversionOfCSharesShares_lbl" xml:lang="en-US">Shares issued with conversion of C shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Employee stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock based compensation related to issuance of common stock restricted stock grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock based compensation related to issuance of common stock restricted stock grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock based compensation related to common stock restricted stock grants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Recovery of doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" xlink:label="SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns_lbl" xml:lang="en-US">Provision for (recovery of) discounts, rebates, distributor fees and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ForgivenessOfPppLoan" xlink:label="SNOA_ForgivenessOfPppLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ForgivenessOfPppLoan" xlink:to="SNOA_ForgivenessOfPppLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_ForgivenessOfPppLoan_lbl" xml:lang="en-US">Forgiveness of PPP loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Deferred income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:label="SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:to="SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount_lbl" xml:lang="en-US">Deferred consideration, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:label="SNOA_IncreaseDecreaseInWithholdingTaxPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:to="SNOA_IncreaseDecreaseInWithholdingTaxPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_IncreaseDecreaseInWithholdingTaxPayable_lbl" xml:lang="en-US">Withholding tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncreaseDecreaseInDeposits1" xlink:label="SNOA_IncreaseDecreaseInDeposits1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncreaseDecreaseInDeposits1" xlink:to="SNOA_IncreaseDecreaseInDeposits1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_IncreaseDecreaseInDeposits1_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl" xml:lang="en-US">Proceeds from Micromed Transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_PaymentsOnPppLoan" xlink:label="SNOA_PaymentsOnPppLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PaymentsOnPppLoan" xlink:to="SNOA_PaymentsOnPppLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_PaymentsOnPppLoan_lbl" xml:lang="en-US">Payments on PPP Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Proceeds from PPP Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of common stock options and purchase warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US">Principal payments on short-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Proceeds on short-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" xlink:label="SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" xlink:to="SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets_lbl" xml:lang="en-US">Benefit from lease assumed less principal payments on ROU Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash operating and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_InsurancePremiumsFinanced" xlink:label="SNOA_InsurancePremiumsFinanced" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_InsurancePremiumsFinanced" xlink:to="SNOA_InsurancePremiumsFinanced_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_InsurancePremiumsFinanced_lbl" xml:lang="en-US">Insurance premiums financed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Recent Developments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity and Financial Condition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Sale of Assets &#8211; Discontinued Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DisclosureLeasesAbstract" xlink:label="SNOA_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DisclosureLeasesAbstract" xlink:to="SNOA_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue Disaggregation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk and Major Customers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Financial Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ShippingAndHandlingCostsPolicyTextBlock" xlink:label="SNOA_ShippingAndHandlingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ShippingAndHandlingCostsPolicyTextBlock" xlink:to="SNOA_ShippingAndHandlingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ShippingAndHandlingCostsPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Income Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Common Stock Purchase Warrants and Other Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Property and equipment estimated useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Computation of earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ScheduleOfAllocationOfSalePriceTableTextBlock" xlink:label="SNOA_ScheduleOfAllocationOfSalePriceTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ScheduleOfAllocationOfSalePriceTableTextBlock" xlink:to="SNOA_ScheduleOfAllocationOfSalePriceTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ScheduleOfAllocationOfSalePriceTableTextBlock_lbl" xml:lang="en-US">Schedule of allocation of sale price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Assets and liabilities of disposal group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease cost information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of minimum operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Weighted-average assumptions of fair value of employee stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Employee stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:label="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:to="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-based awards outstanding by plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of unvested restricted stock activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Income tax provision domestic and foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Reconciliation of federal income tax rate to effective rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregated Revenue by Source</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xml:lang="en-US">Schedule of geographic sales</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_WorkingCapital" xlink:label="SNOA_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_WorkingCapital" xlink:to="SNOA_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful asset life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss from continuing operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2_lbl" xml:lang="en-US">Income from discontinued operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare" xlink:to="SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare_2_lbl" xml:lang="en-US">Loss per share from continuing operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:to="SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_2_lbl" xml:lang="en-US">Income per share from discontinued operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_EarningPerShareBasicAndDiluted" xlink:to="SNOA_EarningPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SNOA_EarningPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Net loss per share: basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Significant customer concentration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:label="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_lbl" xml:lang="en-US">Allowance for sales discounts, rebates, distributor fees and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US">Transfers in or out of Level 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset impairment charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingExpense" xlink:label="us-gaap_MarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingExpense" xlink:to="us-gaap_MarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US">Advertising costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_2_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US">Foreign currency transaction loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xml:lang="en-US">Customer base</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xml:lang="en-US">Less: Funds remaining in escrow</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl" xml:lang="en-US">Less: Services due from buyer</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" xlink:label="SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" xlink:to="SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_lbl" xml:lang="en-US">Less: Working capital adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xml:lang="en-US">Proceeds from sale of business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US">Selling general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Income from discontinued operations before tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_lbl" xml:lang="en-US">Gain on disposal of discontinued operations before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xml:lang="en-US">Total income from discontinued operations, before tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_lbl" xml:lang="en-US">Income Tax benefit (expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3_lbl" xml:lang="en-US">Income from discontinued operations, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Less: allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:label="SNOA_DiscountsRebatesDistributorFeesAndReturns" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_DiscountsRebatesDistributorFeesAndReturns_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_DiscountsRebatesDistributorFeesAndReturns_lbl" xml:lang="en-US">Less: discounts, rebates, distributor fees and returns</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_2_lbl" xml:lang="en-US">Accounts receivable, net&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Inventories, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidTaxes_lbl" xml:lang="en-US">Tax prepaid to Mexican tax authorities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses and other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">&#160;Total prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Manufacturing, lab, and other equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOther" xlink:to="us-gaap_PropertyPlantAndEquipmentOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOther_lbl" xml:lang="en-US">Office equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and fixtures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Salaries and related costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Debt interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Principal payments made</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLoans" xlink:label="us-gaap_ProceedsFromLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Proceeds from loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Approval for forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US">Operating leases:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating lease liabilities &#8211; current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liabilities &#8211; non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xml:lang="en-US">Operating Lease, Payments, Use</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term - operating leases (in months)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments, undiscounted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Annual salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Potential severance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Preferred stock converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Common stock issued upon conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Fair value of common stock on date of grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value of options granted, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Restricted stock units outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" xlink:label="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" xlink:to="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_lbl" xml:lang="en-US">Total options and restricted stock units outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Stock-based awards available for grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted- Average Exercise Price Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of Shares Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Shares Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Shares Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of Shares Outstanding at end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted- Average Exercise Price Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Contractual Term Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares Exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted- Average Contractual Term Exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested restricted stock awards, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average award date fair value per share, outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Restricted stock awards granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average award date fair value per share, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Restricted stock awards vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average award date fair value per share, vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Unvested restricted stock awards, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average award date fair value per share, outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xml:lang="en-US">Shares available for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Shares initially authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Increase in shares authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Decrease in stock based compensation deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Allowances and accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US">Other deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredTaxAssetsLeaseLiability" xlink:label="SNOA_DeferredTaxAssetsLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredTaxAssetsLeaseLiability" xlink:to="SNOA_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right of Use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Income before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Expected federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign earnings taxed at different rates</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ForeignTaxTrueup" xlink:label="SNOA_ForeignTaxTrueup" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ForeignTaxTrueup" xlink:to="SNOA_ForeignTaxTrueup_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ForeignTaxTrueup_lbl" xml:lang="en-US">Foreign tax true-up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Effect of permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Effect of intercompany interest permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_TrueupsOfStateDeferredAssets" xlink:label="SNOA_TrueupsOfStateDeferredAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_TrueupsOfStateDeferredAssets" xlink:to="SNOA_TrueupsOfStateDeferredAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_TrueupsOfStateDeferredAssets_lbl" xml:lang="en-US">True-up of state deferred assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Total effective rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Totals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Research credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl" xml:lang="en-US">Foreign tax credit carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions_lbl" xml:lang="en-US">Company contributions to 401(k) plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_WorkingCapital" xlink:to="SNOA_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_WorkingCapital_doc" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_doc" xml:lang="en-US">Allowance for sales discounts, rebates, distributor fees and returns</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" xlink:to="SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_doc" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Working Capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_DiscountsRebatesDistributorFeesAndReturns_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_DiscountsRebatesDistributorFeesAndReturns_doc" xml:lang="en-US">Discounts, rebates, distributor fees and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_PrepaidRebates" xlink:label="SNOA_PrepaidRebates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PrepaidRebates" xlink:to="SNOA_PrepaidRebates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_PrepaidRebates_doc" xml:lang="en-US">Prepaid rebates</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_EffectOfStateOperatingLossExpiration" xlink:label="SNOA_EffectOfStateOperatingLossExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_EffectOfStateOperatingLossExpiration" xlink:to="SNOA_EffectOfStateOperatingLossExpiration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_EffectOfStateOperatingLossExpiration_doc" xml:lang="en-US">Effect of State operating loss expiration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_TrueupsOfStateDeferredAssets" xlink:to="SNOA_TrueupsOfStateDeferredAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_TrueupsOfStateDeferredAssets_doc" xml:lang="en-US">True-ups of State deferred assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2006Member" xlink:to="SNOA_Plan2006Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_Plan2006Member_doc" xml:lang="en-US">Plan 2006.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2011Member" xlink:to="SNOA_Plan2011Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_Plan2011Member_doc" xml:lang="en-US">One customer member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" xlink:to="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_doc" xml:lang="en-US">Number of options and restricted stock units outstanding, including both vested and non-vested options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ForgivenessOfPppLoan" xlink:to="SNOA_ForgivenessOfPppLoan_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ForgivenessOfPppLoan_2_lbl" xml:lang="en-US">ForgivenessOfPppLoan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncreaseDecreaseInDeposits1" xlink:to="SNOA_IncreaseDecreaseInDeposits1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_IncreaseDecreaseInDeposits1_2_lbl" xml:lang="en-US">IncreaseDecreaseInDeposits1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PaymentsOnPppLoan" xlink:to="SNOA_PaymentsOnPppLoan_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PaymentsOnPppLoan_2_lbl" xml:lang="en-US">PaymentsOnPppLoan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_2_lbl" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" xlink:to="SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets_2_lbl" xml:lang="en-US">BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_2_lbl" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" xlink:to="SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_2_lbl" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2_lbl" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_2_lbl" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:to="SNOA_DiscountsRebatesDistributorFeesAndReturns_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DiscountsRebatesDistributorFeesAndReturns_3_lbl" xml:lang="en-US">DiscountsRebatesDistributorFeesAndReturns</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_2_lbl" xml:lang="en-US">Operating Lease, Payments, Use</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_2_lbl" xml:lang="en-US">DeferredTaxLiabilitiesRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_2_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>snoa-20220331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sonomapharma.com/role/Cover" xlink:href="snoa-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheets" xlink:href="snoa-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:href="snoa-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome" xlink:href="snoa-20220331.xsd#StatementsOfComprehensiveLossIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="snoa-20220331.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StatementsOfCashFlows" xlink:href="snoa-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:href="snoa-20220331.xsd#OrganizationAndRecentDevelopments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:href="snoa-20220331.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperations" xlink:href="snoa-20220331.xsd#SaleOfAssetsDiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivable" xlink:href="snoa-20220331.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Inventories" xlink:href="snoa-20220331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="snoa-20220331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipment" xlink:href="snoa-20220331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="snoa-20220331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Debt" xlink:href="snoa-20220331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Leases" xlink:href="snoa-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:href="snoa-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquity" xlink:href="snoa-20220331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensation" xlink:href="snoa-20220331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxes" xlink:href="snoa-20220331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:href="snoa-20220331.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregation" xlink:href="snoa-20220331.xsd#RevenueDisaggregation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperationsTables" xlink:href="snoa-20220331.xsd#SaleOfAssetsDiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableTables" xlink:href="snoa-20220331.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesTables" xlink:href="snoa-20220331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="snoa-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:href="snoa-20220331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="snoa-20220331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesTables" xlink:href="snoa-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:href="snoa-20220331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesTables" xlink:href="snoa-20220331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:href="snoa-20220331.xsd#RevenueDisaggregationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:href="snoa-20220331.xsd#LiquidityAndFinancialConditionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="snoa-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice" xlink:href="snoa-20220331.xsd#SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations" xlink:href="snoa-20220331.xsd#SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:href="snoa-20220331.xsd#AccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesDetails" xlink:href="snoa-20220331.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="snoa-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:href="snoa-20220331.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="snoa-20220331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="snoa-20220331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:href="snoa-20220331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:href="snoa-20220331.xsd#LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:href="snoa-20220331.xsd#LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="snoa-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="snoa-20220331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-plans" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-optionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetails-restrictedStockActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="snoa-20220331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-deferredTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-incomeSource" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-incomeTaxExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:href="snoa-20220331.xsd#IncomeTaxesDetails-reconciliationOfTaxRate" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="snoa-20220331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="snoa-20220331.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:href="snoa-20220331.xsd#RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions" xlink:href="snoa-20220331.xsd#GeographicInformationDetails-GeographicRegions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:href="snoa-20220331.xsd#RevenueDisaggregationDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredConsiderationNetCurrent" xlink:label="loc_SNOADeferredConsiderationNetCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_SNOADeferredConsiderationNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredConsiderationNetNoncurrent" xlink:label="loc_SNOADeferredConsiderationNetNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_SNOADeferredConsiderationNetNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ContractWithCustomerLiabilityCurrentInvekra" xlink:label="loc_SNOAContractWithCustomerLiabilityCurrentInvekra" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_SNOAContractWithCustomerLiabilityCurrentInvekra" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaapOtherLongTermDebtCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLongTermDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_WithholdingTaxPayable" xlink:label="loc_SNOAWithholdingTaxPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_SNOAWithholdingTaxPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive (Loss) Income">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_EarningPerShareBasicAndDilutedAbstract" xlink:label="loc_SNOAEarningPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_SNOAEarningPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare" xlink:label="loc_SNOAIncomeLossFromContinuingOperationPerBasicAndDilutedShare" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOAEarningPerShareBasicAndDilutedAbstract" xlink:to="loc_SNOAIncomeLossFromContinuingOperationPerBasicAndDilutedShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_SNOAIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOAEarningPerShareBasicAndDilutedAbstract" xlink:to="loc_SNOAIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_EarningPerShareBasicAndDiluted" xlink:label="loc_SNOAEarningPerShareBasicAndDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOAEarningPerShareBasicAndDilutedAbstract" xlink:to="loc_SNOAEarningPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_SNOAWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_SNOAWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapNetIncomeLoss_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" xlink:label="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" xlink:label="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedWithConversionOfCShares" xlink:label="loc_SNOASharesIssuedWithConversionOfCShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedWithConversionOfCShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SharesIssuedWithConversionOfCSharesShares" xlink:label="loc_SNOASharesIssuedWithConversionOfCSharesShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOASharesIssuedWithConversionOfCSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOAChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SNOAChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ForgivenessOfPppLoan" xlink:label="loc_SNOAForgivenessOfPppLoan" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SNOAForgivenessOfPppLoan" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:label="loc_SNOAIncreaseDecreaseInDeferredConsiderationNetOfDiscount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_SNOAIncreaseDecreaseInDeferredConsiderationNetOfDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:label="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncreaseDecreaseInDeposits1" xlink:label="loc_SNOAIncreaseDecreaseInDeposits1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_SNOAIncreaseDecreaseInDeposits1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaapProceedsFromSaleOfIntangibleAssets" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_PaymentsOnPppLoan" xlink:label="loc_SNOAPaymentsOnPppLoan" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SNOAPaymentsOnPppLoan" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfShortTermDebt" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfShortTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" xlink:label="loc_SNOABenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SNOABenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_InsurancePremiumsFinanced" xlink:label="loc_SNOAInsurancePremiumsFinanced" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SNOAInsurancePremiumsFinanced" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:title="00000007 - Disclosure - Organization and Recent Developments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:title="00000008 - Disclosure - Liquidity and Financial Condition">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperations" xlink:title="00000010 - Disclosure - Sale of Assets &#8211; Discontinued Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivable" xlink:title="00000011 - Disclosure - Accounts Receivable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Inventories" xlink:title="00000012 - Disclosure - Inventories">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - Prepaid Expenses and Other Current Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipment" xlink:title="00000014 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000015 - Disclosure - Accrued Expenses and Other Current Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Debt" xlink:title="00000016 - Disclosure - Debt">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Leases" xlink:title="00000017 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DisclosureLeasesAbstract" xlink:label="loc_SNOADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensation" xlink:title="00000020 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxes" xlink:title="00000021 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:title="00000022 - Disclosure - Employee Benefit Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregation" xlink:title="00000023 - Disclosure - Revenue Disaggregation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ShippingAndHandlingCostsPolicyTextBlock" xlink:label="loc_SNOAShippingAndHandlingCostsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAShippingAndHandlingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaapStockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="loc_SNOAPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperationsTables" xlink:title="00000026 - Disclosure - Sale of Assets &#8211; Discontinued Operations (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ScheduleOfAllocationOfSalePriceTableTextBlock" xlink:label="loc_SNOAScheduleOfAllocationOfSalePriceTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_SNOAScheduleOfAllocationOfSalePriceTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableTables" xlink:title="00000027 - Disclosure - Accounts Receivable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesTables" xlink:title="00000028 - Disclosure - Inventories (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:title="00000030 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesTables" xlink:title="00000032 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DisclosureLeasesAbstract" xlink:label="loc_SNOADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:title="00000033 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:label="loc_SNOAScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_SNOAScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesTables" xlink:title="00000034 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:title="00000035 - Disclosure - Revenue Disaggregation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaapScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:title="00000036 - Disclosure - Liquidity and Financial Condition (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_WorkingCapital" xlink:label="loc_SNOAWorkingCapital" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_SNOAWorkingCapital" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:title="00000037 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_SNOAWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAWeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare" xlink:label="loc_SNOAIncomeLossFromContinuingOperationPerBasicAndDilutedShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAIncomeLossFromContinuingOperationPerBasicAndDilutedShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_SNOAIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_EarningPerShareBasicAndDiluted" xlink:label="loc_SNOAEarningPerShareBasicAndDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAEarningPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:title="00000039 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_CommonStockUnitsMember" xlink:label="loc_SNOACommonStockUnitsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SNOACommonStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000040 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_NetRevenuesMember" xlink:label="loc_SNOANetRevenuesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_SNOANetRevenuesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_FirstCustomerMember" xlink:label="loc_SNOAFirstCustomerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOAFirstCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_SecondCustomerMember" xlink:label="loc_SNOASecondCustomerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOASecondCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ThirdCustomerMember" xlink:label="loc_SNOAThirdCustomerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOAThirdCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaapShippingAndHandlingMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapShippingAndHandlingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOAAllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_SNOAAllowanceForSalesDiscountsRebatesDistributorFeesAndReturns" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice" xlink:title="00000041 - Disclosure - Sale of Assets - Discontinued Operations (Details - Allocation of sale price)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_MicromedLabsMember" xlink:label="loc_SNOAMicromedLabsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_SNOAMicromedLabsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredRevenue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" xlink:label="loc_SNOADisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_SNOADisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaapProceedsFromDivestitureOfBusinesses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapProceedsFromDivestitureOfBusinesses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations" xlink:title="00000042 - Disclosure - Sale of Assets - Discontinued Operations (Details - Discontinued Operations)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:title="00000043 - Disclosure - Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DiscountsRebatesDistributorFeesAndReturns" xlink:label="loc_SNOADiscountsRebatesDistributorFeesAndReturns" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_SNOADiscountsRebatesDistributorFeesAndReturns" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesDetails" xlink:title="00000044 - Disclosure - Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsNetOfReserves" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterialsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaapInventoryFinishedGoodsNetOfReserves" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoodsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:title="00000046 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000047 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:title="00000049 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_InsurancePremiums1Member" xlink:label="loc_SNOAInsurancePremiums1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_SNOAInsurancePremiums1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_InsurancePremiums2Member" xlink:label="loc_SNOAInsurancePremiums2Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_SNOAInsurancePremiums2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_PaycheckProtectionProgramMember" xlink:label="loc_SNOAPaycheckProtectionProgramMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_SNOAPaycheckProtectionProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_StatesBankInAtlantaMember" xlink:label="loc_SNOAStatesBankInAtlantaMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SNOAStatesBankInAtlantaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLoans" xlink:label="loc_us-gaapProceedsFromLoans" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:title="00000050 - Disclosure - Leases (Details - Balance sheet information related to leases)">
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DisclosureLeasesAbstract" xlink:label="loc_SNOADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaapLeasesOperatingAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLeasesOperatingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePaymentsUse" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities" xlink:title="00000051 - Disclosure - Leases (Details - Minimum operating lease liabilities)">
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DisclosureLeasesAbstract" xlink:label="loc_SNOADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SNOADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000052 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_TromblyBusinessLawMember" xlink:label="loc_SNOATromblyBusinessLawMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SNOATromblyBusinessLawMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000053 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:title="00000054 - Disclosure - Stock-Based Compensation (Details-Assumptions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation" xlink:title="00000055 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:title="00000056 - Disclosure - Stock-Based Compensation (Details-Plans)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2006Member" xlink:label="loc_SNOAPlan2006Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2006Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2011Member" xlink:label="loc_SNOAPlan2011Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2011Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2017Member" xlink:label="loc_SNOAPlan2017Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2017Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" xlink:label="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:title="00000057 - Disclosure - Stock-Based Compensation (Details-Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:title="00000058 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000059 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2006Member" xlink:label="loc_SNOAPlan2006Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2006Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2011Member" xlink:label="loc_SNOAPlan2011Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2011Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_Plan2021Member" xlink:label="loc_SNOAPlan2021Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCharges" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:title="00000060 - Disclosure - Income Taxes (Details-Deferred taxes)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsGrossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredTaxAssetsLeaseLiability" xlink:label="loc_SNOADeferredTaxAssetsLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_SNOADeferredTaxAssetsLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:title="00000061 - Disclosure - Income Taxes (Details-Income source)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:title="00000062 - Disclosure - Income Taxes (Details-Income tax expense)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:title="00000063 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_ForeignTaxTrueup" xlink:label="loc_SNOAForeignTaxTrueup" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SNOAForeignTaxTrueup" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_TrueupsOfStateDeferredAssets" xlink:label="loc_SNOATrueupsOfStateDeferredAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SNOATrueupsOfStateDeferredAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsForeign" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000065 - Disclosure - Employee Benefit Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitContributions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitContributions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:title="00000066 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_HumanCareMember" xlink:label="loc_SNOAHumanCareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAHumanCareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20220331.xsd#SNOA_AnimalCareMember" xlink:label="loc_SNOAAnimalCareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAAnimalCareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions" xlink:title="00000067 - Disclosure - Geographic Information (Details - Geographic regions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueSegmentMember" xlink:label="loc_us-gaapSalesRevenueSegmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueSegmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtStatementGeographicalAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember" xlink:label="loc_srtLatinAmericaMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtLatinAmericaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative" xlink:title="00000068 - Disclosure - Revenue Disaggregation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699368144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SONOMA PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001367083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0423298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">645 Molly Lane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Woodstock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">759-9305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SNOA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity public float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,658,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">215<span></span>
</td>
<td class="text">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Frazier & Deeter<span></span>
</td>
<td class="text">Marcum llp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Atlanta, Georgia<span></span>
</td>
<td class="text">New York, NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699075952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,396,000<span></span>
</td>
<td class="nump">$ 4,220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,407,000<span></span>
</td>
<td class="nump">2,806,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">2,663,000<span></span>
</td>
<td class="nump">2,530,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,746,000<span></span>
</td>
<td class="nump">3,218,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_DeferredConsiderationNetCurrent', window );">Current portion of deferred consideration, net of discount</a></td>
<td class="nump">218,000<span></span>
</td>
<td class="nump">209,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">16,430,000<span></span>
</td>
<td class="nump">12,983,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">320,000<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right of use assets</a></td>
<td class="nump">559,000<span></span>
</td>
<td class="nump">769,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">829,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_DeferredConsiderationNetNoncurrent', window );">Deferred consideration, net of discount, less current portion</a></td>
<td class="nump">630,000<span></span>
</td>
<td class="nump">763,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">77,000<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">18,845,000<span></span>
</td>
<td class="nump">14,987,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,641,000<span></span>
</td>
<td class="nump">1,769,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,843,000<span></span>
</td>
<td class="nump">1,154,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,223,000<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ContractWithCustomerLiabilityCurrentInvekra', window );">Deferred revenue Invekra</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of debt-PPP</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">688,000<span></span>
</td>
<td class="nump">596,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,819,000<span></span>
</td>
<td class="nump">4,078,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term deferred revenue Invekra</a></td>
<td class="nump">182,000<span></span>
</td>
<td class="nump">229,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion &#8211; PPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,310,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_WithholdingTaxPayable', window );">Withholding Tax Payable</a></td>
<td class="nump">3,838,000<span></span>
</td>
<td class="nump">3,478,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">309,000<span></span>
</td>
<td class="nump">529,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,148,000<span></span>
</td>
<td class="nump">9,624,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2022 and 2021, respectively, no shares issued and outstanding at March 31, 2022 and 2021, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 24,000,000 shares authorized at March 31, 2022 and 2021, respectively, 3,100,937 and 2,092,909 shares issued and outstanding at March 31, 2022 and 2021, respectively (Note 13)</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">197,370,000<span></span>
</td>
<td class="nump">189,217,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(184,363,000)<span></span>
</td>
<td class="num">(179,277,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,312,000)<span></span>
</td>
<td class="num">(4,579,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">8,697,000<span></span>
</td>
<td class="nump">5,363,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 18,845,000<span></span>
</td>
<td class="nump">$ 14,987,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ContractWithCustomerLiabilityCurrentInvekra">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ContractWithCustomerLiabilityCurrentInvekra</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredConsiderationNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredConsiderationNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredConsiderationNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredConsiderationNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_WithholdingTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_WithholdingTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699343328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">24,000,000<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">3,100,937<span></span>
</td>
<td class="nump">2,092,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">3,100,937<span></span>
</td>
<td class="nump">2,092,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock shares authorized</a></td>
<td class="nump">714,286<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699044544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive (Loss) Income - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 12,628,000<span></span>
</td>
<td class="nump">$ 18,629,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">8,635,000<span></span>
</td>
<td class="nump">12,070,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">3,993,000<span></span>
</td>
<td class="nump">6,559,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">555,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">9,755,000<span></span>
</td>
<td class="nump">9,453,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,880,000<span></span>
</td>
<td class="nump">10,008,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,887,000)<span></span>
</td>
<td class="num">(3,449,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Forgiveness of PPP Loan</a></td>
<td class="nump">723,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="num">(394,000)<span></span>
</td>
<td class="num">(594,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on sale of assets</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">(5,418,000)<span></span>
</td>
<td class="num">(3,902,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">332,000<span></span>
</td>
<td class="num">(713,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations, net of tax</a></td>
<td class="num">(5,086,000)<span></span>
</td>
<td class="num">(4,615,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">665,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,086,000)<span></span>
</td>
<td class="num">$ (3,950,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_EarningPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share: basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare', window );">Continuing operations</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (2.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare', window );">Discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_EarningPerShareBasicAndDiluted', window );">Total loss per share</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (1.97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding: basic and diluted</a></td>
<td class="nump">2,653,000<span></span>
</td>
<td class="nump">1,996,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,086,000)<span></span>
</td>
<td class="num">$ (3,950,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">1,031,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (4,819,000)<span></span>
</td>
<td class="num">$ (2,919,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_EarningPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_EarningPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_EarningPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_EarningPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831700175056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 186,559,000<span></span>
</td>
<td class="num">$ (175,327,000)<span></span>
</td>
<td class="num">$ (5,610,000)<span></span>
</td>
<td class="nump">$ 5,624,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2020</a></td>
<td class="nump">1.55<span></span>
</td>
<td class="nump">1,777,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued in connection with exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">511,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">511,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued in connection with exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Shares issued in connection with vesting of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares issued in connection with vesting of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount', window );">Shares issued in connection with exercise of common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,776,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,776,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares', window );">Shares issued in connection with exercise of common stock warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_SharesIssuedWithConversionOfCShares', window );">Shares issued with conversion of C shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_SharesIssuedWithConversionOfCSharesShares', window );">Shares issued with conversion of C shares, shares</a></td>
<td class="num">(1.55)<span></span>
</td>
<td class="nump">17,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Employee stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">332,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">332,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Stock based compensation related to issuance of common stock restricted stock grants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031,000<span></span>
</td>
<td class="nump">1,031,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,950,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,950,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">189,217,000<span></span>
</td>
<td class="num">(179,277,000)<span></span>
</td>
<td class="num">(4,579,000)<span></span>
</td>
<td class="nump">5,363,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,092,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in connection with ATM, net of transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,554,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,554,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in connection with ATM, net of transaction costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued in connection with exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">193,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">193,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued in connection with exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount', window );">Shares issued in connection with exercise of common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares', window );">Shares issued in connection with exercise of common stock warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Employee stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">372,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">372,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock based compensation related to issuance of common stock restricted stock grants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock based compensation related to common stock restricted stock grants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,086,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,086,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 197,370,000<span></span>
</td>
<td class="num">$ (184,363,000)<span></span>
</td>
<td class="num">$ (4,312,000)<span></span>
</td>
<td class="nump">$ 8,697,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,100,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_SharesIssuedWithConversionOfCShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_SharesIssuedWithConversionOfCShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_SharesIssuedWithConversionOfCSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_SharesIssuedWithConversionOfCSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831700151168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,086,000)<span></span>
</td>
<td class="num">$ (3,950,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">186,000<span></span>
</td>
<td class="nump">227,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Recovery of doubtful accounts</a></td>
<td class="num">(125,000)<span></span>
</td>
<td class="num">(903,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns', window );">Provision for (recovery of) discounts, rebates, distributor fees and returns</a></td>
<td class="num">(1,407,000)<span></span>
</td>
<td class="nump">259,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">382,000<span></span>
</td>
<td class="nump">371,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ForgivenessOfPppLoan', window );">Forgiveness of PPP loan</a></td>
<td class="num">(723,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income tax expense</a></td>
<td class="num">(829,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Operating lease right-of-use asset</a></td>
<td class="nump">223,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(770,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,971,000<span></span>
</td>
<td class="nump">2,608,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(65,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(460,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount', window );">Deferred consideration, net of discount</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">143,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(157,000)<span></span>
</td>
<td class="num">(796,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">679,000<span></span>
</td>
<td class="num">(668,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_IncreaseDecreaseInWithholdingTaxPayable', window );">Withholding tax payable</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="nump">397,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(222,000)<span></span>
</td>
<td class="num">(215,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,248,000)<span></span>
</td>
<td class="num">(3,378,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(137,000)<span></span>
</td>
<td class="num">(179,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_IncreaseDecreaseInDeposits1', window );">Deposits</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="num">(43,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from Micromed Transaction</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(99,000)<span></span>
</td>
<td class="nump">388,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">7,554,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_PaymentsOnPppLoan', window );">Payments on PPP Loan</a></td>
<td class="num">(467,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from PPP Loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,310,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options and purchase warrants</a></td>
<td class="nump">216,000<span></span>
</td>
<td class="nump">2,287,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Principal payments on short-term debt</a></td>
<td class="num">(30,000)<span></span>
</td>
<td class="num">(481,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds on short-term debt</a></td>
<td class="nump">123,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets', window );">Benefit from lease assumed less principal payments on ROU Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">192,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,396,000<span></span>
</td>
<td class="nump">3,308,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate on cash and cash equivalents</a></td>
<td class="nump">127,000<span></span>
</td>
<td class="nump">211,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">3,176,000<span></span>
</td>
<td class="nump">529,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">4,220,000<span></span>
</td>
<td class="nump">3,691,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">7,396,000<span></span>
</td>
<td class="nump">4,220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">767,000<span></span>
</td>
<td class="nump">941,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash operating and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_InsurancePremiumsFinanced', window );">Insurance premiums financed</a></td>
<td class="nump">$ 748,000<span></span>
</td>
<td class="nump">$ 596,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ForgivenessOfPppLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ForgivenessOfPppLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_IncreaseDecreaseInDeposits1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_IncreaseDecreaseInDeposits1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_IncreaseDecreaseInWithholdingTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_IncreaseDecreaseInWithholdingTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_InsurancePremiumsFinanced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_InsurancePremiumsFinanced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_PaymentsOnPppLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_PaymentsOnPppLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831702108672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Recent Developments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Recent Developments</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zu6TsBwZut1i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;1&#160;&#8211; <span id="xdx_823_zwraHgvuJF72">Organization and Recent
Developments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sonoma Pharmaceuticals, Inc. (the &#8220;Company&#8221;)
was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware
in December 2006. The Company&#8217;s principal office was moved to Woodstock, Georgia from Petaluma, California in June 2020. The Company
is a global healthcare leader for developing and producing stabilized hypochlorous acid (&#8220;HOCl&#8221;) products for a wide range
of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company&#8217;s products
reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies
of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. The Company&#8217;s stabilized
HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells
in the area treated assisting the body in its natural healing process. The Company sells its products either directly or via partners
in 54 countries worldwide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831702028192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Financial Condition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity and Financial Condition</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zmKHvPxNB3wb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;2&#160;&#8211; <span id="xdx_82A_z8CQz0htyafe">Liquidity and Financial
Condition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reported a net loss of $<span id="xdx_900_eus-gaap--NetIncomeLoss_iN_di_c20210401__20220331_z9uOEU15ipfc" title="Net loss">5,086,000</span>
for the year ended March 31, 2022. At March 31, 2022 and 2021, the Company&#8217;s accumulated deficit amounted to $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20220331_z7QFEq9R169h" title="Accumulated deficit">184,363,000</span>
and $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20210331_zl2MGT0lkuy" title="Accumulated deficit">179,277,000</span>, respectively. The Company had working capital of $<span id="xdx_904_ecustom--WorkingCapital_c20220331_pp0p0" title="Working capital">10,611,000</span> and $<span id="xdx_904_ecustom--WorkingCapital_iI_pp0p0_c20210331_zy7ELL6hSdm3" title="Working capital">8,905,000</span> as of March 31, 2022 and 2021,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that the Company has access
to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other
means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms,
if needed. If the economic climate in the U.S. deteriorates, the Company&#8217;s ability to raise additional capital could be negatively
impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order
to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays
in the Company&#8217;s continued efforts to commercialize its products, which is critical to the realization of its business plan and
the future operations of the Company. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern.
The accompanying consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to
continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>COVID &#8211; 19</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 11, 2020 the
World Health Organization declared the novel strain of coronavirus (&#8220;COVID-19&#8221;) a global pandemic and recommended containment
and mitigation measures worldwide. In an effort to mitigate the continued spread of the virus, federal, state and local governments, as
well as certain private entities have mandated various restrictions, including travel restrictions, restrictions on public gatherings
and quarantining of people who may have been exposed to the virus. As a result of these restrictions, together with a general fear of
the impact on the global economy and financial markets, there is significant uncertainty surrounding the potential impact on the Company.
As events are rapidly changing, the Company is unable to accurately predict the impact that COVID-19 will have on its business due to
uncertainties including, but not limited to, the duration of quarantines and other travel restrictions within China, the U.S. and other
affected countries, the ultimate geographical spread of the virus, the severity of the disease, the duration of the outbreak and the public&#8217;s
response to the outbreak.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701812640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zvBqxU4QvNPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;3&#160;&#8211; <span id="xdx_82D_zyMfraEQ5iu2">Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zdhJQAklOI82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zJrVB9o8qPaa">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#8220;Aquamed&#8221;), Oculus Technologies
of Mexico S.A. de C.V. (&#8220;OTM&#8221;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#8220;SP Europe&#8221;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#8220;U.S.&#8221;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6kTYYWEIm67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_869_zLEfOSLbmZUb">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated
financial statements have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission
("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). The Company&#8217;s fiscal
year end is March 31. Unless otherwise stated, all years and dates refer to the fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMz1LixZSF48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86E_zUzki0mVVL08">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents
include cash on hand and all highly liquid investments with an original maturity of three months or less when purchased. The Company&#8217;s
cash equivalents are held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_840_eus-gaap--UseOfEstimates_z1rPJwv6qHzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_z3atnCgDmdz">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating
to the Company&#8217;s deferred tax assets, valuation of equity, fair value allocation of assets sold to Invekra, and the estimated amortization
periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zOfmMfmTTv2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_z78nGuyLyZK2">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2018, the Company adopted Accounting
Standards Update ("ASU"), "Revenue from Contracts with Customers Topic 606&#8221; (&#8220;Topic 606&#8221;) using the modified
retrospective method. There was no material impact to the Company upon the adoption of Topic 606. Revenue is recognized when the Company
transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive
in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its
obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the promised goods or services in
the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are
distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company derives the majority of its revenue
through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including
hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license
its technology and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers customer purchase orders,
which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers
the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For all of its sales to non-consignment distribution
channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied),
which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on
the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers,
the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able
to estimate the amount of product that will be returned.&#160;&#160;Sales incentives and other programs that the Company may make available
to these customers are considered to be a form of variable consideration, and the Company maintains estimated accruals and allowances
using the expected value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the
Company&#8217;s rebate program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales to stocking distributors are made under
terms with fixed pricing and limited rights of return (known as &#8220;stock rotation&#8221;) of the Company&#8217;s products held in
their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assessed the promised goods and services
in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is
separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as
other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Service revenue from testing contracts is recognized
as tests are completed and a final report is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zQG8MWcuQMee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zZ7aTCwWRBjk">Concentration of Credit Risk and Major Customers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company grants credit to its business customers,
which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. The Company
maintains allowances for potential credit losses. At March 31, 2022, one customer represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZBZeds9Apq8" title="Significant customer concentration">20%</span> of our net accounts
receivable balance, one customer represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbmHbBQlzH1l">15%</span> of our net accounts receivable balance, and one customer represented
<span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvJLSXHG9ntb">14%</span> of our net accounts receivable balance. At March 31, 2021, one customer represented <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR4a2HzAazwk">17</span>% of our net accounts receivable balance, one customer represented <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFiepuzigYl3">16</span>%
of our net accounts receivable balance, and one customer represented <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfGlF255Zn0c">14</span>% of our net accounts receivable balance. For the year ended March 31, 2022, one customer represented <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9ZQvKaieujk">10</span>%, one customer represented <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztnOOVa0t2Ni">17</span>%, and one customer represented
<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHbr1sCM4Di">21</span>% of net revenues. For the year ended March 31, 2021, one customer represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8l6YiasiR53">32</span>%, and one customer represented <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1E7AUHpoJq4">15</span>% of net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zuQPgL1h1zm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zspY2vT1pgK2">Accounts Receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are recorded net of
allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns
are based on analysis of contractual terms and historical trends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents
probable credit losses at March 31, 2022 and 2021 in the amounts of $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20220331_zVsbBVHGWjih" title="Allowance for doubtful accounts">0</span> and $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20210331_zYEROlWyq70d" title="Allowance for doubtful accounts">125,000</span>, respectively. Additionally, at March 31, 2022 and
2021, the Company has allowances of $<span id="xdx_900_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20220331_zw7gjy1tGVMl" title="Allowance for sales discounts, rebates, distributor fees and returns">81,000</span> and $<span id="xdx_909_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20210331_znQlQwN9KDLi" title="Allowance for sales discounts, rebates, distributor fees and returns">1,488,000</span>, respectively, related to potential discounts, returns, distributor fees and
rebates. The allowances are included in Accounts Receivable, net in the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zBN59cHxSaZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_z1QVEANCPHbi">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision
to reduce the carrying amounts of inventories to their net realizable value in the amounts of <span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_c20220331_znPp91x7lir9" title="Inventory reserves">$218,000</span> and <span id="xdx_907_eus-gaap--InventoryValuationReserves_iI_c20210331_zvrHkh3kFRvj" title="Inventory reserves">$223,000</span> at March 31, 2022
and 2021, respectively, which is included in cost of revenues on the Company&#8217;s accompanying consolidated statements of comprehensive
(loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zYOxwuVETy8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_zAUtJIXcoPw7">Financial Assets and Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, including cash and cash
equivalents, accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the
short-term nature of these instruments. The fair value of capital lease obligations and equipment loans approximates their carrying amounts
as a market rate of interest is attached to their repayment. The Company measures the fair value of financial assets and liabilities based
on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes
the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of
inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;1&#160;&#8211; quoted prices in active
markets for identical assets or liabilities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;2&#160;&#8211; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;3&#160;&#8211; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#8217;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#8217;s accounting and finance department
and are approved by the Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022 and 2021, there were <span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20210401__20220331_zOKiwZLZhKX6" title="Transfers in or out of Level 3"><span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20200401__20210331_z1CTkyNVUFY1" title="Transfers in or out of Level 3">no</span></span> transfers
in or out of Level 3 from other levels in the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_ziDHEVgeJb6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zlGufgVVqTze">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost less
accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the
estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over
the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification
is as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z27mgY7Q7NHa" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zdrkbAcSzJt7" style="display: none">Property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 85%"><span style="font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: center"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zxRRadcj8PJk" title="Useful asset life">3</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zR3oWDeVTsG5" title="Useful asset life">5</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_znRvm3Gfvdp3" title="Useful asset life">7</span></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon retirement or sale, the cost and related
accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance
and repairs are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1IwNgiIGVab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_znM5z7vIicDb">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company periodically reviews the carrying
values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying
values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of
impairment include, but are not necessarily limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a significant decrease in the fair value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a significant adverse change in legal factors or in the business climate that affects the value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When circumstances indicate that an impairment
may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows,
assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the
cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment
loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates
used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended March 31, 2022 and 2021,
the Company had noted <span id="xdx_909_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20210401__20220331_zMPvx9klZnHg" title="Asset impairment charges"><span id="xdx_90D_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20200401__20210331_zA5gdjLshMR6" title="Asset impairment charges">no</span></span> indicators of impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbYzOJfC1ib7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_z52U51uSXwr8">Research and Development</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses are charged
to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended
March 31, 2022 and 2021, research and development expense amounted to $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20210401__20220331_pn3p0" title="Research and development expenses">125,000</span> and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20200401__20210331_pn3p0" title="Research and development expenses">555,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_zuiXNNC3aLNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_znaCXPH8z2Zj">Advertising Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising costs are charged to operations as
incurred. Advertising costs amounted to $<span id="xdx_907_eus-gaap--MarketingExpense_c20210401__20220331_z7FHj4x7970c" title="Advertising costs">86,000</span> and $<span id="xdx_902_eus-gaap--MarketingExpense_c20200401__20210331_zPn8rcnKkOYk" title="Advertising costs">41,000</span>, for the years ended March 31, 2022 and 2021, respectively. Advertising costs
are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84C_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zwmlOy3BVSzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_869_zg6JsYKlEnyk">Shipping and Handling Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2022 and 2021, the Company recorded revenue related to shipping and
handling costs of $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_pp0p0" title="Revenues">52,000</span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_pp0p0" title="Revenues">37,000</span>, respectively. These amounts are included in product revenues in the accompanying consolidated statements
of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zv8lOk1b2B69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zz9h0XByutAe">Foreign Currency Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiary, OTM, uses the
local currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional
currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts
are translated at average exchange rates during the period. Resulting translation adjustments amounted to $<span id="xdx_90C_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20210401__20220331_zNm6o6YfPmu8" title="Foreign currency translation adjustment">267,000</span> and $<span id="xdx_900_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20200401__20210331_zD8llMX91eAl" title="Foreign currency translation adjustment">1,031,000</span> for
the years ended March 31, 2022 and 2021, respectively. These amounts were recorded in other comprehensive loss in the accompanying consolidated
statements of comprehensive loss for the years ended March 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency transaction gains (losses) relate
primarily to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are
expected to be settled in the foreseeable future. The Company recorded foreign currency transaction losses of $<span id="xdx_905_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20210401__20220331_zGjcRd60GEe1" title="Foreign currency transaction loss">579,000</span> for the year ended
March 31, 2022, and foreign currency transaction losses of $<span id="xdx_904_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20200401__20210331_zlsJxvRFYBEc" title="Foreign currency transaction loss">690,000</span>, for the year ended March 31, 2021. The related amounts were recorded
in other expense in the accompanying consolidated statements of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zVxi6ReJV8M9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_zVyQqglG9Txg">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of an forfeitures for all stock
options as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zrSNgFEi4rea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zxcOkOQ22MM9">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tax benefits claimed or expected to be claimed
on a tax return are recorded in the Company&#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is
only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based
on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain
tax positions have had no impact on the Company&#8217;s consolidated financial condition, results of comprehensive (loss) income or cash
flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zcS8XeMQAjHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zJ1EihqTTxu6">Comprehensive Loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other comprehensive loss includes all changes
in stockholders&#8217; equity during a period from non-owner sources and is reported in the consolidated statement of changes in stockholders&#8217;
equity. To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other
comprehensive losses at March 31, 2022 and 2021 were $<span id="xdx_90C_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_di_c20220331_zJTmlaS86sF8" title="Accumulated other comprehensive loss">4,312,000</span>, and $<span id="xdx_904_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_di_c20210331_zRGceQToe0Y1" title="Accumulated other comprehensive loss">4,579,000</span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zZIuD7ckLwr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_zwNsb8Rp0xj9">Net Income Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic net loss per share
by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period
and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution
that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#8220;treasury stock&#8221;
and/or &#8220;if converted&#8221; methods as applicable.</p>

<table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zRsXO5wGZkFj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span id="xdx_8B2_zpxwFLCCtP8l" style="display: none">Computation of earnings per share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20210401__20220331_zgB7s2aDRr86" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20200401__20210331_zmixmPzrIO54" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_zQP4TmgcF8gh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: justify">Loss from continuing operations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(5,086</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,615</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_pn3n3_d0_zBX7xn3gTW5b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Income  from discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">665</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_pn3n3_z5VgTLfopGV1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,086</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,950</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pin3_zYmPWPsI6bP3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average  shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,653</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,996</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeLossFromContinuingOperationPerBasicAndDilutedShare_pip0_z02qMOz8gKQ3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Loss per share from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.92</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.31</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_pip0_d0_zOMu6zBGKfAh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Income  per share from discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.33</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EarningPerShareBasicAndDiluted_pip0_zwbOIalyqXZg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.92</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.97</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The computation of basic loss per share for the
years ended March 31, 2022 and 2021 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_ztvvNLsaRsI5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BF_z0EjdoIXDfP7" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Common stock to be issued upon vesting of restricted stock units</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zAp9FNVR20Fa" style="width: 13%; text-align: right" title="Antidilutive shares">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zQSnEapuGNGe" style="width: 13%; text-align: right" title="Antidilutive shares">1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zGFCfY6Bzqba" style="text-align: right" title="Antidilutive shares">466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z9xIv4jNVfIh" style="text-align: right" title="Antidilutive shares">268</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Common stock to be issued upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zALn25cy18v2" style="text-align: right" title="Antidilutive shares">108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zq2rNd0ZLsZf" style="text-align: right" title="Antidilutive shares">119</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon conversion of Series C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zpw5wzu3R7z7" style="text-align: right" title="Antidilutive shares">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zImGLkNONzYa" style="text-align: right" title="Antidilutive shares">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon exercise of common stock units (1)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zfQ3iLmWAPAb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_z3MFiQjglZQ1" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331_z74sV2x6BNJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">621</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331_zcYutqb7JmT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">434</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%"><span id="xdx_F0B_z5FMj7xzgpCd" style="font-size: 10pt">(1)</span></td>
    <td style="width: 94%; text-align: justify"><span id="xdx_F12_zdUEYaIzOBF2" style="font-size: 10pt">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</span></td></tr>
  </table>
<p id="xdx_8A2_zyDhTgPZH63i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_z3VfIE2uf0X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_865_zUk0jJiaGii2">Common Stock Purchase Warrants and Other
Derivative Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies common stock purchase warrants
and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement
or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).
The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if
an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net cash settlement or
settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability.
The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification
between assets and liabilities is required. The Company determined that its freestanding derivatives, which principally consist of warrants
to purchase common stock, satisfied the criteria for classification as equity instruments, other than certain warrants that contained
reset provisions and certain warrants that required net-cash settlement that the Company classified as derivative liabilities. The company
currently does not have any active derivative financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_z5xbRK3EYqgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zth03FqF3sud">Preferred Stock</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the accounting standards for
distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject
to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally
redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the
holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity.
At all other times, preferred shares are classified as stockholders' equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_849_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zwxMwRMLRIY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_zIo7djYjf1Jj">Subsequent Events</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated subsequent events or
transactions occurring through the date these consolidated financial statements were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcic2ZUgyW01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_z8VqGU08W4Bl">Recent Accounting Standards</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated all the recent accounting
standards and determined that none of them are material to it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701823504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Assets &#8211; Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Assets &#8211; Discontinued Operations</a></td>
<td class="text"><p id="xdx_809_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zRcC4XJsVuA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span id="xdx_821_znALJJPmwWP9">Sale of Assets &#8211;
Discontinued Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Sale of Assets to Infinity Labs SD, Inc. and Discontinued Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 24, 2020, the Company closed on an asset
purchase agreement for the sale of its Micromed Laboratories division and testing facility, including all of Micromed&#8217;s assets,
such as testing equipment, certain office furniture and customer list, with Infinity Labs SD Inc. (&#8220;Infinity&#8221;) for an aggregate
purchase price of $850,000. On the closing date, the Company received $610,000 in cash from this sale which was adjusted for working capital,
a credit of $100,000 for future testing services from Infinity over the next two years in lieu of cash, and $60,000 held in escrow for
one year, subject to adjustment for certain indemnity claims or purchase price adjustments. The Company also retained its accounts receivables
outstanding on the date of closing in the amount of approximately $81,000 and an insignificant amount of liabilities. As part of the transaction,
Infinity also assumed the Petaluma lease for the office and lab space. The Company retained the warehouse space to store inventory and
assets until September 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Accounting for the disposition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For accounting purposes, the Company determined
that there was only one discrete component of the sale to Infinity. This component was the customer base and related services to be provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 20%"><span style="font-size: 10pt"><span style="text-decoration: underline">Component of Sale</span></span></td>
    <td style="width: 80%"><span style="font-size: 10pt"><span style="text-decoration: underline">Methodology to Estimate Selling Price</span></span></td></tr>
  <tr style="vertical-align: top; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Customer Base </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Based upon revenues expected from a market participant to provide technical services at expected service levels</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined an arm&#8217;s length selling
price for each component of the sale and then allocated the net proceeds received to the components on a relative selling price basis.
The Company estimated the selling prices of&#160;each component as described below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proceeds were allocated to the components of the sale based upon their
relative selling prices are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfAllocationOfSalePriceTableTextBlock_zDepiG3PBW4l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Sale of Assets - Discontinued Operations (Details - Allocation of sale price)">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span id="xdx_8BA_zVtlVTsr53b6" style="display: none">Schedule of allocation of sale price</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%; text-align: justify">Customer base</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_iI_pp0p0_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zMHZu6cLDip6" style="width: 13%; text-align: right" title="Customer base">850,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less:&#160;Funds remaining in escrow</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zA8OEhbffwTg" style="text-align: right" title="Less: Funds remaining in escrow">(60,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Less:&#160;Services due from buyer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zmTnMXXkPGWg" style="text-align: right" title="Less: Services due from buyer">(100,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Less: Working capital adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zXEXPzywP1Og" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Working capital adjustment">(80,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total proceeds</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ProceedsFromDivestitureOfBusinesses_c20200401__20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Proceeds from sale of business">610,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Discontinued operations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 24, 2020, the Company determined that
the sale of its Micromed division to Infinity qualified as a sale of a component of its business and, as such, all such activity prior
to consummation of the sale is required to be included in discontinued operations on the Company&#8217;s statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no carrying value of the assets and liabilities of discontinued
operations on the consolidated balance sheets as of March 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The operations of the Micromed business included in discontinued operations
is summarized as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zjpUZOSP1Ha4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Sale of Assets - Discontinued Operations (Details - Discontinued Operations)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_z97pWsGLRhSa" style="display: none">Assets and liabilities of disposal group</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20210401__20220331_z4N6S8MWa0v3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20200401__20210331_zSfTP71LSpdi" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_d0_maDGIDOzviC_zxsTEjNmbal3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">214,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_d0_msDGIDOzviC_zCTPMLfSM4Na" style="vertical-align: bottom; background-color: White">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_d0_msDGIDOzviC_zcUZPLRTtrEf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Selling general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">38,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_iT_pp0p0_d0_mtDGIDOzviC_maDOILFzWBf_z1GKUibgaP37" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income from discontinued operations before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_d0_maDOILFzWBf_zEUoslj4DhDj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Gain on disposal of discontinued operations before income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">770,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_iT_pp0p0_d0_mtDOILFzWBf_maILFDOzvre_zcKXL6QfgXzj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total income from discontinued operations, before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">893,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_iN_pp0p0_di0_msILFDOzvre_znjlBqAWoor3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Income Tax benefit (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(228,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pp0p0_d0_mtILFDOzvre_zYRzpFjEDl01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income from discontinued operations, net of tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">665,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831702020880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_803_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zRvo8iavcMui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;5&#160;&#8211; <span id="xdx_820_zmdfGHaGPV1l">Accounts Receivable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable, net consists of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zEDejifOY7j8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B2_zJyLNvxQYP5e" style="display: none">Accounts receivable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20220331_z6bs1ZddSP3k" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20210331_z1GuUwyteqpk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCzGH6_z4OOc0u9TBM9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,488,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">4,419,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di0_msARNCzGH6_zxFa4KsYXg3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: allowance for doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(125,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--DiscountsRebatesDistributorFeesAndReturns_iNI_pp0p0_di_msARNCzGH6_z5XNRjHcRhw9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Less: discounts, rebates, distributor fees and returns</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(81,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,488,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzGH6_zbFmLeoq1e8i" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Accounts receivable, net&#160;</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,407,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,806,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701956496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zRbCQYuiEEh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;6&#160;&#8211; <span id="xdx_829_zahmYzWTk8ci">Inventories</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories consist of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zRU3jnInaWY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BC_zP06Hii7KMr1" style="display: none">Schedule of inventories</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20220331_zhycOw10rW87" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20210331_zBFAAsXszZ0c" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pp0p0_maINzPTc_zLXMYwxsNlW1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,626,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,670,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pp0p0_maINzPTc_zO9Qp0D4sUa2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,037,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">860,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryNet_iTI_pp0p0_mtINzPTc_z65dJ5Z0l1K4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Inventories, net</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,663,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,530,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701890928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_802_eus-gaap--OtherCurrentAssetsTextBlock_zaWjC6bCfQy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;7&#160;&#8211; <span id="xdx_822_zMV3U6agQGs1">Prepaid Expenses and
Other Current Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid expenses and other current assets consist
of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zexLbkZ7Ij3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B2_zIIRrMO3pgq6" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220331_zBpjz9EHFzDi" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20210331_zwrfO6O7sKB7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Prepaid insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">755,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">705,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidTaxes_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax prepaid to Mexican tax authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,371,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,850,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">620,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">663,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="color: rgb(238,238,238); padding-bottom: 2.5pt">&#160;Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,746,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,218,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701950384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_806_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_ztRwaluJTAk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;8&#160;&#8211; <span id="xdx_827_zhOVDfNfSIR1">Property and Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment consists of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--PropertyPlantAndEquipmentTextBlock_zW5jMmMkM8Ig" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BE_zdb8YMwOM2Dg" style="display: none">Schedule of property and equipment</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220331_zf2bZXpoLYH3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20210331_zzKHeGMO06k9" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGzTcR_zRLtBPIUJok8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Manufacturing, lab, and other equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,281,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,170,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0p0_maPPAEGzTcR_zJNBwvfgBcv2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAEGzTcR_zqPximMIx3g7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LeaseholdImprovementsGross_iI_pp0p0_maPPAEGzTcR_zNwqMUhS56Li" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">503,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">486,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGzTcR_maPPAENzONv_z4KLBr1xciwl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: rgb(238,238,238)">Property and equipment, gross&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,031,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,831,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzONv_zEFHP6YBQpof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,711,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,471,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzONv_zFuVsqt4oxV7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: rgb(238,238,238); padding-bottom: 2.5pt">Property and equipment, net&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">320,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">360,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation and amortization expense amounted
to $<span id="xdx_90E_eus-gaap--DepreciationAndAmortization_c20210401__20220331_pp0p0" title="Depreciation and amortization">186,000</span> and $<span id="xdx_90C_eus-gaap--DepreciationAndAmortization_c20200401__20210331_pp0p0" title="Depreciation and amortization">227,000</span> for the years ended March 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701890928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zkZcmG6SMIdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;9&#160;&#8211; <span id="xdx_825_zCW1jyqQtYac">Accrued Expenses and
Other Current Liabilities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses and other current liabilities
consist of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zGDRfarYZHJ7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BD_zIVGEqj7s9i4" style="display: none">Schedule of accrued expenses and other current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20220331_zgMgwi4W5bw7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20210331_zoXHv3sBp8da" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAz40k_zzEBlahCGuE1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Salaries and related costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,059,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">787,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAz40k_zS6K15J1Cfph" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">784,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">367,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pp0p0_mtAPAOAz40k_zEygzqqwz6ia" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Accrued expenses and other current liabilities</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,843,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,154,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701929936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text"><p id="xdx_808_eus-gaap--LongTermDebtTextBlock_zQpb4v1Hd8gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;10&#160;&#8211; <span id="xdx_827_zpQMMfsd38kb">Debt</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Financing of Insurance Premiums</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 1, 2021, the Company entered into
a note agreement for $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zQJTq8bkAug">584,000
</span>with an interest rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210125__20210131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zbJAmrtAVsuj">4.98</span>%
per annum with final payment on October 1, 2021. This instrument was issued in connection with financing insurance premiums. The note
was payable in three quarterly installment payments of principal and interest of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20210401__20211001__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zovrkV3sSHa">199,000</span>,
with the first installment beginning April 1, 2021. These amounts were paid off during the year ended March 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 1, 2022, the Company entered into
a note agreement for $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zJ0Q6KbxHNa9" title="Debt face amount">748,000</span> with an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220125__20220131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zTTlnUb02FRi" title="Debt interest rate">4.68</span>% per annum with final payment on January 1, 2023. This instrument was issued
in connection with financing insurance premiums. The note is payable in ten monthly installment payments of principal and interest of
$<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20220301__20231231__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zf4SeECarcg4" title="Principal payments made">76,000</span>, with the first installment beginning March 1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Paycheck Protection Program Loan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2020, the Company received loan proceeds
in the amount of $<span id="xdx_905_eus-gaap--ProceedsFromLoans_pp0p0_c20200425__20200501__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zpKGkoHG1rc5" title="Proceeds from loan">1,310,000</span> under the Paycheck Protection Program (&#8220;PPP&#8221;), from Coastal States Bank in Atlanta, Georgia. The
PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, &#8220;CARES Act&#8221;, provides for loans to qualifying
businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest
are forgivable after eight or 24 weeks as long as the Company uses the loan proceeds for eligible purposes, including payroll, benefits,
rent and utilities, and maintains payroll levels. The amount of loan forgiveness will be reduced if the Company terminated employees or
reduced salaries during the applicable period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unsecured loan, which is in the form of a
note dated April 29, 2020, matures on <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20210401__20220331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zPlH4lMypSK6" title="Debt maturity date">April 29, 2022</span> and bears interest at a rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210401__20220331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_z8fwqABcnZk3" title="Debt interest rate">1</span>% per annum, payable monthly commencing on May 1,
2021. The note may be prepaid at any time prior to maturity with no prepayment penalties. The Company has used the loan amount for eligible
purposes, such as payroll expenses. The Company met the conditions for $<span id="xdx_909_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20210401__20220331_zEOHeyAOrcpa" title="Approval for forgiveness">723,000</span> in forgiveness of the loan. At March 31, 2022 and  2021 the loan balance amounted to $<span id="xdx_903_eus-gaap--LoansPayable_iI_c20220331_zljo3x16dLC9" title="Loans payable">120,000</span> and $<span id="xdx_90E_eus-gaap--LoansPayable_iI_c20210331_z0a7IYXh7HIk">1,310,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701865264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zDbCO4iFaBc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;11&#160;&#8211; <span id="xdx_825_z20vjlEXVTyd">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating leases are comprised
primarily of facility leases. Balance sheet information related to the Company&#8217;s leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zHpv9Ch3nhA" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span id="xdx_8B5_zgjgIMzk1EKl" style="display: none">Lease cost information</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20220331_zUP5ouNOgUD5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20210331_zPHYAuYgSGL4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeasesOperatingAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Operating leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">559,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">769,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liabilities &#8211; non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">529,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other information related to leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31, 2022</b></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Year ended<br/> March 31, 2021</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Operating lease cost</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseCost_c20210401__20220331_pp0p0" style="width: 13%; text-align: right">367,000</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_eus-gaap--OperatingLeaseCost_pp0p0_c20200401__20210331_zG7hzOy5BJ3a" style="text-align: right; width: 13%">435,000</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">As of March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20210401__20220331_z35iuhcsLCIj" style="text-align: right">(223,000</td><td style="text-align: left">)</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20200401__20210331_zURqMKrkpyW1" style="text-align: right">(215,000</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Weighted-average remaining lease term &#8211; operating leases (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220331_znLaPUYaszJ2" title="Weighted-average remaining lease term - operating leases (in months)">27.3</span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20210331_zsNppxdqe5me">37.7</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220331_zS9Y4njkNw77" title="Weighted-average discount rate - operating leases">6.00</span>%</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20210331_zhoZjWPcAFc9">6.00</span>%</td>
    <td>&#160;</td></tr>
  </table>

<p id="xdx_8AF_zoukrhei48g3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 180.1pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2022, the annual future minimum lease payments of
the Company&#8217;s operating lease liabilities were as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zqhCF8SPPeB9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease liabilities)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B5_zy4v7mNQTqza" style="display: none">Schedule of minimum operating lease liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220331_zxGiy09tRUwh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">For Years Ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzgSf_zKNEfSx9HDL3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">297,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzgSf_z4i1UNi7T6ve" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzgSf_zRkCyd0nldLf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzgSf_zRPwdShP9MD2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzgSf_zWYrPtLzbS29" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">627,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zxP1sj7Y5o6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(68,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">559,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>













<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701924080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zuG2q61SYw04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;12&#160;&#8211; <span id="xdx_823_z64C91qtLhjl">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legal Matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On occasion, the Company may be involved in legal
matters arising in the ordinary course of business including matters involving proprietary technology. While management believes that
such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become
involved in litigation may have a material adverse effect on its business and financial condition of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had employment
agreements in place with three of its key executives. These executive employment agreements provide, among other things, for the payment
of up to twelve months of severance compensation for terminations under certain circumstances. With respect to these agreements, at March
31, 2022, aggregated annual salaries would be $<span id="xdx_90C_eus-gaap--SalariesAndWages_c20210401__20220331_pp0p0" title="Annual salaries">775,000</span> and potential severance payments to these key executives would be $<span id="xdx_908_eus-gaap--SeveranceCosts1_c20210401__20220331_pp0p0" title="Potential severance">775,000</span> if triggered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Party Transactions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ms. Trombly was appointed the Chief Executive
Officer of the Company. Ms. Trombly is the owner of Trombly Business Law, PC which has been retained by the Company to advise on certain
corporate and securities law matters. During the years ending March 31, 2022 and  2021, the Company received $<span id="xdx_900_eus-gaap--LegalFees_c20210401__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_pp0p0" title="Legal fees">170,000</span> and $<span id="xdx_903_eus-gaap--LegalFees_pp0p0_c20200401__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_zwI4l1ctc8kf" title="Legal fees">215,000</span>,
respectively, in legal services from Trombly Business Law, PC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701963792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zZFHN06SH8xa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;13&#160;&#8211; <span id="xdx_826_zQLLTQi1rDCl">Stockholders&#8217;
Equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Authorized Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective September 13, 2018, the Company filed
a certificate of amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware
in order to affect an increase of the total number of shares of common stock, $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20220331_pdd" title="Common stock par value">0.0001</span> par value per share, authorized for issuance from
12,000,000 to a total of <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20220331_pdd" title="Common stock, shares authorized">24,000,000</span>. Additionally, the Company is authorized to issue <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Preferred stock, shares authorized">714,286</span> shares of convertible preferred stock with
a par value of $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Preferred stock par value">0.0001</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Description of Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of common stock has the right to one
vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Description of Series B Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18, 2016, the Company&#8217;s board
of directors approved, and the Company entered into, a Section 382 rights agreement, or the Rights Agreement, with Computershare Inc.,
or the Rights Agent. The Rights Agreement provides for a dividend of one preferred stock purchase right, or a Right, for each share of
common stock, par value $0.0001 per share, of the Company outstanding on November 1, 2016, or the Record Date. Each Right entitles the
holder to purchase from the Company one one-thousandth of a share of Series B Preferred Stock, par value $0.0001 per share, or the Preferred
Stock, for a purchase price of $10.00, subject to adjustment as provided in the Rights Agreement. The description and terms of the rights
are set forth in the Rights Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the adoption of the Rights
Agreement, the Company&#8217;s board of directors adopted a Certificate of Designation of Series B Preferred Stock. The Certificate of
Designation was filed with the Secretary of State of the State of Delaware and became effective on October 18, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s board of directors adopted
the Rights Agreement to protect shareholder value by guarding against a potential limitation on the Company&#8217;s ability to use its
net operating loss carryforwards, or NOLs, and other tax benefits, which may be used to reduce potential future income tax obligations.
The Company has experienced and continue to experience substantial operating losses, and under the Internal Revenue Code of 1986, as amended,
and rules promulgated thereunder, the Company may &#8220;carry forward&#8221; these NOLs and other tax benefits in certain circumstances
to offset any current and future earnings and thus reduce our income tax liability, subject to certain requirements and restrictions.
To the extent that the NOLs and other tax benefits do not otherwise become limited, the Company believes that it will be able to carry
forward a significant amount of NOLs and other tax benefits, and therefore these NOLs and other tax benefits could be a substantial asset
to the Company. However, if the Company experiences an &#8220;ownership change,&#8221; as defined in Section 382 of the Code, its ability
to use its NOLs and other tax benefits will be substantially limited. Generally, an ownership change would occur if our shareholders who
own, or are deemed to own, 5% or more of the Company&#8217;s common stock increase their collective ownership in the Company by more than
50% over a rolling three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exercise of Series C Preferred Stock Units</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended March 31, 2021, investors
who participated in the November 21, 2018 offering exchanged <span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20210401__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z19ZFBopJyGd" title="Preferred stock converted">1.55</span> shares of Series C into <span id="xdx_908_eus-gaap--ConversionOfStockSharesIssued1_c20210401__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Common stock issued upon conversion">17,222</span> shares of common stock. No further shares
of Series C are outstanding as of March 31, 2021 or 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701963792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zhP2zjcosJze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE&#160;14&#160;&#8211; <span id="xdx_82D_zqpuJvESPs7f">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2006 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board initially adopted the 2006 Stock Incentive
Plan on August 25, 2006. On December&#160;14, 2006, the stockholders approved the 2006 Stock Incentive Plan which became effective at
the close of the Company&#8217;s initial public offering. The 2006 Stock Incentive Plan was later amended and restated by a unanimous
board resolution on April&#160;26, 2007, and such amendments were subsequently approved by the stockholders. On September 10, 2009, the
Company&#8217;s shareholders approved a subsequent amendment to the 2006 Stock Incentive Plan. The 2006 Stock Incentive Plan, as amended
and restated, is hereafter referred to as the &#8220;2006 Plan.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2006 Plan provided for the granting of incentive
stock options to employees and the granting of non-statutory stock options to employees, non-employee directors, advisors and consultants.
The 2006 Plan also provided for grants of restricted stock, stock appreciation rights and stock unit awards to employees, non-employee
directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2006 Plan the stated exercise
price may not be less than 100% and 85% of the estimated fair market value of common stock on the date of grant for ISOs and NSOs, respectively,
as determined by the board of directors at the date of grant. With respect to any 10% stockholder, the exercise price of an ISO or NSO
shall not be less than 110% of the estimated fair market value per share on the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2006 Plan generally have
a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2021, there were <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_zcYztFQvJq4e" title="Shares available for future issuance">no</span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2011 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2011, upon recommendation of
the board, the stockholders approved the Company&#8217;s 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;). The 2011 Plan is effective
as of June 21, 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2011 Plan provides for the grant of incentive
stock options as defined in Section 422 of the Internal Revenue Code to employees, and the grant of non-statutory stock options and stock
purchase rights to employees, non-employee directors, advisors and consultants. The 2011 Plan also permits the grant of stock appreciation
rights, stock units and restricted stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has initially authorized <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20110912__us-gaap--PlanNameAxis__custom--Plan2011Member_zySRVCm0C9L9" title="Shares initially authorized for issuance">9,508</span> of the
Company&#8217;s common stock for issuance under the 2011 Plan, in addition to automatic increases provided for in the 2011 Plan through
April 1, 2021. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2011 Plan will automatically increase,
with no further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 15% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount approved by the Company&#8217;s
board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2011 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2011 Plan, the stated exercise
price of an employee incentive stock option shall not be less than 100% of the estimated fair market value of a share of common stock
on the date of grant, and the stated exercise price of an non-statutory option shall not be less 85% of the estimated fair market value
of a share of common stock on the date of grant, as determined by the board of directors. An employee who owns more than 10% of the total
combined voting power of all classes of outstanding stock of the Company shall not be eligible for the grant of an employee incentive
stock option unless such grant satisfies the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2011 Plan. No participant in the
2011 Plan can receive option grants, stock appreciation rights, restricted shares, or stock units for more than 2,381 shares in the aggregate
in any calendar year. As provided under the 2011 Plan, the aggregate number of shares authorized for issuance as awards under the 2011
Plan automatically increases on April 1 of each year by in an amount equal to the lesser of (i) 15% of the outstanding shares on the last
day of the immediately preceding year, or (ii) an amount determined by the board. During the year ended March 31, 2019, the board of directors
approved an increase of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" title="Increase in shares authorized for issuance">102,863</span> shares authorized for issuance. During the year ended March 31, 2020, the board of directors approved
an increase of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20200401__20210331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" title="Increase in shares authorized for issuance">197,450</span> shares authorized for issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan expired on September 12, 2021 in accordance
with its term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022, there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_zz8FD1I8w2Ef" title="Shares available for future issuance">no</span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2016 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2016, upon recommendation of the
board, the stockholders approved the Company&#8217;s 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;). The 2016 Plan is effective
as of September 2, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2016 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2016 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2016 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2016 Plan. No participant in the
2016 Plan can receive more than 11,112 option grants, or other awards with respect to more than 13,334 shares in the aggregate in any
calendar year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has authorized <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160902__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" title="Shares initially authorized for issuance">44,445</span> of the Company&#8217;s
common stock for issuance under the 2016 Plan, in addition to automatic increases provided for in the 2016 Plan through April 1, 2026.
The number of shares of the Company&#8217;s common stock reserved for issuance under the 2016 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 8% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#8217;s
board of directors. During the year ended March 31, 2019, the board of directors approved an increase of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2016Member_zr9jidES3M8g" title="Increase in shares authorized for issuance">4,860</span> shares authorized for issuance.
During the year ended March 31, 2020, the board of directors approved an increase of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2016Member_zM9WTHLlebV3" title="Increase in shares authorized for issuance">105,306</span> shares authorized for issuance. During the
year ended March 31, 2022, the board of directors approved an increase of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20210401__20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zgvz8PxehSyj" title="Increase in shares authorized for issuance">167,432</span> shares authorized for issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022 there were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zTgnKMlbDfF3" title="Shares available for future issuance">112,106</span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2021 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 21, 2021, upon recommendation of
the board, the stockholders approved the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan is effective
as of September 21, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2021 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued under the 2021 Plan will generally
have a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the 2021 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board has authorized <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20200401__20210331__us-gaap--PlanNameAxis__custom--Plan2021Member_zhfQ8mlixOsd" title="Increase in shares authorized for issuance">1,000,000</span> shares of the
Company&#8217;s common stock for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022, there were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220331__us-gaap--PlanNameAxis__custom--Plan2021Member_z3G9lPD2j6Uc" title="Shares available for future issuance">869,999</span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues service, performance and market-based
stock options to employees and non-employees. The Company estimates the fair value of service and performance stock option awards using
the Black-Scholes option pricing model. The Company estimates the fair value of market-based stock option awards using a Monte-Carlo simulation.
Compensation expense for stock option awards is amortized on a straight-line basis over the awards&#8217; vesting period. Compensation
expense includes the impact of forfeitures as they are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expected term of the stock options represents
the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach
prescribed by&#160;the Securities&#160;and Exchange Commission's Staff Accounting Bulletin No.&#160;110 for &#8220;plain vanilla&#8221;
options. The expected stock price volatility for the Company&#8217;s stock options was determined by using an average of the historical
volatilities of the Company and its industry peers. The Company will continue to analyze the stock price volatility and expected term
assumptions as more data for the Company&#8217;s common stock and exercise patterns become available. The risk-free interest rate assumption
is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#8217;s stock options. The expected
dividend assumption is based on the Company&#8217;s history and expectation of dividend payouts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimated the fair value of employee
and non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized
on a straight-line basis over the requisite service periods of the respective awards. The fair value of employee stock options was estimated
using the following weighted-average assumptions:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zx4slDOadTV1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_zOwgBdab50ae" style="display: none">Weighted-average assumptions of fair value of employee stock options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Fair value of the Company&#8217;s common stock on date of grant</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331_pdd" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant">4.60</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331_pdd" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant">8.03</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331_zNTnFN5LZlkf" title="Expected term">6.00</span> yrs</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331_zIUDvpXnvw25" title="Expected term">6.00</span> yrs</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331_zpSQNOTt3tvh" title="Risk-free interest rate">1.60</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20210331_zs2PIM3k0umi" title="Risk-free interest rate">0.5800</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210401__20220331_z0385HWI6YS6" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200401__20210331_zOJxjyqx14cf" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331_zpGP0jQO90Ji" title="Volatility">123.27</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20210331_zSP1gKMGh9Yh" title="Volatility">80.7</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of options granted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331_pdd" style="text-align: right" title="Fair value of options granted, per share">4.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200401__20210331_pdd" style="text-align: right" title="Fair value of options granted, per share">5.48</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share-based awards compensation expense is as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqbYGhIavS6l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Stock-based compensation)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B5_zqCTUmWFDUYi" style="display: none">Employee stock-based compensation expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%">Cost of revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zVSg8YnpOKR8" style="width: 13%; text-align: right" title="Total stock-based compensation">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_pp0p0" style="width: 13%; text-align: right" title="Total stock-based compensation">(27,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zb70l00hndJf" style="text-align: right" title="Total stock-based compensation">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total stock-based compensation">26,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">382,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">372,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_c20210401__20220331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">382,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_c20200401__20210331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">371,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2022, there were unrecognized compensation
costs of $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Unrecognized compensation costs">1,325,000</span> related to stock options which is expected to be recognized over a weighted-average amortization period of <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zepHfdjzt6c6" title="Weighted average amortization period">2.14</span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A tax benefit of $<span id="xdx_90B_eus-gaap--UnrecognizedTaxBenefits_c20220331_pp0p0" title="Tax benefit">54,000</span> has been recognized relating
to stock-based compensation as a result of non-qualified stock options and restricted stock exercised during the year ending March 31,
2022. In addition, the stock-based compensation deferred tax asset has been reduced by $<span id="xdx_901_eus-gaap--IncreaseDecreaseInDeferredCharges_c20210401__20220331_pp0p0" title="Decrease in stock based compensation deferred tax asset">309,000</span> primarily related to the expiration of
stock compensation grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Award Activity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based awards outstanding at March 31, 2022
under the various plans are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zYhBjx8rFIT4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B7_zN2yxi0bx2f" style="display: none">Schedule of stock-based awards outstanding by plan</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unvested</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restricted Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%">2006 Plan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_pdd" style="width: 13%; text-align: right" title="Options outstanding">2,787</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_zZvbDJbXFYMj" style="width: 13%; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_pdd" style="width: 13%; text-align: right" title="Total options and restricted stock units outstanding">2,787</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>2011 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" style="text-align: right" title="Options outstanding">111,949</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_zDEx7OaHmGM6" style="text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" style="text-align: right" title="Total options and restricted stock units outstanding">111,949</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>2016 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" style="text-align: right" title="Options outstanding">221,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zehALydc64Wb" style="text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" style="text-align: right" title="Total options and restricted stock units outstanding">221,497</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">2021 Plan</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">130,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_zZhhEtnY9Wua" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding">130,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">466,234</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331_zNfWEZWyGVC1" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding">466,234</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based awards available for grant as of March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based awards available for grant">982,105</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock options award activity is as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zir3aMqibCs7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B7_zIjDLy19hG2d" style="display: none">Schedule of option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Contractual Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 44%">Outstanding at April 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU9tM3PP1eza" style="width: 11%; text-align: right" title="Number of Shares Outstanding at beginning of period">267,569</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVjk6YVhmDh9" style="width: 11%; text-align: right" title="Weighted- Average Exercise Price Outstanding at beginning of period">25.16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKVzXBFJQQyd" style="text-align: right" title="Number of Shares Granted">272,958</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZwqf2Bm6Yo1" style="text-align: right" title="Weighted- Average Exercise Price Granted">4.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxYAlx53fgYd" style="text-align: right" title="Number of Shares Exercised">(44,042</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHZG9u7arrH5" style="text-align: right" title="Weighted- Average Exercise Price Exercised">4.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zt4hIQCJQ1Rb" style="text-align: right" title="Number of Shares Forfeited">(5,250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUmM96xfRBCj" style="text-align: right" title="Weighted- Average Exercise Price Forfeited">6.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2RUQku8FPt5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Expired">(25,001</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCggLX24sywa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- Average Exercise Price Expired">84.83</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLldnrByxlI2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Outstanding at end of period">466,234</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlAh44K59jq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding at end of period">12.09</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zn27k069GNxl" title="Weighted- Average Contractual Term Outstanding at end of period">8.89</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuN2ExoOhNle" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding at end of period">0</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2LzLbNGgd85" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Exercisable at end of period">115,144</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1uHcDyN8AU9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Exercisable at end of period">32.56</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrpT3dYCyRs1" title="Weighted- Average Contractual Term Exercisable at end of period">6.85</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zl7tfubcGOkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable at end of period">0</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of stock
options is calculated as the difference between the exercise price of the underlying stock options and the fair value of the
Company&#8217;s common stock, or $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Aggregate intrinsic value per share">4.01</span>
and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20200401__20210331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCKFWRYes4oe">7.43</span> per share at March 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted stock award activity is as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z0PMmUQt8vd6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B3_zb8K18jPPAN1" style="display: none">Schedule of unvested restricted stock activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Average Award</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Date Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>per Share</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Unvested restricted stock awards outstanding at April 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOazG785cVV" style="width: 13%; text-align: right" title="Unvested restricted stock awards, beginning balance">833</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIQ6aS3cGMU2" style="width: 13%; text-align: right" title="Weighted average award date fair value per share, outstanding beginning balance">13.68</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock awards granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="text-align: right" title="Restricted stock awards granted">1,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="text-align: right" title="Weighted average award date fair value per share, granted">3.05</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Restricted stock awards vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zH38ybfBvZJc" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted stock awards vested">(2,429</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average award date fair value per share, vested">6.70</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Unvested restricted stock awards outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpbGEFrRfWm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested restricted stock awards, ending balance">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvtOTx7hV8tg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average award date fair value per share, outstanding ending balance">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company did not capitalize any cost associated with stock-based
compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues new shares of common stock
upon exercise of stock options or release of restricted stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701929936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zEXF2n34RYcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;15&#160;&#8211; <span id="xdx_821_zQUxgDPvRiwj">Income Taxes</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has the following net deferred tax
assets:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zr6WYlqNMQPc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BB_z06K2W0Eb5sj" style="display: none">Schedule of deferred tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20220331_zamRBdLxYHcl" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20210331_zqFMWYBOTg2i" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGz412_zTZs95gMXgbf" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">28,224,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">25,687,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGz412_zhyYh7LUfwsh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,850,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,850,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGz412_zKDHJZiXvmna" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,120,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0p0_maDTAGz412_zBsGGRNNH6Oe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Allowances and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,336,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">659,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pp0p0_d0_maDTAGz412_zjR6sJBCY3xh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">398,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pp0p0_maDTAGz412_znoCHGmqJkC7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">63,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">78,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGz412_maDTANzqCr_z0vmMTQhwtCj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Gross deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,782,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,792,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzqCr_zq8q7qO8gmi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Less valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(30,613,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(31,528,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzqCr_maDTALNzfiK_zGhqMg8J0Omf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,169,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">264,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pp0p0_di_maDITLzfJx_zriQ37QHmO33" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pp0p0_di_maDITLzfJx_zNQnYT6zKgwb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(260,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(186,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pp0p0_di_maDITLzfJx_zLuEU6vleCe3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Right of Use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(63,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(75,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pp0p0_di_mtDITLzfJx_msDTALNzfiK_zkPb5cIHAXMc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(340,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(264,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pp0p0_d0_mtDTALNzfiK_zbSiR7MSos8j" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">829,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision (benefit) is based on
the following loss before income taxes, which are from domestic sources and foreign loss before income taxes:</p>

<table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zseH5cht87fe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zPA5UDCgqzuk" style="display: none">Income tax provision domestic and foreign</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended March&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">Domestic</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ProfitLoss_pp0p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zo6vQ1YumKye" style="width: 13%; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(3,516,000)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ProfitLoss_pp0p0_c20200401__20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zsw9EFiq2jLj" style="width: 13%; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(2,052,000)</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Foreign</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--ProfitLoss_pp0p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z8hs79iu2e7a" style="border-bottom: black 1pt solid; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(1,883,000)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--ProfitLoss_pp0p0_c20200401__20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zuStfLXjuOv" style="border-bottom: black 1pt solid; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(1,467,000)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331_z2D6HFIoFef2" style="border-bottom: black 2.25pt double; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(5,399,000)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ProfitLoss_pn3p0_c20200401__20210331_zOzz6OEPJill" style="border-bottom: black 2.25pt double; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(3,519,000)</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s income tax expense/(benefits)
consist of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_znsDd3EjIbs9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_z6xcUQXl30sd" style="display: none">Schedule of income tax expense</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_491_20210401__20220331_z6ZgkUyyeA14" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_494_20200401__20210331_zBOqa0wIo839" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended March&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Current:</span></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">State</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">8,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">1,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CurrentForeignTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Foreign</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">469,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">941,000</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><b style="display: none">Current Income Tax Expense</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">477,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">942,000</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Deferred:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zjis4gxbRI36" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Federal</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zgHHC3PDfJ0l" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">State</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_d0_zpcAJAvJHRs3" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Foreign</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(809,000)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><b style="display: none">Total deferred income tax</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(332,000)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">942,000</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the statutory federal income
tax rate to the Company&#8217;s effective tax rate for continuing operations is as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zV4x1gKKMBd4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_z6uGOswNvCa4" style="display: none">Reconciliation of federal income tax rate to effective rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49F_20210401__20220331_zhL7miAKoiPl" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49E_20200401__20210331_zxHHbKsuXclk" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year&#160;Ended&#160;March&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zUEVliCEaalj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%"><span style="font-size: 10pt">Expected federal statutory rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">21.0%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">21.0%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_z60DI9aSzz71" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">State income taxes</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5.7%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2.1%</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zOLgQzc5D8hd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Foreign earnings taxed at different rates</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3.7%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3.6%</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_ecustom--ForeignTaxTrueup_dp0_zu1v1enA0JZ1" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Foreign tax true-up</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(12.4%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_dpi_zEb84tIE5CT3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Effect of permanent differences</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(3.0%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(9.5%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_zronOu5qGWgg" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Effect of intercompany interest permanent differences</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(12.3%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(17.9%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_ecustom--TrueupsOfStateDeferredAssets_dp_zCe8tbuXo4S6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">True-up of state deferred assets</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(25.6%</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(120.7%</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zwOCtkaa3pcl" style="vertical-align: bottom; background-color: White">
    <td><b style="display: none">Total effective rate</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(10.5%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(133.8%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zh0QHLE6lIAk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">16.7%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">107.1%</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zsFrvUAF0th" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Totals</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(6.2%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(26.7%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had net
operating loss carryforwards for Federal, State and Foreign income tax purposes of approximately $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z4EZX4gPOWL" title="Net operating loss carryforwards">115.3</span>
million, $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zR8tDfyI1y3l" title="Net operating loss carryforwards">44</span>
million and $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pp0p0">541,000</span>,
respectively. Due to the Tax Cuts and Job Act, Federal NOLs generated after March 31, 2018 have an indefinite life. Federal NOL
generated on and before March 31, 2017 will begin to expire 2024, if not utilized. State and Foreign NOLs will  begin to expire in
the year 2029 and 2024, respectively, if not utilized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company had
Federal and California research credit carryforwards of approximately $<span id="xdx_90F_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zpTLy7WEMq5j" title="Research credit carryforwards">1</span>
million and $<span id="xdx_900_eus-gaap--TaxCreditCarryforwardAmount_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_pp0p0" title="Research credit carryforwards">790,000</span>,
respectively. The Federal research credits will begin to expire in 2024 while the California research credits have no expiration
date. In addition, the Company has foreign tax credits of $<span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsForeign_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pp0p0" title="Foreign tax credit carryforward">50,000</span>,
which begin to expire in the year 2023 if not utilized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 382 of the Internal Revenue Code limits
the use of the Federal net operating losses in certain situations where changes occur in stock ownership of a company. If the Company
should have an ownership change of more than 50% of the value of the Company's capital stock, utilization of the carryforwards could be
restricted. The Company is not aware of any changes in ownership that would result in a change in control under Internal Revenue Code
section 382.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company released the valuation allowance recorded
against its Mexico deferred tax assets as of March 31, 2022. Given its recent history of earnings, current earnings and anticipated future
earnings, the Company concluded that there is sufficient positive evidence available to reach a conclusion that the valuation allowance
is no longer needed in Mexico. The release of the valuation allowance resulted in the recognition of deferred tax assets of $829,000.
The Company, after considering all available evidence, fully reserved against all deferred tax assets in the U.S. and Netherlands since
it is more likely than not such benefits will not be realized in future periods. The Company will continue to evaluate its deferred tax
assets to determine whether any changes in circumstances could affect the realization of their future benefit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has filed tax returns for federal,
state and foreign jurisdictions. The Company&#8217;s evaluation of uncertain tax matters was performed for tax years ended through March
31, 2022. Generally, the Company is subject to audit for the years ended March 31, 2021, 2020 and 2019. The Company has elected to retain
its existing accounting policy with respect to the treatment of interest and penalties attributable to income taxes and continues to reflect
interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit as
well as its outstanding income tax assets and liabilities. The Company believes that its income tax positions and deductions would be
sustained on audit and does not anticipate any adjustments to result in a material change to its financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831701963792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zF95oKn7V0E3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;16&#160;&#8211; <span id="xdx_82C_zWyqM9mwUj89">Employee Benefit
Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a program to contribute and administer
a qualified 401(k) plan. Under the 401(k) plan, the Company matches employee contributions to the plan up to 4% of the employee&#8217;s
salary. Company contributions to the plan amounted to an aggregate of $<span id="xdx_900_eus-gaap--PensionAndOtherPostretirementBenefitContributions_c20210401__20220331_pp0p0" title="Company contributions to 401(k) plan">50,600</span> and $<span id="xdx_902_eus-gaap--PensionAndOtherPostretirementBenefitContributions_c20200401__20210331_pp0p0" title="Company contributions to 401(k) plan">89,000</span> for the years ended March 31, 2022 and 2021,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831702020880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Disaggregation</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_z5lQfnB10xoa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE&#160;17 &#8211; <span id="xdx_82A_zJmtVf96s5Gc">Revenue Disaggregation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company generates product revenues from products
which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services
which are provided to medical device manufacturers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents the Company&#8217;s disaggregated revenues
by source:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>

<table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--DisaggregationOfRevenueTableTextBlock_zf8ED1TsLjuc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-align: left"><span id="xdx_8BC_zUH2QemuRLI9" style="display: none">Disaggregated Revenue by Source</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Product</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Human Care</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_pp0p0" style="width: 13%; text-align: right" title="Revenues">9,010,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_pp0p0" style="width: 13%; text-align: right" title="Revenues">15,317,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Animal Care</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">3,169,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">3,200,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Total Product Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3p0" style="text-align: right" title="Revenues">12,179,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3p0" style="text-align: right" title="Revenues">18,517,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Service/Royalty</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pn3p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">449,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pn3p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">112,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,628,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">18,629,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the Company&#8217;s
revenues by geographic region:</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zLFVfyGrcWfc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Geographic Information (Details - Geographic regions)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B4_zU4cJrgRoiA2" style="display: none">Schedule of geographic sales</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 13%; text-align: right" title="Revenues">3,807,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 13%; text-align: right" title="Revenues">5,419,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_pp0p0" style="text-align: right" title="Revenues">2,095,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_pp0p0" style="text-align: right" title="Revenues">5,976,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Europe and Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_z9JI4GGjVUAl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">6,726,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">7,234,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331_z3gxx56LAxPh" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,628,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200401__20210331_zmKl28Cg30Yk" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">18,629,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s service revenues in Latin
America amounted to $<span id="xdx_90C_eus-gaap--Revenues_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pp0p0" title="Revenues">349,000</span> and $<span id="xdx_905_eus-gaap--Revenues_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pp0p0" title="Revenues">112,000</span> for the years ended March 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699020000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zdhJQAklOI82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86A_zJrVB9o8qPaa">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#8220;Aquamed&#8221;), Oculus Technologies
of Mexico S.A. de C.V. (&#8220;OTM&#8221;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#8220;SP Europe&#8221;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#8220;U.S.&#8221;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6kTYYWEIm67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_869_zLEfOSLbmZUb">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated
financial statements have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission
("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). The Company&#8217;s fiscal
year end is March 31. Unless otherwise stated, all years and dates refer to the fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMz1LixZSF48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86E_zUzki0mVVL08">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents
include cash on hand and all highly liquid investments with an original maturity of three months or less when purchased. The Company&#8217;s
cash equivalents are held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_840_eus-gaap--UseOfEstimates_z1rPJwv6qHzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_862_z3atnCgDmdz">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating
to the Company&#8217;s deferred tax assets, valuation of equity, fair value allocation of assets sold to Invekra, and the estimated amortization
periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zOfmMfmTTv2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_863_z78nGuyLyZK2">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2018, the Company adopted Accounting
Standards Update ("ASU"), "Revenue from Contracts with Customers Topic 606&#8221; (&#8220;Topic 606&#8221;) using the modified
retrospective method. There was no material impact to the Company upon the adoption of Topic 606. Revenue is recognized when the Company
transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive
in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its
obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the promised goods or services in
the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are
distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company derives the majority of its revenue
through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including
hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license
its technology and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers customer purchase orders,
which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers
the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For all of its sales to non-consignment distribution
channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied),
which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on
the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers,
the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able
to estimate the amount of product that will be returned.&#160;&#160;Sales incentives and other programs that the Company may make available
to these customers are considered to be a form of variable consideration, and the Company maintains estimated accruals and allowances
using the expected value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the
Company&#8217;s rebate program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales to stocking distributors are made under
terms with fixed pricing and limited rights of return (known as &#8220;stock rotation&#8221;) of the Company&#8217;s products held in
their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assessed the promised goods and services
in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is
separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as
other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Service revenue from testing contracts is recognized
as tests are completed and a final report is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Major Customers</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zQG8MWcuQMee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zZ7aTCwWRBjk">Concentration of Credit Risk and Major Customers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company grants credit to its business customers,
which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. The Company
maintains allowances for potential credit losses. At March 31, 2022, one customer represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZBZeds9Apq8" title="Significant customer concentration">20%</span> of our net accounts
receivable balance, one customer represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbmHbBQlzH1l">15%</span> of our net accounts receivable balance, and one customer represented
<span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvJLSXHG9ntb">14%</span> of our net accounts receivable balance. At March 31, 2021, one customer represented <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR4a2HzAazwk">17</span>% of our net accounts receivable balance, one customer represented <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFiepuzigYl3">16</span>%
of our net accounts receivable balance, and one customer represented <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfGlF255Zn0c">14</span>% of our net accounts receivable balance. For the year ended March 31, 2022, one customer represented <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9ZQvKaieujk">10</span>%, one customer represented <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztnOOVa0t2Ni">17</span>%, and one customer represented
<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHbr1sCM4Di">21</span>% of net revenues. For the year ended March 31, 2021, one customer represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8l6YiasiR53">32</span>%, and one customer represented <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1E7AUHpoJq4">15</span>% of net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zuQPgL1h1zm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zspY2vT1pgK2">Accounts Receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are recorded net of
allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns
are based on analysis of contractual terms and historical trends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents
probable credit losses at March 31, 2022 and 2021 in the amounts of $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20220331_zVsbBVHGWjih" title="Allowance for doubtful accounts">0</span> and $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20210331_zYEROlWyq70d" title="Allowance for doubtful accounts">125,000</span>, respectively. Additionally, at March 31, 2022 and
2021, the Company has allowances of $<span id="xdx_900_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20220331_zw7gjy1tGVMl" title="Allowance for sales discounts, rebates, distributor fees and returns">81,000</span> and $<span id="xdx_909_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20210331_znQlQwN9KDLi" title="Allowance for sales discounts, rebates, distributor fees and returns">1,488,000</span>, respectively, related to potential discounts, returns, distributor fees and
rebates. The allowances are included in Accounts Receivable, net in the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zBN59cHxSaZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_z1QVEANCPHbi">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision
to reduce the carrying amounts of inventories to their net realizable value in the amounts of <span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_c20220331_znPp91x7lir9" title="Inventory reserves">$218,000</span> and <span id="xdx_907_eus-gaap--InventoryValuationReserves_iI_c20210331_zvrHkh3kFRvj" title="Inventory reserves">$223,000</span> at March 31, 2022
and 2021, respectively, which is included in cost of revenues on the Company&#8217;s accompanying consolidated statements of comprehensive
(loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Financial Assets and Liabilities</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zYOxwuVETy8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_zAUtJIXcoPw7">Financial Assets and Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, including cash and cash
equivalents, accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the
short-term nature of these instruments. The fair value of capital lease obligations and equipment loans approximates their carrying amounts
as a market rate of interest is attached to their repayment. The Company measures the fair value of financial assets and liabilities based
on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes
the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of
inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;1&#160;&#8211; quoted prices in active
markets for identical assets or liabilities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;2&#160;&#8211; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level&#160;3&#160;&#8211; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#8217;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#8217;s accounting and finance department
and are approved by the Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022 and 2021, there were <span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20210401__20220331_zOKiwZLZhKX6" title="Transfers in or out of Level 3"><span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20200401__20210331_z1CTkyNVUFY1" title="Transfers in or out of Level 3">no</span></span> transfers
in or out of Level 3 from other levels in the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_ziDHEVgeJb6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_861_zlGufgVVqTze">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost less
accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the
estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over
the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification
is as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z27mgY7Q7NHa" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zdrkbAcSzJt7" style="display: none">Property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 85%"><span style="font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: center"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zxRRadcj8PJk" title="Useful asset life">3</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zR3oWDeVTsG5" title="Useful asset life">5</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_znRvm3Gfvdp3" title="Useful asset life">7</span></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon retirement or sale, the cost and related
accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance
and repairs are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1IwNgiIGVab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_znM5z7vIicDb">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company periodically reviews the carrying
values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying
values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of
impairment include, but are not necessarily limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a significant decrease in the fair value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a significant adverse change in legal factors or in the business climate that affects the value of an asset;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When circumstances indicate that an impairment
may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows,
assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the
cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment
loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates
used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended March 31, 2022 and 2021,
the Company had noted <span id="xdx_909_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20210401__20220331_zMPvx9klZnHg" title="Asset impairment charges"><span id="xdx_90D_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20200401__20210331_zA5gdjLshMR6" title="Asset impairment charges">no</span></span> indicators of impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbYzOJfC1ib7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_z52U51uSXwr8">Research and Development</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses are charged
to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended
March 31, 2022 and 2021, research and development expense amounted to $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20210401__20220331_pn3p0" title="Research and development expenses">125,000</span> and $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20200401__20210331_pn3p0" title="Research and development expenses">555,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_zuiXNNC3aLNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_znaCXPH8z2Zj">Advertising Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising costs are charged to operations as
incurred. Advertising costs amounted to $<span id="xdx_907_eus-gaap--MarketingExpense_c20210401__20220331_z7FHj4x7970c" title="Advertising costs">86,000</span> and $<span id="xdx_902_eus-gaap--MarketingExpense_c20200401__20210331_zPn8rcnKkOYk" title="Advertising costs">41,000</span>, for the years ended March 31, 2022 and 2021, respectively. Advertising costs
are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ShippingAndHandlingCostsPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><p id="xdx_84C_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zwmlOy3BVSzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_869_zg6JsYKlEnyk">Shipping and Handling Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2022 and 2021, the Company recorded revenue related to shipping and
handling costs of $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_pp0p0" title="Revenues">52,000</span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_pp0p0" title="Revenues">37,000</span>, respectively. These amounts are included in product revenues in the accompanying consolidated statements
of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Reporting</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zv8lOk1b2B69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zz9h0XByutAe">Foreign Currency Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiary, OTM, uses the
local currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional
currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts
are translated at average exchange rates during the period. Resulting translation adjustments amounted to $<span id="xdx_90C_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20210401__20220331_zNm6o6YfPmu8" title="Foreign currency translation adjustment">267,000</span> and $<span id="xdx_900_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20200401__20210331_zD8llMX91eAl" title="Foreign currency translation adjustment">1,031,000</span> for
the years ended March 31, 2022 and 2021, respectively. These amounts were recorded in other comprehensive loss in the accompanying consolidated
statements of comprehensive loss for the years ended March 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency transaction gains (losses) relate
primarily to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are
expected to be settled in the foreseeable future. The Company recorded foreign currency transaction losses of $<span id="xdx_905_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20210401__20220331_zGjcRd60GEe1" title="Foreign currency transaction loss">579,000</span> for the year ended
March 31, 2022, and foreign currency transaction losses of $<span id="xdx_904_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20200401__20210331_zlsJxvRFYBEc" title="Foreign currency transaction loss">690,000</span>, for the year ended March 31, 2021. The related amounts were recorded
in other expense in the accompanying consolidated statements of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zVxi6ReJV8M9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_860_zVyQqglG9Txg">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of an forfeitures for all stock
options as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zrSNgFEi4rea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zxcOkOQ22MM9">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tax benefits claimed or expected to be claimed
on a tax return are recorded in the Company&#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is
only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based
on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain
tax positions have had no impact on the Company&#8217;s consolidated financial condition, results of comprehensive (loss) income or cash
flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zcS8XeMQAjHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_866_zJ1EihqTTxu6">Comprehensive Loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other comprehensive loss includes all changes
in stockholders&#8217; equity during a period from non-owner sources and is reported in the consolidated statement of changes in stockholders&#8217;
equity. To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other
comprehensive losses at March 31, 2022 and 2021 were $<span id="xdx_90C_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_di_c20220331_zJTmlaS86sF8" title="Accumulated other comprehensive loss">4,312,000</span>, and $<span id="xdx_904_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_di_c20210331_zRGceQToe0Y1" title="Accumulated other comprehensive loss">4,579,000</span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income Loss per Share</a></td>
<td class="text"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zZIuD7ckLwr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_zwNsb8Rp0xj9">Net Income Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic net loss per share
by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period
and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution
that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#8220;treasury stock&#8221;
and/or &#8220;if converted&#8221; methods as applicable.</p>

<table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zRsXO5wGZkFj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span id="xdx_8B2_zpxwFLCCtP8l" style="display: none">Computation of earnings per share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20210401__20220331_zgB7s2aDRr86" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20200401__20210331_zmixmPzrIO54" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_zQP4TmgcF8gh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: justify">Loss from continuing operations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(5,086</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,615</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_pn3n3_d0_zBX7xn3gTW5b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Income  from discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">665</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_pn3n3_z5VgTLfopGV1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,086</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,950</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pin3_zYmPWPsI6bP3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average  shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,653</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,996</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeLossFromContinuingOperationPerBasicAndDilutedShare_pip0_z02qMOz8gKQ3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Loss per share from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.92</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.31</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_pip0_d0_zOMu6zBGKfAh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Income  per share from discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.33</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EarningPerShareBasicAndDiluted_pip0_zwbOIalyqXZg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.92</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.97</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The computation of basic loss per share for the
years ended March 31, 2022 and 2021 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_ztvvNLsaRsI5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BF_z0EjdoIXDfP7" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Common stock to be issued upon vesting of restricted stock units</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zAp9FNVR20Fa" style="width: 13%; text-align: right" title="Antidilutive shares">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zQSnEapuGNGe" style="width: 13%; text-align: right" title="Antidilutive shares">1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zGFCfY6Bzqba" style="text-align: right" title="Antidilutive shares">466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z9xIv4jNVfIh" style="text-align: right" title="Antidilutive shares">268</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Common stock to be issued upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zALn25cy18v2" style="text-align: right" title="Antidilutive shares">108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zq2rNd0ZLsZf" style="text-align: right" title="Antidilutive shares">119</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon conversion of Series C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zpw5wzu3R7z7" style="text-align: right" title="Antidilutive shares">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zImGLkNONzYa" style="text-align: right" title="Antidilutive shares">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon exercise of common stock units (1)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zfQ3iLmWAPAb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_z3MFiQjglZQ1" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331_z74sV2x6BNJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">621</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331_zcYutqb7JmT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">434</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%"><span id="xdx_F0B_z5FMj7xzgpCd" style="font-size: 10pt">(1)</span></td>
    <td style="width: 94%; text-align: justify"><span id="xdx_F12_zdUEYaIzOBF2" style="font-size: 10pt">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</span></td></tr>
  </table>
<p id="xdx_8A2_zyDhTgPZH63i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Common Stock Purchase Warrants and Other Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_z3VfIE2uf0X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_865_zUk0jJiaGii2">Common Stock Purchase Warrants and Other
Derivative Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies common stock purchase warrants
and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement
or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).
The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if
an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net cash settlement or
settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability.
The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification
between assets and liabilities is required. The Company determined that its freestanding derivatives, which principally consist of warrants
to purchase common stock, satisfied the criteria for classification as equity instruments, other than certain warrants that contained
reset provisions and certain warrants that required net-cash settlement that the Company classified as derivative liabilities. The company
currently does not have any active derivative financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Preferred Stock</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_z5xbRK3EYqgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_867_zth03FqF3sud">Preferred Stock</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the accounting standards for
distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject
to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally
redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the
holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity.
At all other times, preferred shares are classified as stockholders' equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_849_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zwxMwRMLRIY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_zIo7djYjf1Jj">Subsequent Events</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated subsequent events or
transactions occurring through the date these consolidated financial statements were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcic2ZUgyW01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_z8VqGU08W4Bl">Recent Accounting Standards</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated all the recent accounting
standards and determined that none of them are material to it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ShippingAndHandlingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ShippingAndHandlingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126960819&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699469056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Property and equipment estimated useful life</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z27mgY7Q7NHa" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zdrkbAcSzJt7" style="display: none">Property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 85%"><span style="font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: center"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zxRRadcj8PJk" title="Useful asset life">3</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zR3oWDeVTsG5" title="Useful asset life">5</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_znRvm3Gfvdp3" title="Useful asset life">7</span></span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of earnings per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zRsXO5wGZkFj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span id="xdx_8B2_zpxwFLCCtP8l" style="display: none">Computation of earnings per share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20210401__20220331_zgB7s2aDRr86" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20200401__20210331_zmixmPzrIO54" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_zQP4TmgcF8gh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: justify">Loss from continuing operations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(5,086</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,615</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_pn3n3_d0_zBX7xn3gTW5b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Income  from discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">665</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_pn3n3_z5VgTLfopGV1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,086</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,950</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pin3_zYmPWPsI6bP3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average  shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,653</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,996</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeLossFromContinuingOperationPerBasicAndDilutedShare_pip0_z02qMOz8gKQ3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Loss per share from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.92</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.31</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_pip0_d0_zOMu6zBGKfAh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Income  per share from discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.33</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EarningPerShareBasicAndDiluted_pip0_zwbOIalyqXZg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.92</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.97</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_ztvvNLsaRsI5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BF_z0EjdoIXDfP7" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Common stock to be issued upon vesting of restricted stock units</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zAp9FNVR20Fa" style="width: 13%; text-align: right" title="Antidilutive shares">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zQSnEapuGNGe" style="width: 13%; text-align: right" title="Antidilutive shares">1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zGFCfY6Bzqba" style="text-align: right" title="Antidilutive shares">466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z9xIv4jNVfIh" style="text-align: right" title="Antidilutive shares">268</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Common stock to be issued upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zALn25cy18v2" style="text-align: right" title="Antidilutive shares">108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zq2rNd0ZLsZf" style="text-align: right" title="Antidilutive shares">119</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock to be issued upon conversion of Series C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zpw5wzu3R7z7" style="text-align: right" title="Antidilutive shares">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zImGLkNONzYa" style="text-align: right" title="Antidilutive shares">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon exercise of common stock units (1)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zfQ3iLmWAPAb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_z3MFiQjglZQ1" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">46</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331_z74sV2x6BNJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">621</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331_zcYutqb7JmT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">434</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%"><span id="xdx_F0B_z5FMj7xzgpCd" style="font-size: 10pt">(1)</span></td>
    <td style="width: 94%; text-align: justify"><span id="xdx_F12_zdUEYaIzOBF2" style="font-size: 10pt">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831702019568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Assets &#8211; Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ScheduleOfAllocationOfSalePriceTableTextBlock', window );">Schedule of allocation of sale price</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfAllocationOfSalePriceTableTextBlock_zDepiG3PBW4l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Sale of Assets - Discontinued Operations (Details - Allocation of sale price)">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span id="xdx_8BA_zVtlVTsr53b6" style="display: none">Schedule of allocation of sale price</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%; text-align: justify">Customer base</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_iI_pp0p0_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zMHZu6cLDip6" style="width: 13%; text-align: right" title="Customer base">850,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less:&#160;Funds remaining in escrow</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zA8OEhbffwTg" style="text-align: right" title="Less: Funds remaining in escrow">(60,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Less:&#160;Services due from buyer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zmTnMXXkPGWg" style="text-align: right" title="Less: Services due from buyer">(100,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Less: Working capital adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zXEXPzywP1Og" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Working capital adjustment">(80,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total proceeds</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ProceedsFromDivestitureOfBusinesses_c20200401__20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Proceeds from sale of business">610,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Assets and liabilities of disposal group</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zjpUZOSP1Ha4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Sale of Assets - Discontinued Operations (Details - Discontinued Operations)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_z97pWsGLRhSa" style="display: none">Assets and liabilities of disposal group</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20210401__20220331_z4N6S8MWa0v3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20200401__20210331_zSfTP71LSpdi" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_d0_maDGIDOzviC_zxsTEjNmbal3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">214,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_d0_msDGIDOzviC_zCTPMLfSM4Na" style="vertical-align: bottom; background-color: White">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_d0_msDGIDOzviC_zcUZPLRTtrEf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Selling general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">38,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_iT_pp0p0_d0_mtDGIDOzviC_maDOILFzWBf_z1GKUibgaP37" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income from discontinued operations before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_d0_maDOILFzWBf_zEUoslj4DhDj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Gain on disposal of discontinued operations before income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">770,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_iT_pp0p0_d0_mtDOILFzWBf_maILFDOzvre_zcKXL6QfgXzj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total income from discontinued operations, before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">893,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_iN_pp0p0_di0_msILFDOzvre_znjlBqAWoor3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Income Tax benefit (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(228,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pp0p0_d0_mtILFDOzvre_zYRzpFjEDl01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income from discontinued operations, net of tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">665,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ScheduleOfAllocationOfSalePriceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ScheduleOfAllocationOfSalePriceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831702099216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Accounts receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zEDejifOY7j8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B2_zJyLNvxQYP5e" style="display: none">Accounts receivable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20220331_z6bs1ZddSP3k" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20210331_z1GuUwyteqpk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCzGH6_z4OOc0u9TBM9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,488,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">4,419,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di0_msARNCzGH6_zxFa4KsYXg3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: allowance for doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(125,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--DiscountsRebatesDistributorFeesAndReturns_iNI_pp0p0_di_msARNCzGH6_z5XNRjHcRhw9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Less: discounts, rebates, distributor fees and returns</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(81,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,488,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzGH6_zbFmLeoq1e8i" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Accounts receivable, net&#160;</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,407,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,806,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831702048432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zRU3jnInaWY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BC_zP06Hii7KMr1" style="display: none">Schedule of inventories</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20220331_zhycOw10rW87" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20210331_zBFAAsXszZ0c" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pp0p0_maINzPTc_zLXMYwxsNlW1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,626,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,670,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pp0p0_maINzPTc_zO9Qp0D4sUa2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,037,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">860,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryNet_iTI_pp0p0_mtINzPTc_z65dJ5Z0l1K4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Inventories, net</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,663,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,530,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831702122464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zexLbkZ7Ij3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B2_zIIRrMO3pgq6" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220331_zBpjz9EHFzDi" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20210331_zwrfO6O7sKB7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Prepaid insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">755,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">705,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidTaxes_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax prepaid to Mexican tax authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,371,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,850,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">620,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">663,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="color: rgb(238,238,238); padding-bottom: 2.5pt">&#160;Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,746,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,218,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831702009728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--PropertyPlantAndEquipmentTextBlock_zW5jMmMkM8Ig" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BE_zdb8YMwOM2Dg" style="display: none">Schedule of property and equipment</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220331_zf2bZXpoLYH3" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20210331_zzKHeGMO06k9" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGzTcR_zRLtBPIUJok8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Manufacturing, lab, and other equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,281,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,170,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0p0_maPPAEGzTcR_zJNBwvfgBcv2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAEGzTcR_zqPximMIx3g7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LeaseholdImprovementsGross_iI_pp0p0_maPPAEGzTcR_zNwqMUhS56Li" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">503,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">486,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGzTcR_maPPAENzONv_z4KLBr1xciwl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: rgb(238,238,238)">Property and equipment, gross&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,031,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,831,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzONv_zEFHP6YBQpof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,711,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,471,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzONv_zFuVsqt4oxV7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="color: rgb(238,238,238); padding-bottom: 2.5pt">Property and equipment, net&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">320,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">360,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831702076336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zGDRfarYZHJ7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BD_zIVGEqj7s9i4" style="display: none">Schedule of accrued expenses and other current liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20220331_zgMgwi4W5bw7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20210331_zoXHv3sBp8da" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAz40k_zzEBlahCGuE1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Salaries and related costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,059,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">787,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAz40k_zS6K15J1Cfph" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">784,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">367,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pp0p0_mtAPAOAz40k_zEygzqqwz6ia" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Accrued expenses and other current liabilities</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,843,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,154,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831703171632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease cost information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zHpv9Ch3nhA" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span id="xdx_8B5_zgjgIMzk1EKl" style="display: none">Lease cost information</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20220331_zUP5ouNOgUD5" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20210331_zPHYAuYgSGL4" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeasesOperatingAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Operating leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">559,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">769,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liabilities &#8211; non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">529,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other information related to leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>March 31, 2022</b></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Year ended<br/> March 31, 2021</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Operating lease cost</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseCost_c20210401__20220331_pp0p0" style="width: 13%; text-align: right">367,000</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_984_eus-gaap--OperatingLeaseCost_pp0p0_c20200401__20210331_zG7hzOy5BJ3a" style="text-align: right; width: 13%">435,000</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">As of March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20210401__20220331_z35iuhcsLCIj" style="text-align: right">(223,000</td><td style="text-align: left">)</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20200401__20210331_zURqMKrkpyW1" style="text-align: right">(215,000</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Weighted-average remaining lease term &#8211; operating leases (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220331_znLaPUYaszJ2" title="Weighted-average remaining lease term - operating leases (in months)">27.3</span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20210331_zsNppxdqe5me">37.7</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220331_zS9Y4njkNw77" title="Weighted-average discount rate - operating leases">6.00</span>%</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20210331_zhoZjWPcAFc9">6.00</span>%</td>
    <td>&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum operating lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zqhCF8SPPeB9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease liabilities)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B5_zy4v7mNQTqza" style="display: none">Schedule of minimum operating lease liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220331_zxGiy09tRUwh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">For Years Ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzgSf_zKNEfSx9HDL3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">297,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzgSf_z4i1UNi7T6ve" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzgSf_zRkCyd0nldLf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzgSf_zRPwdShP9MD2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzgSf_zWYrPtLzbS29" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">627,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zxP1sj7Y5o6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(68,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">559,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699474048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-average assumptions of fair value of employee stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zx4slDOadTV1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B6_zOwgBdab50ae" style="display: none">Weighted-average assumptions of fair value of employee stock options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Fair value of the Company&#8217;s common stock on date of grant</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331_pdd" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant">4.60</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331_pdd" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant">8.03</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331_zNTnFN5LZlkf" title="Expected term">6.00</span> yrs</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331_zIUDvpXnvw25" title="Expected term">6.00</span> yrs</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331_zpSQNOTt3tvh" title="Risk-free interest rate">1.60</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20210331_zs2PIM3k0umi" title="Risk-free interest rate">0.5800</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210401__20220331_z0385HWI6YS6" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200401__20210331_zOJxjyqx14cf" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331_zpGP0jQO90Ji" title="Volatility">123.27</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20210331_zSP1gKMGh9Yh" title="Volatility">80.7</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of options granted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331_pdd" style="text-align: right" title="Fair value of options granted, per share">4.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200401__20210331_pdd" style="text-align: right" title="Fair value of options granted, per share">5.48</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Employee stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqbYGhIavS6l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Stock-based compensation)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B5_zqCTUmWFDUYi" style="display: none">Employee stock-based compensation expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%">Cost of revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zVSg8YnpOKR8" style="width: 13%; text-align: right" title="Total stock-based compensation">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_pp0p0" style="width: 13%; text-align: right" title="Total stock-based compensation">(27,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zb70l00hndJf" style="text-align: right" title="Total stock-based compensation">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total stock-based compensation">26,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">382,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation">372,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensation_c20210401__20220331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">382,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_c20200401__20210331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation">371,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock', window );">Schedule of stock-based awards outstanding by plan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zYhBjx8rFIT4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B7_zN2yxi0bx2f" style="display: none">Schedule of stock-based awards outstanding by plan</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unvested</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restricted Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%">2006 Plan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_pdd" style="width: 13%; text-align: right" title="Options outstanding">2,787</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_zZvbDJbXFYMj" style="width: 13%; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_pdd" style="width: 13%; text-align: right" title="Total options and restricted stock units outstanding">2,787</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>2011 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" style="text-align: right" title="Options outstanding">111,949</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_zDEx7OaHmGM6" style="text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" style="text-align: right" title="Total options and restricted stock units outstanding">111,949</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>2016 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" style="text-align: right" title="Options outstanding">221,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zehALydc64Wb" style="text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" style="text-align: right" title="Total options and restricted stock units outstanding">221,497</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">2021 Plan</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">130,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_zZhhEtnY9Wua" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding">130,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">466,234</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331_zNfWEZWyGVC1" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding">466,234</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based awards available for grant as of March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based awards available for grant">982,105</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zir3aMqibCs7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B7_zIjDLy19hG2d" style="display: none">Schedule of option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Contractual Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 44%">Outstanding at April 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU9tM3PP1eza" style="width: 11%; text-align: right" title="Number of Shares Outstanding at beginning of period">267,569</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVjk6YVhmDh9" style="width: 11%; text-align: right" title="Weighted- Average Exercise Price Outstanding at beginning of period">25.16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKVzXBFJQQyd" style="text-align: right" title="Number of Shares Granted">272,958</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZwqf2Bm6Yo1" style="text-align: right" title="Weighted- Average Exercise Price Granted">4.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxYAlx53fgYd" style="text-align: right" title="Number of Shares Exercised">(44,042</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHZG9u7arrH5" style="text-align: right" title="Weighted- Average Exercise Price Exercised">4.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zt4hIQCJQ1Rb" style="text-align: right" title="Number of Shares Forfeited">(5,250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUmM96xfRBCj" style="text-align: right" title="Weighted- Average Exercise Price Forfeited">6.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2RUQku8FPt5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Expired">(25,001</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCggLX24sywa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- Average Exercise Price Expired">84.83</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLldnrByxlI2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Outstanding at end of period">466,234</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlAh44K59jq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding at end of period">12.09</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zn27k069GNxl" title="Weighted- Average Contractual Term Outstanding at end of period">8.89</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuN2ExoOhNle" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding at end of period">0</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2LzLbNGgd85" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Exercisable at end of period">115,144</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1uHcDyN8AU9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Exercisable at end of period">32.56</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrpT3dYCyRs1" title="Weighted- Average Contractual Term Exercisable at end of period">6.85</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zl7tfubcGOkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable at end of period">0</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of unvested restricted stock activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z0PMmUQt8vd6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B3_zb8K18jPPAN1" style="display: none">Schedule of unvested restricted stock activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Average Award</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>Date Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"><b>per Share</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">Unvested restricted stock awards outstanding at April 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOazG785cVV" style="width: 13%; text-align: right" title="Unvested restricted stock awards, beginning balance">833</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIQ6aS3cGMU2" style="width: 13%; text-align: right" title="Weighted average award date fair value per share, outstanding beginning balance">13.68</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock awards granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="text-align: right" title="Restricted stock awards granted">1,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="text-align: right" title="Weighted average award date fair value per share, granted">3.05</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Restricted stock awards vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zH38ybfBvZJc" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted stock awards vested">(2,429</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average award date fair value per share, vested">6.70</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Unvested restricted stock awards outstanding at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpbGEFrRfWm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested restricted stock awards, ending balance">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvtOTx7hV8tg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average award date fair value per share, outstanding ending balance">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831703189264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zr6WYlqNMQPc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8BB_z06K2W0Eb5sj" style="display: none">Schedule of deferred tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20220331_zamRBdLxYHcl" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20210331_zqFMWYBOTg2i" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGz412_zTZs95gMXgbf" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">28,224,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">25,687,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGz412_zhyYh7LUfwsh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,850,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,850,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGz412_zKDHJZiXvmna" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,120,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0p0_maDTAGz412_zBsGGRNNH6Oe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Allowances and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,336,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">659,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pp0p0_d0_maDTAGz412_zjR6sJBCY3xh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">398,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pp0p0_maDTAGz412_znoCHGmqJkC7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">63,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">78,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGz412_maDTANzqCr_z0vmMTQhwtCj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Gross deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,782,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,792,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzqCr_zq8q7qO8gmi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Less valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(30,613,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(31,528,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzqCr_maDTALNzfiK_zGhqMg8J0Omf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,169,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">264,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pp0p0_di_maDITLzfJx_zriQ37QHmO33" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pp0p0_di_maDITLzfJx_zNQnYT6zKgwb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(260,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(186,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pp0p0_di_maDITLzfJx_zLuEU6vleCe3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Right of Use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(63,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(75,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pp0p0_di_mtDITLzfJx_msDTALNzfiK_zkPb5cIHAXMc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(340,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(264,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pp0p0_d0_mtDTALNzfiK_zbSiR7MSos8j" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">829,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Income tax provision domestic and foreign</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zseH5cht87fe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zPA5UDCgqzuk" style="display: none">Income tax provision domestic and foreign</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended March&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">Domestic</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ProfitLoss_pp0p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zo6vQ1YumKye" style="width: 13%; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(3,516,000)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ProfitLoss_pp0p0_c20200401__20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zsw9EFiq2jLj" style="width: 13%; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(2,052,000)</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Foreign</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--ProfitLoss_pp0p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z8hs79iu2e7a" style="border-bottom: black 1pt solid; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(1,883,000)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--ProfitLoss_pp0p0_c20200401__20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zuStfLXjuOv" style="border-bottom: black 1pt solid; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(1,467,000)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331_z2D6HFIoFef2" style="border-bottom: black 2.25pt double; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(5,399,000)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ProfitLoss_pn3p0_c20200401__20210331_zOzz6OEPJill" style="border-bottom: black 2.25pt double; text-align: right" title="Income before income taxes"><span style="font-size: 10pt">(3,519,000)</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_znsDd3EjIbs9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_z6xcUQXl30sd" style="display: none">Schedule of income tax expense</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_491_20210401__20220331_z6ZgkUyyeA14" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_494_20200401__20210331_zBOqa0wIo839" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended March&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Current:</span></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><span style="font-size: 10pt">State</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">8,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">1,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CurrentForeignTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Foreign</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">469,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">941,000</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><b style="display: none">Current Income Tax Expense</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">477,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">942,000</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Deferred:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zjis4gxbRI36" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Federal</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zgHHC3PDfJ0l" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">State</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_d0_zpcAJAvJHRs3" style="vertical-align: bottom; background-color: #EEEEEE">
    <td><span style="font-size: 10pt">Foreign</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">(809,000)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><b style="display: none">Total deferred income tax</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(332,000)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">942,000</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of federal income tax rate to effective rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zV4x1gKKMBd4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_z6uGOswNvCa4" style="display: none">Reconciliation of federal income tax rate to effective rate</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49F_20210401__20220331_zhL7miAKoiPl" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49E_20200401__20210331_zxHHbKsuXclk" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year&#160;Ended&#160;March&#160;31,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zUEVliCEaalj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%"><span style="font-size: 10pt">Expected federal statutory rate</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">21.0%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><span style="font-size: 10pt">21.0%</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_z60DI9aSzz71" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">State income taxes</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5.7%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2.1%</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zOLgQzc5D8hd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Foreign earnings taxed at different rates</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3.7%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3.6%</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_ecustom--ForeignTaxTrueup_dp0_zu1v1enA0JZ1" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Foreign tax true-up</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(12.4%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_dpi_zEb84tIE5CT3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Effect of permanent differences</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(3.0%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(9.5%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_zronOu5qGWgg" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Effect of intercompany interest permanent differences</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(12.3%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(17.9%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_ecustom--TrueupsOfStateDeferredAssets_dp_zCe8tbuXo4S6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">True-up of state deferred assets</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(25.6%</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(120.7%</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zwOCtkaa3pcl" style="vertical-align: bottom; background-color: White">
    <td><b style="display: none">Total effective rate</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(10.5%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(133.8%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zh0QHLE6lIAk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">Change in valuation allowance</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">16.7%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">107.1%</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zsFrvUAF0th" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Totals</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(6.2%</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">(26.7%</span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831698907728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregated Revenue by Source</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--DisaggregationOfRevenueTableTextBlock_zf8ED1TsLjuc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-align: left"><span id="xdx_8BC_zUH2QemuRLI9" style="display: none">Disaggregated Revenue by Source</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Product</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Human Care</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_pp0p0" style="width: 13%; text-align: right" title="Revenues">9,010,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_pp0p0" style="width: 13%; text-align: right" title="Revenues">15,317,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Animal Care</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">3,169,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">3,200,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Total Product Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3p0" style="text-align: right" title="Revenues">12,179,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3p0" style="text-align: right" title="Revenues">18,517,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Service/Royalty</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pn3p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">449,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pn3p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">112,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,628,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">18,629,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of geographic sales</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zLFVfyGrcWfc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Geographic Information (Details - Geographic regions)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B4_zU4cJrgRoiA2" style="display: none">Schedule of geographic sales</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year Ended March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 68%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 13%; text-align: right" title="Revenues">3,807,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 13%; text-align: right" title="Revenues">5,419,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_pp0p0" style="text-align: right" title="Revenues">2,095,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_pp0p0" style="text-align: right" title="Revenues">5,976,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Europe and Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_z9JI4GGjVUAl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">6,726,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">7,234,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331_z3gxx56LAxPh" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,628,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200401__20210331_zmKl28Cg30Yk" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">18,629,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831694495568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Financial Condition (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 5,086,000<span></span>
</td>
<td class="nump">$ 3,950,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">184,363,000<span></span>
</td>
<td class="nump">179,277,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_WorkingCapital', window );">Working capital</a></td>
<td class="nump">$ 10,611,000<span></span>
</td>
<td class="nump">$ 8,905,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831694598192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details-Useful lives)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful asset life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful asset life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful asset life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831694574560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details - Earnings per share) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="num">$ (5,086,000)<span></span>
</td>
<td class="num">$ (4,615,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">665,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,086,000)<span></span>
</td>
<td class="num">$ (3,950,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding: basic and diluted</a></td>
<td class="nump">2,653,000<span></span>
</td>
<td class="nump">1,996,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare', window );">Loss per share from continuing operations</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (2.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare', window );">Income per share from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_EarningPerShareBasicAndDiluted', window );">Net loss per share: basic and diluted</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (1.97)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_EarningPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_EarningPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699321616">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details - Antidilutive shares) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">621<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">466<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">108<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SNOA_CommonStockUnitsMember', window );">Common Stock Units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">46<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SNOA_CommonStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SNOA_CommonStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831695892432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns', window );">Allowance for sales discounts, rebates, distributor fees and returns</a></td>
<td class="nump">81,000<span></span>
</td>
<td class="nump">1,488,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves</a></td>
<td class="nump">218,000<span></span>
</td>
<td class="nump">223,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers in or out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">555,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Advertising costs</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">12,628,000<span></span>
</td>
<td class="nump">18,629,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">1,031,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Foreign currency transaction loss</a></td>
<td class="nump">579,000<span></span>
</td>
<td class="nump">690,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">4,312,000<span></span>
</td>
<td class="nump">4,579,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | First Customer [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Second Customer [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Third Customer [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=SNOA_NetRevenuesMember', window );">Net Revenues [Member] | First Customer [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=SNOA_NetRevenuesMember', window );">Net Revenues [Member] | Second Customer [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=SNOA_NetRevenuesMember', window );">Net Revenues [Member] | Third Customer [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant customer concentration</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for sales discounts, rebates, distributor fees and returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_FirstCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_FirstCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_SecondCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_SecondCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_ThirdCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_ThirdCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=SNOA_NetRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=SNOA_NetRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831694673936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Assets - Discontinued Operations (Details - Allocation of sale price) - Micromed Labs [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 24, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Customer base</a></td>
<td class="nump">$ 850,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Less: Funds remaining in escrow</a></td>
<td class="num">(60,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue', window );">Less: Services due from buyer</a></td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital', window );">Less: Working capital adjustment</a></td>
<td class="num">(80,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sale of business</a></td>
<td class="nump">$ 610,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Working Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=SNOA_MicromedLabsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=SNOA_MicromedLabsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831698915200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Assets - Discontinued Operations (Details - Discontinued Operations) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 214,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Selling general and administrative expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Income from discontinued operations before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">123,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Gain on disposal of discontinued operations before income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">770,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Total income from discontinued operations, before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">893,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income Tax benefit (expense)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(228,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 665,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831700363776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 2,488,000<span></span>
</td>
<td class="nump">$ 4,419,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(125,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_DiscountsRebatesDistributorFeesAndReturns', window );">Less: discounts, rebates, distributor fees and returns</a></td>
<td class="num">(81,000)<span></span>
</td>
<td class="num">(1,488,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net&#160;</a></td>
<td class="nump">$ 2,407,000<span></span>
</td>
<td class="nump">$ 2,806,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DiscountsRebatesDistributorFeesAndReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discounts, rebates, distributor fees and returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DiscountsRebatesDistributorFeesAndReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831700472928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,626,000<span></span>
</td>
<td class="nump">$ 1,670,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,037,000<span></span>
</td>
<td class="nump">860,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 2,663,000<span></span>
</td>
<td class="nump">$ 2,530,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699419904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 755,000<span></span>
</td>
<td class="nump">$ 705,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Tax prepaid to Mexican tax authorities</a></td>
<td class="nump">2,371,000<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses and other current assets</a></td>
<td class="nump">620,000<span></span>
</td>
<td class="nump">663,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">&#160;Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,746,000<span></span>
</td>
<td class="nump">$ 3,218,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831694709792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Manufacturing, lab, and other equipment</a></td>
<td class="nump">$ 1,281,000<span></span>
</td>
<td class="nump">$ 1,170,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Office equipment</a></td>
<td class="nump">139,000<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">108,000<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">503,000<span></span>
</td>
<td class="nump">486,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross&#160;</a></td>
<td class="nump">2,031,000<span></span>
</td>
<td class="nump">1,831,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(1,711,000)<span></span>
</td>
<td class="num">(1,471,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net&#160;</a></td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831698907728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 186,000<span></span>
</td>
<td class="nump">$ 227,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831694716480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries and related costs</a></td>
<td class="nump">$ 1,059,000<span></span>
</td>
<td class="nump">$ 787,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">784,000<span></span>
</td>
<td class="nump">367,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,843,000<span></span>
</td>
<td class="nump">$ 1,154,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831694612096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">22 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Approval for forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,310,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=SNOA_PaycheckProtectionProgramMember', window );">Paycheck Protection Program [Member] | States Bank In Atlanta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 29,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums1Member', window );">Insurance Premiums 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 584,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums2Member', window );">Insurance Premiums 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="nump">$ 748,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate</a></td>
<td class="nump">4.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=SNOA_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=SNOA_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SNOA_StatesBankInAtlantaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SNOA_StatesBankInAtlantaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiums2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831700244432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details - Balance sheet information related to leases) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 559,000<span></span>
</td>
<td class="nump">$ 769,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8211; current</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities &#8211; non-current</a></td>
<td class="nump">309,000<span></span>
</td>
<td class="nump">529,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">367,000<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Operating Lease, Payments, Use</a></td>
<td class="num">$ (223,000)<span></span>
</td>
<td class="num">$ (215,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases (in months)</a></td>
<td class="text">27 months 9 days<span></span>
</td>
<td class="text">37 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831694522960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details - Minimum operating lease liabilities)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">$ 297,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">210,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">106,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">627,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(68,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 559,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831703057168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salaries</a></td>
<td class="nump">$ 775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Potential severance</a></td>
<td class="nump">775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SNOA_TromblyBusinessLawMember', window );">Trombly Business Law [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="nump">$ 215,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SNOA_TromblyBusinessLawMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SNOA_TromblyBusinessLawMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831698959632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">24,000,000<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">714,286<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred stock converted</a></td>
<td class="nump">1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Common stock issued upon conversion</a></td>
<td class="nump">17,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831694592224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Assumptions) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Fair value of common stock on date of grant</a></td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="nump">$ 8.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.58%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">123.27%<span></span>
</td>
<td class="nump">80.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of options granted, per share</a></td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="nump">$ 5.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699320688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Stock-based compensation) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 382,000<span></span>
</td>
<td class="nump">$ 371,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 382,000<span></span>
</td>
<td class="nump">$ 372,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699528704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Plans)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">466,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber', window );">Total options and restricted stock units outstanding</a></td>
<td class="nump">466,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock-based awards available for grant</a></td>
<td class="nump">982,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2006Member', window );">2006 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">2,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber', window );">Total options and restricted stock units outstanding</a></td>
<td class="nump">2,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock-based awards available for grant</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2011Member', window );">2011 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">111,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber', window );">Total options and restricted stock units outstanding</a></td>
<td class="nump">111,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock-based awards available for grant</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member', window );">2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">221,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber', window );">Total options and restricted stock units outstanding</a></td>
<td class="nump">221,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock-based awards available for grant</a></td>
<td class="nump">112,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2017Member', window );">Plan 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">130,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber', window );">Total options and restricted stock units outstanding</a></td>
<td class="nump">130,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options and restricted stock units outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831695842800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Option activity) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Granted</a></td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="nump">$ 8.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding at end of period</a></td>
<td class="nump">466,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding at beginning of period</a></td>
<td class="nump">267,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Outstanding at beginning of period</a></td>
<td class="nump">$ 25.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Granted</a></td>
<td class="nump">272,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Granted</a></td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Exercised</a></td>
<td class="num">(44,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Exercised</a></td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Shares Forfeited</a></td>
<td class="num">(5,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Forfeited</a></td>
<td class="nump">$ 6.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares Expired</a></td>
<td class="num">(25,001)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Expired</a></td>
<td class="nump">$ 84.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding at end of period</a></td>
<td class="nump">466,234<span></span>
</td>
<td class="nump">267,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Outstanding at end of period</a></td>
<td class="nump">$ 12.09<span></span>
</td>
<td class="nump">$ 25.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Contractual Term Outstanding at end of period</a></td>
<td class="text">8 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Exercisable at end of period</a></td>
<td class="nump">115,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Exercisable at end of period</a></td>
<td class="nump">$ 32.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Contractual Term Exercisable at end of period</a></td>
<td class="text">6 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value Exercisable at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699320368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Restricted stock activity) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, beginning balance | shares</a></td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average award date fair value per share, outstanding beginning balance | $ / shares</a></td>
<td class="nump">$ 13.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted | shares</a></td>
<td class="nump">1,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average award date fair value per share, granted | $ / shares</a></td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock awards vested | shares</a></td>
<td class="num">(2,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average award date fair value per share, vested | $ / shares</a></td>
<td class="nump">$ 6.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted stock awards, ending balance | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average award date fair value per share, outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831696172176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 02, 2016</div></th>
<th class="th"><div>Sep. 12, 2011</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">982,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Tax benefit</a></td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Decrease in stock based compensation deferred tax asset</a></td>
<td class="nump">309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 1,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average amortization period</a></td>
<td class="text">2 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue', window );">Aggregate intrinsic value per share</a></td>
<td class="nump">$ 4.01<span></span>
</td>
<td class="nump">$ 7.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2006Member', window );">2006 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2011Member', window );">2011 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares initially authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member', window );">2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">112,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares initially authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares authorized for issuance</a></td>
<td class="nump">167,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,306<span></span>
</td>
<td class="nump">4,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2021Member', window );">Plan 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">869,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831694690992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details-Deferred taxes) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 28,224,000<span></span>
</td>
<td class="nump">$ 25,687,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">1,850,000<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">309,000<span></span>
</td>
<td class="nump">3,120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Allowances and accruals</a></td>
<td class="nump">1,336,000<span></span>
</td>
<td class="nump">659,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">398,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">31,782,000<span></span>
</td>
<td class="nump">31,792,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(30,613,000)<span></span>
</td>
<td class="num">(31,528,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">1,169,000<span></span>
</td>
<td class="nump">264,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(17,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(260,000)<span></span>
</td>
<td class="num">(186,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of Use asset</a></td>
<td class="num">(63,000)<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(340,000)<span></span>
</td>
<td class="num">(264,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 829,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831700294960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details-Income source) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Income before income taxes</a></td>
<td class="num">$ (5,399,000)<span></span>
</td>
<td class="num">$ (3,519,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Income before income taxes</a></td>
<td class="num">(3,516,000)<span></span>
</td>
<td class="num">(2,052,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Income before income taxes</a></td>
<td class="num">$ (1,883,000)<span></span>
</td>
<td class="num">$ (1,467,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831695796752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details-Income tax expense) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">469,000<span></span>
</td>
<td class="nump">941,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense</a></td>
<td class="nump">477,000<span></span>
</td>
<td class="nump">942,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(809,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax</a></td>
<td class="num">$ (332,000)<span></span>
</td>
<td class="nump">$ 942,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831700444912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details-Reconciliation of tax rate)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings taxed at different rates</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_ForeignTaxTrueup', window );">Foreign tax true-up</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(12.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Effect of permanent differences</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(9.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Effect of intercompany interest permanent differences</a></td>
<td class="num">(12.30%)<span></span>
</td>
<td class="num">(17.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SNOA_TrueupsOfStateDeferredAssets', window );">True-up of state deferred assets</a></td>
<td class="num">(25.60%)<span></span>
</td>
<td class="num">(120.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Total effective rate</a></td>
<td class="num">(10.50%)<span></span>
</td>
<td class="num">(133.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">16.70%<span></span>
</td>
<td class="nump">107.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Totals</a></td>
<td class="num">(6.20%)<span></span>
</td>
<td class="num">(26.70%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ForeignTaxTrueup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ForeignTaxTrueup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_TrueupsOfStateDeferredAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>True-ups of State deferred assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_TrueupsOfStateDeferredAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831695795424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 115,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research credit carryforwards</a></td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">44,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research credit carryforwards</a></td>
<td class="nump">790,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">541,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign', window );">Foreign tax credit carryforward</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699418864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributions', window );">Company contributions to 401(k) plan</a></td>
<td class="nump">$ 50,600<span></span>
</td>
<td class="nump">$ 89,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831699539984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation (Details - Disaggregation of revenue) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 12,628,000<span></span>
</td>
<td class="nump">$ 18,629,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">12,179,000<span></span>
</td>
<td class="nump">18,517,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Human Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">9,010,000<span></span>
</td>
<td class="nump">15,317,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Animal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,169,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 449,000<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=SNOA_HumanCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=SNOA_HumanCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=SNOA_AnimalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=SNOA_AnimalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831700198000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information (Details - Geographic regions) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 12,628,000<span></span>
</td>
<td class="nump">$ 18,629,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">12,179,000<span></span>
</td>
<td class="nump">18,517,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Revenue, Segment Benchmark [Member] | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,807,000<span></span>
</td>
<td class="nump">5,419,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Revenue, Segment Benchmark [Member] | Latin America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,095,000<span></span>
</td>
<td class="nump">5,976,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Revenue, Segment Benchmark [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 6,726,000<span></span>
</td>
<td class="nump">$ 7,234,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139831704040384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 12,628,000<span></span>
</td>
<td class="nump">$ 18,629,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 349,000<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>sonoma_i10k-033122_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SNOA="http://sonomapharma.com/20220331"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="snoa-20220331.xsd" xlink:type="simple"/>
    <context id="From2021-04-01to2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-07-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2022-07-11</instant>
        </period>
    </context>
    <context id="From2020-04-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:FirstCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:SecondCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:ThirdCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:FirstCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:SecondCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:ThirdCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:FirstCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:SecondCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:ThirdCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_NetRevenuesMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:FirstCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_NetRevenuesMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:SecondCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">SNOA:NetRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ShippingAndHandlingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_ShippingAndHandlingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_CommonStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_CommonStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-24_custom_MicromedLabsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">SNOA:MicromedLabsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-24</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-24_custom_MicromedLabsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">SNOA:MicromedLabsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-24</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-31_custom_InsurancePremiums1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="From2021-01-252021-01-31_custom_InsurancePremiums1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-10-01_custom_InsurancePremiums1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-31_custom_InsurancePremiums2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="From2022-01-252022-01-31_custom_InsurancePremiums2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2022-03-012023-12-31_custom_InsurancePremiums2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiums2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-252020-05-01_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SNOA:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:StatesBankInAtlantaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-25</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">SNOA:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:StatesBankInAtlantaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_TromblyBusinessLawMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:TromblyBusinessLawMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_TromblyBusinessLawMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SNOA:TromblyBusinessLawMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_SeriesCPreferredStockMember44329203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_Plan2006Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2011-09-12_custom_Plan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-09-12</instant>
        </period>
    </context>
    <context id="From2018-04-012019-03-31_custom_Plan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_Plan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_Plan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2016-09-02_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-02</instant>
        </period>
    </context>
    <context id="From2018-04-012019-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_Plan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_Plan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_StockOptionMember44329593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_Plan2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_custom_HumanCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_ProductMember_custom_HumanCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_custom_AnimalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_ProductMember_custom_AnimalCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-04-01to2022-03-31">0001367083</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-04-01to2022-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2021-04-01to2022-03-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-04-01to2022-03-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0224"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0281"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0349"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedWithConversionOfCShares
      contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedWithConversionOfCShares
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedWithConversionOfCShares
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedWithConversionOfCShares
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedWithConversionOfCShares
      contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:SharesIssuedWithConversionOfCShares
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0437"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-04-01to2022-03-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2021-04-01to2022-03-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-04-01to2022-03-31">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-04-01to2022-03-31">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-04-01to2022-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-04-01to2022-03-31">001-33216</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-04-01to2022-03-31">SONOMA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-04-01to2022-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-04-01to2022-03-31">68-0423298</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-04-01to2022-03-31">645 Molly Lane</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-04-01to2022-03-31">Suite 150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-04-01to2022-03-31">Woodstock</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-04-01to2022-03-31">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-04-01to2022-03-31">30189</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-04-01to2022-03-31">(800)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-04-01to2022-03-31">759-9305</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-04-01to2022-03-31">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-04-01to2022-03-31">SNOA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-04-01to2022-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2021-04-01to2022-03-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2021-04-01to2022-03-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2021-04-01to2022-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-04-01to2022-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-04-01to2022-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-04-01to2022-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-04-01to2022-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2021-04-01to2022-03-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">16658750</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-07-11" decimals="INF" unitRef="Shares">3100937</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2021-04-01to2022-03-31">215</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="From2020-04-012021-03-31">688</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2021-04-01to2022-03-31">Frazier &amp; Deeter</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2021-04-01to2022-03-31">Atlanta, Georgia</dei:AuditorLocation>
    <dei:AuditorName contextRef="From2020-04-012021-03-31">Marcum llp</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2020-04-012021-03-31">New York, NY</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">7396000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">4220000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2407000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">2806000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2663000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">2530000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">3746000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">3218000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <SNOA:DeferredConsiderationNetCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">218000</SNOA:DeferredConsiderationNetCurrent>
    <SNOA:DeferredConsiderationNetCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">209000</SNOA:DeferredConsiderationNetCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">16430000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">12983000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">320000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">360000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">559000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">769000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">829000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <SNOA:DeferredConsiderationNetNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">630000</SNOA:DeferredConsiderationNetNoncurrent>
    <SNOA:DeferredConsiderationNetNoncurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">763000</SNOA:DeferredConsiderationNetNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">77000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">112000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">18845000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">14987000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1641000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1769000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1843000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1154000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1223000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">267000</us-gaap:DeferredRevenueCurrent>
    <SNOA:ContractWithCustomerLiabilityCurrentInvekra contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">54000</SNOA:ContractWithCustomerLiabilityCurrentInvekra>
    <SNOA:ContractWithCustomerLiabilityCurrentInvekra contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">52000</SNOA:ContractWithCustomerLiabilityCurrentInvekra>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">120000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">-0</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLongTermDebtCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">688000</us-gaap:OtherLongTermDebtCurrent>
    <us-gaap:OtherLongTermDebtCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">596000</us-gaap:OtherLongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">250000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">240000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">5819000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">4078000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">182000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">229000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1310000</us-gaap:LongTermDebtNoncurrent>
    <SNOA:WithholdingTaxPayable contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">3838000</SNOA:WithholdingTaxPayable>
    <SNOA:WithholdingTaxPayable contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">3478000</SNOA:WithholdingTaxPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">309000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">529000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">10148000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">9624000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">714286</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">714286</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">24000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">24000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">3100937</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">3100937</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">2092909</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">2092909</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">197370000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">189217000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">-184363000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">-179277000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">-4312000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">-4579000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">8697000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">5363000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">18845000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">14987000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">12628000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">18629000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">8635000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">12070000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">3993000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">6559000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">125000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">555000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">9755000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">9453000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">9880000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">10008000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5887000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-3449000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-10000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">723000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-394000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-594000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">150000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">137000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5418000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-3902000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-332000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">713000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-4615000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">665000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-3950000</us-gaap:NetIncomeLoss>
    <SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.92</SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare>
    <SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-2.31</SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare>
    <SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0</SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare>
    <SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.33</SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare>
    <SNOA:EarningPerShareBasicAndDiluted
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.92</SNOA:EarningPerShareBasicAndDiluted>
    <SNOA:EarningPerShareBasicAndDiluted
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.97</SNOA:EarningPerShareBasicAndDiluted>
    <SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="Shares">2653000</SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="Shares">1996000</SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-3950000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">1031000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-4819000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-2919000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2092909</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">189217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-179277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-4579000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">5363000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">950100</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">7554000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">7554000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">44042</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">193000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">193000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12290</SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">24000</SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">24000</SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1596</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">10000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">10000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-04-012022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3100937</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">197370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-184363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-4312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">8697000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">1.55</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1777483</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">186559000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-175327000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-5610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="-3" unitRef="USD">5624000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">93301</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">511000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">511000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3919</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">200984</SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1776000</SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount>
    <SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">1776000</SNOA:SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount>
    <SNOA:SharesIssuedWithConversionOfCSharesShares
      contextRef="From2020-04-012021-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      unitRef="Shares">-1.55</SNOA:SharesIssuedWithConversionOfCSharesShares>
    <SNOA:SharesIssuedWithConversionOfCSharesShares
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">17222</SNOA:SharesIssuedWithConversionOfCSharesShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">332000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">332000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">39000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">39000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-04-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">1031000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">1031000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-3950000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-3950000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2092909</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">189217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-179277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-4579000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">5363000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-3950000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">186000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">227000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-125000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-903000</us-gaap:ProvisionForDoubtfulAccounts>
    <SNOA:ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-1407000</SNOA:ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns>
    <SNOA:ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">259000</SNOA:ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">382000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">371000</us-gaap:ShareBasedCompensation>
    <SNOA:ForgivenessOfPppLoan
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">723000</SNOA:ForgivenessOfPppLoan>
    <SNOA:ForgivenessOfPppLoan
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-0</SNOA:ForgivenessOfPppLoan>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">829000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-223000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">770000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-1971000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-2608000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">65000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">460000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">5000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">160000</SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount>
    <SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">143000</SNOA:IncreaseDecreaseInDeferredConsiderationNetOfDiscount>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-157000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-796000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">679000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-668000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <SNOA:IncreaseDecreaseInWithholdingTaxPayable
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">360000</SNOA:IncreaseDecreaseInWithholdingTaxPayable>
    <SNOA:IncreaseDecreaseInWithholdingTaxPayable
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">397000</SNOA:IncreaseDecreaseInWithholdingTaxPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-222000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-215000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">900000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-15000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-4248000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-3378000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">137000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">179000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <SNOA:IncreaseDecreaseInDeposits1
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-38000</SNOA:IncreaseDecreaseInDeposits1>
    <SNOA:IncreaseDecreaseInDeposits1
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">43000</SNOA:IncreaseDecreaseInDeposits1>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">610000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-99000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">388000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">7554000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <SNOA:PaymentsOnPppLoan
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">467000</SNOA:PaymentsOnPppLoan>
    <SNOA:PaymentsOnPppLoan
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-0</SNOA:PaymentsOnPppLoan>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">1310000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">216000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">2287000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">30000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">481000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">123000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProceedsFromShortTermDebt>
    <SNOA:BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-0</SNOA:BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets>
    <SNOA:BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-192000</SNOA:BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">7396000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">3308000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">127000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">211000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">3176000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">529000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">4220000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-03-31" decimals="-3" unitRef="USD">3691000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">7396000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">4220000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">24000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">12000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">767000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">941000</us-gaap:IncomeTaxesPaidNet>
    <SNOA:InsurancePremiumsFinanced
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">748000</SNOA:InsurancePremiumsFinanced>
    <SNOA:InsurancePremiumsFinanced
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">596000</SNOA:InsurancePremiumsFinanced>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zu6TsBwZut1i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;1&#160;&#x2013; &lt;span id="xdx_823_zwraHgvuJF72"&gt;Organization and Recent
Developments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sonoma Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;)
was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware
in December 2006. The Company&#x2019;s principal office was moved to Woodstock, Georgia from Petaluma, California in June 2020. The Company
is a global healthcare leader for developing and producing stabilized hypochlorous acid (&#x201c;HOCl&#x201d;) products for a wide range
of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company&#x2019;s products
reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies
of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. The Company&#x2019;s stabilized
HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells
in the area treated assisting the body in its natural healing process. The Company sells its products either directly or via partners
in 54 countries worldwide.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_803_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zmKHvPxNB3wb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;2&#160;&#x2013; &lt;span id="xdx_82A_z8CQz0htyafe"&gt;Liquidity and Financial
Condition&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company reported a net loss of $&lt;span id="xdx_900_eus-gaap--NetIncomeLoss_iN_di_c20210401__20220331_z9uOEU15ipfc" title="Net loss"&gt;5,086,000&lt;/span&gt;
for the year ended March 31, 2022. At March 31, 2022 and 2021, the Company&#x2019;s accumulated deficit amounted to $&lt;span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20220331_z7QFEq9R169h" title="Accumulated deficit"&gt;184,363,000&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20210331_zl2MGT0lkuy" title="Accumulated deficit"&gt;179,277,000&lt;/span&gt;, respectively. The Company had working capital of $&lt;span id="xdx_904_ecustom--WorkingCapital_c20220331_pp0p0" title="Working capital"&gt;10,611,000&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--WorkingCapital_iI_pp0p0_c20210331_zy7ELL6hSdm3" title="Working capital"&gt;8,905,000&lt;/span&gt; as of March 31, 2022 and 2021,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management believes that the Company has access
to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other
means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms,
if needed. If the economic climate in the U.S. deteriorates, the Company&#x2019;s ability to raise additional capital could be negatively
impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order
to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays
in the Company&#x2019;s continued efforts to commercialize its products, which is critical to the realization of its business plan and
the future operations of the Company. These matters raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.
The accompanying consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to
continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;COVID &#x2013; 19&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On March 11, 2020 the
World Health Organization declared the novel strain of coronavirus (&#x201c;COVID-19&#x201d;) a global pandemic and recommended containment
and mitigation measures worldwide. In an effort to mitigate the continued spread of the virus, federal, state and local governments, as
well as certain private entities have mandated various restrictions, including travel restrictions, restrictions on public gatherings
and quarantining of people who may have been exposed to the virus. As a result of these restrictions, together with a general fear of
the impact on the global economy and financial markets, there is significant uncertainty surrounding the potential impact on the Company.
As events are rapidly changing, the Company is unable to accurately predict the impact that COVID-19 will have on its business due to
uncertainties including, but not limited to, the duration of quarantines and other travel restrictions within China, the U.S. and other
affected countries, the ultimate geographical spread of the virus, the severity of the disease, the duration of the outbreak and the public&#x2019;s
response to the outbreak.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-184363000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-179277000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <SNOA:WorkingCapital contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">10611000</SNOA:WorkingCapital>
    <SNOA:WorkingCapital contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">8905000</SNOA:WorkingCapital>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zvBqxU4QvNPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE&#160;3&#160;&#x2013; &lt;span id="xdx_82D_zyMfraEQ5iu2"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zdhJQAklOI82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zJrVB9o8qPaa"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#x201c;Aquamed&#x201d;), Oculus Technologies
of Mexico S.A. de C.V. (&#x201c;OTM&#x201d;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#x201c;SP Europe&#x201d;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#x201c;U.S.&#x201d;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6kTYYWEIm67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zLEfOSLbmZUb"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated
financial statements have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission
("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). The Company&#x2019;s fiscal
year end is March 31. Unless otherwise stated, all years and dates refer to the fiscal year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMz1LixZSF48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zUzki0mVVL08"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents
include cash on hand and all highly liquid investments with an original maturity of three months or less when purchased. The Company&#x2019;s
cash equivalents are held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--UseOfEstimates_z1rPJwv6qHzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_z3atnCgDmdz"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating
to the Company&#x2019;s deferred tax assets, valuation of equity, fair value allocation of assets sold to Invekra, and the estimated amortization
periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zOfmMfmTTv2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z78nGuyLyZK2"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 1, 2018, the Company adopted Accounting
Standards Update ("ASU"), "Revenue from Contracts with Customers Topic 606&#x201d; (&#x201c;Topic 606&#x201d;) using the modified
retrospective method. There was no material impact to the Company upon the adoption of Topic 606. Revenue is recognized when the Company
transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive
in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its
obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the promised goods or services in
the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are
distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company derives the majority of its revenue
through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including
hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license
its technology and products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers customer purchase orders,
which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers
the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For all of its sales to non-consignment distribution
channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied),
which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on
the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers,
the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able
to estimate the amount of product that will be returned.&#160;&#160;Sales incentives and other programs that the Company may make available
to these customers are considered to be a form of variable consideration, and the Company maintains estimated accruals and allowances
using the expected value method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the
Company&#x2019;s rebate program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sales to stocking distributors are made under
terms with fixed pricing and limited rights of return (known as &#x201c;stock rotation&#x201d;) of the Company&#x2019;s products held in
their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company assessed the promised goods and services
in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is
separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as
other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Service revenue from testing contracts is recognized
as tests are completed and a final report is sent to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













&lt;p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zQG8MWcuQMee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zZ7aTCwWRBjk"&gt;Concentration of Credit Risk and Major Customers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company grants credit to its business customers,
which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. The Company
maintains allowances for potential credit losses. At March 31, 2022, one customer represented &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZBZeds9Apq8" title="Significant customer concentration"&gt;20%&lt;/span&gt; of our net accounts
receivable balance, one customer represented &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbmHbBQlzH1l"&gt;15%&lt;/span&gt; of our net accounts receivable balance, and one customer represented
&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvJLSXHG9ntb"&gt;14%&lt;/span&gt; of our net accounts receivable balance. At March 31, 2021, one customer represented &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR4a2HzAazwk"&gt;17&lt;/span&gt;% of our net accounts receivable balance, one customer represented &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFiepuzigYl3"&gt;16&lt;/span&gt;%
of our net accounts receivable balance, and one customer represented &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfGlF255Zn0c"&gt;14&lt;/span&gt;% of our net accounts receivable balance. For the year ended March 31, 2022, one customer represented &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9ZQvKaieujk"&gt;10&lt;/span&gt;%, one customer represented &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztnOOVa0t2Ni"&gt;17&lt;/span&gt;%, and one customer represented
&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHbr1sCM4Di"&gt;21&lt;/span&gt;% of net revenues. For the year ended March 31, 2021, one customer represented &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8l6YiasiR53"&gt;32&lt;/span&gt;%, and one customer represented &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1E7AUHpoJq4"&gt;15&lt;/span&gt;% of net revenues.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zuQPgL1h1zm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zspY2vT1pgK2"&gt;Accounts Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivable are recorded net of
allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns
are based on analysis of contractual terms and historical trends.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents
probable credit losses at March 31, 2022 and 2021 in the amounts of $&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20220331_zVsbBVHGWjih" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20210331_zYEROlWyq70d" title="Allowance for doubtful accounts"&gt;125,000&lt;/span&gt;, respectively. Additionally, at March 31, 2022 and
2021, the Company has allowances of $&lt;span id="xdx_900_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20220331_zw7gjy1tGVMl" title="Allowance for sales discounts, rebates, distributor fees and returns"&gt;81,000&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20210331_znQlQwN9KDLi" title="Allowance for sales discounts, rebates, distributor fees and returns"&gt;1,488,000&lt;/span&gt;, respectively, related to potential discounts, returns, distributor fees and
rebates. The allowances are included in Accounts Receivable, net in the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zBN59cHxSaZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z1QVEANCPHbi"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision
to reduce the carrying amounts of inventories to their net realizable value in the amounts of &lt;span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_c20220331_znPp91x7lir9" title="Inventory reserves"&gt;$218,000&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--InventoryValuationReserves_iI_c20210331_zvrHkh3kFRvj" title="Inventory reserves"&gt;$223,000&lt;/span&gt; at March 31, 2022
and 2021, respectively, which is included in cost of revenues on the Company&#x2019;s accompanying consolidated statements of comprehensive
(loss) income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zYOxwuVETy8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zAUtJIXcoPw7"&gt;Financial Assets and Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments, including cash and cash
equivalents, accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the
short-term nature of these instruments. The fair value of capital lease obligations and equipment loans approximates their carrying amounts
as a market rate of interest is attached to their repayment. The Company measures the fair value of financial assets and liabilities based
on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes
the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of
inputs that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;1&#160;&#x2013; quoted prices in active
markets for identical assets or liabilities&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;2&#160;&#x2013; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;3&#160;&#x2013; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#x2019;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#x2019;s accounting and finance department
and are approved by the Chief Financial Officer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2022 and 2021, there were &lt;span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20210401__20220331_zOKiwZLZhKX6" title="Transfers in or out of Level 3"&gt;&lt;span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20200401__20210331_z1CTkyNVUFY1" title="Transfers in or out of Level 3"&gt;no&lt;/span&gt;&lt;/span&gt; transfers
in or out of Level 3 from other levels in the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_ziDHEVgeJb6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zlGufgVVqTze"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost less
accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the
estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over
the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification
is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z27mgY7Q7NHa" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zdrkbAcSzJt7" style="display: none"&gt;Property and equipment estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 85%"&gt;&lt;span style="font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zxRRadcj8PJk" title="Useful asset life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Manufacturing, lab and other equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zR3oWDeVTsG5" title="Useful asset life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_znRvm3Gfvdp3" title="Useful asset life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon retirement or sale, the cost and related
accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance
and repairs are charged to operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













&lt;p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1IwNgiIGVab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_znM5z7vIicDb"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company periodically reviews the carrying
values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying
values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of
impairment include, but are not necessarily limited to:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a significant decrease in the fair value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a significant adverse change in legal factors or in the business climate that affects the value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;When circumstances indicate that an impairment
may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows,
assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the
cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment
loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates
used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended March 31, 2022 and 2021,
the Company had noted &lt;span id="xdx_909_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20210401__20220331_zMPvx9klZnHg" title="Asset impairment charges"&gt;&lt;span id="xdx_90D_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20200401__20210331_zA5gdjLshMR6" title="Asset impairment charges"&gt;no&lt;/span&gt;&lt;/span&gt; indicators of impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbYzOJfC1ib7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z52U51uSXwr8"&gt;Research and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development expenses are charged
to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended
March 31, 2022 and 2021, research and development expense amounted to $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20210401__20220331_pn3p0" title="Research and development expenses"&gt;125,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20200401__20210331_pn3p0" title="Research and development expenses"&gt;555,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_zuiXNNC3aLNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_znaCXPH8z2Zj"&gt;Advertising Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advertising costs are charged to operations as
incurred. Advertising costs amounted to $&lt;span id="xdx_907_eus-gaap--MarketingExpense_c20210401__20220331_z7FHj4x7970c" title="Advertising costs"&gt;86,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--MarketingExpense_c20200401__20210331_zPn8rcnKkOYk" title="Advertising costs"&gt;41,000&lt;/span&gt;, for the years ended March 31, 2022 and 2021, respectively. Advertising costs
are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive (loss) income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zwmlOy3BVSzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zg6JsYKlEnyk"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2022 and 2021, the Company recorded revenue related to shipping and
handling costs of $&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_pp0p0" title="Revenues"&gt;52,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_pp0p0" title="Revenues"&gt;37,000&lt;/span&gt;, respectively. These amounts are included in product revenues in the accompanying consolidated statements
of comprehensive (loss) income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zv8lOk1b2B69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zz9h0XByutAe"&gt;Foreign Currency Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s subsidiary, OTM, uses the
local currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional
currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts
are translated at average exchange rates during the period. Resulting translation adjustments amounted to $&lt;span id="xdx_90C_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20210401__20220331_zNm6o6YfPmu8" title="Foreign currency translation adjustment"&gt;267,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20200401__20210331_zD8llMX91eAl" title="Foreign currency translation adjustment"&gt;1,031,000&lt;/span&gt; for
the years ended March 31, 2022 and 2021, respectively. These amounts were recorded in other comprehensive loss in the accompanying consolidated
statements of comprehensive loss for the years ended March 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Foreign currency transaction gains (losses) relate
primarily to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are
expected to be settled in the foreseeable future. The Company recorded foreign currency transaction losses of $&lt;span id="xdx_905_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20210401__20220331_zGjcRd60GEe1" title="Foreign currency transaction loss"&gt;579,000&lt;/span&gt; for the year ended
March 31, 2022, and foreign currency transaction losses of $&lt;span id="xdx_904_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20200401__20210331_zlsJxvRFYBEc" title="Foreign currency transaction loss"&gt;690,000&lt;/span&gt;, for the year ended March 31, 2021. The related amounts were recorded
in other expense in the accompanying consolidated statements of comprehensive (loss) income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zVxi6ReJV8M9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zVyQqglG9Txg"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of an forfeitures for all stock
options as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zrSNgFEi4rea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zxcOkOQ22MM9"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Tax benefits claimed or expected to be claimed
on a tax return are recorded in the Company&#x2019;s consolidated financial statements. A tax benefit from an uncertain tax position is
only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based
on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain
tax positions have had no impact on the Company&#x2019;s consolidated financial condition, results of comprehensive (loss) income or cash
flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zcS8XeMQAjHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zJ1EihqTTxu6"&gt;Comprehensive Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Other comprehensive loss includes all changes
in stockholders&#x2019; equity during a period from non-owner sources and is reported in the consolidated statement of changes in stockholders&#x2019;
equity. To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other
comprehensive losses at March 31, 2022 and 2021 were $&lt;span id="xdx_90C_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_di_c20220331_zJTmlaS86sF8" title="Accumulated other comprehensive loss"&gt;4,312,000&lt;/span&gt;, and $&lt;span id="xdx_904_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_di_c20210331_zRGceQToe0Y1" title="Accumulated other comprehensive loss"&gt;4,579,000&lt;/span&gt; respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zZIuD7ckLwr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zwNsb8Rp0xj9"&gt;Net Income Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company computes basic net loss per share
by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period
and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution
that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d;
and/or &#x201c;if converted&#x201d; methods as applicable.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zRsXO5wGZkFj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_8B2_zpxwFLCCtP8l" style="display: none"&gt;Computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20210401__20220331_zgB7s2aDRr86" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20200401__20210331_zmixmPzrIO54" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic; text-align: justify"&gt;(In thousands, except per share data)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_zQP4TmgcF8gh" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;Loss from continuing operations&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(5,086&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(4,615&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_pn3n3_d0_zBX7xn3gTW5b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Income  from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;665&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_pn3n3_z5VgTLfopGV1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,086&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,950&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pin3_zYmPWPsI6bP3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average  shares outstanding: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,996&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeLossFromContinuingOperationPerBasicAndDilutedShare_pip0_z02qMOz8gKQ3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Loss per share from continuing operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.92&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.31&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_pip0_d0_zOMu6zBGKfAh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Income  per share from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.33&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EarningPerShareBasicAndDiluted_pip0_zwbOIalyqXZg" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss per share: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The computation of basic loss per share for the
years ended March 31, 2022 and 2021 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_ztvvNLsaRsI5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_z0EjdoIXDfP7" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Common stock to be issued upon vesting of restricted stock units&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zAp9FNVR20Fa" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zQSnEapuGNGe" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zGFCfY6Bzqba" style="text-align: right" title="Antidilutive shares"&gt;466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z9xIv4jNVfIh" style="text-align: right" title="Antidilutive shares"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zALn25cy18v2" style="text-align: right" title="Antidilutive shares"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zq2rNd0ZLsZf" style="text-align: right" title="Antidilutive shares"&gt;119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon conversion of Series C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zpw5wzu3R7z7" style="text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zImGLkNONzYa" style="text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock to be issued upon exercise of common stock units (1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zfQ3iLmWAPAb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_z3MFiQjglZQ1" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331_z74sV2x6BNJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;621&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331_zcYutqb7JmT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 5%"&gt;&lt;span id="xdx_F0B_z5FMj7xzgpCd" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 94%; text-align: justify"&gt;&lt;span id="xdx_F12_zdUEYaIzOBF2" style="font-size: 10pt"&gt;Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zyDhTgPZH63i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













&lt;p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_z3VfIE2uf0X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zUk0jJiaGii2"&gt;Common Stock Purchase Warrants and Other
Derivative Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies common stock purchase warrants
and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement
or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).
The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if
an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net cash settlement or
settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability.
The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification
between assets and liabilities is required. The Company determined that its freestanding derivatives, which principally consist of warrants
to purchase common stock, satisfied the criteria for classification as equity instruments, other than certain warrants that contained
reset provisions and certain warrants that required net-cash settlement that the Company classified as derivative liabilities. The company
currently does not have any active derivative financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_z5xbRK3EYqgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zth03FqF3sud"&gt;Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies the accounting standards for
distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject
to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally
redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the
holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity.
At all other times, preferred shares are classified as stockholders' equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zwxMwRMLRIY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zIo7djYjf1Jj"&gt;Subsequent Events&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management has evaluated subsequent events or
transactions occurring through the date these consolidated financial statements were issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcic2ZUgyW01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z8VqGU08W4Bl"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated all the recent accounting
standards and determined that none of them are material to it.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zdhJQAklOI82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zJrVB9o8qPaa"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#x201c;Aquamed&#x201d;), Oculus Technologies
of Mexico S.A. de C.V. (&#x201c;OTM&#x201d;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#x201c;SP Europe&#x201d;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#x201c;U.S.&#x201d;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6kTYYWEIm67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zLEfOSLbmZUb"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated
financial statements have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission
("SEC") and are in conformity with U.S. generally accepted accounting principles ("GAAP"). The Company&#x2019;s fiscal
year end is March 31. Unless otherwise stated, all years and dates refer to the fiscal year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMz1LixZSF48" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zUzki0mVVL08"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents
include cash on hand and all highly liquid investments with an original maturity of three months or less when purchased. The Company&#x2019;s
cash equivalents are held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_840_eus-gaap--UseOfEstimates_z1rPJwv6qHzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_z3atnCgDmdz"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating
to the Company&#x2019;s deferred tax assets, valuation of equity, fair value allocation of assets sold to Invekra, and the estimated amortization
periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zOfmMfmTTv2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z78nGuyLyZK2"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 1, 2018, the Company adopted Accounting
Standards Update ("ASU"), "Revenue from Contracts with Customers Topic 606&#x201d; (&#x201c;Topic 606&#x201d;) using the modified
retrospective method. There was no material impact to the Company upon the adoption of Topic 606. Revenue is recognized when the Company
transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive
in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its
obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the promised goods or services in
the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are
distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company derives the majority of its revenue
through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including
hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company also has entered into agreements to license
its technology and products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers customer purchase orders,
which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers
the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For all of its sales to non-consignment distribution
channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied),
which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on
the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers,
the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able
to estimate the amount of product that will be returned.&#160;&#160;Sales incentives and other programs that the Company may make available
to these customers are considered to be a form of variable consideration, and the Company maintains estimated accruals and allowances
using the expected value method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the
Company&#x2019;s rebate program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sales to stocking distributors are made under
terms with fixed pricing and limited rights of return (known as &#x201c;stock rotation&#x201d;) of the Company&#x2019;s products held in
their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company assessed the promised goods and services
in the technical support to Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and is
separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as
other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Service revenue from testing contracts is recognized
as tests are completed and a final report is sent to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zQG8MWcuQMee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zZ7aTCwWRBjk"&gt;Concentration of Credit Risk and Major Customers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company grants credit to its business customers,
which are primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. The Company
maintains allowances for potential credit losses. At March 31, 2022, one customer represented &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZBZeds9Apq8" title="Significant customer concentration"&gt;20%&lt;/span&gt; of our net accounts
receivable balance, one customer represented &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbmHbBQlzH1l"&gt;15%&lt;/span&gt; of our net accounts receivable balance, and one customer represented
&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvJLSXHG9ntb"&gt;14%&lt;/span&gt; of our net accounts receivable balance. At March 31, 2021, one customer represented &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR4a2HzAazwk"&gt;17&lt;/span&gt;% of our net accounts receivable balance, one customer represented &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFiepuzigYl3"&gt;16&lt;/span&gt;%
of our net accounts receivable balance, and one customer represented &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfGlF255Zn0c"&gt;14&lt;/span&gt;% of our net accounts receivable balance. For the year ended March 31, 2022, one customer represented &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9ZQvKaieujk"&gt;10&lt;/span&gt;%, one customer represented &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztnOOVa0t2Ni"&gt;17&lt;/span&gt;%, and one customer represented
&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20210401__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--ThirdCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHbr1sCM4Di"&gt;21&lt;/span&gt;% of net revenues. For the year ended March 31, 2021, one customer represented &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--FirstCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8l6YiasiR53"&gt;32&lt;/span&gt;%, and one customer represented &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200401__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetRevenuesMember__srt--MajorCustomersAxis__custom--SecondCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1E7AUHpoJq4"&gt;15&lt;/span&gt;% of net revenues.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_us-gaap_AccountsReceivableMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-04-012021-03-31_us-gaap_AccountsReceivableMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-04-012022-03-31_custom_NetRevenuesMember_custom_ThirdCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-04-012021-03-31_custom_NetRevenuesMember_custom_FirstCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-04-012021-03-31_custom_NetRevenuesMember_custom_SecondCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_843_eus-gaap--ReceivablesPolicyTextBlock_zuQPgL1h1zm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zspY2vT1pgK2"&gt;Accounts Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivable are recorded net of
allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns
are based on analysis of contractual terms and historical trends.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts represents
probable credit losses at March 31, 2022 and 2021 in the amounts of $&lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20220331_zVsbBVHGWjih" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20210331_zYEROlWyq70d" title="Allowance for doubtful accounts"&gt;125,000&lt;/span&gt;, respectively. Additionally, at March 31, 2022 and
2021, the Company has allowances of $&lt;span id="xdx_900_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20220331_zw7gjy1tGVMl" title="Allowance for sales discounts, rebates, distributor fees and returns"&gt;81,000&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_c20210331_znQlQwN9KDLi" title="Allowance for sales discounts, rebates, distributor fees and returns"&gt;1,488,000&lt;/span&gt;, respectively, related to potential discounts, returns, distributor fees and
rebates. The allowances are included in Accounts Receivable, net in the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">125000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">81000</SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns>
    <SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1488000</SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zBN59cHxSaZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z1QVEANCPHbi"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. The Company recorded a provision
to reduce the carrying amounts of inventories to their net realizable value in the amounts of &lt;span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_c20220331_znPp91x7lir9" title="Inventory reserves"&gt;$218,000&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--InventoryValuationReserves_iI_c20210331_zvrHkh3kFRvj" title="Inventory reserves"&gt;$223,000&lt;/span&gt; at March 31, 2022
and 2021, respectively, which is included in cost of revenues on the Company&#x2019;s accompanying consolidated statements of comprehensive
(loss) income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">218000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">223000</us-gaap:InventoryValuationReserves>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zYOxwuVETy8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zAUtJIXcoPw7"&gt;Financial Assets and Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments, including cash and cash
equivalents, accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the
short-term nature of these instruments. The fair value of capital lease obligations and equipment loans approximates their carrying amounts
as a market rate of interest is attached to their repayment. The Company measures the fair value of financial assets and liabilities based
on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes
the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of
inputs that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;1&#160;&#x2013; quoted prices in active
markets for identical assets or liabilities&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;2&#160;&#x2013; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level&#160;3&#160;&#x2013; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#x2019;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#x2019;s accounting and finance department
and are approved by the Chief Financial Officer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2022 and 2021, there were &lt;span id="xdx_907_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20210401__20220331_zOKiwZLZhKX6" title="Transfers in or out of Level 3"&gt;&lt;span id="xdx_901_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pp0p0_do_c20200401__20210331_z1CTkyNVUFY1" title="Transfers in or out of Level 3"&gt;no&lt;/span&gt;&lt;/span&gt; transfers
in or out of Level 3 from other levels in the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_ziDHEVgeJb6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zlGufgVVqTze"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost less
accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the
estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over
the lesser of the estimated useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification
is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z27mgY7Q7NHa" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zdrkbAcSzJt7" style="display: none"&gt;Property and equipment estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 85%"&gt;&lt;span style="font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zxRRadcj8PJk" title="Useful asset life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Manufacturing, lab and other equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zR3oWDeVTsG5" title="Useful asset life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_znRvm3Gfvdp3" title="Useful asset life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon retirement or sale, the cost and related
accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance
and repairs are charged to operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z27mgY7Q7NHa" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zdrkbAcSzJt7" style="display: none"&gt;Property and equipment estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 85%"&gt;&lt;span style="font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zxRRadcj8PJk" title="Useful asset life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Manufacturing, lab and other equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zR3oWDeVTsG5" title="Useful asset life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210401__20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_znRvm3Gfvdp3" title="Useful asset life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-04-012022-03-31_us-gaap_OfficeEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-04-012022-03-31_us-gaap_MachineryAndEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-04-012022-03-31_us-gaap_FurnitureAndFixturesMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1IwNgiIGVab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_znM5z7vIicDb"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company periodically reviews the carrying
values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying
values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of
impairment include, but are not necessarily limited to:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a significant decrease in the fair value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a significant adverse change in legal factors or in the business climate that affects the value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;When circumstances indicate that an impairment
may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows,
assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the
cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment
loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates
used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended March 31, 2022 and 2021,
the Company had noted &lt;span id="xdx_909_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20210401__20220331_zMPvx9klZnHg" title="Asset impairment charges"&gt;&lt;span id="xdx_90D_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20200401__20210331_zA5gdjLshMR6" title="Asset impairment charges"&gt;no&lt;/span&gt;&lt;/span&gt; indicators of impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbYzOJfC1ib7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z52U51uSXwr8"&gt;Research and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development expenses are charged
to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended
March 31, 2022 and 2021, research and development expense amounted to $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20210401__20220331_pn3p0" title="Research and development expenses"&gt;125,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20200401__20210331_pn3p0" title="Research and development expenses"&gt;555,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">125000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">555000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_zuiXNNC3aLNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_znaCXPH8z2Zj"&gt;Advertising Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advertising costs are charged to operations as
incurred. Advertising costs amounted to $&lt;span id="xdx_907_eus-gaap--MarketingExpense_c20210401__20220331_z7FHj4x7970c" title="Advertising costs"&gt;86,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--MarketingExpense_c20200401__20210331_zPn8rcnKkOYk" title="Advertising costs"&gt;41,000&lt;/span&gt;, for the years ended March 31, 2022 and 2021, respectively. Advertising costs
are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive (loss) income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:MarketingExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">86000</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">41000</us-gaap:MarketingExpense>
    <SNOA:ShippingAndHandlingCostsPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84C_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zwmlOy3BVSzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zg6JsYKlEnyk"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2022 and 2021, the Company recorded revenue related to shipping and
handling costs of $&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_pp0p0" title="Revenues"&gt;52,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_pp0p0" title="Revenues"&gt;37,000&lt;/span&gt;, respectively. These amounts are included in product revenues in the accompanying consolidated statements
of comprehensive (loss) income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

</SNOA:ShippingAndHandlingCostsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ShippingAndHandlingMember"
      decimals="0"
      unitRef="USD">52000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012021-03-31_us-gaap_ShippingAndHandlingMember"
      decimals="0"
      unitRef="USD">37000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zv8lOk1b2B69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zz9h0XByutAe"&gt;Foreign Currency Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s subsidiary, OTM, uses the
local currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional
currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts
are translated at average exchange rates during the period. Resulting translation adjustments amounted to $&lt;span id="xdx_90C_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20210401__20220331_zNm6o6YfPmu8" title="Foreign currency translation adjustment"&gt;267,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_c20200401__20210331_zD8llMX91eAl" title="Foreign currency translation adjustment"&gt;1,031,000&lt;/span&gt; for
the years ended March 31, 2022 and 2021, respectively. These amounts were recorded in other comprehensive loss in the accompanying consolidated
statements of comprehensive loss for the years ended March 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Foreign currency transaction gains (losses) relate
primarily to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are
expected to be settled in the foreseeable future. The Company recorded foreign currency transaction losses of $&lt;span id="xdx_905_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20210401__20220331_zGjcRd60GEe1" title="Foreign currency transaction loss"&gt;579,000&lt;/span&gt; for the year ended
March 31, 2022, and foreign currency transaction losses of $&lt;span id="xdx_904_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_c20200401__20210331_zlsJxvRFYBEc" title="Foreign currency transaction loss"&gt;690,000&lt;/span&gt;, for the year ended March 31, 2021. The related amounts were recorded
in other expense in the accompanying consolidated statements of comprehensive (loss) income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1031000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">579000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">690000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zVxi6ReJV8M9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zVyQqglG9Txg"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of an forfeitures for all stock
options as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zrSNgFEi4rea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zxcOkOQ22MM9"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Tax benefits claimed or expected to be claimed
on a tax return are recorded in the Company&#x2019;s consolidated financial statements. A tax benefit from an uncertain tax position is
only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based
on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain
tax positions have had no impact on the Company&#x2019;s consolidated financial condition, results of comprehensive (loss) income or cash
flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_840_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zcS8XeMQAjHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zJ1EihqTTxu6"&gt;Comprehensive Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Other comprehensive loss includes all changes
in stockholders&#x2019; equity during a period from non-owner sources and is reported in the consolidated statement of changes in stockholders&#x2019;
equity. To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other
comprehensive losses at March 31, 2022 and 2021 were $&lt;span id="xdx_90C_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_di_c20220331_zJTmlaS86sF8" title="Accumulated other comprehensive loss"&gt;4,312,000&lt;/span&gt;, and $&lt;span id="xdx_904_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_di_c20210331_zRGceQToe0Y1" title="Accumulated other comprehensive loss"&gt;4,579,000&lt;/span&gt; respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-4312000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-4579000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zZIuD7ckLwr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zwNsb8Rp0xj9"&gt;Net Income Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company computes basic net loss per share
by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period
and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution
that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d;
and/or &#x201c;if converted&#x201d; methods as applicable.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zRsXO5wGZkFj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_8B2_zpxwFLCCtP8l" style="display: none"&gt;Computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20210401__20220331_zgB7s2aDRr86" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20200401__20210331_zmixmPzrIO54" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic; text-align: justify"&gt;(In thousands, except per share data)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_zQP4TmgcF8gh" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;Loss from continuing operations&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(5,086&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(4,615&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_pn3n3_d0_zBX7xn3gTW5b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Income  from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;665&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_pn3n3_z5VgTLfopGV1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,086&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,950&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pin3_zYmPWPsI6bP3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average  shares outstanding: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,996&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeLossFromContinuingOperationPerBasicAndDilutedShare_pip0_z02qMOz8gKQ3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Loss per share from continuing operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.92&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.31&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_pip0_d0_zOMu6zBGKfAh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Income  per share from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.33&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EarningPerShareBasicAndDiluted_pip0_zwbOIalyqXZg" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss per share: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The computation of basic loss per share for the
years ended March 31, 2022 and 2021 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_ztvvNLsaRsI5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_z0EjdoIXDfP7" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Common stock to be issued upon vesting of restricted stock units&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zAp9FNVR20Fa" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zQSnEapuGNGe" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zGFCfY6Bzqba" style="text-align: right" title="Antidilutive shares"&gt;466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z9xIv4jNVfIh" style="text-align: right" title="Antidilutive shares"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zALn25cy18v2" style="text-align: right" title="Antidilutive shares"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zq2rNd0ZLsZf" style="text-align: right" title="Antidilutive shares"&gt;119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon conversion of Series C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zpw5wzu3R7z7" style="text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zImGLkNONzYa" style="text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock to be issued upon exercise of common stock units (1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zfQ3iLmWAPAb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_z3MFiQjglZQ1" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331_z74sV2x6BNJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;621&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331_zcYutqb7JmT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 5%"&gt;&lt;span id="xdx_F0B_z5FMj7xzgpCd" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 94%; text-align: justify"&gt;&lt;span id="xdx_F12_zdUEYaIzOBF2" style="font-size: 10pt"&gt;Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zyDhTgPZH63i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zRsXO5wGZkFj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_8B2_zpxwFLCCtP8l" style="display: none"&gt;Computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20210401__20220331_zgB7s2aDRr86" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20200401__20210331_zmixmPzrIO54" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic; text-align: justify"&gt;(In thousands, except per share data)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_pn3n3_zQP4TmgcF8gh" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;Loss from continuing operations&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(5,086&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(4,615&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_pn3n3_d0_zBX7xn3gTW5b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Income  from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;665&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_pn3n3_z5VgTLfopGV1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,086&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,950&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_pin3_zYmPWPsI6bP3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average  shares outstanding: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,653&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,996&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeLossFromContinuingOperationPerBasicAndDilutedShare_pip0_z02qMOz8gKQ3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Loss per share from continuing operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.92&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.31&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare_pip0_d0_zOMu6zBGKfAh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Income  per share from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.33&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EarningPerShareBasicAndDiluted_pip0_zwbOIalyqXZg" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss per share: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-4615000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">665000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5086000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-3950000</us-gaap:NetIncomeLoss>
    <SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">2653000</SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">1996000</SNOA:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.92</SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare>
    <SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-2.31</SNOA:IncomeLossFromContinuingOperationPerBasicAndDilutedShare>
    <SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0</SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare>
    <SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.33</SNOA:IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare>
    <SNOA:EarningPerShareBasicAndDiluted
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.92</SNOA:EarningPerShareBasicAndDiluted>
    <SNOA:EarningPerShareBasicAndDiluted
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.97</SNOA:EarningPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_ztvvNLsaRsI5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_z0EjdoIXDfP7" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Common stock to be issued upon vesting of restricted stock units&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zAp9FNVR20Fa" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zQSnEapuGNGe" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zGFCfY6Bzqba" style="text-align: right" title="Antidilutive shares"&gt;466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z9xIv4jNVfIh" style="text-align: right" title="Antidilutive shares"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zALn25cy18v2" style="text-align: right" title="Antidilutive shares"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zq2rNd0ZLsZf" style="text-align: right" title="Antidilutive shares"&gt;119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock to be issued upon conversion of Series C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zpw5wzu3R7z7" style="text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zImGLkNONzYa" style="text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock to be issued upon exercise of common stock units (1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zfQ3iLmWAPAb" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_z3MFiQjglZQ1" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210401__20220331_z74sV2x6BNJc" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;621&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200401__20210331_zcYutqb7JmT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 5%"&gt;&lt;span id="xdx_F0B_z5FMj7xzgpCd" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 94%; text-align: justify"&gt;&lt;span id="xdx_F12_zdUEYaIzOBF2" style="font-size: 10pt"&gt;Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      unitRef="Shares">1000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      unitRef="Shares">1000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="-3"
      unitRef="Shares">466000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="-3"
      unitRef="Shares">268000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-012022-03-31_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">108000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012021-03-31_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">119000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-012022-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="-3"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012021-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="-3"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-012022-03-31_custom_CommonStockUnitsMember"
      decimals="-3"
      id="Fact000765"
      unitRef="Shares">46000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012021-03-31_custom_CommonStockUnitsMember"
      decimals="-3"
      id="Fact000767"
      unitRef="Shares">46000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="Shares">621000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="Shares">434000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_z3VfIE2uf0X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zUk0jJiaGii2"&gt;Common Stock Purchase Warrants and Other
Derivative Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies common stock purchase warrants
and other free standing derivative financial instruments as equity if the contracts (i) require physical settlement or net-share settlement
or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).
The Company classifies any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if
an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net cash settlement or
settlement in shares (physical settlement or net-share settlement), or (iii) contain reset provisions as either an asset or a liability.
The Company assesses classification of its freestanding derivatives at each reporting date to determine whether a change in classification
between assets and liabilities is required. The Company determined that its freestanding derivatives, which principally consist of warrants
to purchase common stock, satisfied the criteria for classification as equity instruments, other than certain warrants that contained
reset provisions and certain warrants that required net-cash settlement that the Company classified as derivative liabilities. The company
currently does not have any active derivative financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84C_eus-gaap--StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_z5xbRK3EYqgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zth03FqF3sud"&gt;Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies the accounting standards for
distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject
to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally
redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the
holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity.
At all other times, preferred shares are classified as stockholders' equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_849_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zwxMwRMLRIY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zIo7djYjf1Jj"&gt;Subsequent Events&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management has evaluated subsequent events or
transactions occurring through the date these consolidated financial statements were issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcic2ZUgyW01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z8VqGU08W4Bl"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated all the recent accounting
standards and determined that none of them are material to it.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_809_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zRcC4XJsVuA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span id="xdx_821_znALJJPmwWP9"&gt;Sale of Assets &#x2013;
Discontinued Operations&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Sale of Assets to Infinity Labs SD, Inc. and Discontinued Operations&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 24, 2020, the Company closed on an asset
purchase agreement for the sale of its Micromed Laboratories division and testing facility, including all of Micromed&#x2019;s assets,
such as testing equipment, certain office furniture and customer list, with Infinity Labs SD Inc. (&#x201c;Infinity&#x201d;) for an aggregate
purchase price of $850,000. On the closing date, the Company received $610,000 in cash from this sale which was adjusted for working capital,
a credit of $100,000 for future testing services from Infinity over the next two years in lieu of cash, and $60,000 held in escrow for
one year, subject to adjustment for certain indemnity claims or purchase price adjustments. The Company also retained its accounts receivables
outstanding on the date of closing in the amount of approximately $81,000 and an insignificant amount of liabilities. As part of the transaction,
Infinity also assumed the Petaluma lease for the office and lab space. The Company retained the warehouse space to store inventory and
assets until September 30, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Accounting for the disposition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For accounting purposes, the Company determined
that there was only one discrete component of the sale to Infinity. This component was the customer base and related services to be provided.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 20%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Component of Sale&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 80%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Methodology to Estimate Selling Price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Customer Base &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Based upon revenues expected from a market participant to provide technical services at expected service levels&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company determined an arm&#x2019;s length selling
price for each component of the sale and then allocated the net proceeds received to the components on a relative selling price basis.
The Company estimated the selling prices of&#160;each component as described below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Proceeds were allocated to the components of the sale based upon their
relative selling prices are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfAllocationOfSalePriceTableTextBlock_zDepiG3PBW4l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Sale of Assets - Discontinued Operations (Details - Allocation of sale price)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_8BA_zVtlVTsr53b6" style="display: none"&gt;Schedule of allocation of sale price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 84%; text-align: justify"&gt;Customer base&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_iI_pp0p0_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zMHZu6cLDip6" style="width: 13%; text-align: right" title="Customer base"&gt;850,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Less:&#160;Funds remaining in escrow&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zA8OEhbffwTg" style="text-align: right" title="Less: Funds remaining in escrow"&gt;(60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Less:&#160;Services due from buyer&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zmTnMXXkPGWg" style="text-align: right" title="Less: Services due from buyer"&gt;(100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less: Working capital adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zXEXPzywP1Og" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Working capital adjustment"&gt;(80,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total proceeds&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ProceedsFromDivestitureOfBusinesses_c20200401__20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Proceeds from sale of business"&gt;610,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Discontinued operations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 24, 2020, the Company determined that
the sale of its Micromed division to Infinity qualified as a sale of a component of its business and, as such, all such activity prior
to consummation of the sale is required to be included in discontinued operations on the Company&#x2019;s statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;There were no carrying value of the assets and liabilities of discontinued
operations on the consolidated balance sheets as of March 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The operations of the Micromed business included in discontinued operations
is summarized as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zjpUZOSP1Ha4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Sale of Assets - Discontinued Operations (Details - Discontinued Operations)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_z97pWsGLRhSa" style="display: none"&gt;Assets and liabilities of disposal group&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20210401__20220331_z4N6S8MWa0v3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20200401__20210331_zSfTP71LSpdi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_d0_maDGIDOzviC_zxsTEjNmbal3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;214,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_d0_msDGIDOzviC_zCTPMLfSM4Na" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_d0_msDGIDOzviC_zcUZPLRTtrEf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Selling general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_iT_pp0p0_d0_mtDGIDOzviC_maDOILFzWBf_z1GKUibgaP37" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income from discontinued operations before tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_d0_maDOILFzWBf_zEUoslj4DhDj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gain on disposal of discontinued operations before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;770,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_iT_pp0p0_d0_mtDOILFzWBf_maILFDOzvre_zcKXL6QfgXzj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total income from discontinued operations, before tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;893,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_iN_pp0p0_di0_msILFDOzvre_znjlBqAWoor3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Income Tax benefit (expense)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(228,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pp0p0_d0_mtILFDOzvre_zYRzpFjEDl01" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income from discontinued operations, net of tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;665,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <SNOA:ScheduleOfAllocationOfSalePriceTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfAllocationOfSalePriceTableTextBlock_zDepiG3PBW4l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Sale of Assets - Discontinued Operations (Details - Allocation of sale price)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_8BA_zVtlVTsr53b6" style="display: none"&gt;Schedule of allocation of sale price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 84%; text-align: justify"&gt;Customer base&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_iI_pp0p0_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zMHZu6cLDip6" style="width: 13%; text-align: right" title="Customer base"&gt;850,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Less:&#160;Funds remaining in escrow&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zA8OEhbffwTg" style="text-align: right" title="Less: Funds remaining in escrow"&gt;(60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Less:&#160;Services due from buyer&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zmTnMXXkPGWg" style="text-align: right" title="Less: Services due from buyer"&gt;(100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less: Working capital adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital_iNI_pp0p0_di_c20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_zXEXPzywP1Og" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Working capital adjustment"&gt;(80,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total proceeds&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ProceedsFromDivestitureOfBusinesses_c20200401__20200624__us-gaap--DisposalGroupClassificationAxis__custom--MicromedLabsMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Proceeds from sale of business"&gt;610,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</SNOA:ScheduleOfAllocationOfSalePriceTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="AsOf2020-06-24_custom_MicromedLabsMember"
      decimals="0"
      unitRef="USD">850000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="AsOf2020-06-24_custom_MicromedLabsMember"
      decimals="0"
      unitRef="USD">60000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue
      contextRef="AsOf2020-06-24_custom_MicromedLabsMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue>
    <SNOA:DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital
      contextRef="AsOf2020-06-24_custom_MicromedLabsMember"
      decimals="0"
      unitRef="USD">80000</SNOA:DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="From2020-04-012020-06-24_custom_MicromedLabsMember"
      decimals="0"
      unitRef="USD">610000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zjpUZOSP1Ha4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Sale of Assets - Discontinued Operations (Details - Discontinued Operations)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_z97pWsGLRhSa" style="display: none"&gt;Assets and liabilities of disposal group&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20210401__20220331_z4N6S8MWa0v3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20200401__20210331_zSfTP71LSpdi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_d0_maDGIDOzviC_zxsTEjNmbal3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;214,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_d0_msDGIDOzviC_zCTPMLfSM4Na" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_d0_msDGIDOzviC_zcUZPLRTtrEf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Selling general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_iT_pp0p0_d0_mtDGIDOzviC_maDOILFzWBf_z1GKUibgaP37" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income from discontinued operations before tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_d0_maDOILFzWBf_zEUoslj4DhDj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gain on disposal of discontinued operations before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;770,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_iT_pp0p0_d0_mtDOILFzWBf_maILFDOzvre_zcKXL6QfgXzj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total income from discontinued operations, before tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;893,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_iN_pp0p0_di0_msILFDOzvre_znjlBqAWoor3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Income Tax benefit (expense)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(228,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pp0p0_d0_mtILFDOzvre_zYRzpFjEDl01" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income from discontinued operations, net of tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;665,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">214000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">53000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">38000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">123000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">770000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">893000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">228000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">665000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_803_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zRvo8iavcMui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE&#160;5&#160;&#x2013; &lt;span id="xdx_820_zmdfGHaGPV1l"&gt;Accounts Receivable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable, net consists of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zEDejifOY7j8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_zJyLNvxQYP5e" style="display: none"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20220331_z6bs1ZddSP3k" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20210331_z1GuUwyteqpk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCzGH6_z4OOc0u9TBM9" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,488,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;4,419,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di0_msARNCzGH6_zxFa4KsYXg3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(125,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DiscountsRebatesDistributorFeesAndReturns_iNI_pp0p0_di_msARNCzGH6_z5XNRjHcRhw9" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: discounts, rebates, distributor fees and returns&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(81,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,488,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzGH6_zbFmLeoq1e8i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Accounts receivable, net&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,407,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,806,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zEDejifOY7j8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_zJyLNvxQYP5e" style="display: none"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20220331_z6bs1ZddSP3k" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20210331_z1GuUwyteqpk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCzGH6_z4OOc0u9TBM9" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,488,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;4,419,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di0_msARNCzGH6_zxFa4KsYXg3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(125,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DiscountsRebatesDistributorFeesAndReturns_iNI_pp0p0_di_msARNCzGH6_z5XNRjHcRhw9" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: discounts, rebates, distributor fees and returns&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(81,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,488,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCzGH6_zbFmLeoq1e8i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Accounts receivable, net&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,407,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,806,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2488000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">4419000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">125000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <SNOA:DiscountsRebatesDistributorFeesAndReturns contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">81000</SNOA:DiscountsRebatesDistributorFeesAndReturns>
    <SNOA:DiscountsRebatesDistributorFeesAndReturns contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1488000</SNOA:DiscountsRebatesDistributorFeesAndReturns>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2407000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2806000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zRbCQYuiEEh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE&#160;6&#160;&#x2013; &lt;span id="xdx_829_zahmYzWTk8ci"&gt;Inventories&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories consist of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zRU3jnInaWY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BC_zP06Hii7KMr1" style="display: none"&gt;Schedule of inventories&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20220331_zhycOw10rW87" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20210331_zBFAAsXszZ0c" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pp0p0_maINzPTc_zLXMYwxsNlW1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,626,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,670,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pp0p0_maINzPTc_zO9Qp0D4sUa2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,037,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;860,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryNet_iTI_pp0p0_mtINzPTc_z65dJ5Z0l1K4" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Inventories, net&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,663,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,530,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zRU3jnInaWY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BC_zP06Hii7KMr1" style="display: none"&gt;Schedule of inventories&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20220331_zhycOw10rW87" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20210331_zBFAAsXszZ0c" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pp0p0_maINzPTc_zLXMYwxsNlW1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,626,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,670,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pp0p0_maINzPTc_zO9Qp0D4sUa2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,037,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;860,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryNet_iTI_pp0p0_mtINzPTc_z65dJ5Z0l1K4" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Inventories, net&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,663,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,530,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1626000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1670000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1037000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">860000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2663000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2530000</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_802_eus-gaap--OtherCurrentAssetsTextBlock_zaWjC6bCfQy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;7&#160;&#x2013; &lt;span id="xdx_822_zMV3U6agQGs1"&gt;Prepaid Expenses and
Other Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prepaid expenses and other current assets consist
of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zexLbkZ7Ij3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_zIIRrMO3pgq6" style="display: none"&gt;Schedule of prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20220331_zBpjz9EHFzDi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20210331_zwrfO6O7sKB7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;755,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;705,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidTaxes_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax prepaid to Mexican tax authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,371,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;620,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;663,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: rgb(238,238,238); padding-bottom: 2.5pt"&gt;&#160;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,746,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,218,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;











</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zexLbkZ7Ij3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B2_zIIRrMO3pgq6" style="display: none"&gt;Schedule of prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20220331_zBpjz9EHFzDi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20210331_zwrfO6O7sKB7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;755,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;705,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidTaxes_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax prepaid to Mexican tax authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,371,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;620,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;663,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: rgb(238,238,238); padding-bottom: 2.5pt"&gt;&#160;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,746,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,218,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">755000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">705000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidTaxes contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2371000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1850000</us-gaap:PrepaidTaxes>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">620000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">663000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">3746000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3218000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_806_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_ztRwaluJTAk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;8&#160;&#x2013; &lt;span id="xdx_827_zhOVDfNfSIR1"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment consists of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--PropertyPlantAndEquipmentTextBlock_zW5jMmMkM8Ig" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BE_zdb8YMwOM2Dg" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20220331_zf2bZXpoLYH3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20210331_zzKHeGMO06k9" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGzTcR_zRLtBPIUJok8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Manufacturing, lab, and other equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,281,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,170,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0p0_maPPAEGzTcR_zJNBwvfgBcv2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAEGzTcR_zqPximMIx3g7" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LeaseholdImprovementsGross_iI_pp0p0_maPPAEGzTcR_zNwqMUhS56Li" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;503,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;486,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGzTcR_maPPAENzONv_z4KLBr1xciwl" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="color: rgb(238,238,238)"&gt;Property and equipment, gross&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,031,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,831,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzONv_zEFHP6YBQpof" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,711,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,471,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzONv_zFuVsqt4oxV7" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="color: rgb(238,238,238); padding-bottom: 2.5pt"&gt;Property and equipment, net&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;320,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;360,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation and amortization expense amounted
to $&lt;span id="xdx_90E_eus-gaap--DepreciationAndAmortization_c20210401__20220331_pp0p0" title="Depreciation and amortization"&gt;186,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DepreciationAndAmortization_c20200401__20210331_pp0p0" title="Depreciation and amortization"&gt;227,000&lt;/span&gt; for the years ended March 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--PropertyPlantAndEquipmentTextBlock_zW5jMmMkM8Ig" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BE_zdb8YMwOM2Dg" style="display: none"&gt;Schedule of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20220331_zf2bZXpoLYH3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20210331_zzKHeGMO06k9" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGzTcR_zRLtBPIUJok8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Manufacturing, lab, and other equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,281,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,170,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentOther_iI_pp0p0_maPPAEGzTcR_zJNBwvfgBcv2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FurnitureAndFixturesGross_iI_pp0p0_maPPAEGzTcR_zqPximMIx3g7" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LeaseholdImprovementsGross_iI_pp0p0_maPPAEGzTcR_zNwqMUhS56Li" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;503,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;486,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGzTcR_maPPAENzONv_z4KLBr1xciwl" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="color: rgb(238,238,238)"&gt;Property and equipment, gross&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,031,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,831,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzONv_zEFHP6YBQpof" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,711,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,471,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzONv_zFuVsqt4oxV7" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="color: rgb(238,238,238); padding-bottom: 2.5pt"&gt;Property and equipment, net&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;320,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;360,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1281000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1170000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOther contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">139000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">109000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">108000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">66000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">503000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">486000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2031000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1831000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1711000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1471000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">320000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">360000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">186000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">227000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80C_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zkZcmG6SMIdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;9&#160;&#x2013; &lt;span id="xdx_825_zCW1jyqQtYac"&gt;Accrued Expenses and
Other Current Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accrued expenses and other current liabilities
consist of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zGDRfarYZHJ7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zIVGEqj7s9i4" style="display: none"&gt;Schedule of accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20220331_zgMgwi4W5bw7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20210331_zoXHv3sBp8da" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAz40k_zzEBlahCGuE1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Salaries and related costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,059,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;787,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAz40k_zS6K15J1Cfph" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;784,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;367,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pp0p0_mtAPAOAz40k_zEygzqqwz6ia" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Accrued expenses and other current liabilities&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,843,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,154,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zGDRfarYZHJ7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BD_zIVGEqj7s9i4" style="display: none"&gt;Schedule of accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20220331_zgMgwi4W5bw7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20210331_zoXHv3sBp8da" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAz40k_zzEBlahCGuE1" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Salaries and related costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,059,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;787,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAz40k_zS6K15J1Cfph" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;784,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;367,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pp0p0_mtAPAOAz40k_zEygzqqwz6ia" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Accrued expenses and other current liabilities&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,843,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,154,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1059000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">787000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">784000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">367000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1843000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1154000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:LongTermDebtTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_808_eus-gaap--LongTermDebtTextBlock_zQpb4v1Hd8gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;10&#160;&#x2013; &lt;span id="xdx_827_zpQMMfsd38kb"&gt;Debt&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Financing of Insurance Premiums&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 1, 2021, the Company entered into
a note agreement for $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zQJTq8bkAug"&gt;584,000
&lt;/span&gt;with an interest rate of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210125__20210131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zbJAmrtAVsuj"&gt;4.98&lt;/span&gt;%
per annum with final payment on October 1, 2021. This instrument was issued in connection with financing insurance premiums. The note
was payable in three quarterly installment payments of principal and interest of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20210401__20211001__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums1Member_zovrkV3sSHa"&gt;199,000&lt;/span&gt;,
with the first installment beginning April 1, 2021. These amounts were paid off during the year ended March 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 1, 2022, the Company entered into
a note agreement for $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zJ0Q6KbxHNa9" title="Debt face amount"&gt;748,000&lt;/span&gt; with an interest rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220125__20220131__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zTTlnUb02FRi" title="Debt interest rate"&gt;4.68&lt;/span&gt;% per annum with final payment on January 1, 2023. This instrument was issued
in connection with financing insurance premiums. The note is payable in ten monthly installment payments of principal and interest of
$&lt;span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20220301__20231231__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiums2Member_zf4SeECarcg4" title="Principal payments made"&gt;76,000&lt;/span&gt;, with the first installment beginning March 1, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Paycheck Protection Program Loan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 1, 2020, the Company received loan proceeds
in the amount of $&lt;span id="xdx_905_eus-gaap--ProceedsFromLoans_pp0p0_c20200425__20200501__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zpKGkoHG1rc5" title="Proceeds from loan"&gt;1,310,000&lt;/span&gt; under the Paycheck Protection Program (&#x201c;PPP&#x201d;), from Coastal States Bank in Atlanta, Georgia. The
PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, &#x201c;CARES Act&#x201d;, provides for loans to qualifying
businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest
are forgivable after eight or 24 weeks as long as the Company uses the loan proceeds for eligible purposes, including payroll, benefits,
rent and utilities, and maintains payroll levels. The amount of loan forgiveness will be reduced if the Company terminated employees or
reduced salaries during the applicable period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The unsecured loan, which is in the form of a
note dated April 29, 2020, matures on &lt;span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20210401__20220331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_zPlH4lMypSK6" title="Debt maturity date"&gt;April 29, 2022&lt;/span&gt; and bears interest at a rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210401__20220331__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StatesBankInAtlantaMember_z8fwqABcnZk3" title="Debt interest rate"&gt;1&lt;/span&gt;% per annum, payable monthly commencing on May 1,
2021. The note may be prepaid at any time prior to maturity with no prepayment penalties. The Company has used the loan amount for eligible
purposes, such as payroll expenses. The Company met the conditions for $&lt;span id="xdx_909_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20210401__20220331_zEOHeyAOrcpa" title="Approval for forgiveness"&gt;723,000&lt;/span&gt; in forgiveness of the loan. At March 31, 2022 and  2021 the loan balance amounted to $&lt;span id="xdx_903_eus-gaap--LoansPayable_iI_c20220331_zljo3x16dLC9" title="Loans payable"&gt;120,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--LoansPayable_iI_c20210331_z0a7IYXh7HIk"&gt;1,310,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-01-31_custom_InsurancePremiums1Member"
      decimals="0"
      unitRef="USD">584000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-01-252021-01-31_custom_InsurancePremiums1Member"
      decimals="INF"
      unitRef="Pure">0.0498</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2021-04-012021-10-01_custom_InsurancePremiums1Member"
      decimals="0"
      unitRef="USD">199000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-01-31_custom_InsurancePremiums2Member"
      decimals="0"
      unitRef="USD">748000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2022-01-252022-01-31_custom_InsurancePremiums2Member"
      decimals="INF"
      unitRef="Pure">0.0468</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2022-03-012023-12-31_custom_InsurancePremiums2Member"
      decimals="0"
      unitRef="USD">76000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ProceedsFromLoans
      contextRef="From2020-04-252020-05-01_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember"
      decimals="0"
      unitRef="USD">1310000</us-gaap:ProceedsFromLoans>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-04-012022-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember">2022-04-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-04-012022-03-31_custom_PaycheckProtectionProgramMember_custom_StatesBankInAtlantaMember"
      decimals="INF"
      unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">723000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:LoansPayable contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">120000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1310000</us-gaap:LoansPayable>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_808_eus-gaap--LesseeOperatingLeasesTextBlock_zDbCO4iFaBc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;11&#160;&#x2013; &lt;span id="xdx_825_z20vjlEXVTyd"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s operating leases are comprised
primarily of facility leases. Balance sheet information related to the Company&#x2019;s leases is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zHpv9Ch3nhA" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_8B5_zgjgIMzk1EKl" style="display: none"&gt;Lease cost information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20220331_zUP5ouNOgUD5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20210331_zPHYAuYgSGL4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LeasesOperatingAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;559,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;769,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;240,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;529,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Other information related to leases is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year ended&lt;br/&gt; March 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseCost_c20210401__20220331_pp0p0" style="width: 13%; text-align: right"&gt;367,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--OperatingLeaseCost_pp0p0_c20200401__20210331_zG7hzOy5BJ3a" style="text-align: right; width: 13%"&gt;435,000&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;As of March 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Other information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20210401__20220331_z35iuhcsLCIj" style="text-align: right"&gt;(223,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20200401__20210331_zURqMKrkpyW1" style="text-align: right"&gt;(215,000&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average remaining lease term &#x2013; operating leases (in months)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220331_znLaPUYaszJ2" title="Weighted-average remaining lease term - operating leases (in months)"&gt;27.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20210331_zsNppxdqe5me"&gt;37.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220331_zS9Y4njkNw77" title="Weighted-average discount rate - operating leases"&gt;6.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20210331_zhoZjWPcAFc9"&gt;6.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zoukrhei48g3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 180.1pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of March 31, 2022, the annual future minimum lease payments of
the Company&#x2019;s operating lease liabilities were as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zqhCF8SPPeB9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease liabilities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B5_zy4v7mNQTqza" style="display: none"&gt;Schedule of minimum operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220331_zxGiy09tRUwh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;For Years Ending March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzgSf_zKNEfSx9HDL3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 84%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;297,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzgSf_z4i1UNi7T6ve" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzgSf_zRkCyd0nldLf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzgSf_zRPwdShP9MD2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzgSf_zWYrPtLzbS29" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments, undiscounted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;627,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zxP1sj7Y5o6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(68,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;559,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;













</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zHpv9Ch3nhA" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_8B5_zgjgIMzk1EKl" style="display: none"&gt;Lease cost information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20220331_zUP5ouNOgUD5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20210331_zPHYAuYgSGL4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LeasesOperatingAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;559,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;769,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;240,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;529,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Other information related to leases is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year ended&lt;br/&gt; March 31, 2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseCost_c20210401__20220331_pp0p0" style="width: 13%; text-align: right"&gt;367,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--OperatingLeaseCost_pp0p0_c20200401__20210331_zG7hzOy5BJ3a" style="text-align: right; width: 13%"&gt;435,000&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;As of March 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Other information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20210401__20220331_z35iuhcsLCIj" style="text-align: right"&gt;(223,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--OperatingLeasePaymentsUse_iN_pp0p0_di_c20200401__20210331_zURqMKrkpyW1" style="text-align: right"&gt;(215,000&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average remaining lease term &#x2013; operating leases (in months)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220331_znLaPUYaszJ2" title="Weighted-average remaining lease term - operating leases (in months)"&gt;27.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20210331_zsNppxdqe5me"&gt;37.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220331_zS9Y4njkNw77" title="Weighted-average discount rate - operating leases"&gt;6.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20210331_zhoZjWPcAFc9"&gt;6.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">559000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">769000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">250000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">240000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">309000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">529000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">367000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">435000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">223000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">215000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-03-31">P27M9D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2021-03-31">P37M21D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-03-31" decimals="INF" unitRef="Pure">0.0600</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2021-03-31" decimals="INF" unitRef="Pure">0.0600</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zqhCF8SPPeB9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease liabilities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B5_zy4v7mNQTqza" style="display: none"&gt;Schedule of minimum operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220331_zxGiy09tRUwh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;For Years Ending March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzgSf_zKNEfSx9HDL3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 84%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;297,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzgSf_z4i1UNi7T6ve" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzgSf_zRkCyd0nldLf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzgSf_zRPwdShP9MD2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzgSf_zWYrPtLzbS29" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments, undiscounted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;627,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zxP1sj7Y5o6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(68,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;559,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">297000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">210000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">106000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">14000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">627000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">68000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">559000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zuG2q61SYw04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;12&#160;&#x2013; &lt;span id="xdx_823_z64C91qtLhjl"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Legal Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On occasion, the Company may be involved in legal
matters arising in the ordinary course of business including matters involving proprietary technology. While management believes that
such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become
involved in litigation may have a material adverse effect on its business and financial condition of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2022, the Company had employment
agreements in place with three of its key executives. These executive employment agreements provide, among other things, for the payment
of up to twelve months of severance compensation for terminations under certain circumstances. With respect to these agreements, at March
31, 2022, aggregated annual salaries would be $&lt;span id="xdx_90C_eus-gaap--SalariesAndWages_c20210401__20220331_pp0p0" title="Annual salaries"&gt;775,000&lt;/span&gt; and potential severance payments to these key executives would be $&lt;span id="xdx_908_eus-gaap--SeveranceCosts1_c20210401__20220331_pp0p0" title="Potential severance"&gt;775,000&lt;/span&gt; if triggered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Related Party Transactions&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Ms. Trombly was appointed the Chief Executive
Officer of the Company. Ms. Trombly is the owner of Trombly Business Law, PC which has been retained by the Company to advise on certain
corporate and securities law matters. During the years ending March 31, 2022 and  2021, the Company received $&lt;span id="xdx_900_eus-gaap--LegalFees_c20210401__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_pp0p0" title="Legal fees"&gt;170,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--LegalFees_pp0p0_c20200401__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TromblyBusinessLawMember_zwI4l1ctc8kf" title="Legal fees"&gt;215,000&lt;/span&gt;,
respectively, in legal services from Trombly Business Law, PC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SalariesAndWages
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">775000</us-gaap:SalariesAndWages>
    <us-gaap:SeveranceCosts1
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">775000</us-gaap:SeveranceCosts1>
    <us-gaap:LegalFees
      contextRef="From2021-04-012022-03-31_custom_TromblyBusinessLawMember"
      decimals="0"
      unitRef="USD">170000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2020-04-012021-03-31_custom_TromblyBusinessLawMember"
      decimals="0"
      unitRef="USD">215000</us-gaap:LegalFees>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zZFHN06SH8xa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;13&#160;&#x2013; &lt;span id="xdx_826_zQLLTQi1rDCl"&gt;Stockholders&#x2019;
Equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Authorized Capital&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective September 13, 2018, the Company filed
a certificate of amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware
in order to affect an increase of the total number of shares of common stock, $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20220331_pdd" title="Common stock par value"&gt;0.0001&lt;/span&gt; par value per share, authorized for issuance from
12,000,000 to a total of &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20220331_pdd" title="Common stock, shares authorized"&gt;24,000,000&lt;/span&gt;. Additionally, the Company is authorized to issue &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Preferred stock, shares authorized"&gt;714,286&lt;/span&gt; shares of convertible preferred stock with
a par value of $&lt;span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" title="Preferred stock par value"&gt;0.0001&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Description of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Each share of common stock has the right to one
vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Description of Series B Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 18, 2016, the Company&#x2019;s board
of directors approved, and the Company entered into, a Section 382 rights agreement, or the Rights Agreement, with Computershare Inc.,
or the Rights Agent. The Rights Agreement provides for a dividend of one preferred stock purchase right, or a Right, for each share of
common stock, par value $0.0001 per share, of the Company outstanding on November 1, 2016, or the Record Date. Each Right entitles the
holder to purchase from the Company one one-thousandth of a share of Series B Preferred Stock, par value $0.0001 per share, or the Preferred
Stock, for a purchase price of $10.00, subject to adjustment as provided in the Rights Agreement. The description and terms of the rights
are set forth in the Rights Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the adoption of the Rights
Agreement, the Company&#x2019;s board of directors adopted a Certificate of Designation of Series B Preferred Stock. The Certificate of
Designation was filed with the Secretary of State of the State of Delaware and became effective on October 18, 2016.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s board of directors adopted
the Rights Agreement to protect shareholder value by guarding against a potential limitation on the Company&#x2019;s ability to use its
net operating loss carryforwards, or NOLs, and other tax benefits, which may be used to reduce potential future income tax obligations.
The Company has experienced and continue to experience substantial operating losses, and under the Internal Revenue Code of 1986, as amended,
and rules promulgated thereunder, the Company may &#x201c;carry forward&#x201d; these NOLs and other tax benefits in certain circumstances
to offset any current and future earnings and thus reduce our income tax liability, subject to certain requirements and restrictions.
To the extent that the NOLs and other tax benefits do not otherwise become limited, the Company believes that it will be able to carry
forward a significant amount of NOLs and other tax benefits, and therefore these NOLs and other tax benefits could be a substantial asset
to the Company. However, if the Company experiences an &#x201c;ownership change,&#x201d; as defined in Section 382 of the Code, its ability
to use its NOLs and other tax benefits will be substantially limited. Generally, an ownership change would occur if our shareholders who
own, or are deemed to own, 5% or more of the Company&#x2019;s common stock increase their collective ownership in the Company by more than
50% over a rolling three-year period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Exercise of Series C Preferred Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended March 31, 2021, investors
who participated in the November 21, 2018 offering exchanged &lt;span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20210401__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z19ZFBopJyGd" title="Preferred stock converted"&gt;1.55&lt;/span&gt; shares of Series C into &lt;span id="xdx_908_eus-gaap--ConversionOfStockSharesIssued1_c20210401__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Common stock issued upon conversion"&gt;17,222&lt;/span&gt; shares of common stock. No further shares
of Series C are outstanding as of March 31, 2021 or 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">24000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">714286</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2021-04-012022-03-31_us-gaap_SeriesCPreferredStockMember44329203"
      decimals="INF"
      unitRef="Shares">1.55</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2021-04-012022-03-31_us-gaap_SeriesCPreferredStockMember44329203"
      decimals="INF"
      unitRef="Shares">17222</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zhP2zjcosJze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE&#160;14&#160;&#x2013; &lt;span id="xdx_82D_zqpuJvESPs7f"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2006 Stock Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The board initially adopted the 2006 Stock Incentive
Plan on August 25, 2006. On December&#160;14, 2006, the stockholders approved the 2006 Stock Incentive Plan which became effective at
the close of the Company&#x2019;s initial public offering. The 2006 Stock Incentive Plan was later amended and restated by a unanimous
board resolution on April&#160;26, 2007, and such amendments were subsequently approved by the stockholders. On September 10, 2009, the
Company&#x2019;s shareholders approved a subsequent amendment to the 2006 Stock Incentive Plan. The 2006 Stock Incentive Plan, as amended
and restated, is hereafter referred to as the &#x201c;2006 Plan.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2006 Plan provided for the granting of incentive
stock options to employees and the granting of non-statutory stock options to employees, non-employee directors, advisors and consultants.
The 2006 Plan also provided for grants of restricted stock, stock appreciation rights and stock unit awards to employees, non-employee
directors, advisors and consultants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with the 2006 Plan the stated exercise
price may not be less than 100% and 85% of the estimated fair market value of common stock on the date of grant for ISOs and NSOs, respectively,
as determined by the board of directors at the date of grant. With respect to any 10% stockholder, the exercise price of an ISO or NSO
shall not be less than 110% of the estimated fair market value per share on the date of grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Options issued under the 2006 Plan generally have
a ten-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At March 31, 2021, there were &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_zcYztFQvJq4e" title="Shares available for future issuance"&gt;no&lt;/span&gt; shares available
for future issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2011 Stock Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 12, 2011, upon recommendation of
the board, the stockholders approved the Company&#x2019;s 2011 Stock Incentive Plan (the &#x201c;2011 Plan&#x201d;). The 2011 Plan is effective
as of June 21, 2012.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2011 Plan provides for the grant of incentive
stock options as defined in Section 422 of the Internal Revenue Code to employees, and the grant of non-statutory stock options and stock
purchase rights to employees, non-employee directors, advisors and consultants. The 2011 Plan also permits the grant of stock appreciation
rights, stock units and restricted stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The board has initially authorized &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20110912__us-gaap--PlanNameAxis__custom--Plan2011Member_zySRVCm0C9L9" title="Shares initially authorized for issuance"&gt;9,508&lt;/span&gt; of the
Company&#x2019;s common stock for issuance under the 2011 Plan, in addition to automatic increases provided for in the 2011 Plan through
April 1, 2021. The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2011 Plan will automatically increase,
with no further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 15% of the outstanding
shares of the Company&#x2019;s common stock on the last day of the immediately preceding year, or (ii) an amount approved by the Company&#x2019;s
board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Options issued under the 2011 Plan will generally
have a ten-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with the 2011 Plan, the stated exercise
price of an employee incentive stock option shall not be less than 100% of the estimated fair market value of a share of common stock
on the date of grant, and the stated exercise price of an non-statutory option shall not be less 85% of the estimated fair market value
of a share of common stock on the date of grant, as determined by the board of directors. An employee who owns more than 10% of the total
combined voting power of all classes of outstanding stock of the Company shall not be eligible for the grant of an employee incentive
stock option unless such grant satisfies the requirements of Section 422(c)(5) of the Internal Revenue Code.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2011 Plan. No participant in the
2011 Plan can receive option grants, stock appreciation rights, restricted shares, or stock units for more than 2,381 shares in the aggregate
in any calendar year. As provided under the 2011 Plan, the aggregate number of shares authorized for issuance as awards under the 2011
Plan automatically increases on April 1 of each year by in an amount equal to the lesser of (i) 15% of the outstanding shares on the last
day of the immediately preceding year, or (ii) an amount determined by the board. During the year ended March 31, 2019, the board of directors
approved an increase of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" title="Increase in shares authorized for issuance"&gt;102,863&lt;/span&gt; shares authorized for issuance. During the year ended March 31, 2020, the board of directors approved
an increase of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20200401__20210331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" title="Increase in shares authorized for issuance"&gt;197,450&lt;/span&gt; shares authorized for issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The plan expired on September 12, 2021 in accordance
with its term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At March 31, 2022, there were &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_do_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_zz8FD1I8w2Ef" title="Shares available for future issuance"&gt;no&lt;/span&gt; shares available
for future issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2016 Stock Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 2, 2016, upon recommendation of the
board, the stockholders approved the Company&#x2019;s 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;). The 2016 Plan is effective
as of September 2, 2016.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2016 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Options issued under the 2016 Plan will generally
have a ten-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with the 2016 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2016 Plan. No participant in the
2016 Plan can receive more than 11,112 option grants, or other awards with respect to more than 13,334 shares in the aggregate in any
calendar year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The board has authorized &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160902__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" title="Shares initially authorized for issuance"&gt;44,445&lt;/span&gt; of the Company&#x2019;s
common stock for issuance under the 2016 Plan, in addition to automatic increases provided for in the 2016 Plan through April 1, 2026.
The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2016 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 8% of the outstanding
shares of the Company&#x2019;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#x2019;s
board of directors. During the year ended March 31, 2019, the board of directors approved an increase of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2016Member_zr9jidES3M8g" title="Increase in shares authorized for issuance"&gt;4,860&lt;/span&gt; shares authorized for issuance.
During the year ended March 31, 2020, the board of directors approved an increase of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2016Member_zM9WTHLlebV3" title="Increase in shares authorized for issuance"&gt;105,306&lt;/span&gt; shares authorized for issuance. During the
year ended March 31, 2022, the board of directors approved an increase of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20210401__20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zgvz8PxehSyj" title="Increase in shares authorized for issuance"&gt;167,432&lt;/span&gt; shares authorized for issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At March 31, 2022 there were &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zTgnKMlbDfF3" title="Shares available for future issuance"&gt;112,106&lt;/span&gt; shares available
for future issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2021 Stock Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 21, 2021, upon recommendation of
the board, the stockholders approved the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan is effective
as of September 21, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2021 Plan provides for the grant of options,
including incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted
awards, performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Options issued under the 2021 Plan will generally
have a ten-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with the 2021 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Shares subject to awards that expire unexercised
or are forfeited or terminated for any other reason will again become available for issuance under the 2021 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The board has authorized &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20200401__20210331__us-gaap--PlanNameAxis__custom--Plan2021Member_zhfQ8mlixOsd" title="Increase in shares authorized for issuance"&gt;1,000,000&lt;/span&gt; shares of the
Company&#x2019;s common stock for issuance under the 2021 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At March 31, 2022, there were &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220331__us-gaap--PlanNameAxis__custom--Plan2021Member_z3G9lPD2j6Uc" title="Shares available for future issuance"&gt;869,999&lt;/span&gt; shares available
for future issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issues service, performance and market-based
stock options to employees and non-employees. The Company estimates the fair value of service and performance stock option awards using
the Black-Scholes option pricing model. The Company estimates the fair value of market-based stock option awards using a Monte-Carlo simulation.
Compensation expense for stock option awards is amortized on a straight-line basis over the awards&#x2019; vesting period. Compensation
expense includes the impact of forfeitures as they are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The expected term of the stock options represents
the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach
prescribed by&#160;the Securities&#160;and Exchange Commission's Staff Accounting Bulletin No.&#160;110 for &#x201c;plain vanilla&#x201d;
options. The expected stock price volatility for the Company&#x2019;s stock options was determined by using an average of the historical
volatilities of the Company and its industry peers. The Company will continue to analyze the stock price volatility and expected term
assumptions as more data for the Company&#x2019;s common stock and exercise patterns become available. The risk-free interest rate assumption
is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#x2019;s stock options. The expected
dividend assumption is based on the Company&#x2019;s history and expectation of dividend payouts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company estimated the fair value of employee
and non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized
on a straight-line basis over the requisite service periods of the respective awards. The fair value of employee stock options was estimated
using the following weighted-average assumptions:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zx4slDOadTV1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B6_zOwgBdab50ae" style="display: none"&gt;Weighted-average assumptions of fair value of employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Fair value of the Company&#x2019;s common stock on date of grant&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331_pdd" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant"&gt;4.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331_pdd" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant"&gt;8.03&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331_zNTnFN5LZlkf" title="Expected term"&gt;6.00&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331_zIUDvpXnvw25" title="Expected term"&gt;6.00&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331_zpSQNOTt3tvh" title="Risk-free interest rate"&gt;1.60&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20210331_zs2PIM3k0umi" title="Risk-free interest rate"&gt;0.5800&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210401__20220331_z0385HWI6YS6" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200401__20210331_zOJxjyqx14cf" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331_zpGP0jQO90Ji" title="Volatility"&gt;123.27&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20210331_zSP1gKMGh9Yh" title="Volatility"&gt;80.7&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value of options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331_pdd" style="text-align: right" title="Fair value of options granted, per share"&gt;4.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200401__20210331_pdd" style="text-align: right" title="Fair value of options granted, per share"&gt;5.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Share-based awards compensation expense is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqbYGhIavS6l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Stock-based compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B5_zqCTUmWFDUYi" style="display: none"&gt;Employee stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%"&gt;Cost of revenues&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zVSg8YnpOKR8" style="width: 13%; text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_pp0p0" style="width: 13%; text-align: right" title="Total stock-based compensation"&gt;(27,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zb70l00hndJf" style="text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total stock-based compensation"&gt;26,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;382,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;372,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_c20210401__20220331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;382,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_c20200401__20210331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;371,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At March 31, 2022, there were unrecognized compensation
costs of $&lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Unrecognized compensation costs"&gt;1,325,000&lt;/span&gt; related to stock options which is expected to be recognized over a weighted-average amortization period of &lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zepHfdjzt6c6" title="Weighted average amortization period"&gt;2.14&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A tax benefit of $&lt;span id="xdx_90B_eus-gaap--UnrecognizedTaxBenefits_c20220331_pp0p0" title="Tax benefit"&gt;54,000&lt;/span&gt; has been recognized relating
to stock-based compensation as a result of non-qualified stock options and restricted stock exercised during the year ending March 31,
2022. In addition, the stock-based compensation deferred tax asset has been reduced by $&lt;span id="xdx_901_eus-gaap--IncreaseDecreaseInDeferredCharges_c20210401__20220331_pp0p0" title="Decrease in stock based compensation deferred tax asset"&gt;309,000&lt;/span&gt; primarily related to the expiration of
stock compensation grants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Award Activity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock-based awards outstanding at March 31, 2022
under the various plans are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zYhBjx8rFIT4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_zN2yxi0bx2f" style="display: none"&gt;Schedule of stock-based awards outstanding by plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unvested&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Plan&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Restricted Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 52%"&gt;2006 Plan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_pdd" style="width: 13%; text-align: right" title="Options outstanding"&gt;2,787&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_zZvbDJbXFYMj" style="width: 13%; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_pdd" style="width: 13%; text-align: right" title="Total options and restricted stock units outstanding"&gt;2,787&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;2011 Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" style="text-align: right" title="Options outstanding"&gt;111,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_zDEx7OaHmGM6" style="text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" style="text-align: right" title="Total options and restricted stock units outstanding"&gt;111,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;2016 Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" style="text-align: right" title="Options outstanding"&gt;221,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zehALydc64Wb" style="text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" style="text-align: right" title="Total options and restricted stock units outstanding"&gt;221,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;2021 Plan&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;130,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_zZhhEtnY9Wua" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding"&gt;130,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;466,234&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331_zNfWEZWyGVC1" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding"&gt;466,234&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based awards available for grant as of March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based awards available for grant"&gt;982,105&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock options award activity is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zir3aMqibCs7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B7_zIjDLy19hG2d" style="display: none"&gt;Schedule of option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual Term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 44%"&gt;Outstanding at April 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU9tM3PP1eza" style="width: 11%; text-align: right" title="Number of Shares Outstanding at beginning of period"&gt;267,569&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVjk6YVhmDh9" style="width: 11%; text-align: right" title="Weighted- Average Exercise Price Outstanding at beginning of period"&gt;25.16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKVzXBFJQQyd" style="text-align: right" title="Number of Shares Granted"&gt;272,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZwqf2Bm6Yo1" style="text-align: right" title="Weighted- Average Exercise Price Granted"&gt;4.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxYAlx53fgYd" style="text-align: right" title="Number of Shares Exercised"&gt;(44,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHZG9u7arrH5" style="text-align: right" title="Weighted- Average Exercise Price Exercised"&gt;4.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zt4hIQCJQ1Rb" style="text-align: right" title="Number of Shares Forfeited"&gt;(5,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUmM96xfRBCj" style="text-align: right" title="Weighted- Average Exercise Price Forfeited"&gt;6.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2RUQku8FPt5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Expired"&gt;(25,001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCggLX24sywa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- Average Exercise Price Expired"&gt;84.83&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLldnrByxlI2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Outstanding at end of period"&gt;466,234&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlAh44K59jq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding at end of period"&gt;12.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zn27k069GNxl" title="Weighted- Average Contractual Term Outstanding at end of period"&gt;8.89&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuN2ExoOhNle" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding at end of period"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2LzLbNGgd85" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Exercisable at end of period"&gt;115,144&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1uHcDyN8AU9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Exercisable at end of period"&gt;32.56&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrpT3dYCyRs1" title="Weighted- Average Contractual Term Exercisable at end of period"&gt;6.85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zl7tfubcGOkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable at end of period"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate intrinsic value of stock
options is calculated as the difference between the exercise price of the underlying stock options and the fair value of the
Company&#x2019;s common stock, or $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Aggregate intrinsic value per share"&gt;4.01&lt;/span&gt;
and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20200401__20210331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCKFWRYes4oe"&gt;7.43&lt;/span&gt; per share at March 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Restricted stock award activity is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z0PMmUQt8vd6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zb8K18jPPAN1" style="display: none"&gt;Schedule of unvested restricted stock activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Average Award&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Unvested restricted stock awards outstanding at April 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOazG785cVV" style="width: 13%; text-align: right" title="Unvested restricted stock awards, beginning balance"&gt;833&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIQ6aS3cGMU2" style="width: 13%; text-align: right" title="Weighted average award date fair value per share, outstanding beginning balance"&gt;13.68&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock awards granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="text-align: right" title="Restricted stock awards granted"&gt;1,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="text-align: right" title="Weighted average award date fair value per share, granted"&gt;3.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Restricted stock awards vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zH38ybfBvZJc" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted stock awards vested"&gt;(2,429&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average award date fair value per share, vested"&gt;6.70&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Unvested restricted stock awards outstanding at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpbGEFrRfWm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested restricted stock awards, ending balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvtOTx7hV8tg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average award date fair value per share, outstanding ending balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company did not capitalize any cost associated with stock-based
compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issues new shares of common stock
upon exercise of stock options or release of restricted stock awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-03-31_custom_Plan2006Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2011-09-12_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">9508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2018-04-012019-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">102863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2020-04-012021-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">197450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2016-09-02_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">44445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2018-04-012019-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">4860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2019-04-012020-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">105306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2021-04-012022-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">167432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">112106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2020-04-012021-03-31_custom_Plan2021Member"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-03-31_custom_Plan2021Member"
      decimals="INF"
      unitRef="Shares">869999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zx4slDOadTV1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B6_zOwgBdab50ae" style="display: none"&gt;Weighted-average assumptions of fair value of employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Fair value of the Company&#x2019;s common stock on date of grant&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331_pdd" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant"&gt;4.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331_pdd" style="width: 13%; text-align: right" title="Fair value of common stock on date of grant"&gt;8.03&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20220331_zNTnFN5LZlkf" title="Expected term"&gt;6.00&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331_zIUDvpXnvw25" title="Expected term"&gt;6.00&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331_zpSQNOTt3tvh" title="Risk-free interest rate"&gt;1.60&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20210331_zs2PIM3k0umi" title="Risk-free interest rate"&gt;0.5800&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210401__20220331_z0385HWI6YS6" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200401__20210331_zOJxjyqx14cf" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331_zpGP0jQO90Ji" title="Volatility"&gt;123.27&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20210331_zSP1gKMGh9Yh" title="Volatility"&gt;80.7&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value of options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331_pdd" style="text-align: right" title="Fair value of options granted, per share"&gt;4.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200401__20210331_pdd" style="text-align: right" title="Fair value of options granted, per share"&gt;5.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">4.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">8.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-04-01to2022-03-31">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-04-012021-03-31">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0.005800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">1.2327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0.807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">4.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">5.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zqbYGhIavS6l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Stock-based compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B5_zqCTUmWFDUYi" style="display: none"&gt;Employee stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%"&gt;Cost of revenues&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pp0p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zVSg8YnpOKR8" style="width: 13%; text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_pp0p0" style="width: 13%; text-align: right" title="Total stock-based compensation"&gt;(27,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pp0p0_d0_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zb70l00hndJf" style="text-align: right" title="Total stock-based compensation"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="text-align: right" title="Total stock-based compensation"&gt;26,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_c20210401__20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;382,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_c20200401__20210331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation"&gt;372,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_c20210401__20220331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;382,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_c20200401__20210331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation"&gt;371,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012022-03-31_us-gaap_CostOfSalesMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_CostOfSalesMember"
      decimals="0"
      unitRef="USD">-27000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">26000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012022-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">382000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">372000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">382000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">371000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">1325000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562">P2Y1M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">54000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">309000</us-gaap:IncreaseDecreaseInDeferredCharges>
    <SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zYhBjx8rFIT4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_zN2yxi0bx2f" style="display: none"&gt;Schedule of stock-based awards outstanding by plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unvested&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Plan&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Restricted Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 52%"&gt;2006 Plan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_pdd" style="width: 13%; text-align: right" title="Options outstanding"&gt;2,787&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_zZvbDJbXFYMj" style="width: 13%; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2006Member_pdd" style="width: 13%; text-align: right" title="Total options and restricted stock units outstanding"&gt;2,787&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;2011 Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" style="text-align: right" title="Options outstanding"&gt;111,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_zDEx7OaHmGM6" style="text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2011Member_pdd" style="text-align: right" title="Total options and restricted stock units outstanding"&gt;111,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;2016 Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" style="text-align: right" title="Options outstanding"&gt;221,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zehALydc64Wb" style="text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_pdd" style="text-align: right" title="Total options and restricted stock units outstanding"&gt;221,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;2021 Plan&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;130,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_zZhhEtnY9Wua" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331__us-gaap--PlanNameAxis__custom--Plan2017Member_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding"&gt;130,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;466,234&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_d0_c20220331_zNfWEZWyGVC1" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units outstanding"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options and restricted stock units outstanding"&gt;466,234&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based awards available for grant as of March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20220331_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based awards available for grant"&gt;982,105&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2006Member"
      decimals="INF"
      unitRef="Shares">2787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2006Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2006Member"
      decimals="INF"
      unitRef="Shares">2787</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">111949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2011Member"
      decimals="INF"
      unitRef="Shares">111949</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">221497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2016Member"
      decimals="INF"
      unitRef="Shares">221497</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2017Member"
      decimals="INF"
      unitRef="Shares">130001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2017Member"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_Plan2017Member"
      decimals="INF"
      unitRef="Shares">130001</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">466234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">466234</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">982105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zir3aMqibCs7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B7_zIjDLy19hG2d" style="display: none"&gt;Schedule of option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual Term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 44%"&gt;Outstanding at April 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU9tM3PP1eza" style="width: 11%; text-align: right" title="Number of Shares Outstanding at beginning of period"&gt;267,569&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVjk6YVhmDh9" style="width: 11%; text-align: right" title="Weighted- Average Exercise Price Outstanding at beginning of period"&gt;25.16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKVzXBFJQQyd" style="text-align: right" title="Number of Shares Granted"&gt;272,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZwqf2Bm6Yo1" style="text-align: right" title="Weighted- Average Exercise Price Granted"&gt;4.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxYAlx53fgYd" style="text-align: right" title="Number of Shares Exercised"&gt;(44,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHZG9u7arrH5" style="text-align: right" title="Weighted- Average Exercise Price Exercised"&gt;4.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zt4hIQCJQ1Rb" style="text-align: right" title="Number of Shares Forfeited"&gt;(5,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUmM96xfRBCj" style="text-align: right" title="Weighted- Average Exercise Price Forfeited"&gt;6.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2RUQku8FPt5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Expired"&gt;(25,001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCggLX24sywa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted- Average Exercise Price Expired"&gt;84.83&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLldnrByxlI2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Outstanding at end of period"&gt;466,234&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zlAh44K59jq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding at end of period"&gt;12.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zn27k069GNxl" title="Weighted- Average Contractual Term Outstanding at end of period"&gt;8.89&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuN2ExoOhNle" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding at end of period"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2LzLbNGgd85" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Exercisable at end of period"&gt;115,144&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1uHcDyN8AU9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Exercisable at end of period"&gt;32.56&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrpT3dYCyRs1" title="Weighted- Average Contractual Term Exercisable at end of period"&gt;6.85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20220331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zl7tfubcGOkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable at end of period"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">267569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">25.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562"
      decimals="INF"
      unitRef="Shares">272958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562"
      decimals="INF"
      unitRef="USDPShares">4.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562"
      decimals="INF"
      unitRef="Shares">44042</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562"
      decimals="INF"
      unitRef="USDPShares">4.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562"
      decimals="INF"
      unitRef="Shares">5250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562"
      decimals="INF"
      unitRef="USDPShares">6.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562"
      decimals="INF"
      unitRef="Shares">25001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562"
      decimals="INF"
      unitRef="USDPShares">84.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">466234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">12.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562">P8Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">115144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">32.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562">P6Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember44329562"
      decimals="INF"
      unitRef="USDPShares">4.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember44329593"
      decimals="INF"
      unitRef="USDPShares">7.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z0PMmUQt8vd6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zb8K18jPPAN1" style="display: none"&gt;Schedule of unvested restricted stock activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Average Award&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: center"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Unvested restricted stock awards outstanding at April 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOazG785cVV" style="width: 13%; text-align: right" title="Unvested restricted stock awards, beginning balance"&gt;833&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIQ6aS3cGMU2" style="width: 13%; text-align: right" title="Weighted average award date fair value per share, outstanding beginning balance"&gt;13.68&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock awards granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="text-align: right" title="Restricted stock awards granted"&gt;1,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="text-align: right" title="Weighted average award date fair value per share, granted"&gt;3.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Restricted stock awards vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zH38ybfBvZJc" style="border-bottom: Black 1pt solid; text-align: right" title="Restricted stock awards vested"&gt;(2,429&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average award date fair value per share, vested"&gt;6.70&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Unvested restricted stock awards outstanding at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpbGEFrRfWm1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested restricted stock awards, ending balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20210401__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvtOTx7hV8tg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average award date fair value per share, outstanding ending balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">13.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">3.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">2429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-04-012022-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">6.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zEXF2n34RYcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;15&#160;&#x2013; &lt;span id="xdx_821_zQUxgDPvRiwj"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has the following net deferred tax
assets:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zr6WYlqNMQPc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BB_z06K2W0Eb5sj" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20220331_zamRBdLxYHcl" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20210331_zqFMWYBOTg2i" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGz412_zTZs95gMXgbf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;28,224,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;25,687,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGz412_zhyYh7LUfwsh" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGz412_zKDHJZiXvmna" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,120,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0p0_maDTAGz412_zBsGGRNNH6Oe" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Allowances and accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,336,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;659,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pp0p0_d0_maDTAGz412_zjR6sJBCY3xh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pp0p0_maDTAGz412_znoCHGmqJkC7" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;63,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;78,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGz412_maDTANzqCr_z0vmMTQhwtCj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,782,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,792,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzqCr_zq8q7qO8gmi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,613,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(31,528,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzqCr_maDTALNzfiK_zGhqMg8J0Omf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,169,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;264,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pp0p0_di_maDITLzfJx_zriQ37QHmO33" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pp0p0_di_maDITLzfJx_zNQnYT6zKgwb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(186,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pp0p0_di_maDITLzfJx_zLuEU6vleCe3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right of Use asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(63,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(75,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pp0p0_di_mtDITLzfJx_msDTALNzfiK_zkPb5cIHAXMc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(340,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(264,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pp0p0_d0_mtDTALNzfiK_zbSiR7MSos8j" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;829,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The income tax provision (benefit) is based on
the following loss before income taxes, which are from domestic sources and foreign loss before income taxes:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zseH5cht87fe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zPA5UDCgqzuk" style="display: none"&gt;Income tax provision domestic and foreign&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended March&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Domestic&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ProfitLoss_pp0p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zo6vQ1YumKye" style="width: 13%; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(3,516,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ProfitLoss_pp0p0_c20200401__20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zsw9EFiq2jLj" style="width: 13%; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(2,052,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ProfitLoss_pp0p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z8hs79iu2e7a" style="border-bottom: black 1pt solid; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(1,883,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ProfitLoss_pp0p0_c20200401__20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zuStfLXjuOv" style="border-bottom: black 1pt solid; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(1,467,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331_z2D6HFIoFef2" style="border-bottom: black 2.25pt double; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(5,399,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ProfitLoss_pn3p0_c20200401__20210331_zOzz6OEPJill" style="border-bottom: black 2.25pt double; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(3,519,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s income tax expense/(benefits)
consist of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_znsDd3EjIbs9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_z6xcUQXl30sd" style="display: none"&gt;Schedule of income tax expense&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20210401__20220331_z6ZgkUyyeA14" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20200401__20210331_zBOqa0wIo839" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended March&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Current:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;State&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CurrentForeignTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;469,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;941,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Current Income Tax Expense&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;477,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;942,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zjis4gxbRI36" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zgHHC3PDfJ0l" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;State&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_d0_zpcAJAvJHRs3" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(809,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Total deferred income tax&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(332,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;942,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A reconciliation of the statutory federal income
tax rate to the Company&#x2019;s effective tax rate for continuing operations is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zV4x1gKKMBd4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_z6uGOswNvCa4" style="display: none"&gt;Reconciliation of federal income tax rate to effective rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20210401__20220331_zhL7miAKoiPl" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20200401__20210331_zxHHbKsuXclk" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year&#160;Ended&#160;March&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zUEVliCEaalj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Expected federal statutory rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21.0%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21.0%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_z60DI9aSzz71" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;State income taxes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.7%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2.1%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zOLgQzc5D8hd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Foreign earnings taxed at different rates&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3.7%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3.6%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ForeignTaxTrueup_dp0_zu1v1enA0JZ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Foreign tax true-up&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(12.4%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_dpi_zEb84tIE5CT3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Effect of permanent differences&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(3.0%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(9.5%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_zronOu5qGWgg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Effect of intercompany interest permanent differences&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(12.3%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17.9%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--TrueupsOfStateDeferredAssets_dp_zCe8tbuXo4S6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;True-up of state deferred assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(25.6%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(120.7%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zwOCtkaa3pcl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Total effective rate&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(10.5%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(133.8%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zh0QHLE6lIAk" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;16.7%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;107.1%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zsFrvUAF0th" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Totals&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(6.2%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(26.7%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2022, the Company had net
operating loss carryforwards for Federal, State and Foreign income tax purposes of approximately $&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z4EZX4gPOWL" title="Net operating loss carryforwards"&gt;115.3&lt;/span&gt;
million, $&lt;span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zR8tDfyI1y3l" title="Net operating loss carryforwards"&gt;44&lt;/span&gt;
million and $&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pp0p0"&gt;541,000&lt;/span&gt;,
respectively. Due to the Tax Cuts and Job Act, Federal NOLs generated after March 31, 2018 have an indefinite life. Federal NOL
generated on and before March 31, 2017 will begin to expire 2024, if not utilized. State and Foreign NOLs will  begin to expire in
the year 2029 and 2024, respectively, if not utilized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2022, the Company had
Federal and California research credit carryforwards of approximately $&lt;span id="xdx_90F_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_dm_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zpTLy7WEMq5j" title="Research credit carryforwards"&gt;1&lt;/span&gt;
million and $&lt;span id="xdx_900_eus-gaap--TaxCreditCarryforwardAmount_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_pp0p0" title="Research credit carryforwards"&gt;790,000&lt;/span&gt;,
respectively. The Federal research credits will begin to expire in 2024 while the California research credits have no expiration
date. In addition, the Company has foreign tax credits of $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsForeign_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_pp0p0" title="Foreign tax credit carryforward"&gt;50,000&lt;/span&gt;,
which begin to expire in the year 2023 if not utilized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Section 382 of the Internal Revenue Code limits
the use of the Federal net operating losses in certain situations where changes occur in stock ownership of a company. If the Company
should have an ownership change of more than 50% of the value of the Company's capital stock, utilization of the carryforwards could be
restricted. The Company is not aware of any changes in ownership that would result in a change in control under Internal Revenue Code
section 382.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company released the valuation allowance recorded
against its Mexico deferred tax assets as of March 31, 2022. Given its recent history of earnings, current earnings and anticipated future
earnings, the Company concluded that there is sufficient positive evidence available to reach a conclusion that the valuation allowance
is no longer needed in Mexico. The release of the valuation allowance resulted in the recognition of deferred tax assets of $829,000.
The Company, after considering all available evidence, fully reserved against all deferred tax assets in the U.S. and Netherlands since
it is more likely than not such benefits will not be realized in future periods. The Company will continue to evaluate its deferred tax
assets to determine whether any changes in circumstances could affect the realization of their future benefit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has filed tax returns for federal,
state and foreign jurisdictions. The Company&#x2019;s evaluation of uncertain tax matters was performed for tax years ended through March
31, 2022. Generally, the Company is subject to audit for the years ended March 31, 2021, 2020 and 2019. The Company has elected to retain
its existing accounting policy with respect to the treatment of interest and penalties attributable to income taxes and continues to reflect
interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit as
well as its outstanding income tax assets and liabilities. The Company believes that its income tax positions and deductions would be
sustained on audit and does not anticipate any adjustments to result in a material change to its financial position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zr6WYlqNMQPc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BB_z06K2W0Eb5sj" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20220331_zamRBdLxYHcl" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20210331_zqFMWYBOTg2i" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGz412_zTZs95gMXgbf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;28,224,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;25,687,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGz412_zhyYh7LUfwsh" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGz412_zKDHJZiXvmna" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,120,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pp0p0_maDTAGz412_zBsGGRNNH6Oe" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Allowances and accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,336,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;659,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pp0p0_d0_maDTAGz412_zjR6sJBCY3xh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pp0p0_maDTAGz412_znoCHGmqJkC7" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;63,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;78,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGz412_maDTANzqCr_z0vmMTQhwtCj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,782,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,792,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzqCr_zq8q7qO8gmi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,613,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(31,528,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzqCr_maDTALNzfiK_zGhqMg8J0Omf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,169,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;264,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pp0p0_di_maDITLzfJx_zriQ37QHmO33" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pp0p0_di_maDITLzfJx_zNQnYT6zKgwb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(186,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pp0p0_di_maDITLzfJx_zLuEU6vleCe3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right of Use asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(63,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(75,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pp0p0_di_mtDITLzfJx_msDTALNzfiK_zkPb5cIHAXMc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(340,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(264,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pp0p0_d0_mtDTALNzfiK_zbSiR7MSos8j" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;829,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">28224000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">25687000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1850000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1850000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">309000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3120000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1336000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">659000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">398000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <SNOA:DeferredTaxAssetsLeaseLiability contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">63000</SNOA:DeferredTaxAssetsLeaseLiability>
    <SNOA:DeferredTaxAssetsLeaseLiability contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">78000</SNOA:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">31782000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">31792000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">30613000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">31528000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1169000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">264000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">17000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">260000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">186000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <SNOA:DeferredTaxLiabilitiesRightOfUseAsset contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">63000</SNOA:DeferredTaxLiabilitiesRightOfUseAsset>
    <SNOA:DeferredTaxLiabilitiesRightOfUseAsset contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">75000</SNOA:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">340000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">264000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">829000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zseH5cht87fe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zPA5UDCgqzuk" style="display: none"&gt;Income tax provision domestic and foreign&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended March&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Domestic&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ProfitLoss_pp0p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zo6vQ1YumKye" style="width: 13%; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(3,516,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ProfitLoss_pp0p0_c20200401__20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zsw9EFiq2jLj" style="width: 13%; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(2,052,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ProfitLoss_pp0p0_c20210401__20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_z8hs79iu2e7a" style="border-bottom: black 1pt solid; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(1,883,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ProfitLoss_pp0p0_c20200401__20210331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zuStfLXjuOv" style="border-bottom: black 1pt solid; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(1,467,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ProfitLoss_pn3p0_c20210401__20220331_z2D6HFIoFef2" style="border-bottom: black 2.25pt double; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(5,399,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ProfitLoss_pn3p0_c20200401__20210331_zOzz6OEPJill" style="border-bottom: black 2.25pt double; text-align: right" title="Income before income taxes"&gt;&lt;span style="font-size: 10pt"&gt;(3,519,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012022-03-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">-3516000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-04-012021-03-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">-2052000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-012022-03-31_us-gaap_ForeignCountryMember"
      decimals="0"
      unitRef="USD">-1883000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-04-012021-03-31_us-gaap_ForeignCountryMember"
      decimals="0"
      unitRef="USD">-1467000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">-5399000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">-3519000</us-gaap:ProfitLoss>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_znsDd3EjIbs9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_z6xcUQXl30sd" style="display: none"&gt;Schedule of income tax expense&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20210401__20220331_z6ZgkUyyeA14" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_494_20200401__20210331_zBOqa0wIo839" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended March&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Current:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;State&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CurrentForeignTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;469,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;941,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Current Income Tax Expense&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;477,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;942,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zjis4gxbRI36" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zgHHC3PDfJ0l" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;State&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_d0_zpcAJAvJHRs3" style="vertical-align: bottom; background-color: #EEEEEE"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(809,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Total deferred income tax&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(332,000)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;942,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">8000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">469000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">941000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">477000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">942000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-809000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-332000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">942000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zV4x1gKKMBd4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_z6uGOswNvCa4" style="display: none"&gt;Reconciliation of federal income tax rate to effective rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49F_20210401__20220331_zhL7miAKoiPl" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49E_20200401__20210331_zxHHbKsuXclk" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year&#160;Ended&#160;March&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zUEVliCEaalj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%"&gt;&lt;span style="font-size: 10pt"&gt;Expected federal statutory rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21.0%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21.0%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_z60DI9aSzz71" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;State income taxes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.7%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2.1%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zOLgQzc5D8hd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Foreign earnings taxed at different rates&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3.7%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3.6%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ForeignTaxTrueup_dp0_zu1v1enA0JZ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Foreign tax true-up&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(12.4%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_dpi_zEb84tIE5CT3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Effect of permanent differences&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(3.0%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(9.5%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_zronOu5qGWgg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Effect of intercompany interest permanent differences&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(12.3%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(17.9%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--TrueupsOfStateDeferredAssets_dp_zCe8tbuXo4S6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;True-up of state deferred assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(25.6%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(120.7%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zwOCtkaa3pcl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Total effective rate&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(10.5%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(133.8%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zh0QHLE6lIAk" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;16.7%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;107.1%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zsFrvUAF0th" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Totals&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(6.2%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(26.7%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">-0.057</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">-0.021</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <SNOA:ForeignTaxTrueup
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0</SNOA:ForeignTaxTrueup>
    <SNOA:ForeignTaxTrueup
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">-0.124</SNOA:ForeignTaxTrueup>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0.095</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">-0.123</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">-0.179</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <SNOA:TrueupsOfStateDeferredAssets
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">-0.256</SNOA:TrueupsOfStateDeferredAssets>
    <SNOA:TrueupsOfStateDeferredAssets
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">-1.207</SNOA:TrueupsOfStateDeferredAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.105</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">1.338</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.167</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">1.071</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">-0.062</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">-0.267</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      unitRef="USD">115300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-3"
      unitRef="USD">44000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-03-31_us-gaap_ForeignCountryMember"
      decimals="0"
      unitRef="USD">541000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      unitRef="USD">1000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      unitRef="USD">790000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign
      contextRef="AsOf2022-03-31_us-gaap_ForeignCountryMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80A_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zF95oKn7V0E3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;16&#160;&#x2013; &lt;span id="xdx_82C_zWyqM9mwUj89"&gt;Employee Benefit
Plan&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has a program to contribute and administer
a qualified 401(k) plan. Under the 401(k) plan, the Company matches employee contributions to the plan up to 4% of the employee&#x2019;s
salary. Company contributions to the plan amounted to an aggregate of $&lt;span id="xdx_900_eus-gaap--PensionAndOtherPostretirementBenefitContributions_c20210401__20220331_pp0p0" title="Company contributions to 401(k) plan"&gt;50,600&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--PensionAndOtherPostretirementBenefitContributions_c20200401__20210331_pp0p0" title="Company contributions to 401(k) plan"&gt;89,000&lt;/span&gt; for the years ended March 31, 2022 and 2021,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">50600</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">89000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_z5lQfnB10xoa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;17 &#x2013; &lt;span id="xdx_82A_zJmtVf96s5Gc"&gt;Revenue Disaggregation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company generates product revenues from products
which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services
which are provided to medical device manufacturers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents the Company&#x2019;s disaggregated revenues
by source:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--DisaggregationOfRevenueTableTextBlock_zf8ED1TsLjuc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span id="xdx_8BC_zUH2QemuRLI9" style="display: none"&gt;Disaggregated Revenue by Source&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; text-align: left"&gt;Human Care&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_pp0p0" style="width: 13%; text-align: right" title="Revenues"&gt;9,010,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_pp0p0" style="width: 13%; text-align: right" title="Revenues"&gt;15,317,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Animal Care&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;3,169,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;3,200,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Total Product Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3p0" style="text-align: right" title="Revenues"&gt;12,179,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3p0" style="text-align: right" title="Revenues"&gt;18,517,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Service/Royalty&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pn3p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;449,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pn3p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;112,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,628,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;18,629,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table shows the Company&#x2019;s
revenues by geographic region:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zLFVfyGrcWfc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Geographic Information (Details - Geographic regions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B4_zU4cJrgRoiA2" style="display: none"&gt;Schedule of geographic sales&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 13%; text-align: right" title="Revenues"&gt;3,807,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 13%; text-align: right" title="Revenues"&gt;5,419,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Latin America&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_pp0p0" style="text-align: right" title="Revenues"&gt;2,095,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_pp0p0" style="text-align: right" title="Revenues"&gt;5,976,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Europe and Rest of the World&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_z9JI4GGjVUAl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;6,726,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;7,234,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331_z3gxx56LAxPh" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,628,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200401__20210331_zmKl28Cg30Yk" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;18,629,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s service revenues in Latin
America amounted to $&lt;span id="xdx_90C_eus-gaap--Revenues_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pp0p0" title="Revenues"&gt;349,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--Revenues_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pp0p0" title="Revenues"&gt;112,000&lt;/span&gt; for the years ended March 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--DisaggregationOfRevenueTableTextBlock_zf8ED1TsLjuc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span id="xdx_8BC_zUH2QemuRLI9" style="display: none"&gt;Disaggregated Revenue by Source&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.6pt 0pt 0; text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Product&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; width: 68%; text-align: left"&gt;Human Care&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_pp0p0" style="width: 13%; text-align: right" title="Revenues"&gt;9,010,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember_pp0p0" style="width: 13%; text-align: right" title="Revenues"&gt;15,317,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Animal Care&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;3,169,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;3,200,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Total Product Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3p0" style="text-align: right" title="Revenues"&gt;12,179,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember_pn3p0" style="text-align: right" title="Revenues"&gt;18,517,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Service/Royalty&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pn3p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;449,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ServiceMember_pn3p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;112,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,628,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331_pn3p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;18,629,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_custom_HumanCareMember"
      decimals="0"
      unitRef="USD">9010000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012021-03-31_us-gaap_ProductMember_custom_HumanCareMember"
      decimals="0"
      unitRef="USD">15317000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_custom_AnimalCareMember"
      decimals="0"
      unitRef="USD">3169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012021-03-31_us-gaap_ProductMember_custom_AnimalCareMember"
      decimals="0"
      unitRef="USD">3200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember"
      decimals="-3"
      unitRef="USD">12179000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012021-03-31_us-gaap_ProductMember"
      decimals="-3"
      unitRef="USD">18517000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ServiceMember"
      decimals="-3"
      unitRef="USD">449000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012021-03-31_us-gaap_ServiceMember"
      decimals="-3"
      unitRef="USD">112000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">12628000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">18629000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zLFVfyGrcWfc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Geographic Information (Details - Geographic regions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B4_zU4cJrgRoiA2" style="display: none"&gt;Schedule of geographic sales&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 13%; text-align: right" title="Revenues"&gt;3,807,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_pp0p0" style="width: 13%; text-align: right" title="Revenues"&gt;5,419,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Latin America&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_pp0p0" style="text-align: right" title="Revenues"&gt;2,095,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_pp0p0" style="text-align: right" title="Revenues"&gt;5,976,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Europe and Rest of the World&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_z9JI4GGjVUAl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;6,726,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200401__20210331__srt--ProductOrServiceAxis__us-gaap--ProductMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;7,234,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20220331_z3gxx56LAxPh" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,628,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200401__20210331_zmKl28Cg30Yk" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;18,629,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US"
      decimals="0"
      unitRef="USD">3807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US"
      decimals="0"
      unitRef="USD">5419000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember"
      decimals="0"
      unitRef="USD">2095000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember"
      decimals="0"
      unitRef="USD">5976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember"
      decimals="0"
      unitRef="USD">6726000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012021-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember"
      decimals="0"
      unitRef="USD">7234000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">12628000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">18629000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="From2021-04-012022-03-31_us-gaap_ServiceMember"
      decimals="0"
      unitRef="USD">349000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-04-012021-03-31_us-gaap_ServiceMember"
      decimals="0"
      unitRef="USD">112000</us-gaap:Revenues>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000765"
          xlink:label="Fact000765"
          xlink:type="locator"/>
        <link:footnote id="Footnote000772" xlink:label="Footnote000772" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000765"
          xlink:to="Footnote000772"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000767"
          xlink:label="Fact000767"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000767"
          xlink:to="Footnote000772"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .^![50'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #O@>U4D:]!^>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R';8"B;UI66G#08K;.QF;+4UC1-C:R1]^R59FS*V!]C1TN]/
MGT"UC<IV"5]2%S&1QWPWA*;-RL8U.Q)%!9#M$8/)Y9AHQ^:^2\'0^$P'B,:>
MS %!<OX  <DX0P8F8!$7(M.UL\HF--2E"][9!1\_4S/#G 5L,&!+&40I@.EI
M8CP/30TWP 0C3"%_%] MQ+GZ)W;N +LDA^R75-_W95_-N7$' >_/3Z_SNH5O
M,YG6XO@K>T7GB&MVG?Q6;;:[1Z8EE[+@JT)4.\F5N%=B]3&Y_O"["8?.^;W_
MQ\9705W#K[O07U!+ P04    " #O@>U4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M .^![51P%+"I^P<  "D\   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9MM<Z,V%(7_BL;M=+8S<<R+[3B[B6<<3+9N-TX:9W=GV^D'!62;64"N$''2
M7U^!7X@RXMK,W/V2&.S[ .> T$'B8LW%]VS)F"3/29QFEZVEE*OWG4X6+%E"
MLU.^8JGZ9LY%0J5:%(M.MA*,AF51$G<<R^IW$AJEK>%%N>Y.#"]X+N,H97>"
M9'F24/%RQ6*^OFS9K=V*^VBQE,6*SO!B11=LQN3GU9U02YT])8P2EF813XE@
M\\O6R'[ON^=%0?F++Q%;9Z\^D^)0'CG_7BQ,PLN65>P1BUD@"P15_YZ8Q^*X
M(*G]^'<+;>VW612^_KRC7Y<'KP[FD6;,X_'7*)3+R]:@14(VIWDL[_GZ-[8]
MH%[!"WB<E7_)>O/;;K=%@CR3/-D6JSU(HG3SGSYOA7A5X#HU!<ZVP'E38-=M
MP=T6N,<6=+<%W6,+>MN"\M [FV,OA1M328<7@J^)*'ZM:,6'4OVR6ND5I<6)
M,I-"?1NI.CGT^!,3I$T^S\;DW<^_7G2D@A9?=8(MX&H#<&H MD-N>"J7&?'3
MD(4ZH*/V9K]+SFZ7KAR0>$/%*7'M$^)8CF/8(>_X<MM0/H;+?\_C4V+7;]V'
MRV=LI;9NF;:NB>'N_7%+G@OZ\_?H,9-"753_F S:$+IF0M'2O,]6-&"7+=64
M9$P\L=;PEY_LOO7!)"XF;(P)\Y%@F@W=O0U=B#X<\R!7S:,D#R\K9O( +K>M
M]A\FL<&JIF)CPGPDF"9V;R]V#U1KI)0.2[6O8[HPJ0W7SVF<F4SRP+*F<F/"
M?"28)G=_+W?_N'-[E*8YC<D]6W$A3;+#'"ERH^I@55/5,6$^$DQ3_6RO^MF1
M+8J@JMM5]IKJE8=9M2<\6-94>DR8CP33I!_LI1\<)_T=$Q$/BXX+49TG8[L.
MD_9]C=J^"EC?U %,F(\$TQPXWSMP?IP#UU$6J"9G:\2U6IV97(!IU]],RH,U
M397'A/E(,$UYVZHZ_%8C[;\Q*NJ5/P"K.^WALJ;JH])\+)JN_ZO 98.2>;D0
M;^6'6J #N';;<MNN*>AX<&5C$S!I/A9--\&I3'! U?Q41O)%>1 S,LV31R:,
MTL,0R[+;KNO8?:/X8&UC\3%I/A9-%[^*M#88U7;BW[-%5*1:=2U,:6(^]V'0
M['9Z>S,B=[^-[F]&GO_Y8>*-/LU.R&3JG1H]00VWJ#0?BZ9[4N5;&TZH6T\\
MU3()U2I-TI ]DS_8B]$5&&6IZ\+MGUD#U^@!:N9%I?E8--V#*O;:<&[=>O!
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MH>6%JKZ7<[,X'^4C,I<W8EV9+^K^3]D%E%A_,U7I]G]RW]E&(S);:Z.6W6!
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M-3#/ET+HQXF] =0WOO@/4$L#!!0    ( .^![52[CS7LE@4  - 7   8
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M;B!^?V",OQSD+P7O7V2__@]02P,$%     @ [X'M5(4"C \\"   ;28  !@
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M-I>F.?9KF6\X(>%J-.N)F\6)>QN2^RE9\7M1UW8UP2P]<:90#WQN9F[+Z7F
M;:;GD1GH,9O%,1MQ@=OSB8AXGZ=X'""&+[T\%=_C-XO_F'RWW^TJ]Q,\I!Y[
M1E5)O5<-V)Y+0EA6S>L;@#:T!LS.^M/RN7H['9&C'Y?CI'?3Z<XA[4]GH@:D
M0 F/NHTP&2GM$+,TG(*S'MQ9'-RG0@U[Q)-MYN,WQXH[Q&Z>1>*CIW0VC2ZQ
MWV0]=&OIZ)@#XN+-.XPL6@2\>W6=J;?3P>CK@"Q>!WRM(;S<G@&ZWXK]5K<#
M\?)-E=;WW'M-(<?.>Q"["7;D.CIZ<6?+U;U[GTDG[O2W>2&FN]N],W7MWA1Z
M<?\FO;AMWGSJNVE>Q/K&%.1M#67-&KH<?\Y!E&K>;6J^&+ESKP>MI#%RZRXW
MG)5<60/X_UI*\_S%/J![PVSQ?U!+ P04    " #O@>U4(!PXO8@$  #:"0
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MWV(# 433MSX#I&Q8W@$QQ/3 :L(PEJ$'=B]X=Q"L1L+6YA!.(8W-@:9M@N&
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M.!A!NP0\+Y6RVX6[8!BUV3]02P,$%     @ [X'M5(J#G>'. @  L@8  !D
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MGCN93\5H,)P<'5JP<NF[8W_.#GHS_&8..ZY6YZKRJ5D3ACKD/9I ;C6 #OG
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ML6RLUPH!?:]O\3@R'Z7S5EW4]-FJK=2%4+<$-: \RF:CABA=S"(93P?*KF^
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M497Z!S43KBW*<E<#UV:7$CL-'?1X2<ZB5?T9G _1I9FB3>'V\Y1YXGP/DSE
MJ3BI#IP)B:90 &.#,REU%#X"/:BR7-N\WF B\=@*-2O#R N1D ^J7-O&RNC-
MX-&)=:7+B)Q5H*S"6(@;03]Q[5AH]NGOM=6NT%R@^U[?[SOW>0,[ZJKIF:0%
MC1M> E7H!G3T74RQ<'Y[AUH!?Q7*PIKZ>AV*,^D4)UR!;>7=?CUQZ2R_,QA&
MR)JF!XL%35?L7JV'WQ$[F(W2X\?X\ <PLH;JC;Q(*((H&<># :=84U=\N36E
MSBGT?DUYNHV6D'Z/T'@^7#>K"6TCI!0[L"SYL 5<K%[6OJGNO5V+2)MT<L&6
M%1F6_!_"^HU5ZM;S>7^M[G"6T@Y5!H?#C#)58ZUWAT]P@#8F%;B2G:*Z=4QN
M:D\Y6A H'=:FX\+0SB%S'_&E*C4&@0N-[*%N;H<T<<,GBZ+.XP!NII>K'86(
M#Y,Q!9C4J#B^VN;,I26+[V"@N$1,[^<5[1=68R[%P448>JJ6"L5'SQMC!N+0
M9ZMAYY/B1MEK_G#*)5OY\'6Q?=I^F[T(GR3OR<.'7>3K-5J=*-4*K%@VISUA
MP\?2<./-EC]0+HWW9L.7:R51OT2 ]RMC?'-#"MHOUN?_!5!+ P04    " #O
M@>U4XK+/8J,"  #G!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R-
ME$UOVS ,AN_]%82[%1L0Q!])TZQ- C1=A^W0+>C'=AAV4&+:%BI+KB0W[;\?
M)<=>-B3!+K%(DP]?QB(G:Z4?38%HX:44TDR#PMKJ/ S-JL"2F;ZJ4-*;3.F2
M63)U'II*(TM]4BG")(I&8<FX#&83[UOHV4355G")"PVF+DNF7^<HU'H:Q$'K
MN.5Y89TCG$TJEN,=VH=JH<D*.TK*2Y2&*PD:LVEP&9_/AR[>!WSGN#9;9W"=
M+)5Z=,:7=!I$3A *7%E'8/1XQBL4PH%(QM.&&70E7>+VN:5_\KU3+TMF\$J)
M'SRUQ308!Y!BQFIA;]7Z,V[Z.76\E1+&_\*ZB1U0Q55MK"HWR6277#9/]K+Y
M'[82QM&>A&23D'C=32&O\B.S;#;1:@W:11/-'7RK/IO$<>D^RIW5])93GIU=
MEY50KX@P1XD9M[ 03$Y"2V@7$*XVF'F#2?9@X@1NE+2%@6N98OHW("1-G;"D
M%39/#A)OF.[#(.Y!$B7) =Z@:W3@>8,]O%NT7"-=)]NV:N#GY=)831?CUZZ.
M&]YP-\\-R[FIV JG 4V#0?V,P>SD.!Y%%P?4#CNUPT/T__\L!S&[17[]=G\-
M\0A.CL=)'%_ O[6.7"VX+Q"N5%DQ^0H%,\"@TBK7K 2K8$7?6O-E;1&83(&E
M=#.YL:B/&#S53/",8PK#*'[W^!XJPO7A@>Z%!DO4+7?/.]HR-&.T<PQ@*Z@K
M0_-K7%T7[?*@KIPY? LJ\\XVQ?=T=F&.#!.T8_H=>S^*E:J6EN22TYEYKC%G
MU!FAW\!IU!M%$8P_]")Z[/JRX=;PE:ASOV(,%21J,X>=M]MBE\WP_@EO5B#=
M^9R3/($9I4;]L], =+-6&L.JRH_R4EE:#/Y8T"9&[0+H?::4;0U7H-OML]]0
M2P,$%     @ [X'M5(%FR[F^ P  EP@  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&ULE59=;]LV%'W7K[A0@SX)T8<_Y#BV <?)T 'K&MCIBF'8 RU=
M2T(D4B.IN/[WNZ1DQ6E==WNPS8]S#\\]O"0]VPOYK')$#5^KDJNYFVM=3WU?
M)3E63%V+&CG-[(2LF*:NS'Q52V2I#:I*/PJ"L5^Q@KN+F1U[E(N9:'19<'R4
MH)JJ8O)PAZ78S]W0/0ZLBRS79L!?S&J6X0;UY_I14L_O6=*B0JX*P4'B;NXN
MP^G=T. MX(\"]^JD#2:3K1#/IO-K.G<#(PA+3+1A8/3S@BLL2T-$,O[I.-U^
M21-XVCZR_V)SIURV3.%*E%^*5.=S=^)"BCO6E'HM]A^PRV=D^!)1*OL-^Q8[
MC%U(&J5%U063@JK@[2_[VOEP$C )?A 0=0&1U=TN9%7>,\T6,RGV( V:V$S#
MIFJC25S!S:9LM*39@N+T8HTOR!N$^T*Q+).8,6/6S-?$;1!^TO'<M3S1#WC"
M"#X*KG,%#SS%]"V!3Z)Z9=%1V5UTD?$CD]<P"#V(@BBZP#?H,QU8OL%/,MU)
M4<&*M$JJ"');Y["R/J.$OY9;9<?_/N= RS\\SV].SU35+,&Y2\=#H7Q!=_'^
M73@.;B^H'_;JAY?8_\<^7>0YK_+W3T\/$,;P_MTD"L-;.+\8/.5(QE4UXP?(
MD*-D&A744J0-.2G;(-4:W(TJ9Y\720Y,(BA1IE!P+4 34=Y4C XE3^E35*R$
M'%FI\\0@Z7IX1JT\.ZW/KFJ4%PE^LVK)MH+FA3P @73!LR/P5 AI>RFH2(&D
M5)@6":V>HJ4C3<V.]K^1*-6US7@G2KJY#)5FV])$DVU<JU-AUKCX5D'ZZACQ
M'\4YVP-EW\@$I\[]&\31:0)L+,#Y$YELSQ#0"2#%= 0<<P3,.0B=Q]97YX.U
M;V72N8(;+P@#+P@":H<C;Q#&IN,L6V,M:."%XQL+&7AT8=OY)Z%INF/LI821
M%\8M-)QXHXYKT]KHK\6!MND PV$'(?@KUY6)'D>3HY8)=5K<.2=5+O9G;73Z
M7=V:/1>99#7M'OF941U.G0T]36E##&)W.JU825[_Q,#/O##&;[0MHRNR8Q+$
MG=Z1-PRM7.<WJG@.2[H3J#J 4KP96<S(NXG'%O'02'H9;86NJ=2,%)/)%R&I
MRL=>'%D8Q%XT&/YGA[XMI^^JG$19:<Y1&JM$PW5;RY3,VUV!<Q>/?_)8$$EF
MGT0%B>%IWXU^M']UE^UC\PIOGVSR-RNX@A)W%!I<QR,79/L,MATM:OOT;(6F
M"]8VZ9BG* V YG="Z&/'+-#_%UG\"U!+ P04    " #O@>U48659[C B  !6
M;0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R=/6MOVSBVW_4KB.S<
MW01PW-AITK2=%DC3=K? =*9HVAU<7-P/LDS;G,J21Y22>'_]GA=?MJQT"LS#
ML<1#\O"\'_3/]W7SS:ZT;M7#NJSLJZ-5VVY>/'EBBY5>YW9<;W0%3Q9UL\Y;
M^+-9/K&;1N=S&K0NGTS/SBZ?K'-3';W^F;[[U+S^N>[:TE3Z4Z-LMU[GS?:-
M+NO[5T>3(_?%9[-<M?C%D]<_;_*EOM7MU\VG!OYZXJ',S5I7UM25:O3BU='U
MY,6;Z24.H#?^;?2]C3XKW,JLKK_A'Q_FKX[.<$6ZU$6+('+XWYV^T66)D& =
M?PK0(S\G#HP_.^CO:?.PF5EN]4U=_F[F[>K5T=61FNM%WI7MY_K^7UHV=('P
MBKJT]%]US^\^>WJDBLZV]5H&PPK6IN+_YP^"B&C U=F! 5,9,*5U\T2TRK=Y
MF[_^N:GO58-O S3\0%NET; X4^&IW+8-/#4PKGU]RZ>AZH6Z-<O*+$R15ZVZ
M+HJZJUI3+=6GNC2%T58=NT\G/S]I86H$\*20:=[P--,#TTRFZF-=M2NKWE5S
M/4\!/($U^X5/W<+?3 <A?LR;L3J?C-3T;#H=@'?N$7%.\,X/P.O;\?]=SVS;
M .'\?]^.&=[3?GC(32_L)B_TJR-@%ZN;.WWT^N]_FUR>O1Q8[5._VJ=#T%]_
M:DQ5F$T)BX23NZDK"VN>YTCH?4L=!-:_U($9U)>5!G8JZO4FK[:(L<(_UG.U
M,%4.0_-2V1:^ !9N;0; RFZN52M# =4$&/^^84 JK^;*P-?WJ[HLMZ?U?070
M;#>S9F[R!@YDI*[_[/(U?/M%%ZNJ+NLE??NA*L;J^.]_NYI.SU[**_37Y.7)
M2/U6=&5GDR$9S/Q1/YBB5K?CZS&PL;H9_SO ^.W+QS >EW5;5_4Z5Y]6.4B"
M0G<ML$EIU:\:UM^4\ :LXDT,X?:3>M<U(#P=G+%?^RJWJJJ!N9L&4)/!.PVA
MU<(K)2 M8D-3M;HI''H<VG!!0):5S4FR68!XI]5,ZTKITH"0H&,P570L\-J8
MCFW1530(3H<74&P5R/8L.H=_#)P 0"WJ9E,W- 5(>7C"A_JU,OC5+1ZY]6CX
M.KX=.PPH8P'1@,>PP+(NHH6,,]Q_LN=DF[CO60[8+O1W[WF URX\KUT,\MJ;
MW!JB56*.JCW(98-@^KFL%_8P?V5]_!6A R!M\@:0,=LFW+7I&MLA4;4U?=]T
MR-N(TT8ONY))T+$DGINZU7 RIC7RVKN'8I572X*X-A;U<G9\=/ONYNB$GL.D
M<@!H+)AV"ZJL73&HI:Z RH&F<%]Z@V>5!X&[";+F^.B?U]>?CDZ86F7M2$&3
M9R\MB!8+!)-M==XHC=+"*M #Q0H4P1@H$ # #I E[XW5C)XY,#!0%0[A;<R)
M0$'WZ\:A@L'2.X,4<^DIYG*08FYRNZ*YZ,.[/SMSEY=X3'U4,PBJGVH.PE?^
M28$?='CB!3 ] !I;T9'AOX"=%=@N<#:E@0'(17?:MDQ7=(1YI>K&+ U*#3"$
MD"BV3"F-UFK-BKUN%.'_?H5$V,&I@+$T[SW';'=U1#LK71(' S6L":K>PFS-
M-]WNKPC4<@V$8S?(& W,O<PK\Q^AX?N5 9) D #$M#4R QJ 2)I ;UT-VF"&
MC#=XV,_\83\;/.RO0&F BW>V-6LDK;XS'H30?\:[8 F/S-LL).#A]ZC=/7Y$
M_@+R!^3#7(#@"HQO?!F989U_TTK[*8D\+!CL&T9LN\I;E2\68%&S"-&@"8B7
MUUZAP_M:=%1I\IDI28!DQ'G 9F5MNX9M"CZ-)4X=O:ERALUL*N+HT8VR3CRP
MI$;?Z:KC_63Z 1P:"W_,@8R!A,(@DD2Z,?4<-7'1=C #+!7,>PL+Z$K<P *E
MQJ*IUSC.1K@:)^;S810*&V9RSOS"/3"4/IV#ND7!5-(NX30:76C@D)F3T\@%
M%9 SV3R\[J*^ [E*N"..+($K3DOP<^9R$/PBL%G'5 /<7M^C!N6)8,^9",%=
M63M'"8FLT^8/'E@ !),A#;7;D5KDIJ$GFL 7_@6A!3@ZVL\'6/^W)A_YPW)H
MHM." V &SN00$$*W 60#0C=-/>\*))0"/4(XJ84F*8X80IK (V%W23=P&)\(
M!!IIY7:4J$'-6W!',_\#!MGXP$ M-7.8H=P.BH<K+QZN!L7#9R8^]1G."@CD
MD.TP"*1?0O1 5K]5ZAKD9ZG(,9I<I7O/YS6IWN#K9&"O5?.\ 6Q_W2![@0*^
MOOUZ!&;OD8-/N 4'@#PAD;\W#M7J2[TQA;H\NQ0SSYM^NP].5&<=PZWA;!8&
M;)E&@R"W&TV^N5J#.5VSR@#A?<]V,AY+@]QN8!.%-U_<GCI0 >Q5X.:$\/S<
M8^5V88A:$%'_ 0R0DHK 9&1H+G!#0&I@W< [RYJ(L%&(;X,VITSMZ&R$V@IT
M(XL:EHY@5V# P7JQ!?:Q"&Q62PDM/FSX7<?K&@6V=G86B&UXO08QL[>4,3 3
M<"A@!DQ?A]5\ VN'T\=CE#4%Z8>3S'2,@]PFBUETY<*4X-2 "Y;5L](L19UV
MX+$W/,$2]#W*VY2L@%]1PS"X18T2!I=D6[VQ+]2Q <L?[/Z6A*,[H9:TV4%,
MFRH3!!+5 549 .,V[*' ,:*U]Q@T- 5DD23ZHMV-1"+C@B-H6QR3@<(")BG0
M_G#GV>J'-M)*876PO+7.4;F1,I57(O\%[9I"Q_,Y$H&7# ZI0(C"Z8&\3RGG
M979L[DYV9&LO=$>A!S;[DF3>,<!J(ID1T0BQQ3&@+K<G"7M8 & 7J)YU#D3<
M#S^Q]6 [:.UO-B6.8BO[3I\B42#[ZQ+76@2I@C.;%MD4#G)&2""&@N_N@2SA
MU1(9*]OG*QZ%!-:6K#CWF:B'A7!<X/H=UDZW E.9.]G%.O^C=O8O!BL$=;"N
MINZ68)GF$C+!AZ*V0)F"L56T@!"8!QV7SFIQ1^ +)+/&S#I0[3:=."]M#0M&
MKO2@8$#NUTD1R8BF,A 7&]/"N!&0(RE !1H3V :^F-<%3C%2&PYCD!T13\[&
M"/C^&G?1NQ@,7A \\K9Q+4XFT,I8/X,8PS]=P(4C.VX#*5!WE#9LR?D.<%CX
M8)2QX(1#M? <'1AAZ24:/Q5[NNL<**L1[(<UC43LQ>SJG)KHL-\#71!ANW=2
M ><7F46"ADA&Z,=O;L1@2#0Y)\1)D7@M3B#"X@_P:J^$CQ@^$X;O-6U2N8CO
M 8?8;O:'9@4*6@JD.G(#&T#._G?S,=P*/*^4U> 5.8S6*:^,-^78CW&)/J6P
M )\(O%35U2E!6U8TG2<\W PR:Z61:IO#^IH.IRXC]4$V(;SISJ%A_H\Y&63S
M6(^=?+$'T$WX$1DW/W$DUVXW;$*JNBBZ1J04;51MT+C=DQMLCMB5V= >87?B
M.A" 8';X]T7OVV1'R-3HLA*YX8EX1\A3-M-P*K(0\PZ$1SONF6SSTWP^UQCL
M07E"\@!/!,86WY"\]N0 B*E3%%/!K![%44*U!)R3_&N[AM3/G2GU,DP:AG'@
M3A=Y9U."16&2D\^B5C!]W8B+NC,\'@+GA+H!J<[9[(P8;^\X#)#V(-5!9@^N
M$LGSEA #_(@4ZQPPBAGA2-C46OS<>-9UOF7?.+_+3>D6P"Z@7R@QN^,7)D28
M.4<-M,:%]2OWX V%R4"PPK\V]H^*HNDPXBP1&_;A;!9,:F9'>)4=L<B43M"=
MR.Z8'?.F07W)4A/-4&8!5INXLU(OO"&TJ9'XK7/S*L%?WK2DX9#"P(6.E!8"
M(#?0^<Z! PB1IIG3<._:.L/#RP"O:3UW &H]2H&K\4#S)05- .?F 44KBK[@
M D3RY(ZCV7.] 3)'%))]SD(SAY7 0C#\;C-RL%G%P(ET#<N-!ND0=JWZ'I/D
M!F8S?+R[= 2DU^$D;CO E!V;<)'KCX,ZC@#!QVS7-V_T# E?"-81-6*^GYTQ
M%);/-9OR&4L4XK2 )QS$09LU!?(;3&=*^(0X_/A;5=]7Z#6(@T=SJ:;FH+7W
M\M*DCE^R)P4)\Z$L,8V/:6S#,1&)>/F5;"15"M[U\VI8HDJH) 2)T? =:X8H
M6,_[? ?$@S,3,R%YLF;(GK+=!L-%442#C,P<7JE.*33- 0Q$U4P37KT-X,"R
MB''#"W B9[K2"U"KM/N:=17AF\+<F>7 GP9=Y&P'(GQZG<QM)\)P(WRZD=>"
M-LU8_1,$7A6DV]ZBA*@QX=."<#>D^O!-FX/AE8-;2)/L(RF>SF^JUY22J#^&
M;,0PWUL%*85#'L:MO-3$Q-*BH.0TB5AX":%DZ.EJVSH)O=Z4FH0JRE(*)Y82
M B0S0(<<2="M Y&@YSX2]'PX*U"3T@GAVQN0''#BGXW]1FOYB*Y%"*WTA8D&
M9SB0+/B+TZKW/KYJT#?MQ+A'JMG4K79T(>9D8A.P3DFG*WBZ!J<CA6-;E_!A
MTVI!.8G17LJ"S\<E/4,P=#R0Y6!)Q_J3\X&+9#>F[5P<=C]K.7(Y8:>1H_1N
M*CS0WWP )<C".MXAP\V0.LD:D0(12<99?6@])$$D9,WN*^6R6):^UV@ME.HM
M$*DU*#><)KJ19"R9L/BM%@EN&4M9'Y9\I@4FU:#_0:-6WZSD[^B ,3\,1_--
M;UJ,QZ,'LH;Y2]A6:;W% EY$C7D;3#VZ5V)<@(BM"T,Y2V>MKE,\B@TI@\1P
MG*%1@[N/#,_@36%V")0W9JLP&L*'S.<VDI2[/[_D= $A=8D*%C$)!QA2DBCS
M)"$B8JE!91F%WY-59\% "Y88C?/LX794DIT$IE#K\Y1<L#("$9]X 9+_A05,
MS_Y'32[@WZ?P[S,UN81/:G*&GZ<3=3Z%AT/2:'(6*G_.!N71M6.MSWZCO84]
M@U#Z94X/:/6%D-K#SW2L**T;]$_0Z:P7V0YFB80Q?\2#%^SIK($\-_F6(Y+S
MNINUBZ[T4S"=LB'!-@R<1,BG]8#=>Y_D2; W@2NVDJ]WJ@:31&Q/X6#V8LA*
M:!N]*S:"+80%1B1%R!<GI-%ZNDK"7 9=#(\KOP)B#]!DP?=Q?F'L_G#T+"%!
M9!(<#'S"JK)7KL:LN8DR*&"%WV$Y'('H.\$D=.#MZ#C;A+O;.R$R.#1*.BQ!
MB_"<H!H\[5;-NP@?P65;Y!328NW$UC6NN=7!RFET7DIFB9T5-SV]/Z.:!5K9
M6/VV#[,_#.22Z0E*8Y)((LP150BUHH<!Z*I\H#!R(BG1-P=O>MY1;8R(B,(T
M1;=&NZS01-H>1UC,-,^W+M2"13F8U,$E@=;Q !#P4J/#L %ABD4?WOLD9P0K
M*(6:N"P'.!*+=0KP&>],4XN;*#5:0=1)6J:N,H['T6L87G(>!>B8]:QK+,<M
M-H@B3F&(E @U/7.,;3C'.>$%MMQ6>;,,_E$@KGR!L3\,.JTU> (9\6?I"C^C
M2J&'50[H$-./'5FW#210R:<29T:.?*/7\!JSQV,4[26YS0YP8KZK"V@Q\&'B
MC)(H=?V3 L$_O1B=G9VIJPG];S)Z>G5%GX:T0%3_.1G4 A]"4KE7^@^.[I?^
M$4@5?Z8@0,OQC%8([=YY;19$./XW8Y?)BQ/Q]*WD*>D=KMY0QV(58-KKP:=O
MB?_H+1JX,(UM3PU0.G\"]N#A)R/TXU'=B(3 HZ+@R5B]Y7P9I1!P-5*& C3!
M7CW&>7UL9M&!KL",/ED0$G:62 3%>B,4Q(4WXA&+7*J _4(4.18[7)[5E%OE
MQ;!SFM6?6-'%=1,".F.60VU*?E13WQGK8K=89Z"PSL 9F"1)9[9&AR@"*Y98
MV&,_FKXDJQ0%'LV9D7J#+4D /F\:*F>+"#Q&#O.UZ3^4/N:83I@1?II.SQ_E
MB&G@B.D@1P3_YSK4LOP2*E1ZV6009#^;/#9/OR,6)Q"+V _*(@M_U&]GQ?X4
M:")O?.'!&.9*9D1FK*@V:*9+HRE:&C-;5/@Q[USR,;,K\*1/D7U5A<5BCA&L
MCO<AY:@! OF!E+L"/X/2/U$.F@+2L#\.JY=U7NTLA0EGE\(RBB4(]S9B+U&!
M*1I1&$MNV[Q8>9UBR!1G'9V2M^1V)9.9K#IX=/VU3VS89!*K\HE)E[_!*#6E
M"&;.Y1 O!%4\ D0QM<G-/$DXY7Z&K3K.D9]-RR!/?)#6.=D(8(T",9_?Y10D
MK3N;"59<&,9/%>!R=0-EX<JD%!>6VMZC0A48%+G%J8@Q>?8X&8Z%)3OHS.'@
M,*J;19%.$$3 &425IMIT@DGR+"D '+W:5?LO4W*%IZ4"(7](Z=0=I6VH<I']
M670W!(0W(V<T$Z%<-A+!>Z%^P8%J0I'0R>0EB.&Z=?%FLK6YV41PS+X&A^V*
M0"81KI%*&.;T $R$8 $/H BR V3FIY5CL7TPPBH"P"3.8]RING(_V#HZR R:
M*P@H?W_*6?%YYFO":+#HY+U"=G^>\=<B.Q".A*F38]W9CZ#HW*,H/C4<'%-%
M=HS;U0\Y1OM84B[ W."U(WW(X.!UA"J]$S]34IC8B"J:2R53,IU;2[U3<,>)
M&$Z#^X7&.) 1/<4CJ9@A>RDLA]-]T2L1 "RP;?42M"KE3CDVZ[:T#WQE=(,6
M:5HIY[W5J% ;SX_%'>8MD.W9][Y?U2Z"ZLJS .@B"QKLMP5L%TNF@I_H,I.,
MIXUKNA'3J "[H7&1ESFNO=YX#V2O$(A$0X],0!J@C6?GAW#%FPK/@#<*7PZ/
MA\5.))4:FU!I^4.8RER=/.FNNZA(']&E]M!%233L5>EW&$8<A5/WFIATT/P)
M?5"3P<:EUY\PA(:)/*KY=SJWU^CY@0ZH?N@J^3HH^M1C(*,>:\PQ$M"M.\Z6
MS='CPC CE;=6:2WI&&.FX3''1_IF(H]O#33CN9OR'EB:M5RUI[@W866%+B('
M>;UY#+H"O<"2$LI"'$@R4M?( GM_+63GK# M"DXTTH.(X+^V%E*AB!9VI=JD
ML-:O;!'\D3"7$N4/K)!+E8GF9#7#A.6%D)D'QJ8"@<0 0PE_^]J^#(TJ*U6
M]D5VX&![%YC]+S9I9$S[T<OGV<>\ZC L0YI]I,I\%L6 PHL7V?NNJ0S9G,R
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M=2%*LX#F<R'T<\<$Z"K-V7]02P,$%     @ [X'M5)&]34%W P  A @  !D
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M!"G9@S9IE:IV#R^FO3!P!*M@,]LTW;??V1":231OPMF^^_E_Y]PM=U(]Z0K
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M$D/#B^M+CZA^2/0+(UO7F)DTV.;.K'"N@K(.>%Y*:?8+>\$XJ=-_4$L#!!0
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MV*;8SB1H$UV%%]<I)E8AX709NBAI:E#/L>0]2<)TDH1Q'#LY&<=6'GRO*E;
MCF.2?71.2>S>@ZM."8;PX& K]FAEC<<3YS8:.:]O@$-:2UX2UB#[![!8FIS&
MF?,:3KS;8F]A(5DIJ35)PSCS#)-PXB4$UGJ*:Z3HFHY3 R5./UY:P:C?+XA#
M&ZD,^^<-1TDX3CS(L56&XUYY-;< >SM9&O=WDXV\M._CB79FO@&U<IM-DT)V
MPOCQWUJWR_/,[XQG=[]YL9DK)C3A4&%H?#(^#8CRV\PK1K9N@RREP7WDQ!I_
M *"L YY74IJ-8A-L?RGY?U!+ P04    " #O@>U4=7=+K8 "  #2!0  &0
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M>D8.+U?"^"_9A;.C"TKRQEA5M<'(H.(R_-EC>P\' 9/XA8"T#4@][Y#(L_S
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MZ(:4'Z->,+)UHVLM#0U"MRSIGP<JJT#GA91F)U@'PW^9U;]02P,$%     @
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M?J+DEBCD!C1<6%>M-!@G:DS*K5%P*D#.S#_5N:PXN6,/7)/#.[8HN3XZF1B
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M,+DF%R*!Y&\ '_FW242;)&91)^*<JD/2"P](%$11!UZO+4K/X?5WX'U/L0Q
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MH^Y47K;SRH%DN6EPO3 I668>$XQBS/4&M;YA3.X'^@5U4W7^'U!+ P04
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MT9C]J+KS37EGU'%GB, =R^16@-^SF,1-@+Y*H\X%/>=R@YR(=YA?@ "^ VB
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MT-C2V,\%=IT@C0&NSX30VX'9H.ICH[]02P,$%     @ [X'M5&026,:2 @
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MH&P SI=2FJ>.K9G]$YG^!5!+ P04    " #O@>U4/BO?*$\"   K!@  &0
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M=(#:7W..AXENR.W[&_X!4$L#!!0    ( .^![512?_Z"^P(  %H)   9
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MM8$%I*DF0AF/.TZCF5(##]M[]IO*.WI940D+GOYBD4KFAF^0"&):INJ6;[_
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M86FMF@G^_(#0 ?@]YESM.[J^-K]3P3]02P,$%     @ [X'M5.2[$-Q? @
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M -($Z/V5$+B?F*;3_6/2OU!+ P04    " #O@>U40/.<PHP%  "<,0  &0
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M<3LQITP6Y4PQT&+A*H(GH4U]X;IS4P*"M ;F_U0(O1G8!:JB<O '4$L#!!0
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M:V[H*@)M%]!\H12^=FQY["ZW] ]02P,$%     @ [X'M5!)FF*'> @  1 D
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MDSB/Z&6 (R-P98#/EXS)W49=4 RA[C]02P,$%     @ [X'M5&Z=BX+0 P
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M: I<WZ!^7S(F'T[TQE2SKYC\#U!+ P04    " #O@>U4X\4R9,$$   [&0
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M]7H#JBO+6T39T&)E3^Z9T'0/L*]+NGFA- /H^UP(_=(P!>J[7/P+4$L#!!0
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M2?%T*?A<R/P"\_I=ENFG@SS!9J?VY']02P,$%     @ [X'M5._$6V+5 P
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M](&EN5SK,R41!J"?+SE7QX$YM72GU.P_4$L#!!0    ( .^![51L P2N]0(
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M>AC+3@V8,I#O-Y2*TT1M4/5^P5]02P,$%     @ [X'M5#?=I%"E P  G0P
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MQR@@ZKZFGBA>5+W$DBOL3*IA@KT@"+T GZ\X5T\3W9ZTW67X!U!+ P04
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MI&I4\]L(: !<&ZCG2\;D;J 7J/Z=F/X"4$L#!!0    ( .^![52 HR>!EP(
M "\(   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;+56T6[:,!3]%2N;
MIE;:FL2!T'8A4H%5JS2FJJC;P[0'DUP2JXF=V0:ZOY_MA Q*0-O$7HCMW'-\
MSO6-+]&:BR>9 RCT7!9,#IU<J>K:=6620TGD!:^ Z3<++DJB]%1DKJP$D-2"
MRL+%GA>Z):',B2.[=B_BB"]501G<"R2794G$SQ$4?#UT?&>S\$"S7)D%-XXJ
MDL$,U&-U+_3,;5E26@*3E#,D8#%T;OSK\<#$VX O%-9R:XR,DSGG3V9REPX=
MSPB" A)E&(A^K& ,16&(M(P?#:?3;FF V^,-^ZWUKKW,B80Q+[[25.5#Y])!
M*2S(LE /?/T1&C]]PY?P0MI?M*YC^X&#DJ54O&S 6D%)6?TDSTT>M@!^> "
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #O@>U4D:]!^>X    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #O
M@>U4F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( .^![51P%+"I^P<  "D\   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #O
M@>U4GO4L[90&  ##'0  &               @($^$   >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ [X'M5.@ING[5 @  _0D  !@
M         ("!"!<  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( .^![52[CS7LE@4  - 7   8              " @1,:  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #O@>U4]?(_7K8'  #4/@
M&               @('?'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ [X'M5(4"C \\"   ;28  !@              ("!RR<  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .^![50@'#B]B 0
M -H)   8              " @3TP  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " #O@>U4KINL<H(&  "@#@  &               @('[
M-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ [X'M5+!^
MU()H(   7U\  !@              ("!LSL  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( .^![50SI.KY5 <  -01   9
M  " @5%<  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M[X'M5#E_RIJ> @   P8  !D              ("!W&,  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " #O@>U48K']C70"  !V!0  &0
M            @(&Q9@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( .^![52*@YWAS@(  +(&   9              " @5QI  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ [X'M5."[&&3\ @
MY08  !D              ("!86P  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " #O@>U4ECT1OYD"  !$!@  &0              @(&4
M;P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .^![528
MKBNKW0(  %X&   9              " @61R  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ [X'M5-945^JW P  1 D  !D
M     ("!>'4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .^![53BLL]BHP(  .<%   9              "
M@<&<  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ [X'M
M5(%FR[F^ P  EP@  !D              ("!FY\  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " #O@>U48659[C B  !6;0  &0
M        @(&0HP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( .^![53"2DPI"00  '4*   9              " @??%  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ [X'M5)&]34%W P  A @
M !D              ("!-\H  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " #O@>U4*G;-V84"  "U!0  &0              @('ES0
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .^![51;P/?
M8 (  $H%   9              " @:'0  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ [X'M5-L_L8^S @  2@8  !D
M ("!.-,  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #O
M@>U49'I01,X"  !>!@  &0              @($BU@  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .^![51U=TNM@ (  -(%   9
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M970S-2YX;6Q02P$"% ,4    " #O@>U4Z%0V8L8"   E!P  &0
M    @(%@[0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M .^![51TS/*+M (  &\)   9              " @5WP  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ [X'M5,V3Y5,V P  $0H  !D
M             ("!2/,  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " #O@>U4',8,/3T$  !@%0  &0              @(&U]@  >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .^![526+%4MU04
M  DA   9              " @2G[  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ [X'M5('N38(% P  7@<  !D              ("!
M-0$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #O@>U4
MLTLP=$@#  #3"@  &0              @(%Q! $ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( .^![51D$EC&D@(  "X'   9
M      " @? ' 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ [X'M5#XKWRA/ @  *P8  !D              ("!N0H! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #O@>U4(@2IA+4"  "+!P
M&0              @($_#0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( .^![512?_Z"^P(  %H)   9              " @2L0 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ [X'M5.2[$-Q?
M @  N04  !D              ("!71,! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " #O@>U4,O[(5'("  !O!@  &0
M@('S%0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( .^!
M[51 \YS"C 4  )PQ   9              " @9P8 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ [X'M5,'_CX-! P  8 H  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( .^![512F7D(70,  ) .   9
M  " @8PN 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M[X'M5&Z=BX+0 P  8Q0  !D              ("!(#(! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    " #O@>U4X\4R9,$$   [&0  &0
M            @($G-@$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( .^![52WM$Y-* ,  -<)   9              " @1\[ 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ [X'M5*V^)(>4!@
MM3T  !D              ("!?CX! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    " #O@>U4[\1;8M4#  "Q#@  &0              @(%)
M10$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( .^![51L
M P2N]0(  !L+   9              " @55) 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ [X'M5//W%;?M @  !PH  !D
M     ("!@4P! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .^![50%G!S$D ,  *D0   9              "
M@<)< 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ [X'M
M5("C)X&7 @  +P@  !D              ("!B6 ! 'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"% ,4    " #O@>U4R_ 2V3(#  #P$@  #0
M        @ %78P$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .^![527BKL<
MP    !,"   +              "  ;1F 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( .^![51HRR']+@4  /$L   /              "  9UG 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #O@>U4%MUK%"8"  !C*   &@
M    @ 'X; $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #O@>U4X>Q>$?0!  "B)P  $P              @ %6;P$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     3 !, ,L4  ![<0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>120</ContextCount>
  <ElementCount>349</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Organization and Recent Developments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/OrganizationAndRecentDevelopments</Role>
      <ShortName>Organization and Recent Developments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Liquidity and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LiquidityAndFinancialCondition</Role>
      <ShortName>Liquidity and Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Sale of Assets ??? Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperations</Role>
      <ShortName>Sale of Assets ??? Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccountsReceivable</Role>
      <ShortName>Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Revenue Disaggregation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregation</Role>
      <ShortName>Revenue Disaggregation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Sale of Assets ??? Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperationsTables</Role>
      <ShortName>Sale of Assets ??? Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccountsReceivableTables</Role>
      <ShortName>Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccountsReceivable</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Inventories</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PropertyAndEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Revenue Disaggregation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregationTables</Role>
      <ShortName>Revenue Disaggregation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/RevenueDisaggregation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Liquidity and Financial Condition (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative</Role>
      <ShortName>Liquidity and Financial Condition (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/LiquidityAndFinancialCondition</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives</Role>
      <ShortName>Summary of Significant Accounting Policies (Details-Useful lives)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare</Role>
      <ShortName>Summary of Significant Accounting Policies (Details - Earnings per share)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares</Role>
      <ShortName>Summary of Significant Accounting Policies (Details - Antidilutive shares)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Sale of Assets - Discontinued Operations (Details - Allocation of sale price)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice</Role>
      <ShortName>Sale of Assets - Discontinued Operations (Details - Allocation of sale price)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Sale of Assets - Discontinued Operations (Details - Discontinued Operations)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations</Role>
      <ShortName>Sale of Assets - Discontinued Operations (Details - Discontinued Operations)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccountsReceivableDetails</Role>
      <ShortName>Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccountsReceivableTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/InventoriesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/DebtDetailsNarrative</Role>
      <ShortName>Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Debt</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Leases (Details - Balance sheet information related to leases)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases</Role>
      <ShortName>Leases (Details - Balance sheet information related to leases)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/LeasesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Leases (Details - Minimum operating lease liabilities)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities</Role>
      <ShortName>Leases (Details - Minimum operating lease liabilities)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/LeasesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/StockholdersEquity</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Stock-Based Compensation (Details-Assumptions)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions</Role>
      <ShortName>Stock-Based Compensation (Details-Assumptions)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation (Details-Stock-based compensation)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Stock-Based Compensation (Details-Plans)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-plans</Role>
      <ShortName>Stock-Based Compensation (Details-Plans)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Stock-Based Compensation (Details-Option activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity</Role>
      <ShortName>Stock-Based Compensation (Details-Option activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity</Role>
      <ShortName>Stock-Based Compensation (Details-Restricted stock activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Income Taxes (Details-Deferred taxes)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes</Role>
      <ShortName>Income Taxes (Details-Deferred taxes)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Income Taxes (Details-Income source)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource</Role>
      <ShortName>Income Taxes (Details-Income source)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Income Taxes (Details-Income tax expense)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense</Role>
      <ShortName>Income Taxes (Details-Income tax expense)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate</Role>
      <ShortName>Income Taxes (Details-Reconciliation of tax rate)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - Employee Benefit Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative</Role>
      <ShortName>Employee Benefit Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue</Role>
      <ShortName>Revenue Disaggregation (Details - Disaggregation of revenue)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/RevenueDisaggregationTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - Geographic Information (Details - Geographic regions)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions</Role>
      <ShortName>Geographic Information (Details - Geographic regions)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sonoma_i10k-033122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - Revenue Disaggregation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative</Role>
      <ShortName>Revenue Disaggregation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/RevenueDisaggregationTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="sonoma_i10k-033122.htm">sonoma_i10k-033122.htm</File>
    <File>snoa-20220331.xsd</File>
    <File>snoa-20220331_cal.xml</File>
    <File>snoa-20220331_def.xml</File>
    <File>snoa-20220331_lab.xml</File>
    <File>snoa-20220331_pre.xml</File>
    <File>sonoma_ex2301.htm</File>
    <File>sonoma_ex2302.htm</File>
    <File>sonoma_ex3101.htm</File>
    <File>sonoma_ex3102.htm</File>
    <File>sonoma_ex3201.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>a1.jpg</File>
    <File>a10.jpg</File>
    <File>a11.jpg</File>
    <File>a2.jpg</File>
    <File>a3.jpg</File>
    <File>a4.jpg</File>
    <File>a5.jpg</File>
    <File>a6.jpg</File>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="659">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sonoma_i10k-033122.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 120,
   "dts": {
    "calculationLink": {
     "local": [
      "snoa-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "snoa-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sonoma_i10k-033122.htm"
     ]
    },
    "labelLink": {
     "local": [
      "snoa-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "snoa-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "snoa-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 523,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 57,
    "http://sonomapharma.com/20220331": 14,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 75
   },
   "keyCustom": 33,
   "keyStandard": 316,
   "memberCustom": 18,
   "memberStandard": 29,
   "nsprefix": "SNOA",
   "nsuri": "http://sonomapharma.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://sonomapharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Sale of Assets \u2013 Discontinued Operations",
     "role": "http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperations",
     "shortName": "Sale of Assets \u2013 Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Accounts Receivable",
     "role": "http://sonomapharma.com/role/AccountsReceivable",
     "shortName": "Accounts Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Inventories",
     "role": "http://sonomapharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Property and Equipment",
     "role": "http://sonomapharma.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Debt",
     "role": "http://sonomapharma.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Leases",
     "role": "http://sonomapharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Commitments and Contingencies",
     "role": "http://sonomapharma.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://sonomapharma.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "role": "http://sonomapharma.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Stock-Based Compensation",
     "role": "http://sonomapharma.com/role/Stock-basedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Income Taxes",
     "role": "http://sonomapharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Employee Benefit Plan",
     "role": "http://sonomapharma.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Revenue Disaggregation",
     "role": "http://sonomapharma.com/role/RevenueDisaggregation",
     "shortName": "Revenue Disaggregation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SNOA:ScheduleOfAllocationOfSalePriceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Sale of Assets \u2013 Discontinued Operations (Tables)",
     "role": "http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperationsTables",
     "shortName": "Sale of Assets \u2013 Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "SNOA:ScheduleOfAllocationOfSalePriceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Accounts Receivable (Tables)",
     "role": "http://sonomapharma.com/role/AccountsReceivableTables",
     "shortName": "Accounts Receivable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Inventories (Tables)",
     "role": "http://sonomapharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://sonomapharma.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Property and Equipment (Tables)",
     "role": "http://sonomapharma.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Leases (Tables)",
     "role": "http://sonomapharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Income Taxes (Tables)",
     "role": "http://sonomapharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Revenue Disaggregation (Tables)",
     "role": "http://sonomapharma.com/role/RevenueDisaggregationTables",
     "shortName": "Revenue Disaggregation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Liquidity and Financial Condition (Details Narrative)",
     "role": "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative",
     "shortName": "Liquidity and Financial Condition (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "SNOA:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-012022-03-31_us-gaap_OfficeEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives",
     "shortName": "Summary of Significant Accounting Policies (Details-Useful lives)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-012022-03-31_us-gaap_OfficeEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare",
     "shortName": "Summary of Significant Accounting Policies (Details - Earnings per share)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares",
     "shortName": "Summary of Significant Accounting Policies (Details - Antidilutive shares)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Comprehensive (Loss) Income",
     "role": "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome",
     "shortName": "Consolidated Statements of Comprehensive (Loss) Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "SNOA:ScheduleOfAllocationOfSalePriceTableTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2020-06-24_custom_MicromedLabsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Sale of Assets - Discontinued Operations (Details - Allocation of sale price)",
     "role": "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice",
     "shortName": "Sale of Assets - Discontinued Operations (Details - Allocation of sale price)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "SNOA:ScheduleOfAllocationOfSalePriceTableTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2020-06-24_custom_MicromedLabsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Sale of Assets - Discontinued Operations (Details - Discontinued Operations)",
     "role": "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations",
     "shortName": "Sale of Assets - Discontinued Operations (Details - Discontinued Operations)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Accounts Receivable (Details)",
     "role": "http://sonomapharma.com/role/AccountsReceivableDetails",
     "shortName": "Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Inventories (Details)",
     "role": "http://sonomapharma.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Property and Equipment (Details)",
     "role": "http://sonomapharma.com/role/PropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Property and Equipment (Details Narrative)",
     "role": "http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative",
     "shortName": "Property and Equipment (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentDecreaseForgiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - Debt (Details Narrative)",
     "role": "http://sonomapharma.com/role/DebtDetailsNarrative",
     "shortName": "Debt (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentDecreaseForgiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2020-03-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2020-03-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - Leases (Details - Balance sheet information related to leases)",
     "role": "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases",
     "shortName": "Leases (Details - Balance sheet information related to leases)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - Leases (Details - Minimum operating lease liabilities)",
     "role": "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities",
     "shortName": "Leases (Details - Minimum operating lease liabilities)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesAndWages",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "role": "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesAndWages",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "role": "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-012022-03-31_us-gaap_SeriesCPreferredStockMember44329203",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - Stock-Based Compensation (Details-Assumptions)",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions",
     "shortName": "Stock-Based Compensation (Details-Assumptions)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - Stock-Based Compensation (Details-Stock-based compensation)",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation",
     "shortName": "Stock-Based Compensation (Details-Stock-based compensation)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-012022-03-31_us-gaap_CostOfSalesMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - Stock-Based Compensation (Details-Plans)",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
     "shortName": "Stock-Based Compensation (Details-Plans)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - Stock-Based Compensation (Details-Option activity)",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
     "shortName": "Stock-Based Compensation (Details-Option activity)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-012022-03-31_us-gaap_StockOptionMember44329562",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2021-03-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
     "shortName": "Stock-Based Compensation (Details-Restricted stock activity)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2021-03-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://sonomapharma.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - Income Taxes (Details-Deferred taxes)",
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes",
     "shortName": "Income Taxes (Details-Deferred taxes)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - Income Taxes (Details-Income source)",
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
     "shortName": "Income Taxes (Details-Income source)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - Income Taxes (Details-Income tax expense)",
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense",
     "shortName": "Income Taxes (Details-Income tax expense)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)",
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate",
     "shortName": "Income Taxes (Details-Reconciliation of tax rate)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_DomesticCountryMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - Income Taxes (Details Narrative)",
     "role": "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_DomesticCountryMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PensionAndOtherPostretirementBenefitContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - Employee Benefit Plan (Details Narrative)",
     "role": "http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative",
     "shortName": "Employee Benefit Plan (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PensionAndOtherPostretirementBenefitContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)",
     "role": "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
     "shortName": "Revenue Disaggregation (Details - Disaggregation of revenue)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-012022-03-31_us-gaap_ProductMember_custom_HumanCareMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure - Geographic Information (Details - Geographic regions)",
     "role": "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions",
     "shortName": "Geographic Information (Details - Geographic regions)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-012022-03-31_us-gaap_ProductMember_us-gaap_SalesRevenueSegmentMember_country_US",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000068 - Disclosure - Revenue Disaggregation (Details Narrative)",
     "role": "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative",
     "shortName": "Revenue Disaggregation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-012022-03-31_us-gaap_ServiceMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Organization and Recent Developments",
     "role": "http://sonomapharma.com/role/OrganizationAndRecentDevelopments",
     "shortName": "Organization and Recent Developments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Liquidity and Financial Condition",
     "role": "http://sonomapharma.com/role/LiquidityAndFinancialCondition",
     "shortName": "Liquidity and Financial Condition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "sonoma_i10k-033122.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for sales discounts, rebates, distributor fees and returns",
        "label": "Allowance for sales discounts, rebates, distributor fees and returns"
       }
      }
     },
     "localname": "AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_AnimalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Animal Care [Member]"
       }
      }
     },
     "localname": "AnimalCareMember",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets",
        "negatedLabel": "Benefit from lease assumed less principal payments on ROU Assets"
       }
      }
     },
     "localname": "BenefitFromLeaseAssumedLessPrincipalPaymentsOnRouAssets",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for (recovery of) discounts, rebates, distributor fees and returns"
       }
      }
     },
     "localname": "ChangeInProvisionForDiscountsRebatesDistributorFeesAndReturns",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_CommonStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Units [Member]"
       }
      }
     },
     "localname": "CommonStockUnitsMember",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_ContractWithCustomerLiabilityCurrentInvekra": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue Invekra"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrentInvekra",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_DeferredConsiderationNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of deferred consideration, net of discount"
       }
      }
     },
     "localname": "DeferredConsiderationNetCurrent",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_DeferredConsiderationNetNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred consideration, net of discount, less current portion"
       }
      }
     },
     "localname": "DeferredConsiderationNetNoncurrent",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredTaxLiabilitiesRightOfUseAsset",
        "negatedLabel": "Right of Use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_DisclosureLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "DisclosureLeasesAbstract",
     "nsuri": "http://sonomapharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "SNOA_DiscountsRebatesDistributorFeesAndReturns": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/AccountsReceivableDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounts, rebates, distributor fees and returns",
        "label": "DiscountsRebatesDistributorFeesAndReturns",
        "negatedLabel": "Less: discounts, rebates, distributor fees and returns"
       }
      }
     },
     "localname": "DiscountsRebatesDistributorFeesAndReturns",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Working Capital",
        "label": "DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital",
        "negatedLabel": "Less: Working capital adjustment"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherWorkingCapital",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_EarningPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total loss per share",
        "verboseLabel": "Net loss per share: basic and diluted"
       }
      }
     },
     "localname": "EarningPerShareBasicAndDiluted",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "xbrltype": "perShareItemType"
    },
    "SNOA_EarningPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share: basic and diluted"
       }
      }
     },
     "localname": "EarningPerShareBasicAndDilutedAbstract",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "SNOA_FirstCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Customer [Member]"
       }
      }
     },
     "localname": "FirstCustomerMember",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_ForeignTaxTrueup": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign tax true-up"
       }
      }
     },
     "localname": "ForeignTaxTrueup",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "SNOA_ForgivenessOfPppLoan": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ForgivenessOfPppLoan",
        "negatedLabel": "Forgiveness of PPP loan"
       }
      }
     },
     "localname": "ForgivenessOfPppLoan",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_HumanCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Human Care [Member]"
       }
      }
     },
     "localname": "HumanCareMember",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_IncomeLossFromContinuingOperationPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Continuing operations",
        "verboseLabel": "Loss per share from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationPerBasicAndDilutedShare",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "xbrltype": "perShareItemType"
    },
    "SNOA_IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued operations",
        "verboseLabel": "Income per share from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "xbrltype": "perShareItemType"
    },
    "SNOA_IncreaseDecreaseInDeferredConsiderationNetOfDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred consideration, net of discount"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredConsiderationNetOfDiscount",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_IncreaseDecreaseInDeposits1": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IncreaseDecreaseInDeposits1",
        "negatedLabel": "Deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeposits1",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_IncreaseDecreaseInWithholdingTaxPayable": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding tax payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInWithholdingTaxPayable",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_InsurancePremiums1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Premiums 1 [Member]"
       }
      }
     },
     "localname": "InsurancePremiums1Member",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_InsurancePremiums2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Premiums 2 [Member]"
       }
      }
     },
     "localname": "InsurancePremiums2Member",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_InsurancePremiumsFinanced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance premiums financed"
       }
      }
     },
     "localname": "InsurancePremiumsFinanced",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_MicromedLabsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Micromed Labs [Member]"
       }
      }
     },
     "localname": "MicromedLabsMember",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_NetRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Revenues [Member]"
       }
      }
     },
     "localname": "NetRevenuesMember",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_PaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paycheck Protection Program [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramMember",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_PaymentsOnPppLoan": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PaymentsOnPppLoan",
        "negatedLabel": "Payments on PPP Loan"
       }
      }
     },
     "localname": "PaymentsOnPppLoan",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_Plan2006Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan 2006.",
        "label": "2006 Plan [Member]"
       }
      }
     },
     "localname": "Plan2006Member",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_Plan2011Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One customer member",
        "label": "2011 Plan [Member]"
       }
      }
     },
     "localname": "Plan2011Member",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_Plan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2016 Plan [Member]"
       }
      }
     },
     "localname": "Plan2016Member",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_Plan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2017 [Member]"
       }
      }
     },
     "localname": "Plan2017Member",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_Plan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2021 [Member]"
       }
      }
     },
     "localname": "Plan2021Member",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment estimated useful life"
       }
      }
     },
     "localname": "PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SNOA_ScheduleOfAllocationOfSalePriceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of allocation of sale price"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfSalePriceTableTextBlock",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock-based awards outstanding by plan"
       }
      }
     },
     "localname": "ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SNOA_SecondCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Customer [Member]"
       }
      }
     },
     "localname": "SecondCustomerMember",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options and restricted stock units outstanding, including both vested and non-vested options.",
        "label": "Total options and restricted stock units outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsOutstandingNumber",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans"
     ],
     "xbrltype": "sharesItemType"
    },
    "SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with exercise of common stock warrants"
       }
      }
     },
     "localname": "SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsAmount",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with exercise of common stock warrants, shares"
       }
      }
     },
     "localname": "SharesIssuedInConnectionWithExerciseOfCommonStockWarrantsShares",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "SNOA_SharesIssuedWithConversionOfCShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued with conversion of C shares"
       }
      }
     },
     "localname": "SharesIssuedWithConversionOfCShares",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_SharesIssuedWithConversionOfCSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued with conversion of C shares, shares"
       }
      }
     },
     "localname": "SharesIssuedWithConversionOfCSharesShares",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "SNOA_ShippingAndHandlingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shipping and Handling Costs"
       }
      }
     },
     "localname": "ShippingAndHandlingCostsPolicyTextBlock",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "SNOA_StatesBankInAtlantaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "States Bank In Atlanta [Member]"
       }
      }
     },
     "localname": "StatesBankInAtlantaMember",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_ThirdCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Customer [Member]"
       }
      }
     },
     "localname": "ThirdCustomerMember",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_TromblyBusinessLawMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trombly Business Law [Member]"
       }
      }
     },
     "localname": "TromblyBusinessLawMember",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "SNOA_TrueupsOfStateDeferredAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "True-ups of State deferred assets",
        "label": "True-up of state deferred assets"
       }
      }
     },
     "localname": "TrueupsOfStateDeferredAssets",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "SNOA_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average shares outstanding: basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "xbrltype": "sharesItemType"
    },
    "SNOA_WithholdingTaxPayable": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding Tax Payable"
       }
      }
     },
     "localname": "WithholdingTaxPayable",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "SNOA_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital",
        "label": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://sonomapharma.com/20220331",
     "presentation": [
      "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r565",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r565",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r565",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r565",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity public float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latin America [Member]"
       }
      }
     },
     "localname": "LatinAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r201",
      "r317",
      "r321",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r201",
      "r317",
      "r321",
      "r530"
     ],
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r198",
      "r256",
      "r257",
      "r317",
      "r319",
      "r487",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r198",
      "r256",
      "r257",
      "r317",
      "r319",
      "r487",
      "r527",
      "r528"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r199",
      "r200",
      "r317",
      "r320",
      "r529",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r317",
      "r320",
      "r529",
      "r538",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.",
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r66",
      "r483"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r29",
      "r50",
      "r202",
      "r203"
     ],
     "calculation": {
      "http://sonomapharma.com/role/AccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r202",
      "r203"
     ],
     "calculation": {
      "http://sonomapharma.com/role/AccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails",
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37",
      "r240"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r53",
      "r79",
      "r80",
      "r81",
      "r517",
      "r535",
      "r536"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive loss",
        "negatedLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r78",
      "r81",
      "r87",
      "r88",
      "r89",
      "r139",
      "r140",
      "r141",
      "r435",
      "r477",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r379",
      "r380",
      "r381",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.",
        "label": "Stock based compensation related to issuance of common stock restricted stock grants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Employee stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r57",
      "r205",
      "r213",
      "r214",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r57",
      "r205",
      "r213"
     ],
     "calculation": {
      "http://sonomapharma.com/role/AccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedLabel": "Less: allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r116",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r39",
      "r133",
      "r185",
      "r190",
      "r196",
      "r211",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r429",
      "r436",
      "r452",
      "r481",
      "r483",
      "r501",
      "r516"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r32",
      "r65",
      "r133",
      "r211",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r429",
      "r436",
      "r452",
      "r481",
      "r483"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r27",
      "r35",
      "r118"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r110",
      "r118",
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r110",
      "r455"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash operating and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r130",
      "r133",
      "r151",
      "r152",
      "r153",
      "r155",
      "r156",
      "r161",
      "r162",
      "r163",
      "r211",
      "r260",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r283",
      "r284",
      "r288",
      "r292",
      "r299",
      "r452",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r75",
      "r505",
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r258",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r139",
      "r140",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock shares authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r49",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r49",
      "r483"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.0001 par value; 24,000,000 shares authorized at March 31, 2022 and 2021, respectively, 3,100,937 and 2,092,909 shares issued and outstanding at March 31, 2022 and 2021, respectively (Note 13)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r327",
      "r328",
      "r335",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r83",
      "r85",
      "r94",
      "r427",
      "r439",
      "r508",
      "r524"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r201",
      "r450",
      "r451",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r201",
      "r450",
      "r451",
      "r537",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r201",
      "r450",
      "r451",
      "r537",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r166",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk and Major Customers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r170",
      "r171",
      "r201",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Significant customer concentration"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r201",
      "r450",
      "r451",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r126",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r121",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Preferred stock converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r121",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Common stock issued upon conversion"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r283",
      "r284",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r99",
      "r487"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r409",
      "r416",
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r409",
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r169",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Approval for forgiveness"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r271",
      "r274",
      "r275",
      "r463",
      "r464",
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r72",
      "r273",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r73",
      "r272",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r74",
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Principal payments made"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r410",
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r410",
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "verboseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r134",
      "r410",
      "r416",
      "r417",
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Total deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r43",
      "r44",
      "r399",
      "r502",
      "r514"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Long-term deferred revenue Invekra"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r410",
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": {
     "auth_ref": [
      "r405",
      "r407",
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.",
        "label": "Foreign tax credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r405",
      "r407",
      "r408"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Other deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Allowances and accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r116",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r116",
      "r180"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r137",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Common Stock Purchase Warrants and Other Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregated Revenue by Source"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r338",
      "r339",
      "r373",
      "r374",
      "r376",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r3",
      "r5",
      "r7"
     ],
     "calculation": {
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Gain on disposal of discontinued operations before income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r15",
      "r92",
      "r522"
     ],
     "calculation": {
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Total income from discontinued operations, before tax"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r15",
      "r20",
      "r392",
      "r415",
      "r422"
     ],
     "calculation": {
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "negatedLabel": "Income Tax benefit (expense)"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r1",
      "r2",
      "r17",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "negatedLabel": "Less: Funds remaining in escrow"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r16",
      "r23"
     ],
     "calculation": {
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "verboseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue": {
     "auth_ref": [
      "r1",
      "r2",
      "r17",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue",
        "negatedLabel": "Less: Services due from buyer"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {
     "auth_ref": [
      "r16",
      "r23"
     ],
     "calculation": {
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)",
        "totalLabel": "Income from discontinued operations before tax"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "auth_ref": [
      "r1",
      "r2",
      "r17",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.",
        "label": "Customer base"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Selling general and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r16",
      "r23"
     ],
     "calculation": {
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r24",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Sale of Assets \u2013 Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Income Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Totals"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r135",
      "r393",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Expected federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r393",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r393",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Foreign earnings taxed at different rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r393",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "negatedLabel": "Effect of permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r393",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effect of intercompany interest permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "negatedLabel": "Total effective rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r393",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedLabel": "State income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Salaries and related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r87",
      "r88",
      "r89",
      "r139",
      "r140",
      "r141",
      "r143",
      "r148",
      "r150",
      "r160",
      "r212",
      "r299",
      "r306",
      "r379",
      "r380",
      "r381",
      "r412",
      "r413",
      "r447",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r477",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.",
        "label": "Transfers in or out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.",
        "label": "Foreign currency transaction loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Reporting"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r116",
      "r237",
      "r242"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain on sale of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r116",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Forgiveness of PPP Loan"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r98",
      "r133",
      "r185",
      "r189",
      "r192",
      "r195",
      "r197",
      "r211",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r452"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r235",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r91",
      "r185",
      "r189",
      "r192",
      "r195",
      "r197",
      "r500",
      "r506",
      "r510",
      "r525"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r133",
      "r142",
      "r185",
      "r189",
      "r192",
      "r195",
      "r197",
      "r211",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r427",
      "r448",
      "r452"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Loss from continuing operations",
        "totalLabel": "Loss from continuing operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r20",
      "r23",
      "r423",
      "r522"
     ],
     "calculation": {
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income from discontinued operations, net of tax",
        "totalLabel": "Income from discontinued operations, net of tax",
        "verboseLabel": "Income from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-DiscontinuedOperations",
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r2",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r18",
      "r21",
      "r22",
      "r23",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r243",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r135",
      "r394",
      "r397",
      "r404",
      "r414",
      "r420",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r149",
      "r150",
      "r183",
      "r392",
      "r415",
      "r421",
      "r526"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r388",
      "r389",
      "r397",
      "r398",
      "r403",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r115",
      "r484"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredCharges": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.",
        "label": "Decrease in stock based compensation deferred tax asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income tax expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r115",
      "r470"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r509"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r108",
      "r112",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r58",
      "r220"
     ],
     "calculation": {
      "http://sonomapharma.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r28",
      "r63",
      "r483"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://sonomapharma.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories, net",
        "totalLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r61",
      "r127",
      "r159",
      "r217",
      "r218",
      "r221",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r59",
      "r220"
     ],
     "calculation": {
      "http://sonomapharma.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r63",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease cost information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesOperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases:"
       }
      }
     },
     "localname": "LeasesOperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of minimum operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments, undiscounted"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r69",
      "r133",
      "r191",
      "r211",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r430",
      "r436",
      "r437",
      "r452",
      "r481",
      "r482"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r56",
      "r133",
      "r211",
      "r452",
      "r483",
      "r504",
      "r519"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r71",
      "r133",
      "r211",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r430",
      "r436",
      "r437",
      "r452",
      "r481",
      "r482",
      "r483"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Accounts Receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LoansPayable": {
     "auth_ref": [
      "r42",
      "r503",
      "r515"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Loans payable"
       }
      }
     },
     "localname": "LoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-term debt, less current portion \u2013 PPP"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r74",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Manufacturing, lab, and other equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketingExpense": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.",
        "label": "Advertising costs"
       }
      }
     },
     "localname": "MarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r110",
      "r114",
      "r117"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r23",
      "r82",
      "r84",
      "r89",
      "r93",
      "r117",
      "r133",
      "r142",
      "r144",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r154",
      "r185",
      "r189",
      "r192",
      "r195",
      "r197",
      "r211",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r448",
      "r452",
      "r507",
      "r523"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative",
      "http://sonomapharma.com/role/StatementsOfCashFlows",
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Current portion of debt-PPP"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r185",
      "r189",
      "r192",
      "r195",
      "r197"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r469",
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeaseLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities \u2013 current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities, less current portion",
        "verboseLabel": "Operating lease liabilities \u2013 non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "auth_ref": [
      "r468",
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments, Use",
        "negatedLabel": "Operating Lease, Payments, Use"
       }
      }
     },
     "localname": "OperatingLeasePaymentsUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease, right of use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r472",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted-average discount rate - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r471",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining lease term - operating leases (in months)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r26",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization and Recent Developments"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/OrganizationAndRecentDevelopments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r427",
      "r428",
      "r434"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r427",
      "r428",
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLongTermDebtCurrent": {
     "auth_ref": [
      "r40",
      "r41"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.",
        "label": "Short-term debt"
       }
      }
     },
     "localname": "OtherLongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r64",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitContributions": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.",
        "label": "Company contributions to 401(k) plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r48",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Convertible preferred stock par value",
        "verboseLabel": "Preferred stock par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Convertible preferred stock shares authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r48",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Convertible preferred stock shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Convertible preferred stock shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r48",
      "r483"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2022 and 2021, respectively, no shares issued and outstanding at March 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets",
        "verboseLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r30",
      "r222",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r31",
      "r223",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Tax prepaid to Mexican tax authorities"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from sale of business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssets-DiscontinuedOperationsDetails-AllocationOfSalePrice"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLoans": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from principal payments made on loans related to operating activities.",
        "label": "Proceeds from loan"
       }
      }
     },
     "localname": "ProceedsFromLoans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from PPP Loan"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Micromed Transaction"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds on short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r105",
      "r378"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of common stock options and purchase warrants"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r23",
      "r82",
      "r84",
      "r89",
      "r109",
      "r133",
      "r142",
      "r149",
      "r150",
      "r185",
      "r189",
      "r192",
      "r195",
      "r197",
      "r211",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r427",
      "r432",
      "r433",
      "r438",
      "r439",
      "r448",
      "r452",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Income before income taxes"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r249",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r36",
      "r239"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r241",
      "r483",
      "r511",
      "r520"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Office equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r241",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Useful asset life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r96",
      "r215"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Recovery of doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r204",
      "r208",
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "verboseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r329",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r329",
      "r478",
      "r480",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Principal payments on short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r386",
      "r486",
      "r553"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r52",
      "r306",
      "r483",
      "r518",
      "r534",
      "r536"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r139",
      "r140",
      "r141",
      "r143",
      "r148",
      "r150",
      "r212",
      "r379",
      "r380",
      "r381",
      "r412",
      "r413",
      "r447",
      "r531",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r176",
      "r177",
      "r188",
      "r193",
      "r194",
      "r198",
      "r199",
      "r201",
      "r316",
      "r317",
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue Disaggregation"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r90",
      "r133",
      "r176",
      "r177",
      "r188",
      "r193",
      "r194",
      "r198",
      "r199",
      "r201",
      "r211",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r452",
      "r510"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative",
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Annual salaries"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueSegmentMember": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified business segment, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Segment Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/GeographicInformationDetails-GeographicRegions"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of antidilutive shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r2",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r18",
      "r21",
      "r22",
      "r23",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Assets and liabilities of disposal group"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SaleOfAssetsDiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Reconciliation of federal income tax rate to effective rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r372",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Employee stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Income tax provision domestic and foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r34",
      "r60",
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of unvested restricted stock activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r97",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of geographic sales"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r343",
      "r359",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Weighted-average assumptions of fair value of employee stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r130",
      "r161",
      "r162",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r292",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r201",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r251",
      "r252",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r46",
      "r48",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Potential severance"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://sonomapharma.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-stock-basedCompensation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Restricted stock awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted average award date fair value per share, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested restricted stock awards, ending balance",
        "periodStartLabel": "Unvested restricted stock awards, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average award date fair value per share, outstanding ending balance",
        "periodStartLabel": "Weighted average award date fair value per share, outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted stock awards vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted average award date fair value per share, vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Restricted stock units outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Increase in shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Shares initially authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Stock-based awards available for grant",
        "verboseLabel": "Shares available for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of Shares Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted- Average Exercise Price Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Shares Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of Shares Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Weighted- Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.",
        "label": "Aggregate intrinsic value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of Shares Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Fair value of options granted, per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Aggregate Intrinsic Value Outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Options outstanding",
        "periodEndLabel": "Number of Shares Outstanding at end of period",
        "periodStartLabel": "Number of Shares Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price Outstanding at end of period",
        "periodStartLabel": "Weighted- Average Exercise Price Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted- Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted- Average Exercise Price Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Fair value of common stock on date of grant",
        "verboseLabel": "Weighted- Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r342",
      "r365",
      "r366",
      "r367",
      "r368",
      "r371",
      "r382",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate Intrinsic Value Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted- Average Contractual Term Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted- Average Contractual Term Outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r125",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r8",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r201",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r245",
      "r251",
      "r252",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r130",
      "r133",
      "r151",
      "r152",
      "r153",
      "r155",
      "r156",
      "r161",
      "r162",
      "r163",
      "r211",
      "r260",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r283",
      "r284",
      "r288",
      "r292",
      "r299",
      "r452",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r76",
      "r87",
      "r88",
      "r89",
      "r139",
      "r140",
      "r141",
      "r143",
      "r148",
      "r150",
      "r160",
      "r212",
      "r299",
      "r306",
      "r379",
      "r380",
      "r381",
      "r412",
      "r413",
      "r447",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r477",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r160",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued in connection with ATM, net of transaction costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r299",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock based compensation related to common stock restricted stock grants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r48",
      "r49",
      "r299",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Shares issued in connection with vesting of restricted stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r49",
      "r299",
      "r306",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Shares issued in connection with exercise of stock options, shares",
        "negatedLabel": "Number of Shares Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued in connection with ATM, net of transaction costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r48",
      "r49",
      "r299",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "verboseLabel": "Stock based compensation related to issuance of common stock restricted stock grants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r299",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Shares issued in connection with vesting of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r299",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Shares issued in connection with exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r49",
      "r54",
      "r55",
      "r133",
      "r206",
      "r211",
      "r452",
      "r483"
     ],
     "calculation": {
      "http://sonomapharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets",
      "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r131",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r306",
      "r307",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r46",
      "r47",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Liquidity and Financial Condition"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/LiquidityAndFinancialCondition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Research credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r387",
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r164",
      "r165",
      "r167",
      "r168",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=51888271"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126960819&loc=d3e20905-112640"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r554": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r555": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r556": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r557": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r558": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r559": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r561": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r562": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r563": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r564": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r565": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r566": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r567": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r568": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r569": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r571": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r572": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r573": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r574": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001683168-22-004940-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-22-004940-xbrl.zip
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MQ9+V;WA]:1DT@RU&P,@@/*=$PXF")^' T'5PF;6VCH!:/7XHF]SYG"$[/H
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M7]=I+>N3/Y*I&IKH?/V2-3EH^HOM.F-A-Z16N%9'W^;-M=EX/\+&FF0N@<1
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MWA^RGSPH.[&BIL._7_4BI'61"AO?%3&0\J-T-[*[\/(8#1(>B$#@W BB4-&
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M>_EF5<A&%?^E%Q&^=]5=K*(O\G+CO]A]K>DIC<W3B4OY]UH;;9[RVNJ?Q7+
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MW:J;<Z0')P6]%VY,,V+]Q3>J\D]*U82)J.[;_"4>6NAA;A5BY>%X.%"R;>8
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M-NT\/G(8>SKXAK56+?%.+Z&DZ%UQQ*QSS\L]#H1'3%U/YLZ !PNM5(X?\XR
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MHS_B,T9.H<Q]5=[E&&(YZTW'!KGYW2:E$6&M].1!$BJPA\S*V<(+F-"VVV@
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M>#@6C,#U8DS!8&X29.)DKW ^VI35D<\(HT]O+XGY6GKS[SUC 4%A.3$MPNL
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M0^J('3J@M0?;A^,]!Q)=*Z^3'-L6+5#5D4J6^FS%[NYWLGQ.8;D.[=:VE5K
M:7L#M46TZM,&3WPTU*YQ@NK13%U.&BA'ICH)L.3 $O1E ^:J#CA<E8C4-\_H
M<]4R5V;VXO9$=U-4[M><_<%DYA;Z?&P200>P>E7(SE@OY)8IJ ,^=F^ YFHB
MH/8*=\HM+D))?688A"K_0N$^+.IW*$^ +\$SJ>0H64;!!]:K>FAE*O22U-_9
MM+$*6FC=+__K@;9%GU 7(,]"!]-O%.QCGGTE?PB_<'[$#V)$(6,6,B_[B6>_
MST%\3R*65NWYT3G"NI^DBZ7\4'0I<QY6.D#3FU5S5[U!D: EJPI2J)9!WG/8
M$[!&#F#4.ZZ28.W)<3$* :5R;.4N:$#4JY]2SW]XZH ;ESIQBV7\4'0M<S(]
M'/5W/9],/+L\1UB^:JAOXK1I3!)RF#@=W198.HB'/B8G4T*5"J@FHPLGO]O\
MD@BY)Z!=*"@.=%W0 =C<5)<TZ=/3!L4ZH/F-_I\>,?[Z/V$,[]<!LG]-'X'>
MD="9>YW.V)6Z-ABKV?\CO#Y) ^LSJ$\;5$#-5X336*2Q /4V5P\=( R+=1V0
MBOM3H0%GJ?[0^A[E5B>X$DV Q^@FESG*G3[H@HA%BL00FI8>_CRD!^525]CC
M!5K%\I2]SV3Q6.DYL6=?-,Y)L.M[S(>;X&\'&#D/NA1% ,U=IKV%]A"SM6VO
M.XT-_E,'T/!>IU$G+3-.H:,.I3<1S]_..?K]"M:.E4: ,#D>&KQ:BR[EG>HV
M4**=A:K/H.UTIK'WHRH3,Z <T '+?#F_*BPJP7F_G<\/#W3 @,/?)KFJ6,:@
MS9,-K77 $V9> 1ZI^UPP15!TUWLC#K&N45I)Q\@-^F+G;#-)F]H 2<[&+7TT
M1Y?5-FS3 4?7@<H6@>881M;@M,U \P9%8K4P'&UH+D/DFP8GXW+2YW?W+1-Y
M:YK=[)/8"N.!&,;"WKY>[(]?Z("7BQJI?_B>E'FIY0H*.-23!S+UJ[DSQPL^
M#OUEQ]%R& ^NLIC+RTF2M>"C_"'HU?*"?SE2+IX](KVV<.63G%7R2)4A)\LP
M>1?A\%*QZM<&EG0N7GT=?U$'M AXZJ6ZO2WJ=0.W%<9=[(5=H& %);M*2U'A
M>!GCM0[83KX@Z]\FJ?KJUR ;,1VED4_Q*$[*#%8LUTEW(OTWG-$>65 )CW7
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M68.Y:(_>&^"UN3C%_4@P)+.?5NTF_L[47G$?HZ_RE*38]__Y]+]UMU<'!'N
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MK$@L2SQDW$]Q/HE(:RF\16XD7ES^NW?I>1<?0/N$8Q%3JX?9BO@8PP]M=,$
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M [8V<C_=0N8?P.0\@'U6NPMQ,W@IT?VUU\7?>EP1*^_K[XY>Q;LH)A)B>*=
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M9H_W?:Z8)".(=HZ(L?:D 0LOC?*P&?2?^2K(T)DQ WL")*<_D-4]UM_H++Z
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M,&LY#8Y-T32GSNG]NW1CI69CCZ]G[G_Y[W^.^S^V;^4/_AM02P,$%     @
M[X'M5-:VQ3U,%   ;!4   8   !A,BYJ<&>=5WE8$W>W'C9QHXAL+JVIJ*@@
MIJ* I4):%5 0(_LF286J0 J(R+Y,W2A+E0\4*%!( 1$A0D0(D754-A%#RAIE
M"X1-E@ )2Q(FF;E#[_=]]WGN<_^X]YZ9/,\\\SN3.>_OO.<]9]"/Z BPS=KR
MO"4@)R<'_(@= #H G $4Y.773\P4L5-IHY*2HJ+29F7E#1NW;MZZ=<OF+5M4
MOMB^3>4+M2^V;-FFM4U-74-34W.KJO8.+8T=VS4T-=;_1$X!>T91:9.2TB8-
ME2TJ&O]G0U\#:AN!)L!704X'D%>34U"30YL ' #(*<G];< _34X>BW&#\L9-
MF[=@#HQM@+R<@H*\HL)ZU-AJ#+8.**HI;=][[(<-ZG97E'6"- QOI^1MW'>Z
M_(VF?>?B_N->-^]LVJREO6/GK@.Z!P\=UCMA9&QR\EO3,V<M+*W.G;=V<'1R
M=G%U<_?^Z>JUZSZ^?L&W0D+#PB,B[]Z['_=K?$)BZJ/':>D9OV=FY1<\*7Q:
M]*RXY&5%):.*^:JZYFUC4W-+Z[NV]UW=/;U]G(^?^D=Y8^,3DU.?IV<$PJ7E
ME5616+*VCDL.4)#[E_V/N-0P7/**B@J*RNNXY.3#UAW4%)7V'MNP_0<[Y2M!
MZCJ&MS=JG$[)*W^S:=]Q^T5-KYN=F[7VGQ@](%B']C>R_QVP._\O9/\&]E^X
M^H&M"G)8\A34  (@^UI\GY?$WCS]#Z)?>4;*JK& Y!(LV$?N>0'YI]B 6\EX
MY"ZI?BQJ=U2I.=YT?P9%6IMA].[,UDME'_,=42"(,A[TZ>AWWS0%6ZG/3:/
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MC,*6+KQHZ3(9<A<.>;O>?M*38A) #66+U3NWI22-M*+ A5<H4.8TNT?;O]\
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M)WS7M6.KA0_L;F<ZRZX/1&"GG8SX(_-U"<YAX)JW H3<O2Q#@29]#0HX[$[
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MX4$3H+"Z'[=W\ 000&U@%2?_B@9]CL";$O[B?I/P<(VKJ2HWV[@:)363:T!
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M_DU8\;7]@KEOKK\AH:%_!U!+ P04    " #O@>U4X3U=%-D,  #$#0  !@
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M,16=%8X(T$OD*ZXZUW>2AH1?E:()L$GJ"5%/><S(:03091X(R.)XN0$<91_
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M9+Y;2%Y&RX1I93MA(K6$4^T_*DM(>?LI%IHQ(AA9MXV1%4W6K?[L>96\%]2
MU_0!^]^_U/J$2D.&G+?8>NQ&@[W#X1?*OC"V.FSFS]8I_N[\:BV;7O+$Z'X3
M683=@>DZB5E.H&NV0RSC4^LMVJF,2;\#?;[VPFTU8H(.D1 WH/C)_Q&KJJN
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M_?D>U'OZ=-LG2>F]6[77E^X'^I=_6'^XN#J%L9'N?)LTCM8=\LG2[NI-U5=
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M!NM-X.MY7#+7<521J32-29G6;$^\"!1:OQOGL.;N0:K_NG 4],Q%UX*F OR
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M1 \27G?8>1_HTOO__!K9_];4@ 'X_C;;_\J,S/X/!_M_L*VJT?\$4$L#!!0
M   ( .^![50WPS)+!A    41   -    :6UA9V5?,# Q+FIP9YV7=U33T9+'
M?R% I :0(* 0BE)$.HK4@!H@H" E0%! *2)5>E,Z"$0ZT@*"-&D&1)J(-*4I
M@BV =$(O4A):0$D6W]FW;\^>_6/?SCW?OV;N/>=S9^Z<.[2?M!F 0U\'I0.
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ME'NOHM\EZIG5-4]6JD9^V?VU#S4_ZH08$&NQ<Z=SS^J :/"S_V _F_3SI*S
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M_9:/>C<?D58X(L'(SP5_UZKG<EZV%P40& RK5TO7NQ478TH:-*JVW?X:*U%
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MD)I2<,[(=V<0_VG%YKB$D=#,G%F6[L]LI&D ;--MT%_L&5K'=8AM;*S2*'&
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M/A\>/CT]O4G18_B$\%_9FPBMS1#>Y6%>9%ML;Y_?5G]*\-\3F/[UF?[O(<Q
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M]DI!PC3<%[V:-'!FROK% V49"< GE1D%>#U"N$EB<(D6%.KR2/*=F,5D9:T
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M!24J5Q$H)>$&HT=(Y/'UY4=&"R%M=W&J%PN4MR%M</Q_G&T595GJYK6YR#-
MIL^H++Y/_IV :IX\6=.I\%_LNUQ=9M"NW='>6K01DD_*91QGA#CB$L]0\9 O
MBJ2N(B-7JAK*]9G*WLHT$<H$Y5F8.[U,6]30%5I9!/J!>"CZ[GT9AR!\ 5AJ
M\2W("YR*=,>JF^R'T_5Q27_-#L"\?X.7O;3[5?8VEB =2]+>]5G(W@-6+8CQ
MARHQI"597*0@(W'GS69SA4*1&FA;<5/7A5WV&U@J]KW:RB6!%J:WI,] ^?=E
MRI455<70AN"N"[_L/9RLQ.2Y@MOGW;I#8U-X,Q7_^II4K!*45SK>G6.7#WRW
M2FMOZVJ;) :HX<UT_,E?'=L)RBL=\^;)OWYB,XI%T(8[!V_]5;"-E#Q7;^,)
M>1N]ML ,%>KQ7I"17#S79/OA%1ME=B$-]>GQKI"I=(94J62)(H_INF7=YXMZ
M42Q9PO1#9:A-'[>%^C/MWYZ!)/#K5(ZVCI Y>$-U^[A79,GI:]4QW9VVJ)>^
M%U)#:_!XBVD F8Z_#\43:5.HT!C:4)N^;E=92LGSD2TN_V<UCF4H#/7\JG:R
M-/+R6]G*XO0V*M<@,E3\J]K?,I*=3^J7R("N"+,]LSZ$.!P=0(<O+,_F'IU$
M_RP@!M*7\A3'T18X/,T746BU>SAM+3!'JTMVQ2@[,@XV&A">IH,8*$G+FH=[
M.(3-"("8I8"7.\67:1ZF2T@#6LV!B0FLI_D@%D/.6$"OP']<P#1,H_W\AQ"'
M>^.]S+*"UHUC==OT=6<-0#WU%@H=*DQ7*9[Q%Z>UXYJGZ@P)03M/_8&!&B0,
M>>X%V-:&KJBH%,#3^;[?H!&(PJ=)ON6:Z'B>;]BEK?-G@".8 46Q/@-03_/]
M^FE2*1Z?='H+-O6,L;A;(9S7+YW(=:D \32YSUR'6G%X.XT:*D\!XFE>8,\!
M:*B\@>..ZFXYI8#M^9&(O5B#^ K0(G&0L+&AM?IK%WV+"NF:AZ+KC<W3K$##
M&&9/(7HU1*D8Z'_4JS^2Y1S+EZ%IWU$.8OH+EO7=_-!H>0,P1#&_Q*_N+)X_
M1RS+_#;,P?EB 2+5G>*)Z7"]F'$C=_ZZE>W.LI>U(WT6IFIG90]ACK=B\%F8
MJ@G:HZ"U9&V^:+([3_<2[%:$9;VJ,/F&4;&AQ9.%=2KD$ZT/M+E>2GEAXCXH
MPF3H3']'?XZ785K=$V7L1H2Y1I%PR27V7X)90!E-4%9@0'YHX@G"- Y*3$$;
MU:AW\*\@T4X,\Q?"1S5YT?>OTO)=+#$?OW;YV")A3&S1! T\XQ82H*,*OY 5
M)URF< $C>K96YOJPRA0)C)H3<8N93UUF*F2TE$ #7;##%^P0CLL5.[PH0W/-
M^&AR=/26XX@@HNR4J(*__^W7=T='OP5-G(%H]AN%*T72>XN+HRX7-6 @NA8P
M"JFB=.X6C>^Z- HSW$>AK9V:3*^^EN53RE=$.^NY%M'ONT17J((:%QO$#%M0
MH0NZR^*16"J/QH6GXBT6/O LE*",=$'^P%B63',')2H0I12VF#@6&#C%I]*#
M,$US%.9:NSXMNC]VZ6YO?HWCI6@$(Y$CYU7KQJ-21 _E("LV1!5?5N-;@E3J
M9XXXI]G P#3=P3%RY1VC>D)'O'-LE@JB?N27R6H%D8YG#]);XTVRW_$>D$&S
M.^>!^#;]2 Z$OX#;(I1S<B5$T+F;/ IQY^M-@EY 7<V3)B2)B>2\7 T95*!!
M"3LJM=7C6X2.<+G$8*G0/N?@*MB@"^Q!3*J,3=]Q?LX\-@U^JO\U^@M\1HS>
MTWA-PB;G"6W8+!&/SJ0V%E<QR+E,NXA\*B;YT%S%%.=W!0'Z5)0WXFX5R9P/
M;L!-1:I)X*[B@7/)QN'[=!SR<;R"H_><MQ9'\Q.. K.P7L63:/5J$=Q/Q6L9
M*JL8X9Q_"3+9O"L.^U04<^Y?%OQ--SEMHT 5W9RS;\:"4]$J#+-45'.^6QQL
M36;0RNW,,_I>?))=A[A\ E#,$N>MM=N;P4\5YF"+VH^HJR)K5F1@4217A"Z)
M&CEG;A."U;W\8+T$">W&+_[/0YR2S_1HA%4?$PN!"P]Z"($NCZK. N+$@HQV
MYY<P3LC7&"8%-5,F#8E-[+$SWA1'L[M2''X9AWHV^,#O)?20PG330F.=,A,O
M5+9FD+"S94B?%:)@-QA&$AEPT4QG_3*3KUP:=K#MCT)F%,.&=NF12"Q.63YP
M@5$?F4B:_.RF<G7K4+9Y5,L+I?%JJ[H ]#XX'550-J>XBG4&X7Z+RW7BU_Y6
MT*VVW%N@/J7,6'!!GZ;/JK?IFP_2[V4?/%+726TN#44F8J]25RWXZ3X9/8C)
M\$A=I^ZY-!F9B'TS&9YR@W>?.L_T*<UGF X\<%-#2JJ_7<D,U2_?):"[*CA:
M28JQ6U5#&]:Z]NG( Q\WKI6-H1>?3,_?M_RF>L+5\)T^ \O8P^X\L@@AW?1Q
MT2K=6/A[RRE'C\[UQ#*6C9@*4A/U3)]3S1\^5]LDXNT7[I1'>/I<H7"TG\*S
M1&^-E*=]<H-60[D9LSQ-+.KIP4L;SO5,;:*ASJ@S$X5/$R[=>'VBI40$#R3M
MN-#KT@Z-ZPFVCVK["&J">EW[OB,U^)M1XVT0V&C-DC5/_5XC!4GI\ 3I 8W<
M);>.KB;EA2A+%<0W6[E:CE0TW(9/WXG!8!@F99QU"S* &^?C"OH5L*X=FD@3
M7+%-4Q'XY,2V5%_ %&8K$+.M7UO-J8!=.RP;U>F%X-N529.T1^7\QR4:6>0]
M;F?'Z1,?E3QQF4:RS$>WT[NT9BF+?.7#3@?G9B;Y'D8KF +\8L&)"L;UE&^F
MG<Y,HA>"3Y._E$4VW'L88 7G>LKOI3HS8?BDO@L2@$,2A0.6E/E,_Y5I!IP"
MQ/42I9?2M"+P25\LQ9M>\KM<;S!Z!.R.HD9A*AC7U31Z:4PO!)]4)F51N2)3
M0WGKV.0!LJ&F/5+<2105:RI5$)N\2M^CWOYP/7CK+N4&,;1XO=L^4JPY-(G-
M7,J_9O$Q71*S\0TLY>**R^:WO8+EQ^'1[JVJ^@DKXT? +% X*D-6722_!6R$
M-BC2GD88@+KV7]8:[-;?,I6.3_Y,PJ)6GSHXU[YG7V6:R<6W73M:VL7,FW"7
MA2BH ]]17D^M+W1\#1-ZGG>W B"_3!<(KZLT<S:B[I&BKLPQ=_&GOOFZN[Y1
MH0\RBC^ NPX"7/80Y"A(&-BT?'^'*5P7:_'S:;)R$\?<-1^>XPIQ@&K,)7M!
MLL/MR%_2XL8 2!Z,JXL=GZDN:YAC<+4L-Z/O?T"([Y_0_HQN$;GVI+:ZY9;R
MO03GDUNU8H'T.8"9-U"Y=KY3ZK\IO-=J 1>H4.R*VV-RO>4ZH?Z;HGN-ZC]9
MY  S1AJA6G\;Z*!SO9,[D2$(A>A;;*ZH0&@4LA]S-YB5%0E=7&;GJA2:,2:N
M ".L6NB**[ZD31VZA_2MCHW\XODQ7Q1.6M]F>]5_A],Q=YE%&<=COBZ<EM-&
M]T'4:.&8[0U9)TK4R=>&TS))=Z==*Q(Q<ZI>.1!7#SWFB\IH62M?_ K""J]C
M)O&VCCUKJ.:6KQZCY797)S]@ \,3OC73J[@HK(K1Z2;71JVM6L@Q6 ",02PO
MP_J1V^IIE][:E@>I, 4Y_>ZJ2,>.G3*]37,P+VOOZ/)7EYI=,$8O41 S>5D@
M_!3BV(8E%1+7>Q=J?76O=-F+QZ=%"D<^^<<I^1GF+=)IKBHA>&6A81TBUSL4
M^VG93$R^:[K^5IVO-CT!6:!4M:(S5G'L:]?ST'H>=N:P?V^N=S7VMIFA!/[*
M#*M.=:>Y&_1 +4QL?(4A/M<['4,;AT)HKTS]FIQ?<PRNW]H=6L5CY?_*;B5V
M*6IOIPDTQ"[LZ:!</Z)KIA4C5E[!\%*FAXI;>Q=0R[/_-+KT63%_A$E1RK2^
ME&RA)Q&P=Q&RA=KDPO"K>%=%]W83PBA+3PWEW!P;U/1(/K9&Y,OLHM*AW%QM
MA.7I]--BH75GTU[+'7!?IJ !="L4S*0Q5X.<6]K7?/&#/?0N=.B=<$4%Z\NJ
MV$1)%FQY/>:J\'%'OEU8U@7T90[5<*;S^M>V>G,>TECQJ31PWZZ9",Y5(/MT
MAPHL*1O_4?FZW>Y8I?J:,4P.#HA@_:E;&+;%C."M5P4S>?@<@!*= XXPB% :
M$9MBG; :<O3Q;C%C7+:$F+';%DY:Z)[RB G:Z1E4'U!^U+RD,_FAI."E13-&
MN 0(X<N+#C@2/A/4>$6A\966)FD7=6^QR*4_R-X/:CV:T/P-L41<PHS-]3>
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MY[%/_TZ"^,F(=C6:CN@'9'$6HA]*BY4"M4?;)9Z#*/B33S&3:'H-??K*4_@
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M:YTXDU-QS:#.1$4UU"4[!R<3C/.QRQ,4L<H'Z1V8ZX!\/WXZAI&_H-_<=WD
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MM[[>6$R;>17[>$E9JO4*SS%P5M8X'*!?4=.TU@%<P4AOG<[IQXGI;"*PNHL
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M[*0UFC5KZ)#L(%V7LB/#MR*7,S6V+,W1,Z/<0TV=4.4AMNI0:WU_.YP'JC6
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M;?R3KW4V)_4R!:-E[R(XD>$.[TR-(?=.3NJ&)(ZFWZED1=_&D:O9Y*\ IZT
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M@(&IC99BL&C#4\>V<R[T+>7+OX,S'W#=;C=L?.E/=T0ZMZ^Q%&KV7V -B,
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MBM 9QG3ZA7&AAJT^"?."I+]E29D6 >%OR8G,,RGHW")'H68?,0,B0$B1:Z9
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M9OC<?9.EJT=,UA=4*SUPU.3.3SDU2@L'G1):,#@R*"B\=7FF*#HM*"T'D7\
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M+$M3S->"Z&M</*/%X\^[X(3=0I'2Y0#6; JSZU$W'IT]1@#PE!AB@<\.%W2
MBJK.B]"C<*/\M]L-O_RY?,4DC'-ENL@)<@#@V&RFK=N5"H&.<J/FHT&/:P$,
M]%5RP6P#X[&P=J#/@'2M( !0MS#4VH4?)=C-JL^']J-P[_=TJT[BL*ASNB^^
M!B3BV_ZKC"QQ7)1$F:]C?[$ 1L3H1K"="VQD0A\M8PT9/79>J&P>1,7R_C6?
MJ481U%%3V33_L!DC%\"X&=\,UA/+6Q@YHRV9<^C,-?$HHF^ZF<NOT_-6KU^H
M6LUL>KOLY*/^)2!TZU/DBW56"I>,\XAT%HTSD_%M5,Z>\KR/@QF-V&OE%79S
MF7^MQ4,; !7CK"W8B(0_ /K&[S\ *L8C'P ](^8?  YG F9J5>DIYRDLSNW
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M5R%0EX?[+0N/8I.CUENYR?FVWN5\QV96+@P];:5+0Z@8OHK3( UGV/)H!0'
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M0H4GL.)T_-#(UI3!@R,3&Y@UN;VND@=(G+-RKBQVF<6N/=5LWF$X8O#-MKZ
MOJZ89SWA=!UA?\D\V8(IX0K0(,P+*M\N/V99E#]D2;1_&XD2@8):9?K4W>-
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M*#6U-T/)C@W4]5#'G#O"K@B*[1VUHF!WLO\H8W[ .JI1-%+\0]%HHAF;2A&
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M3_GMDJ_3FP.AZ@6 ;&+3TSM;%MBHW2X1=,3>@6:KH7 *5RT7&(IROL5J#^2
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ME@*Z-Q=I1/]"Z'[5$ FQA[BCZW>]%7N!@=\PU\*1_Q@-27NTD>WLWXV&TN
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M+_KGYD_T_WL*<DS_\K\!4$L#!!0    ( .^![51E%"(?,$@  +#Q!  5
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M]A@&_D48>UJ_O-8,JE_$7:A$+!3UGGC19YIM4O_UEL8^(?SX)-F.-L"&",@
M"@GB_M1*%3CA@GB]YI>)8O]S_IK0398F?$)D_=,&#;1T4&@P+W$"!$?R@I+=
M12^R.'F]XX6;>9K" WE)3]B'/NN=(@ Y%!_4BD)@-6!$^&-Z$=#UI<(_;32!
MJAMEVRL5!T>EZG/M6@.H.E$VM!)1<)1Y5;PLIE7HKA&XM!NB4ILB213[][>M
MWE^Q'XQ:YKCZ<,XN9%0K=_Q^]F:V/0X3]8ZC) Z#!9_:9@7]K&#0VT267O(H
M0,B2-RO/V^1V0L(T*7^R,YCB!W]L.W>SW)[?W<9Y:$!3+KD@AU'W-_XNDN6O
MC)EE:+;#JK%LI=+Z2%%(,L(LU!V(\NTW(!ZMYFBEFH?"1:$ ='A.O>2)/S/%
M_N"O-3U[(??!YNFI1^DK<XI_\\),MCH7]$!RM$K0( SB+B(Y@E_[W<IKDJIW
MVZ4^M%1HY:,[H 61'QVD\OW.5]8W-2CU5F@UI3N (),/7>GU5TC+5R5K8JFQ
M !&C5:+N )&%-OHB)WE0Z_IF_L=9\1(5=X*#1?$$L':RXF1&*K3BU#8@@"1Q
M9-P 1TBWL3!\:*G+FF&P>M;W'*JK7&IE#T7WTCCU0M$2;Z;+GP'FCTREU;>
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MH=WE<LO+1@X)GO6EZF#4Z$G"'7 Q :O6TH&-\LN(>>'L0X&=5UHC0T_Q'<$
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MO_%XJ&^?L%YP+PLZ;I0$DWKM1"LT^FF![#66<G2^?O12?H3Y"@>L S.T:/U
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M&_>JP<> R;86WKO^)I.L(7:V MB>JN?=:HG1M[DU>?0SP253<[0*V&R0[T*
M(\>6*7(V$8)7I!N8W2"9DEF=>@D_H^)_\#>*GMD^-1K(N%2LL2>12=F8'I^!
M0SC.6NE9(5MQ<#.(>;9X8J=Q3<HN%8A@&J3"X;$02D1/0:_0]V6*G7"&:&M#
MJ _?V(:H>.,3LBC>J'@F22H>>[Q9GF0)4QT_>59/<R!B[*PU_/G,0L>N%":#
M'VC(?RL_T7@_Q(F&HLGQ0,,U;VE(+\G6.QIQYS_ ^4)W)4XZ-<)FOQ$G:7*S
M_!#'B^0^W@'2;R?88HJ]!]R[.:GT^K785?$70+9H+Z;8>[B]VY5*KU.*0;$F
M2<)\M660ZE\)[<,3>\>U=\M0:+7SA)/&;.N%/=U(Q/2"J/+6G]#.S5+:-$]S
MR[<EVJ2QP3^$O14;S/C&T+\+4Y4LN&]\1;*?/77Y /9UI1'MJ+N^#VU&8Z*=
M+Y?$3Q7#R-+.S.RP;U>-:%5074XZE-CE47E5+AB4"_8-KF%LIHOF!IUN,&*,
M[6(-18Q/'CO\OAD[+.EG.P;;,"%2,'#7$T# 3]K8E7K.PFO/KVF8GUY0TB$'
MZS1P&*LYRQ0PZ2 )K%Z*&7([-M@!-@L3Z*(?-\^9>U6@L:#'CG(!P+64"!_5
M$>9RYCETF,FK5-A!JSX3>5OZR7M.9=&=W=M0<I?IAZ;+5"'$=I6VA8-V'32[
M3%HBY!)0=]Z7CVSPT\ +<U_=HA24AA8]$=8(DZHBE%$AZ &W;5<O@BA(GLA"
M'(O9@J<CQG9_>L!GUHD[^&G+<=5;8?LL/1"1%[Z:YA)V2\G&"Q;%:2'WP?(K
MX_E*G:<#:=>V'YMK6\%Q5K*<>=%B)IC."JYEEA'RRE>FK(JC^"*5,/B3+ H!
M2E44.K!8'7LSQLI %-V[C%AG^/Y+EV[8;(F=#30,E*UT0;E"T.?;HF,/WHL^
M*;3:"GL%'!6BFB;0X1&"U"=6X[Y/1X.]5(X#G5E+Z$#6>U>7TX@HB!A[0S_J
MJ(3H;>!0+HX+%6\(35^9G/Q*EBCLJ'69?FJ[3#D'X2IM>6#[1V6O;D/^&G9%
M.+,'!"#%*E+)QD-$: TL<<2@%D9'@U]L'P91JWJE20T.S+T*T<1<TL'T"CIL
M/Z@K9#!]H,-VD=%(7*IA7;P(7OC?$L/XTI!@>SY=P3)J 1VG*^(EY"D.%Y?K
M#8V?Q8TL$U Z&FQ'IBM29CV@0Z44S0"7B0X["77PF5 %V]2R "OU&\\(Z[P?
M%%>L-R$1X$2+^9I7;_U3_%RI#^TIXT!?P,Y [6I$0^MXTD?52NFT\7P]%782
MZ>"SRV%%_95;UFN/\D3'9T4MU)\M]ZZS+;_C+G; DXO=C-68J'2G$AJBB>YC
M 8HX@  36ZMH1E1G=%>!]QB$06I*0OE%DK?+V>H.ZBJ\T:-1WFN>=\1@YAWW
M0D!JKY8(9^R>KS=A_$K('1'.1T7#QH@R@!1[')M!:HQ@L#K0MV%Y##L?,S:H
MF>C0 U+6F,$T@0Y8F8)8"+@]AFAUW)R-"6"!'JJRAM%:/Y-W>\_((]#-_;6Y
M6')2=YQ:(8A51HJ\/=*3U-OWS>^?F,/V0.B:=]!00%]/Y4CM7RTNS>>IM0+A
M5Z2O]>K*7#Q>U=X-:"!&UWH_7"X0?AWUN@CL0_KJZ8KFAP',3A[T\N:M?IF*
MFBL)'(%&9V8F3,8M6[Y-RKNE9!UDZ^2=MGBYNCFV^VVPF>K]*9/,?3UNJ*K?
MVZGZO:6J1SMPZJ/J]XY5BK^*HU4*7@#DK1V99.SG?[DXE1V6&YB89G]5>S=P
MT5F8 8]QIWZV7V4FXW^^I7%*_.)T;D6]M79:,E)A5[#06T]U<@(J 'V.*F)Z
MMQY-JR],)B>OU=_H9RX;'FZ,FP[SF8V0E40:?%1-,YRLK1LHV=NF!K-QYSM1
M,3LY\:+/E]$\Y2=DGG:FT[3'GN/4ME.=WXP"H\]L?$ S%S&E&3^DO/!\,E_S
M6*H^ B>G0#ZRT4=Y6N>M>KD= ^8R8@LJ2=([9D]G&0VBU2VA0:PK8@RD=VK7
M:(>:22F.89AW+O"9TZ//:3.089_/]$!,H0)TH*K/*5S%GK22S2[!H]D4.V/8
M"A"EJ.@@U$WEHY>R(<T65S:XH4.E3N-4D,9NG,B$=PR?,^)3GG%^P;@$SX2_
M.0*%24J*G7[; RV-*M!!$T.\.!?7Q6^JK; 37JV@D DHT3K&(;VXD;%]U:;Z
M2M!EM(Q9T_PU#K&1>(CSUM)#_!^_:Q[BYXVK;]@4[&<)YS\+=A^8T?P+LS2>
MA8*LVU&_ICA<WJV\3YHC_+)RFKPYXNVA9/O6@#D!04F M?O1:U4^9O1"HT]:
MVYZ)CMX%JZ?T9ODIR1\C54-C(,/>Z9BT'ML(TT)J>N5#ZQ*665JOYC1$ QWV
M_J@/SBHM'"+0UW'D=\2Z2HJ]^QH$[K8N#@AQ7I(#"G'>%FWKUF$Q5<OJV#I:
M!%V23[HWJC0D:#NTWJ!())_T+<>Z=+\3[AR0Q9R-?&]%[@@_C2A_R;=1[Z!P
M0SBA;0Y[6P%<3XX-W$;'R^+3/.Q]2ZAOL8!".*&=K T-L$9/3@8(/C)K7&=K
MN8<0J$(#[\RA@8+Q+"XYYW& 6;CC?0P)5$,";(M%%(Y:N92<9>0_B4<?OL2Z
M4($EHTF%$#HI"7UFM>HW^Z8N:&K/"BT$,3;"54U-"N.+.-.4X++GA!9\&!GA
MJIXF _!\F1(J>E^Y'M<=Y08[M,##B%!+-389O/M#/*W0@ZU>)EQ)2BOJIVA1
M^/J\MH3/FIJ2V#JRFU((I)?&#B@\LI79.LH\Y6!'2VI'MKRG\7H=I&)BFD>+
M4_$HY8I$_J[FB_X^^X_OF_O="D=1]Z7&TYV+[CK!+>Z_6[+!OA9_1I9!1!8G
M)&)_27E1I$HW$_ ]>1 ;-]+Q.^&LO$\/$AS_@GV[FY7)RWS?'DCN!L"=C+N5
M/P82&/]Z_M=^\:D[Q!UN0N%=]S_>A%**-LY-J ?6]\?P]21+ IXN>N5]T5Z$
M4C?'3G:!W8,RB8L>8;CW0H^_8<F6[-^]E:Z05KLE_HM1\+6WZ6@HQ,;'@_ S
MO,@7^12)Y@"[U1 [RZ\7''*IT=&X8IOZD#]LK NH;)M@3TE]$&A)ZLBV^3Z-
M_<^\N#^A"2\IRR9;T&[Y^^9NN<KH7__EE_?O?O[;+&?HSE8Y[X]Y+]QLA[W9
M%;H]>3T-O02^M940N>%-R5%05WYKRX&_+Q6]*?H&V(<JFKN!!\#.&N HQ,'?
M58IK\3Q$4NVAH?";FF2J\&A$0M\05KMDVA#*VCJ"B<G.- -FH/W? ''CB#F%
M:<#LZ+8\B1$=5&X8MX%( R&VGZ:VL28L,!6@N\GWA.^E3NU@TA)AWVT 0P00
M'1T>'IF/(]&S6X_>4#$[+'[SPHRGA]XSCUOCL(&(D2,!6F^G-:; RG ).-&Q
M9)ZE3S'EK[N" &L380<).B*EDG[2=X7J<P8<8!.=2\N;"6.8#@X(9OL)&$KO
MTI)I![O%/#P]^',?+F$@%+K)C;QP[<A"$^(%D&*7>K&;SX&:<&#=E?;T,DFR
M+H!MZ;!+O0R 5D,'+D6)WSQZ"5DPKX&_A>7E3T'F%XR8U-EZ(XY$Y='B'Z31
MXC<GG.&LRG$;*WXSW_'$>D%DV^&;9;6/Q<FD.$H1H F]E%FQ@)=&>O+%*MS/
M>G32M( YI5ZTRI\$/GG=M2EZ/?_BT<5-CN('UC)-+J.\5%OC2MWY"Z%^D+!M
M>.#KHMO[[ 3V\>L@YM=Z@F#O***O-CLE*60N1'YLBGSA!50X3)6YB+\$Z/.R
M2OKKSV-^$WN/.9YAC@J2&W:H&WNJH2<3\2Y(/E]00JJE2GO,F_T_C;TKQIDN
MAX+LL(RS'']GP7.P8+[F'HU3_FGLO;O[QJF#[#"-\[>8Z5[<9$$PS^;'L>,,
MTS%0.6S3-5&(7RU^R4OV;A4S@KEV[0AVT,4MT^T'YS3"/8G\U_+0SX_VH9_*
MYV=^I<4Q#N1"'&B;CE2^2WY/Z'/ ZP]+ATPHNB'"G'?$CU<1/WC*AX60$)S/
M..CGW$@C&F?J&D=C^#F7PXC3BLM+TG^'_I ;UC;JR&T8X> JQ,\MO8S86D2V
MF7]71=?UV:5:HJ_/++3J0,]-5?3.E*9J(',#98#UPK!R)WTU26^6]UY($G/"
M:JLI=@P=9&JM$V.%Q.B;WSNF//;YIWFT."//)(PW7"B^8X\28D('1(P=P.N"
MEX56T!&\)R%CM_I (K9##5F/YXMU$ 7<T>3WM8I.&T>:)1OLT$$75#MI"A]?
MZ5IN&T5"/Q,?:0L "OZ,E"WG8'QG$WJJ1)Z?[*,YHK;%,73C5.BF>QH(_/II
MWT^XX3>/'*+IK27\L$SG4#D@$C,$;S?L:/"Q-]2!A5,Q%KY67'MKH@^JU%M]
M'?C6948/E93=,<5&FNW< $MF9@I]CUNMB7^%=?\G;8VF9B/LV(4<^VI5)KE8
M?3=!6AV^>P?0X:X1=K8:5(=-L<;5(<0.W]G:X6@Q&; .]VJ'/T-T^+.E#D?+
M^P'K\.=)!#3@"1HW69JD7K0(HM5U9@AJ#?\IY##*<"[[P&DS2E2F:V_7<90+
MEY<]VCWNO1<3M/HZMF/AGEEV &^DU:6S"" SXY\8] O8_M7PIC2XBB8_L0DY
MBOUN,G_V@I#O7R]B*O(;QYC,3%_$]D@=G,!@($TC[S064_'<3X/GZOL3M0.*
MG^T/*/(9?N85?(]'%<>CBN-1Q?&HXGA4<3RJT-A2+B;[@/ZLHM'LZT"X(33Z
M:45W*7>21 OHF<<X7W/#<J16/UB-"9W\V/FFPH_,745C%ER[J?.AE1XCH%5]
M6*&HZ6YUCS%C%_>V%C%CNT2]C4@5O$\]FJ*6MAM0,R.56QJJ \Y/CPX8MV6M
MI:_3Y.OWKC_0.!ECRZ;[V.%%OL?4UE0\@Z^UN-T!ALI'K7 WO?JYPEW/JXZ>
M992M,[G<^8%!Q9=/2M$UE;.[\,+.@!G/$#LKUMZ>''HCO??X*]6!/9M:]@/[
M+IN[$VHG0-UW"0Q27\1T28*4O^8[CQ;G+YN "@Y;+8SGEP(^#;36GP[/6H>"
M[; GZ;Y:PHDW].P6<%#\?!P47>">_(R^USF\SZS]RU=GH%_M/&WVO?8U-0_>
M$Z"Q_WIXQCX2J).?@#'/W_YX;W%*<7@FV45=@QQ)G$>.S\ '<@9G8]_'8SB-
M$@_'ZEMYV(#7.(SZNB,\=83]_#2.1-YIYH7\F8[WAA&P[\Y Q\)$S_%PL#TD
M#^22B1A$2>"/7(]=\TFHC1[@(5Y?G"9OB<6ZPY-PQ_:%)9^"6MX$3^W&PN60
M+ ['DP5W &J=!W@6-RR&;MAL#U]%+:_*5QGC3;\^G8':\D1/ZG"P/22[KOLW
M^S'?UC>A5CK1H[-1D9K&W6O^8"%;&M+B27G])>Q?["]AWVWYS\3S0L?KV'*^
MQ^O8Q^O8Q^O8Q^O8Q^O8Q^O8Q^O8Q^O87^MU[+NZ/PIX9$;6W/E[A\-=R]8J
MS(T-<9=%J%V8+WTB].')*PKW)==Q],Q$)XO1PN3V73A>Y1X(Q:_WOBM<8QAO
M20_:.^<G:8>'2Y>7IX\CJ:[,^H50C-'2[,'QCOE (!ZPW]/Q!7H\LQYN)?B*
M\EW&,H,#'AB_B841<SIO]N!PK\#O&<3#ONLSD+*<7 JLN_CU7K??MQD<\%+@
M7FS(XAK&1#-^]J7%0;:U3MS#<"1"X&9XR&+ 3#3YR $%CS26W$MSNO9H_HR[
M/*_I5^N\IMF6XS&/Z9C'=,QC.N8Q'?.8CGE,QQ>P.^![? '[^ *V(VD[QQ>P
MCR]@6^APM$B-DR]@OX?8X7M;.QROZ A4B4VYT..BQY1GVY3G]^YN$8XIS\>4
M9R=>H,)+GC@^0:79I$[WM>6O)^IN_]CR!)^+&$@Y6?H4T^!/[6L2PW\*>^/H
MO,VV8)G^C#E?+ ).XH5[-#W=1[%WWNX:H1DJ=',\7V_"^)60>T*? Y_(1=Z>
MK@KIDH<X]<+J[_F9R76<_B=)[X@?KR*],8[XR8--J!T=IL,UQ#P]C#DMQ8]X
M.TU9F7WWXV"397$ 1;?C3Q'=]O3!>SDA$5D&J2:>I20XV)10@XK0(;R,?$J8
M4&<D__,R.BNV-:=,WA71@ D@Q0ZRCP8K6&WH '=60<?W8_956[=OOXZ)AZ,"
M[DAE-#9.XS5A$R])RFIEBV*@BA]*<P5_^JZ9*YBSF0F27=VS<LC/4OYSI"3!
MK82[#ILS +5$.//4V0Z6>9*0-!&O# .2&0UTR)%. #R-\0M3!/JZTNKFS8;P
MB2):7;'NGGJ4OBYC*CQ="_!T3+ #@$!@#&B:U>0>M.POI^S?05KK[QU3/^OE
MDP6\)D;8X;5A((:IRTF8RY^Q99]Y#J3F042+<O<B=S'X_M7.%OI_#3L(-IC!
M#*7X21]0 13#1Q%]%J[IW/=IYH4VRPN0'W:<:BRKTBAO"K.1N C5"^V" W:T
M:2Q\:PH:*5&PU8TK'O^X"KS'(*P4E6YD#AJIL"-%=I" 1')U8 G);#=4^ &3
M809-3?C.BV7*8_=N+94\^I)C$8;Q%R_2O>8"(L9^L'@8O-5JF73!D9:<U\3&
M]Q:ML1_I'0;@BN"',9S+%20@=M$O*1WZL[=]0=9HPZ65M=+-6QIO"$U?>;9K
MRB/H_\R"#0^RVZ*H881^\0*($ 16H[X.9:*NR4PV7E"Z[3!G3$>._N+IH/8@
MU0VF%9BW0I7^W_'3L9OEIX2("<^\(=+1HF?^VP%K(1D^JH.-[>T93T5>\Y"6
M4Z&_SMEK).LTT1?J!Y><M&+'OY/2SO]N$J*_>MEW_M;I8U"WW)$D@D#\Z#[.
MJ"^O-_33.U@.0?'31' ZIA#TDD-]M&JH^V,D=./ZI'TN@5$P_ (\ZBY>F2OL
M@(C=  ]HG&  KURJ?+.US.+61_JJO]>N:C]EJ%0RH5>[:7?,= ==3>$&0'IS
M,^+BRJ5PU@^2I(%_&F=12E]-%\,5S;'3HDSFU70:=4*CA_0N8DJ"501$1-X:
M.R?%$A"=R.AXW-)X&:17V@/+:AOD;$\+9Z99L:LEJ+L9U$'YHR)&)]\ O;?:
M *7>RXSD[(Z[H%YRG&:46^H%89;NA??,$GCMC2OVK7 '69%09A:P&[?))5WW
M41KZ)%ET7M]K(\0F<F?\#%M087IQ!<5B.;;'3TV(G57=?3@:=.$*9I>-!1$*
MF9+.&1?2%C&#)M !*T/6 ZV.'=EAYQ=WOY0TS06RT7OKX0JEQ\XK[HWK5(9O
MS?XZPPGC@IV9W!U4&RT=Q+V1PE_H/KX-]-@IT#W&-T@S!V$$G='O"_MHF=#=
M8;>?SQT),?&B*9$?A('XR,V2_?*.36;R2-/WL$C378WG+%Z*H!-E;(\1IW[E
MK)9+XO-WDK9]XUC5U3VOQE8RUH?76F.UO(,PGUP\:D"5HCMM$%GDKHHNC:X?
MU^D%LX;0XJ2S+2$*:+HYO,59P @Y)($7]C,G,_?I1=J&U.I(-TYW4< 'FI%L
M(P&1MVLWFU 432[ A";PZY@[?1EK]AB2QKE@M]$FYSB]T%E?[1W\I"T3WG#5
MOR?;Z<7I!M'C2/-S/ELE-TOA?I1;SSPC7#%7ZTDF%'$S"S.A.5P8R_9'T4KD
MJ]P2ZFLO+_;G/+VPVE#://BY_?2)5YW<54=]Z%*N8/ /32^@-Y*N'9V63F.V
MKX@R-FB*A+HXLHX$R'E@USP8"GF=AIR-ZNI?:/_I!U 8%_U5]D.)VAYO2QUO
M2QUO2[EQ(>=X6^IX6^IX6^IX6VIBMZ5JYTW_.Z-!L@A\KDGS&Z<&0F<.4F P
M 16!#MCQ>IM;>'2IF3] B7SWKK]95<6?7F[:@ZPB_'S-;5(-M)8(>QWK#C5
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MAXB?:W:'Q+M]I/=*MW=7>V?-+['VKOL34$L#!!0    ( .^![51H'VHU% <
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MEA UKMR!'L7D"YRV?Q!0N[9:=#?DM\JURNA= WK'P+UT0.\F_ M02P,$%
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M'.P!SZZ9<<?C /OK>\;&--UL=S>H9!,>C,?G\IW+-\<CFW?>YW&O7#+O'&N
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M5\SFK3F^V#@@QIC+BR9PS<8!/KZ -QH\M7'P_C_WO/%]*&R\CM50ZJ)[\T&
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M&#B)'9^%JI=GGH(F+KG2H1[G8Z]H9TEHYP7*G;-N%S874YJ'N!LOFVZR JT
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M.;:61>N'\]=N)CF?F:;;CA/**%+_^>3ZLEG.4/\=W?TYZD5A]]OVS!BJY.7
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M_R5GO606YGOIBRMJ7A0UW_8EQIO&2/KGYB\\V3[(8R1FQQ*>EU*T2>H=J1Z
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MW;\+O(!WOIN9]Z>]1]6=HMU? IJ@/)+'_TO<>%2#)SS*0;K,;'[K,X9I0_9
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MH'Y!:CE<Y3_/7NQ&68"+7) M3!@LBIN9D"7_+\*%/8P-*C)]&IF>^<HSUV)
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MKZ&2R2GO:;9%6M\4< B"L<TQ$#'.52HKH6:F)124*<[X+^D?!'SUOP2F'X^
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MS%T9152W4[,>3P4ST$XRS,OO<T],TT0,+2>B.OB3^LF?I'51U1^G/=1X-O!
M!&]2GUF.*SI4%*(_R..-/<Q!4C/UQ#'54->EH'*4O9!GTPV".'TUS#_$2K(X
MP)8V+EIYO5!T8^F\<@*RY5+T,WD'ZJ.J+#R9D/ZA<E34V=#/O 2VF<HH."CK
MX!;!:PUTTAPHJ2ZV2<>%\=2YRSFTV'E V<P\WY,S"ACY_8G\LKZ&VXCCX59F
ME9??:5[4QNR+$GS8RD*?N8?>=PC;ZP*9]5!@'>1)*ORL2X5[N"SF^/);XP_;
MS]S]8\B=FKJ$9"V[.;#_& YFTV"1*AO/;@5DOP=>00Z7MAK#*=]<N:#E6MX;
MG &RO!:PVL^079(E [L($I>@0! *[+GRN"V"GS^$8B XZ0YS7):!<5]&Z.Q/
M%636+BRL],SA>A#*O<*#3='NV8?N,=P)NKVIV-WV947PTXYCGEPPWC.D8H29
M,D)>WTOS,\VTCBJH^JP7P>?$#@Z]D1\M-/MZ%1C@)(46UM2N#!V)<,#2MUT-
MEX>PQB#X\6M0@@:PXPF".0RP&%1F=DUF"&4I!YW &65 Q>G]DMXK[@!!(6 6
MWLA",SDDV  ?DYQMG!K\(V#8GR!KK&*!DG>M^Y9G'I(47T+$" )4J6,++(%P
M?://6,6##^7!S% RO3X^==@TG7-Y,RC?/JC ?>PDRCP1EA<PERL7!@]NBQN$
MZ7MQL;W)Z#F7;@JT;1UJ?,R50^[Y"XU@0G<G1!5,%+F6HPP0E'&DUM<,V'$+
MNU>QBQE^>R/]A#R."CR'P-X0$2 _#'J?CS\?6N<$25BS/GTZ9'<B5WO<2HU\
MSX3%F*D(DTHX]=+S&&8@%S7/,&I&NK5DKN<@D^YGX?L"JVYK.8!]7!?^K1I%
ML),\_W-&#KSEMI"%@?$/U<B10.XTYCYZB_NC"/-S\.+RDS#26(:LV.6\\8AN
M1W"9H?)S$V0[ ^YO6NTXPXY=7T/P6%B"+]-=A=W'_> &8ZW&3QJQS4=X,)N0
M;R(%GT-AK YBU"!P_\1!FCNE@ZROE8U":YHXTO9#IY-?IX+&-<?%MQL#[\UB
MG;L/'T0M$RC@>]=I@@.78@/?-^/&3T #D[_>^VG*@;2:-%&<9,:TTV9T[TEL
MM::]4Y%3[IVK@:>U2F]Y4.K(3I4ZLH#4D:TJ=>2E,,M,L/D1WMCSX+I/0 4Y
M1PB],!Z]B/8']T (1XE-^+&.',*50@A[J'19%/XP^]XP2&0!Z=H$MD4X866A
M4^=L#8&:]5*E\D<_N*WW@]L:C3ED7S+JED%"S5,QQ***AM.1B4T8XA:U,M;0
MUM<H<H,W5:P^9ZW,& 357@;%+8Q%".61E-<J_(,3IS1/8SD!@Z.#OEA#9%<<
MCG3"@83)<DH!%6>OK]UB*R%X/G*!:VL,H:DB\12EXKZR&@&<[3+0XSE% K<!
MYIAM$]I[-^S!4.FH \*\9J18 D!&?10^!<U>,!HM3&Q]K9-$" 8=9?#K:4-;
M;2T(:C^0H@4CT(UY0&68FC2%VR#T'&QYE+57UX9(3&VK(FF'A#V;GB^H8$"L
MKI_0(O4[R$/C^GYPHVQ;CH?786,DI:4 3>"Z$C]%I548\E:.\,K/:D7TE;:'
M[- C0PMV_AJ[R;H]1K8VZ-78 6 &@WZ03"41B1]D8/J:=OR1)LA;;&75P;R'
M*$'G W*/@H9#Z *0!\2))=2+C<#P:85E7/+(YOH:(M%%-O X-<C*7FL("H0I
MQB:]\@X]'-1@<"C!R@I">H<.S.J/L3*#@$TQ1T@9:L; >K0.8@]X#J.)KZ^Y
M7>I[3_<S+@SL0!#C?D\ZAJD7T:]M3[@#+6^ S-#LO$6#K^\."<^67A1IY^.8
M5'F?A#C8 !B_9HZK:'A]+;5)(W?@>J#',_NKX@U\,N$]E+0PE7B4_@H["Q,H
M.IPNY?^H":T4-K.67MQSSO6TCQH%#<+4%FZ:]37\4,&OF^CN=(+4-D)M8U:7
M$\H>$NF;(KPN(^/6**?!$;54;F; M/#'H<3.T)QS0'"S5AML*3BT&N)R:U<=
M-\N@AS1D;>EH!?Q93I(K>Y#Q;;,7_"ZH*8?"P?V(%]0? <:GZ#*XD,.D Y2$
M:S?!<&G\% ^7/$$:'9QDBT'@Z88S[G"9P#=<):ZI'0V5=K2^YHG;B)IL.VZ$
M/4-07 A,O!ND[]'7JH@(WL"0<*5CFE=X)VU.2JW7+3(_< 0F(%-P(*2]DAR,
MD Y[4'ZW*(Y+F=NX-+-[# WRX\'0"T:2@B! 38E'72TU_+(;!>%XNQ!Y)S$7
MDF['+L@VN"(%-SW)-H5.WO<5B1-)PYQ<,/KIA0R\HMZH^HVK]XV47@'?@<1Z
MV!1!?V'7'LCS6VX\Q,CU=/4P9'287OK92M2!<EHG-GCO^1PGHA8*A@Z#J1J:
MTFT4=GPAT/C,C-F4U600_X:P93R,2W&W^#)2@)6S2Y+&D%J9RC2A(XF>/A:F
M&86):^F;=(:_*7T!<'3B"V#Q(*06#*@:(SNBI,8XTV!(.P677)Y,"C(;-S,$
MWNPF'O(0:=*62M-T"6Z;,XR(C$$VB1"=.R(RR7#EFCT=:M[4^):KH+K]I945
M:?6\H(/=F"UAAV ;P$UV(TG(H *"+<JB-R9R.^AM<@2BB2,T)!=#"M6@*I$A
M,'$F-7^:]X9STQ!NLVMVD55@ZB7Z_HJ1E'MPE.WF3'L+3WZC7M[\7X;&NAE#
MR7=Z44UQX*('O=SG9C\&C&G:VKN&74XPHH_4TH>+%.A3=KO<D\X2_!],8Y<.
MM4$IZP1>F@@#Y.:)P2!+G!3<M(Q:'(^])Y>3+="TR5WG8+:HQ)JT)7F@4["Q
M%TEJ&'"OB0%9(#1?1B&+([TC'E[P$6T'+CL>J:8]4<SQHK(]LHB%S!B:G8FJ
M<AN9C*&R(E$SA]7&2!R^6H:!ZV Y0]IY77VD:L+Y0]RDCAO 3U1L*[.,\;+A
MSC-_)[ZM/0!PF:0#(2 ;K4KMFPO&-6A-?,,0((X3V&1FD2M%;5]D>7 NL1Y&
MV5=Z&G1=.0G=LL,@9M7%HDX5?+34Q8FF87RF-@ C*W:*-HZ=FCA@0_W=3&IB
M#U..G$C[']\5EG@QJ*%VWU)Z*ESQ"%.>N%SB$DL1JD"Y+N"PJ/,#+$%@\0E6
M^0.WD48E?3#(>I*Z,G>\((!]N<$GO"@W [W'8P24XTBD-M)[ZW%PIZ"_2"F-
M^E@AT@514-BEL6Z6*^+-6*6W/"CZLEM%7Q80?=FNHB\OA5GFIW[]E>K%;=*+
M#U'T?N9^92NG 5[F7(:ERF M5?/Y3@)SNL1R,%0=K4BI&(.#]Q&POSVB=G3!
M+5R/J+&0[YA=/[J1G#%</@6G3*5"=P=;16S>&Y=Y725VWJA0@W'!UU#-N<5V
M5PBC'0QDUM6*EV6Z8PS ;;SET>,+&EM";CVLRN0NKC$Y/+A:R!,CZI>)7?=0
M9_%N4#S3Q-.RRG'-B_0_4*^X,2#[+FY()S)5DWOU+Z5.LJZ3:E?9H:!W@72%
M3%&J=Q+7<W1@3)(78D7T ^"A]WPP5ILM!%CEH>'Q/U?1G95CZ+_(OT6$S>8.
M$@88]:JAJ^X5K%I-KJ]QM_!!X$D[P4"CP6EF_4(M(SV4!KIQ>4TY$5,U%<FL
M(VU\?>)'K&FH+.R4KL%L X4UC+'!GQLX5*@.MIM$[Q61**G,5BC\'J-6ID9>
M&HG41ETPR=RBM5* E=-;(S1 >/%4N$<=D:.LF^E*!3LNZ?0Y'&M&OY29F?,/
M&<F-]SF+2I(D)_F&=&]/L'W^#N"HX9QHG-)XF[;NE$'W9L'B9SG0/>Y-2A]+
M%G\@6(5ZK!P]HRO@VA^!9CP:= *O1'N'D5]OW9]VKUZPO_?3)+EW;Z)Z#RLV
M)*:F#ZC%8]#S22*_G51A\;!=*MV3.>W $U:=]L]E+2$+J[ 2,P&I W.*M3>%
M^TMFW9:'8@2\_>/LFH--8]T.%SGX,L:(SXHOWVBUK#.@/&[1KGJ-FBE5<%?B
M_=PA'R+A-OH8!TYOZ/09C+5QJC*B2OAH.*/"O-I;F?6Z4!%1W!0%F4\:C:KZ
MIQ N!T5SW:UK*M*F O[%!H=FEIK.O\#+$!Y_:U$+O17>VZ[K@UFAD1/Z"6P<
M;BMH(;I23U-O;G^QKW-AKQ1F*;O?L9T\:(MSKRQZ7H.E<_ !>QA3!Q3=07Q!
M4<R%1M2,5:H8>&PDK1129T0,E@'&H+AY-WKVA<)\PAHT3X5B:KG,R"S!A9SP
M$5L<BEEE/N\RQJ!35%-0(-JFR9$G3"3FE,Q,$$A$YD$;! 4"$/4@4(F'#C$P
MQPG,BPJI?##DYU,JK^E,3+2%&+^)_HDY850D99.5DDE]M,)<SGA4#H="__--
MJ^UY6O,W,Y:,%7&&GDJZ*)5AP*AIBU:L;.H91Z:K>(=@N:'7B)PP QDBV[O?
M&+$$\W\HJ0$L2A'6E"0P[*Y"5"/I_*VR0T*W%X1<0B_K:>B">\:J/V*,]I@Y
M/GK:E >GVYGHIN]';393E)?+7&V>^,:(9]/2Y?QYXJLIRC,I#K](5%HK5LCT
MTJI_2G#A_4L)J7BA< S1I*@(9D@I13E=AQ'3;+ FZM=2#M,L%PZDDJ/*O'F(
M<\ T3\F-3"W=.(F()+W).- WJ4MOUM,\2WDTQS';.Y&+3' 4#RT^S\4A5 8.
MO0 H!WFX=%=K$[?5,G:UEE(OS@EO=!_T(TP""[JY"9!3@4;4-Q.>CKJ0<FEJ
MM?1E,'CBT7_,8\3K*/!<6^?I8+9%C\?&ACR>[+D1/XS<8_Z4'2(Z'5:YZA+/
MP30-3XR4@U'O_$JY(>!>^=4]^*Q$U!&)J-S5AMZPA5QO!0_<_-]Y%5@.D?6M
MU%Y7K :D*CR-5)DQ& /#)9S#EO%P5!3O=$MR<T8R$3,LD<Q133!81<C%6@9!
M10(HJ_86!MY?+M64JG['$!93[$4*I^?K;\U$;:OMC])$;J7TV? CU]%F";)-
M+OW;]C#?K^MB@*%DZ;E;*W<]*4&_(I[KU0BC+5'D?*^*G"\@<KY31<Z7G%D^
M%P1J0?5&53D3JZ0_IN:3H=!828HU_)XU..M]$#C649CP97(81 ."SFW;\::!
M3#S]Z=J8S!<DZK-K =3,@&K-2;U'H%WZ5D9OK$/\AW52T_\XP3M&__N$55\]
ME$)BI'QQ?I65'QF5X=SXNG6B-](UC5B)KX(IA/B+2!AN=#W6@8VB3[EEI<HT
MIX@1W@H<=!AX<"=*A1X)^YZHA"^57EB(@;$V%:%1.F(KHR-58B6]//&SC<-C
MR/[*[2XHKK0J-A(HWTS6@;=]9\"9FOQH-\V)%\5=S$AC?:T/]_9($CG!;%#I
M]BC#72,(ZR'P)2KI,C4ZW8C*K'0QP(K<YHH"<WL^OJG9,0/3F>>,.A-N)=7;
M,<R(<+ 0#WF4T@TC212D6WLJ2DK#:L7/T\3)S#;+Z%2I8R!MP99FA!?3DO[G
M_[UN-??>1M:_$JXNN21$54.CUYU[(XS^P?)@W!ZR>\[@5: G=EK"0O4I;S&1
M@IW86$>%I40T(II)Q#6>&V6>0:51AI*FR;F8Y'N),FZC(EX8-P[!TN\F;+%C
M[N0 3#4I2,G5)O=;/2P[<O2BU:NQZ3*KZ)@$3$(2(^':]4!X-0IK"71XV'LZ
M=2:PD_S9$Z<:4C<N/:6L"%%E+ \E=WM2WY."[&!E#YJ?:(9C25&F"AL2A).9
MRZ5(?IF;<) W+FKEIO%OCJJPUJ*4A$$B4V])W&^J26"JHC -R$\J-\4?*X/'
M8'M@]4R$I'Z;3>LOK'HNVD<H&R(<+*9,\R&0)<R$:JU@*P=N#/LQ<7 P@ *?
MR8D<'2J'&QT1091*0WI%YCG Q'*@39!+DFNAQ;BDU+MVDC((3 /O@NC);^&?
M2 ;14[\AWV3)GB!L*B]75]SVX N8V.;Z6ELE7*BW*MLS&ANDQB5,@9-M5^:@
M,)/5"4JO2]5S6&;*] 1GD".G&E4EX>]OV<&!Q6&<+H5=O\7?Z%=DOPDB6\91
MCFU2IPXF]Z-Q.+9B_#E-3%N!I1?)REP<!7\G"0_*8Q'>K1A%9MG<^IJ*D4RX
M6PT[FR5+R!E",<TS'8A,_BG,JB\6-:U,+U*CX%2 ):-(:UA^[NWT"I\*^6"A
MC$67:4;R#HO?Z"WMZ0^Q!.A('2#B^]'T',/E(6*1^494$@O#V8%YQIY@Y9=5
M3;.C]!+K![<9)QL,K+ K\6=(R.3=UJ%8]30FVS-X16"SO,8=MS&<13N)&Q:A
M*X454Q2NM!AUH3QDB[!J5Z<NUM31T3U!.IZ?##H@ KBZG/(&:J 28FT"!U32
M=F/I/2+H;C0+5$B?-716>!8NRQ[B4=#[L"#=$ATPP&Y<!0<XY<#,"W]%^/0=
MW- 66Y_,6DKT%G1^V+LL3H+:1.K91\  ([ 4FI%0_"NOBI O,?![@2)8O M=
M"OZC9YIM,Z0FPP.=D5A(]WN45ONCNEFNFD59-,((.U@J[%!34S0FK73#3):P
M:A:9BED6>C?#-T:I*J&O</ER=V14 P&Q LT-(MUY6UW 8[$OY6$N[&;>S.64
M0U4[D_C"]X$-;2)>*K6E:11TGC)=^3$Z,#Y_R! 8U@?4AS_G-OV\3!\F6;*^
MID-'9$421 Q#$KA^%I11BK/&UDU5_20R@'CYS'.DACE%]K7@0JD(VP;9],_Q
M.!1:WJ"T>%YVA>0B4WC(H(. P<>ZW[C;VH BY6@@3&Y%)$"!W9!:^\"2?!$8
M >&\B4'5@V-B@J_'$8<"DCA*RQ%3Q)-2M:CLS@\8X#+QL]MQ@MX&BAHBE%#P
M6&'$:.IW JG-<HZ>&]"6FN53<PXC@;@<UV>E-1LA_;7)FB00$S_U_R-K47A.
M0P4$W6Z=:'$!Q*(^='V4/O#@YH[K+S98EID1R$>.!M;);QDZ6+H"T4M(5I)@
M&K%0PA\B+D8Q6)HJY65W$AQ56C^+=!1$)$2 :D(I(KC$\:Y7.;^,D.U2'(>:
ME)!F#W0<,NB50*^VM&X$8@L0RHQ$T6ZKCJ1V%DE%$>=0=06F>%.P"4M=07=E
M=)%;P27 GHQC1MX@58,2B64ZDE+JJHSA'R9C&#-E2))V70*)=WVJ5$[IRG9O
M7.R$#;HGWH8KG6O'N@)=*ZB=X?5+C.A^4WD0.HR\TKL %.&1?&&0-ZF\/'")
M@')BJV01UL=8:K'S4W!Z$E9%)W#=^)'*VXB#&#_K)[&#]=39+A8:>:W</H:R
MRX@X2%8R8LWUX:I&EQPV/P3%X5WKA(( OQZZ/T9>E0?WJC/2KKJ5WBD[= >N
M2EF/$)]J(A.M2@KO"Q]?NPDH1H&:)ADP*DURQ& MVO'*184CTD+!U!=NB/[;
M(3:)J'$&7#=1YBF6^FJPQKP&NB(&X"J]Y4$9-:^KC)H%9-3L5ADU+X59%B&0
MA3- ]QKYA#,H3^7J0R\A._:S$H*B$XYL[+(:"_;/A;YVVW,]3LD(Y$8@#S2[
MA%1&:R%S2,6 S+PB-:F<^]]JIT5M'L+4(:1J/@E_I/VVRM8?FTY 0434U(V\
M_MQ+UM=44QK&8 5M!1://EI&,\:^K1;JO5YY(83.<2?'OI&H8G:X4+YB_L!6
M3KK#8W)38]+]BMP+E$-]1A[[S-==6K6SRFG=\$)DRG/M! 5Y/6)W_66"9;R^
MQ$2VE<.4>,":+07IAXET!-"+M-%J-!N$."I8)"&MM+O Y0[=^@2LT[;C+/*?
M#]V,BZ":Y81)SRB#$CI91C^(WFZ/0=Y!((:H@K#+D220%IQ#O02"D8T##4WL
M1UWU8N#T1&HD&V[HG'J^^6F46&@%IGV?3& 95HN-5ZZO99C?G#R/L5)N6(C2
MEXQN AC'&';A553'D_8UM-B@HW:),**.R.?WCL+):@K"]Q,*.=.>8#"*]!*R
M\3DK%,Z!N]?SGZZ#U*&REA#6CQI2<9FP^G>Z@Q-V#O[Q#SA\%28FFX"G88E>
M#]%HR75,#QE/Z>,P-H"1;@67O%M<\JZB[,I90:5,(2*3=&1?>%T6P>D0)KPU
MQ18CO'T4$6N7$,*F&N#'705N/$#G4):Y$.E-T<6#PC<@DVM "GX0BA AM7MN
M%V/NM-%X_ER%T0T"Q D,X0[UK)_S+?C2X#VFO&%& OOO?X%!G,16L<6L1M'N
M"VP-2]HSJ@%IH6$8C(3'81YN@("]T57TD4MP.=")+O\,ACXLHTC,ON/C+M\*
M]#X2LF6B7DC(G#"\N%;DE04=TD7@#'JA&-38"Q+5C$0W6+-R7]*=*A0L->*Q
MJRU7E)82VJ813*5N'8A&,@A\U<-!^X*Y"6+@U[-8[B:P04$:&.5T:3FX3C)A
M7L+3B<#>#:F_Z"9V;*$\"JKN+$8Z=0$S1O,PM5?W$=!#K8INX!Y\Y! 1"?1#
M5$:%*HZ[D.Z@@^C<1%<@VJX(N>)<$([[.4%7K-QU>9AF>J2=<%R_4-R.#0T5
M\A8Y39'I*;&\IKOEU#3,E\(HXN18RJ< N8?W@&WN=)C;::7L9R@AN>Z&M.U9
M6I19WTO K:%[@^.KW[B429HFIF#)F<,#!6%/^*KJE^ZA(BH)-Y7Q;8PFHIJ=
M]<G04@_>9:L$7BTILBWAC0I5>L>'W#0M/<M((LX7O 6L"<&0;\"_C#F+;U X
M;? "<P\(@,Z\&G B9J%#+8_SK^99,S>ASC!((0%5#3C)BL=.>]30N8-XRVK2
M;\GRN)66$Z20\L5NK#E]6M_OG#JI<LELP?[Z#+Z8?&\J\Y["I;C".MY.-E4Q
M<PZ^G1CX<8[T8&TA$57VDRPB7#P0\PBHVAK%>&[RJ39!;3>5+E&S"@1E,U6H
M%C(90%G)YL*JL#10U4<P:B!($3I=AC]F%F!:(6X9X%9S9](<1P2A492>Y1RS
MAJ&[1S,51^3^M F@R.%D/$W"C#C H2$DF BC1[!;A)^,P )9E\@H[3":;2 A
M<XVC]^0:(>AP?5?<@#;!%[QB= =SP@9*-:"31H6IJ\HIB0NX"Q*2;-%>YDR@
M4 R1#%7*&GPPX@1B#=J8WS6ZB8.H6,.2'VS3.K[!W@><.\+9NP7:X3H5\AUT
MI/1+D^A5JI46G7GX!&RN 2-@:@2?/B55#W1EB9G3",?O>N52$O-+S.5E$^):
M>-VP*).(&@GM_V?O79OC-I(UX>^,X'] S-H;<@3$EQ=1EW&<$\&1[+%F+$MK
M>8[?W2\;8#>:Q @-] '0I'I^_58^F5F5!:!)RB.UI&:?B#.FR&Z@+EE9>7T>
M18OH;=QV]6L7__ECDRT%^_2<S):?L^OMNY]?CF*-7.?]6L$K!H#8WQ.L L$&
M)Z%"I<V"[4<A7#/073._BMDY2MN1@AY''HG*Q1B8"9W7DWS191)0:O+YLA+V
M;73!L8T) GM"<>233X177%[O3X3P$T=MY=:/\:=A*K6CF>(R])#(2--;% BI
M\(8+-W/**V?V+C?M)9H9N*(LE$N& Z77&590$_(&XR4Y(_S6OQ>3=^?DO+]E
M6 8I*,.;GO.S*7# ]8YSLL?1M10V)WJ-KS_#!3&!NBX$6K+J% /DJBZO JFY
MF3\MLM-%JV QO76.'G%8VZN(OO2NX-; 66*PD(Q]P _P[_0Z<03[C91Q0^9"
MS=6 #8IPY]2:AU<)6D#_CC:W<<H]2_E[^";C.$OA$O=D/^=UUDRU4,M@8GD'
MSKV-/;<>@H:E2O+=1Q0Q]O/:W_-3MZ5K9N+,[$3S>TV8P9CB2Z[,=5/YJ_1)
MB7](G(BL-5Z02];IC?53X"[Y"<6F;X.\RQ*B##X:FY4$[5H)II I =8E<Q(&
M(KR"VP"D2-NC[%C8TK&OVUE"8H;3)"-$<$/FM3/6 & KCWDC9_*ORV+*+0#S
MC)D0A+#=%N*-S7*]2G(:QM=@:STX8C!71-\@9 \KPBT24KE;3Z^Y0@D9F; _
M0ZWB% 07YP375,HI0;;8M$*.K!^UBA7E>!_C#<MD5LE9>>[$.V,AHY.=.>>U
M+-S*545&8_,Q26?HQEA,@@^'58EC;M#'\$)&=SP10K%)W2SJ1A?NIL&JPOW;
MDEH&C@\/CY,WT6!:YV";(_JJ'SX5#CGWDBFU#23$-MMH 276ZZ<@&F\LX.26
MQ":VZ2UWRLT_V^7F-Y";?[++S7\MA^43/?\%4Q:%Y@S2O[0[T\Y3@\**:YFJ
M@)#)!)6[\X8IRNG=/:0TSWQ#M :].US <T#]G^>&:59SSR9^QU8\@"RD02]Z
M(3D/?%T#FND@^:^B]GT"\<@$JZ$!MO=DV;:P0LBY =_@N3-TKE-4U5(S/0@+
M47X-D]R7_FG\/4VFV9SY=8D5PEF:G!%Q)BK7<H.L%W6X3'N%2$VQ\&EFC2RE
M(445C(K89TFLTV+ ZR9+<M?*N21"4"2\E"8L;) 4$'O\*ACK5V&%N/M86$#5
MD CM;=P@+0#Y(;07/ %"FRU\'H=Z39/HK<AS3++V,IFYQ=V6*]BY]K%1N)4Q
M!6;T\#O9BR0, @A,TO'PG:Z)=UEO,:0U6H#@0PM>.3HN1)#.\75Z \7S^)2V
MP"SDY"37ZS"$,849F.05<5SG:W+Q=P@S2,ZW7-FL+U.%2\PA+\1IH)BA>YXX
M9HB6NNNEF"X%#CEC$) 0=Q@).X08RS#N(+@"I'D::C#4V; GQQ-JQ,U6+)#^
M*U.#MB+I/D5F1 CU3L-0[]]'N7W^O)!&[FD^*QC%GD9!'7+'A]_;9<6OCKZ'
M:X>XXWE39]-RQ2G719-WTM#O6Q6J%=PRG_"TX78,J.BH-9;2.)QR]K#>:6_1
M&!U3RB,H,. <',&XO<XH$<!01 \U'9IJ-DCEPX^%:'PHJX4$. GC+/- HYJ6
M_4M..0KV<<9E>9Z](V^[!++&2/L8;3#I2@)RV=]C$D;2HZE7KKW<RVUA@VLJ
MS,C:=XK-1+ZUP?'F;A%^J]L1.E,5K:ML(W5/$L11<T[),]U(W-CJPL:Q'L[T
MX'Q0)[T;DLXU.F@%W>T )G"W3IN4-6?5L]+'.:*^8))NXE;TF0S@$?"P6.V@
M]07U(1VO"7S^E?O/!9I].5J1=1H)DP2 )*>U6M^?S5N]^X/]/2@N=[=*\C[C
M/#T[FN%P<LR=U&%!^+'YI&ASB0%1[,@8+69.;6A"5:@;+G[)9!9L0LG2HAT1
MOS9=!QXA9>%TSI+PL'ZJKZF9<(TDR:;6>*DH4K=7[6QEX"S(7+-+3]J$;_6D
M0) 6&2/JNITT;A35JH>D'#5'!BSBH&5ND68FD3($WR!:7T65&BC/)VLD#NYI
MY1"G44.I#<4:-0TDP$,:.(/VS%5EFIO-6Z-J#0NJ&1)+NH3N(XP 7%0A !3M
M,8M:0/<.%^;PEHR"CLBNMDR8RI;9M%Z0\"*^U 9V,R/&^WMK8LQB\RX6?-'U
MKS9/P8$V=F-KCL73W6Z'!"CN?3+K[1"I3-:]#@.%/C*]SYHQ]5G2$5-]7:PM
M-CTLHL?,DT:$PAA!@5AY,]XW=[B=)FT!RWRJF3%CF+,FN<GVWKKLF,T_;*49
M:RW00;8E&)_>WB3_C5%") V$Q$]J#%);J2"?Q0T1?=R=I_ -_CS_'2?;ZS<A
MN5<#SE>T^W-MTTQ:W75UQW-CT*H64'TCW^PO201P:?[F-,Q$,9F=C2% ]WV+
MPMWJSAZ9JRDA<5E2<&H_MY+TIKO&/2:N<>RY_M QEYRO0DD=5T*TE/.62OUA
MO  W8J889VW>=1R#[VE9K9NUBM9ID(E7M,A/Y I_TZV1(BR+,2M>P*(CN@MI
MLH68N:D='QZ>IL: TH>9D6MU1G"O X4-5RCR6)&,<B.U M>B0AEU)2V0L+N0
M/%@G_3#.V#CA!_-3O0I' ID@;B:<R@T(3++-^!1D 3X4FP?.=OI?\F<-RV-Q
MC?D0H;#A J5I)JL\HQHN/5Z>36O)5WN<]0D<@)2HSIA:TCDKE$S$NB@&B(XB
MA2W!]P5Q".6]:V D'$.U+E$T1O? [MK0K6JY:)1-)X1A(A@I.CD,GU(O._9@
MZ(J6H[(U$9*?7KXY.]N^V^0ZA#XH)DAI1SK2>G:#)N T%+7K:%78F]JI'"EZ
M9"Y>>+7Z*U$41\^>/<;U@07\\W@1QN J8>*U0=G&/".\D5;\F<&CVD$,9EW8
M)7\/SP/78CNYS.=ZWF1(*_MP=FR[$&;P_GVHQ)1B(PX0]6=S]W'15]W&(&3B
M=-_$#8*C0%PD13\O%S:V2<E$!(F<KRX1 /]'>1Z%5@AJH4.585P%X@<I7%L5
M VP%96LK$%&?M_*U>L,50F8:P0Y3PK(E*F";WG*7/.7QX2Y/N8$\Y=-=GO)K
M.2R?O#GC90!:3-[0O3+AZ^&MNZL(X&'KK(_@1E&#L=0T%1;2+,*>9&QF#9M0
MH*]I,MQ,P_+/$#$^\,0&H(T"P-^RO(!Y8YTKV"=Q(2)%QP5*<5+6+<=.]_>&
M8R._35Q&W-/NT5K&=:#.X_/>'WQII4G&<-\A.[E<Q]<+VDC-(5GX^WL<#).@
MG[B0YFGDC-R\I%J":<'HV!58S\$W7!.X!"-K,JL#"SFM-+#K4BE;#.Q@T8*M
M3!"!_GCMY-YY?QI_Y486=:W-PK$>V]]C5ZMN='AH_[QY:$X^0ES\Q@&Q8Q.-
M1'"X52K#MZ60<G5;VAU<Z;1_AO84M&,*%4J5H>^3*K^HT3Q#6P1:)S8,8:>A
M,Y]?YQD IH5D$+D:&8FK:/'ZY&G7B-3WL*9M+]Y9V=;J\8.VW#=1X(,5M?)V
MVE'4/P41<97OQR7$8[(N6PFLQTVEC!'=IB:L[0<G<9+HS&(J""9T0*UU/\J9
M##D$Y?Z00REX\":G$&\E1UEI"[41T:CE5M1R#S7AYN WHAJ<VS%!;!+<$54S
M(KJ^6$(KIUD"&8""ZQNXX\B9\B@Y]TI"F'3CDF$A:$14NX5RT[4Z2-XB-A:*
MZ6E?*5FPH!5;&&0%U;ZZ.%2<>4V0^"%ZGJ&GW,= ]).$ORT>AT3SPYE&_6\5
MO< ]2JM*38UX5PO[QJ#4=.3DFS$*9'O2U.0)YB'3I"4]VG'@=H=Q-A'VIVA*
M%R52:EGDP*0KXCHEX>Y"Q3H(+WP*WL10D.P=8''V<PXF';$E3A4C1/PHH"+W
M@WCP]\L<AP[MSAV)F%PO )*Q+-69]@PX[6FA_/SO]0":A.<:_E2RD0;DN]HX
M[3NKI.6LS^1:&XI27/:VEPNB3?UGX;E,B>,6@L,A [ 65!!(78P"R0 K%S^&
M<K#.K:T>)4JZ\Z*UE]2:W7CUD'7QG667D0<09>?9OM%\ARI%*F:(9YT:(G?J
MT1<B8>Z%';3SN@TB#7Q%+>U0<A1[&9^? 7'FL01%:O;1+T9_,V3$U)DG\-/:
M:X%FJ?V]MQ)5#Z0OI.4\-I%I) *!UL,%^H^$-+8PVQ2E9BG=[JL,LW.B0 ##
M0 _A?:O2B5 .,2[1/=%1MY/";I$7^MHR<<>$=B,,K[Y -Q8,V'V^N8JP _I@
MWOX54F8Q?(;O<#3$,5$;5K_4R"OC>+/:Y 6* 9WU(3RP[JT>/,PC\FH]53#,
MG956O*<? CI6FS >B'1'DSH-?X2U1@U&+?,[X5/>!>E;8S_\(V)AYHH+2M*=
MESD7TU#_6]0)*115E%B*ENN'";7W$2FAT[6^^O"''\Y2L)TO)"%%OSQ^ZE8'
MB3Y1C+)D;C0T O_('XDC\+>&2@W/Q$O EKAG__#C;V>IN=]>3IR#5DW3Y)>Z
MN<[DPOJYR">7Q,;8Y>[B ZR9%X?^'MZP7>3KT+4\S_, AA1=8#8UPHOFN<.<
M!PE+5YI2(YB&U!/"Q\V%TI.H[Q4X#,Y&X**X<-<:'29#RJA?"YPBWN@(FYZ*
M7T@C0HJ(:!I;I*ZWPWA]726OG'%R_#@E&*TG'!ZASOJUVTLUDI-L;ML651$X
MT75FCEL]5%9@]8TUH)PU*-KCZE6F20D\FY)MKNV@C@]M^8,9VO[>B.BIM$5\
MSN>1.B0RI>*"K%>AW4SQU-XW)E1'%;[%YT.?#AB$\U*3QPR6 =QXAKT8,NUX
MF $DV.(..AVCU9BHHLR'; J(L$A'<M8T*P-P,4.9M?9X./F5'*;2;D0^/5N_
M(R#2H*!O._V#>_A5[L:'-T1'&"G6O+JDOTA=LNHAMS-9EYV321; O[PHL3I:
M3IT,N67%Y"_KDG.HH&9H8V^7UK,'"T')E!SVHR_.\3J08'&T;5R-<']O&'=B
M2P[P-KWE3BF]HUU*;P,IO6>[E-[7<E@V2.2-L*; ;\J5'<PF%'<9FFQAIDUC
MGMJ_0,]'OQ+>[!B5;]3HLGA* F2F*%.#<21QC"?V;?K&+*%7"-Y1RG%F<C#
MFC>60\J$A=M=*:NVD%IGC]7;YX7DP&I@B,T%WL!B-E$;!0_7F+^"U:C45;C(
M.="RY- .[T:[I/I]8 #F]!O%!Q9H(J+Q]0OH?K^LKD$+D2#PPE:<8B3TAT@C
MTKH83QW+]>D4NKG."Z'QHO5H1VG)E<#V]USX*4U5/R.880H+JK1I+76H-8<\
MQ.B*2G(8:4P:(IWGAPRA'Q]L&><GH,C?W/>4I%)R9*I6'7=/,X\7':R& 6->
MPO5"JUJA:I0X[4;':$LLCM\]U>^4,:C)*F8Q97OOY)GV%>.8.S?2G?H!Q*YT
M0934@^KD&1D0<MW[?CNGB4)L0U -Z?=SLN79\/,I2.DOTE3'W)GKFHCUF\X;
MF;=T$S&5( W;OE<9\N@_W"$5'5:N50WIE!JMBKV14GTTPK]2(.?^,&,H5?!A
M4FKK.H"+K'PF=*P7ZT:YBG!/QA'*MT/R;"1SE.$2,=^MB^VM!Y>WCB9B&A%L
M"YHJPZF)@_"A1S.N2$%'ZSA=*P42V[P3NM%"[]T^TL[%LJ""RPH4]3Z2PIU9
M-SZ^L$3/?&>%M +#9-*],YX=@@VQ@@K0?$C@6FT9WHQ'NK\7J$RUD@.,]/UA
MJ:F1&LZO%D2LVMU$O=%57B;_332M_J*.7.U0>H'@I$F-[>^AYD'38P'$,R-Z
M1/R-8,A[PY*QKWSB2X$-#Y(?ETW'7+=AWK0>]61";>-7$D)Q(\W[QM&6Z(=S
M#OJ_ISZ&>Y+E(,OY%=)B7-\L97A%GU>)2J.==KC@2J<VJPI 5WMN#X!?N(6K
M#Y*W@S]RC<%%4R\7'#I5N! #94VOJZGXIQ,SVN")"_=Y&@5A.3QC:=MI8%J/
M,L^S%G8^+OQ,"1CS]X3;:?3"<.[L38ROB>>R+CU\(97D4?T<&\UHA27UJ%+T
MMG,#\%!U/8N<'@&J *M!NPB314^:=H?+6'[.KM4$X@2J)TSW5""]=[GG""M!
MC.+KE0MY! 10AQ\CI9%Z,XC_@?Q(&H!"^,N>I9G:SZLI<S,C6$NV-_X5P%*5
MM]D#3=-MLI*VNY#ZD-5@PE7JYR<)[(4BQQAC@7! B6!T[<CO/28<R66&]K/.
MB<+"B2),L@L"K25GP+-74_CR0H +E3ZXT9O+H_$R"@"#*7= LUA*5JEUUB#X
M/REE@J9O--EUG5/.FS2L-J,^0Y1]3%BS4%O$I.'&]FCE%+B=$[P.ZUY):4BF
ME6Q>OYS9,D0M,>7T#IH1W?&3K[SV%_ O-6VC+TA]O73WJ)Y5=PB=3UL :>_U
M9%DZK^*W?')9@<2#LV:LX]RR')P=.+E*GA_\UT%*XT:3WA2E!;V9)M%$^Z%H
M"3$W4KM9,(: +?%-QN=+J #.F,FXCH:@(.R:Z?P'$]^.F[IG(-&IZL\TA<O%
M^P6J)]E:@)KX:A\O5/ 'Q ,H#-U]BPY=<4]5:@3N$LWS+#I:7AVR!Q[>]HVO
M[Z-*RXQ*F\.6_DIQCY$03QOB)['])G$?;\:5]223ZKK_DRWJ!:VG"BF;G3F[
MDI,)$=IH(IJO"Y-=J_7B:O7"VCY124?ILQ0DG=2/B>N0.4V<D"'E;>A40JU1
M &9F_EY4HGJ$C81 )[K+55R[C-IF;A9M$DVS<1Q)8,6+?^7!^T)L HPA&BD+
MPB$C][67]%J?T[J)+.P: SUG[ 8?_R,'#KH; !>*[XR00Y,[":RV1"BVZ2UW
MRGH=[[)>GS[K=7RXRWI]Z8?E_#_/F*C&B;#I-=N0>Z^3W$"%-2.7*2U/"6#E
M%H#P'.4[<+=-ZNZ*G/NYV+DGIVXAIBXN)R9#X_0)PND_NA7C61P=/OQ[2J$K
MJD2&^3G^H?\5B+U&/_+TX=\Y9T,X>5+2QXY?JR14+?@_V[H&+@E!3M14,>>1
MOTU]4$Z%'4U=2=VO8KDT%F&.>3H]Q+9XF=)A*&A#R0]"4["_%VPZE)Z\_>'Y
M@4#KAY7T]=JV\D3\S%PL?"#/:X.Y_I(L?.DIL8P)N)@]!+<2%G:72!::/1EN
M"8<OW""]TTY?84SMBBIRBDY<81E>&Q;9&0?O5]* %Z81FO@%:Z^6,&'X"%'E
M-0@IP#1NQ'R%%]+;$9^CH"&ZSUQ?7Q^T^>3@HK[ZQ,:%_+*H*-WG/GAP6E2?
MR$/F6!Z(YXOI?_PI^[^'AX_HI@:O_,O??G@E^^6<2/( DA^Y;>RC*H8-*QSW
M,C@SR:\AID=5Q7\17WCK-"Q':W]7M+3$G4V8VDYUEC77!1JLG1K,C4A7"[*.
M6QO^'+<>2OJ1 /\2XNQT/_B47\ 7@4^+SK63(U0W'B?9<@I'A"(09+7U\(8,
M!(<TVQ)U8^BP8U60M:#]."?O#PT0TWIYWIES/7!59"X(L%W4S'+EC!VX"-L;
M+O\]\"*Z>=/^:8N+)U,+^+I,'7J:'CY]G!X>'F(#OWF4/CXZQ3\U0("JU815
M?W]OW3?<#T>I=L 55R!T/.O6?Q([-9DLYTL^AU.&K]K?8Z0M/IG?'#U]E)X\
M/@GC.GKR+#U^\H1^T7\;9-R):,T%[Y,,G:M"GNJF<Q2>\C1]=LBSRSA>-A@E
M,40,)_2"HQMW7@ZZR8!!K9':D&(S79'1C!^EQX^>AI&>I"=/\,^4?-MH<4=&
MCK-,BX"7<OFL^X&"!<ZKUC3[-T_2DV?8:RR:>V@E,9RZ[102JR.X(7?^W KR
M5&5=8?4T.3,EQ<H!&@8(P!8G$5 \Z%+U0*%6X80S"F6#]95GJN21N]#F.<PG
MQ5K_/6>@Q5@34<^9.P/<_FN4$M=-@,4W*ZA]-Y2_J)A0A0,036T-1$1"8T@1
M4^H*SQ$"HV%0#7$8KK9&1+44W"&^7AO1 -UR<=,NHX8"=J[5NF<HP.N<*XG7
MS>)@?^]W*MDIL1KZ%=;\S)U)"RXS#CVPTKL1H/,EE5$W'CN31 A(PMRJ3M#(
M^7FG"AR_"%0L<)[/:]$O*5(*;(T1TBQECF?:/Q/:=9$3&YO4:%<YS8,AZ+'.
M4:?TFDV30FFX&^$E/@,7Q)J9$8NHD*XBC"3IIL]0NJV0@$D<F%+YL_CEH-3.
M.21J"NH9&PM\@#(&CLLQUK,]0P(S4# <?DX=VIQWFDDR/(K)19)GR0<FY#A,
M6-@Y\D:?ES2E2&QHK2XSKE(3V%L^>1&NOXR>D;Y$*(>WLY.$9?<!-S/$15H3
M0C71UQ;2,Y:7$R(I([-[:KDUKW):"ES1D#"!:)!JDI?55?ZNR9)IN'TBS7S+
M):0&F;Q&3 %]*/3)-*>R&=*T5*BF+PDM+,*IQ=_HZFMDBCLPJ1,*9Q3[WYAA
MM:'6H<'*T5K^3)>X,D)5_M ($9K35RWU>C@YUT5SWN=KYSQ1<]OQ$W0A/>;>
MDF^.T\-GI^'"/TV?/GG\;QI>^WNOZK8+\"%V]$9R\%4>!4^L 6*-;SY#R7 U
ME70W3=LT-7DTCB22T3#/E"8*,^I0X+4-;GGT':_4N3Z2D^S^"B:[OZ2N==%#
MI)V%EM2OJ'N'5!GJ,\^71=D%$;5Y7)+1Y&W!EVI>I?'A,+4>_MSQZ: \!*MF
M @*H>(BX5*FT@5A&= 5IY^3+OF)3%1[L)UO09CZ< &I=>G^(D($N_\Z0L;&I
M@6=Z=%1)M8&8E4R#&T\Y<%!YJ=R97C9R!*C<@J N5M*IY!%51V]J_2O>RT2(
M7+Q<:O;'*7Q6Z6&+>52ZV".$+7P]CQ"\Z-TOI=!4-8=J[JWA?-^FM]PIS7.R
M2_-L(,USM$OS?"F'90/0A,'8I(8A;BDHFFG"!-NV,9?#&QS&CTQQ]S,#J.2<
M 5 GSE] ^CR&Q%-*9^<V=H)'(JXPVYR 4%(N8+$I ;9+C[QP[B4]JG(J'08_
M>;OB8D3NH_A$\(#8(65HIJ7<<.+L>>C=X ?9KOFMCO:]MFZ;+&^(PP*$YR'^
M2<@\#XGTWJVX#T3I92R" TJ QE.O&9>-@9B1H<O?%RT7BOO-C'U^=1R-/,EN
MLRQ1:[G_+C/PD"3 LM'P1?^)Y)J(B5CF0D,OUH3$,?!26PHGHY#8AP9J?&\3
M4.,Z1#RXV@B&U#7)7 .CAZ.#W(U>J.'$W+T!EH@M;=]G(Y)H:E&IMA-=+&(L
M 3P,'.,9,GS>I@,3,$7!]O>LI^CC$=VEIZJ.#R,994HSC"2E9U*.AL5X%&XQ
M+XN%T*2$LQN6NY:-D'PH$5/06R,= D0AF;H--VR)2:;Y$A"2<]:":L1#>X%X
M[Q P HIDM"T;4A.[7)/**N+).ET'=J;\JNZ,IQ,= #I#?K<BG!?JQ_*Z%-9R
M ]$B-XZJA2M!22TBCB/L/\.,(SAW31).Q%-R*<#[XF^9D5Q%@'X1!@EG9'T[
MF/9_^98--O[]0F@?FVCPOOHV/69R8 NX'%[D>H.RG%-4L,Y+&8)SB)_K[M3:
MM*F!0EM+#OYOQ5VI&Q_0C3O?MD32?ZM#+)M]?*JPZ,)5[E-^0J9G,#MMK#;>
MC(A):SVON^"F^CWW#1)!O'^P"LQ<&;W#43".*M&X^5.9/Z2X[7(.A__-N*(3
M0%Z4,?<>>0[*D.6"NS/I[$0-QHB)JK>*[(PO8T3U?9<#O6/)AY5ND!4%V N/
MJ$0/ ."KQ+KYJD63%]WH@N$6V,77J&I_CHAS2FM2@M[7X=*-VU<HE3ON5^Z?
M\.N=HI!0=;826A.JW/0O[0*?6?Q^;BCVZ06:UKM\Q1;F< FXU(7?5#F!U$I.
MJ46>:VSY+RM&AV7L*F@D,W@OEL1\!VCF>D'YSF7E@4:-_2IQ5-_=;FY.HFD3
M9K5K@F1A<>7V;IX9(NYJ[^#+#]FF'AJR!\DK9SC4R''U<415$6LT->N9N?[(
MI/:C<45N1(O'K)&]#=P2I12WN'79>P#5BNG?&ML?5$<L(4Z'" @P_N$.@--5
M[Q<P/SFUR+7PH=[>=%)\0".%1<5FX2=<'PB'&V?M&;4HE#@G2.QP*/_Q%CEQ
M3A+.&34S'<;7B([567_N!J0G>F ",KD4&93^,"%\6_G]/P[<H^F7"MZ](8?G
M^X1HOZAEKII26*5N_DQ&<I=O1E)N>#T'>(\/#Q]AA<LZJY@E,*2G-($G2NO?
M$8H#"MVJ/ZSRES1*FC5;<MU=87F-#_;WQG/XXX.IK\FAH0+Y]P55!3J#ZYNC
MHX/C9%Z49<'$WHN&<"(6E#/]YLG!B?T3_"(D__@Z1E)9195CK]\</8V_XY1Z
ML^2R/DR(B_:BLT;K2HH)QJS[BIO!$WRL08=;52<7RZPA)(X\V,3#3B9%!W,#
M4;B!;-7#)@AFM[OKESXVC?P%K7'MI$5N+>2FZ1:./N&L 0K>A4^04XN\-KCC
M?:^!M#7AV,H^4)7CG,^CF\/)X;=,DSS8C4-=/I2"7A." SB.>;X#93%+CDZ_
M_>3UA%_J$>6U]2"4@-J4G+_/2C,1!!![/1-!]MX)!ZHW#?)%ABU]V-4/I50!
MIXR6^.3/1TQ![\_E@BC66&2@337GX]UI1BKFN AZ(^G9^913?/G[B;.%V:^W
M+Q&OHJ!(<3UY1QN=-WYV,BKIG).;2QMT54!""841.%7I6H W=8-WSW#N59YW
MOD:6+7$Y>C2QU)=^,%@(43/(V>*W2R'PR,6IP1\1?AH$]]40TK"J57?^.NI2
MHPX@W,OY=(WFPET-74*+1C51(?HDI3Z^+QO*>#8C (9@>HJOS,4 [? .E0;G
MT:G(0A8CW5 ^(=9BX+A#1T?'-S[5AK3]H)A0 \ S!%3AC(!&FRE7A\M,9/QN
M';$#-PSIWNJ"^_WZ.V7-'NVR9AO(FAWOLF;;>[PV_>(8 2)R3=4&R;P54N9
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M#/T\W+.)5!8A)_DB.]Z'I"=P24:0GBW54ULL.]N11\@4M@E*3C%!:P0JM.B
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M\PA$OB=9W*.?,VZ"00<+G(:(1GOQP_-FY9(L-0$5^0VM%QR-P41%9&74BB!
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M0L>2P5R(#<.4!9*U9_ TLT5AJ(28VPY;Y*GB+-,2/?4<@)H^*!WW.:,1..0
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M^<T<R9_6^A[L.T3TJG &*<:8N!N@IG!.A<@D0Z@U?$\T$AHC2@SUY$ONZ4A
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MTAL K@R@.X#":N'K4" :" UY,/$Q$8I17F(3#AT5X9'$F9=Q[ (.H]; YN)
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M!0&ZO.*"8LS'J;-V7J (F[5[$4_:_7-"6AX,7G5/<>,1 S[,@^1%WBX*XFK
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MT'U.99%:NEAF /8PHU'IH9R#D\[RFJA8J9R:VEG=T Z2MTBJ,L$SP5 (0F9
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MO=&QGZ:/CIY]I6-_<)0^/AKHY!M?,;AL/L:X;UZ1=8,_.?SVCPS]WSI[O_?
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M/EFO9P\]T97Q1ZZ(=3+F+RQ^*U)VH40&*)0D4V70; K^##39LW[VY]BS65O
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MVVLCE@65:T6\31AP/1,(G.[<F^/MB[_"$+BG/3DVZHBQR31;C*1G\4 #D=!
M)%VKJ72 ?&!H(?6"9_7$'#"M?,,V'2$NJ5I]2O\Q2I,?MT+H0Z?##+?4%MK
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MQI!NNJ].;]09UC3M,;O!& /A\>>KFEQ[&M;,[$?(VPTD])OH,* 6^[5FO]0
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MM9>3*^>QY&P9)L+Y[>CLQ+AZMO3.%DV,4*SP<E;J#5XF#[FDD!'>!T!0B@%
M0)9![-"[[J_*X.*XD##Z<;;I3HX[5_E6X:2[7_H+31 .39!9$O[85@Q=;:G[
M9P^%!+$)\DTWO5_KNKD'\R6S[E[A1<*%=XU?;X/,\V6MN$%L B)>1NK+^#Q]
MW[]X;GU);((C6;-0#%SX'13B-" 5NW;''J/I/M;?QL/[P]M)>;/]S2I-MWKG
MG)W^;IN-<4DLTJ_Z_;3._299?X"5&8I3(/;(:(LH ;L[0O5[*CRX*\(-#.2)
M%_$%U5^C!BRU6:EB);1&:ZFZIB*>IFB6"CVOE"%OK;&[8_=,R_D!EB[A93#
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MB9C@Z/]*D!6HF^@S^B'=T%\!\47D0[\;N=3@^OOW ]61-=W^<2<PWC\K"*]
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M4@:YI#@S^O/K9<S2^QG32Q@*#O390P]W VQ,Z&B69P)!!5"*M3*S'5;EHU/
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M3"QFZ,'B48=0V4V1DRG6&M,X_\8KHTW;FQZ1</N0M WBBJP9M8#Z@&D&1'F
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M'^1\P9M-]^ET>%!JOYR/K7<7*419,H6F.[ZT6^7K0?KMN?+M)U$$).;<!+T
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M(@=[?&F>Q/<DQ1R2>RC61;GD*/'NS\ ^;*^>$DKT6#K+G[9=B6HIN52E$)9
M\+[-BFTKOE.O6*_#+*Z-N!GWW7IG$RF_.7+G PNF5&DLY1)#*?4.^KGMNA]
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MW'D]?;S<S[O*=);?&COY5)IN[_:I7'UHR/>_/U<CGX.FJ^7Z5Y=53:N]%3]
M4B3?:.> C#2209VUY_?8$7MA1+_4='/WG=/#[+"3_OWN]CI+=0\M--V[E_3S
MF28?:UK6<VNCHT-J<-7@@>L+H#S4:8](?S6$57@/VE.OC?V?T'4TT+E'EVU;
MZT"(..#O]]0KKG/1KCFTAV+'4HG]Q;OK*#Y%_:Z^FD]1Z!7#6I1J'=YKU 'S
MQ):^:_\0A8_\TE*E06]B8Y=E6W6(N4?;CUK0+.@'K>KT?[Z[0W[Q72,O=^&S
M0K=A29;:/5-K8P0#7H5.P5,C"G_3"%.!]CGV^@9]7V(:_^SM[D00DW9%XLO$
M3C_B6L-F]EWC&-=D$>Q!_ 71=J%CDO!\@(J$JK YDCK"J4(G(=;EM4,_3'^A
M43@\31'>-G7>RYHMX9_4%%FQ-%*U!K+ES-!6FJ7M[DZ0N*L0-271S273@$E"
M@W#HI^1( \L<:39VG0:6TI 7R<*QLSN\)'O-[2=3.P./8#=8OD5MKX!8P];;
MJAK"S]@\5I7;/=8M%W\+G;')CB@J(4M?,U1H/T]GPGK:PKJ#G]G=::G.6%4-
MWH0>=H=/%3LVV7S#%=I,G,_;^XI"MW+>9%-D)AJ9Z\ BC*0-L(29==P5$_UV
M=T3K23ST*<DF(]F$?Q6Z]Y9&OJ[)6$X]13CA3/LGG;?^Q;;CO+F[;[3! MB.
M0G?UV4TE5 E_BQ,G]-QX[=]GCJ$"TQ3$DT!R2N8V?6-WA[8;=J#HVR3[ 5WE
ML;$Y\@YV4UTHYKY>'_(;H?_:(6[V);&BKU5%5?N@!P:C[:<01J8*PI0R(?JO
M5QZSZ1;>6M>_<H>/K]WN1G4-L"![Z=S1ZU'.'BK??GI3I.K&'Z8P8-<W!I8@
M^Y7S*)!D2[%!6.SN*!H6.@XUNP>_%64=8FPQV4%$I^').(VUJ)N6-$0J]+%;
MG=>1'*3@P-L%E%U[M,4BDQ=XHPQ;SVK;07'7A\DYIC4ADD11^Y@C3JX8[/;W
M#SX=E!G>-1+48\A,X%DV&P5NAXZL6=((C.2@X [H5414PQ=!(H/8X[PNK@$G
MSR6XU_U]^@&ZNHXJ.X!H(*P%#39A\>QR')/_^/W=A?M^=X>>052'**'@4A-&
M]'H1HD)AH6U)WAT:7$*C5D%%)3' 52(ZA:\Q,K >\3;_>@J(ZY!/F!8 ,;#.
M\;L[50<;&[+;@_+GS-IGMTEL$/G_\-$V(X8W+XR'+1MM?.<0"4^E8OQ.J;'>
M;[KCMXOQ]<7Y]>EC^;U"-DJ>IIONJ5E2GA^?.YFSYV\__9E)=&I?JT_JA6S(
M72JZ>J U@;# ?O2VOVYVED!R$I7>L&GHQF9GCPI&RQQV>[2#**J@/175-P.]
M7SB@KY80:>RH5&B-58NG>'T]#87,UD=O:5BF88)\ZL<]'\5 *XOEAFJZ;:V=
M?;KK3A[2F_5]5)IN^?[U^"Y=?LCOZ]]^7JO@211A;&[X9;QAW60S(%/B-1L\
M47"'P &Q*$5\]828I9Y^@N!X4V850-^PF[%/KW@9+1\=+D7-^>B#LP''H&8/
M3%O6CXF4&?C-ML+[V_B@2A$'*RU>/.\=NNE>MVOYWV?V_;":X$&[K-\>2GF)
M)?M*4X<NFVFZ1O7\[*S1'S\T*N32DBE$4I4:].RUW1UQ69*_+N\@;L1 X.RT
M[KMS:M'D;)P:Y-(!/?E<;MG2S4$*.I_OX1F+I,17D4-U0SH;$KF1S2.B7#HU
MY80P;< /-CP/U>Z.YW61NY9*50+>FMQFI 73YD)KDV-,7B9$)8HRL5O C(#N
MZ38WB!P&)-.1VVBGI"3!>:BCEL]'\71PZGM*$5DX)#8&*N)T$%"<!S";E.=^
M,3L=\/-UAA;97; UT#>#.85$0]>)=9="=7^& >C^?V<=Q/EO6??P?W"Y0(\N
M(4"7R%B!)@.+>1;_4RZD4^ET>D^J,].%D)*[WH)$!D&OC0BE_E/,X#OH>P/_
M$%J9Q!RQ*66I736&KN4*;"!H2V0J8]-Z@9&)8 24*$(;66H3DT-#,_,_F30=
M%![M#)$.G&:V:HW(?)DYZU'!'*ET/PW",9(S-B6*0$BF1:SF(:8GD.FED)[_
M*=+A>RJVB <!;9EC:D##A02OID3SC,[=XQN^69I!K#;\/#&/M#[HD=(46?TW
M[:"=*NLVF'W4)X?<QVY-FQ$7#%6;S,?O*B$QPQ#54%@0VQYF^LF8]83P<8.!
M9;YI<)<2Z_ _Y0RN%JUHF+0M8/#Y+P5\=%5B LN6PYW4@FY,MLHC.JZ!</>P
MSQR7#;(>?=B7)5T%$O SQI@:G:]R2X(0\Y35[A$"'A\310#@PE3Z)&P X7_0
MI@U0U\&;0(8B+$.E(6@:.I$? P=S;"&=!<7"II6'J/!FK>FZ67LP_*7)DU+R
M"2Q+Q5V=_-73X^1T/Z<J6S0Q8J@>-?:K-<O2Z]K'96@,@G'\WY?I7/KU3*F7
MDLK\>5_22#9&TLAAT\T=3T:O1P_VVUOY;]+(QI)&BLLDC1#^/W"'IX,S_?>;
MTTTP:82(IJ=K]Z*73E\>3UJ?*VNDU'0O#VZ?Y5_'[M%34BEO\Z37MD,Y<S>&
MX)_@%[*"IB'ZQA-P]FW&"C@"C=9?&M&[R))@#"<TC+N[P\.5EHKZJ&D0W0BT
M/6@[0O0/&I0D/S \M0<U6,'8 IU%LX7G8!Q4E+F"WD(C@^@YEJI37R-75VG)
M)P9=E75Z!&?(_8E3M+-I+_DZ,M-9_"WRA:*V36KB_DM403(M70,XY9JXF6 _
M>YZ Q0G:Y37.XT)U>J9BZF9W CQP2+@7]')"5FR9+C7 3 B96YSZ*[SO9HNO
M_L\A_D]$.)Z_F!IGWWU@W[D4FI.V'C4Z#,JJG"WPMP\)FZEO Q4SS=&*DX&E
M7R G088%:@.9)M^PTT+.?[MGL"P6=IP@/X2/P7Y(;ON1JMN+<LT_BWR+R$8!
M(][J>[X%736Z#F1E(#<1JQZM3I#SF#X3+M+0D0$18%G7S3;**6HZ8U9(6U45
MV[?PR3XX/4$XVNA:H0*.8O131J9?AJX ]E0.D,IXGGXE\#S4#5!R3DT7\T>(
M7-9:JD(Q_O_]D/CB^[FEP2F* 2&!XK-T%;:HY1\:[&D X>LP@M/HK S1?S+R
MV/Y7-$?7Y*O&AB%"%P&Z!*R\ L&*$NP6CM<[.A:4A59G2WV*J,KJ0#O.-?8?
M\OK\+@1!)^J/*$=IH >!-P%X$W<&R;[MC0@B*HK*^]6F>^_H][>V5<BU_%SK
M>;T((DBPQ0T)8K8 >!\0>3FRBJLF:H-)X"S_9\9FK)2K49&?^8&?4\.1C:Y&
M3A0]%DWMM#D8I <<3Z>8S0M@ H&!:X%TH2 @ />!@W.:X]]<G#P-B^WS VU0
M] I+ Z1:#P;R.Q8?K!BMVO4.K1@M_B!48(7]LRN+64&:CFK!]NTG\[M_(I1C
MOU6K:MO_TD\?D3% ;^C+-*7,<ZPGB1F[Q&[79+M7-13X#R1 CLA>&,#PEYSC
M%6W]3%\MUP][K4YG?-OUF!YI)D62:QX 5$1+KQ5X/YP:'W4"BO$.P"R3A+1/
M31KD*8SW;[A=H@Q9,]/6<*):Z^;\TFJ<?\ 2^JZI^94PR_=OC8O?OU\:QP_3
M+!]!I<TP_!01/HK366CS@UC]_;U[Z4X^!..W0IASRQ"7.*,NP2A8K\866*/K
M2_C$_#[\W7 GXT:F/GUBHNG\'K2D>8TAWT>H#].@XAVJF#!('W>I1/:<O35A
M^[EWYJ,0:L(,#[&9$?=UT*['V'0)DC?JG?VAK1E8"#8%.K/.<X0'U#M GM\%
M+QJ>YM-B$TD4OB8&&1: TVQ"Y<JL=F96@JWY@AU7,;9V$-6R_NO6)%7143DG
M 6\JQQ<";Q%I=EYFG9C0^#HD7^2%)K+WHAST9<,X_"R#/QL+7""_+H5I>#33
M#NH'8<B!I6&&OXEI^^ AY.XL;VI"(2A'9Z6U0)@@IH1O,T_(FBZZ\:H :'\?
M_GB"0;_W#WA+ Z/P+X/02;:L"2@>6&'%*1511$M^*Q)H=V>60H%RB9:LRY#\
M8/=4E5:I0]9D>)/@]=,L"<H%>(+2RF-RCTMC,-3NCA;H=)RL7W^V8_%2*>/D
MUV2!-YS7]^FNWL"F5@VEJO#:.]\);[\G0) );6F\L1DWW>?!W5/]II$YD?-K
MCS-$/+)-88:P4$*E-'BPC\^O>S=R5"BA.D]FX-9)H#@/UAI.X)/,5ZK-,*S-
M_&7QIGSQ(*='N5#G T_V^HANR/[<"\TP?,:;SFVCE#F_&2C:VN>^MM[)B39*
M#EOMHRI;T^WFEYU4?(,O$0+$[^P;1H"8_8K?#XR]OOG&:3L<O4'>.4D?K>85
MY=Y0)=WLRP?'IP=U=Z35FNZ;?7OX?-DG6HHO'!+J9 PUA#0C)MDPX8;C:J$N
MUKA P&&-(F:,U[BM(3ZH$>Y64GY5Z-L9XF<S^>3"E?ZQ+JP8YC-MQZYWCDU3
ML6],7<'S;0OGNW;;N#COW%SD+^45SO>T!_TG?(_V%0^>Y*02(M87 9PBU!8<
MUV0UJVVAZ=H.8B&W8BAI\>%;,=+(_F!T#]\&JF&K,X>O???4.+^^=:S#3C*7
MZ_1B(\)8//VVJQIDQCHMCE, #,=V+)IGI](E+'2V)Q_16CW2LS;&GM[8+1 6
MGZP1S&?9Q+5))W)&UQB36RRR5DP+(H_8=L,R.YIS3O[4U&YYI)>(+L<77<1&
MJ)^>'[D/^YVFFSG^=:>UNG(C5UJ##A$MJ*G'BH:PHIS0M$Y+<N2W3W--3M%\
MK<(D*M[UQ^@@<8C[CD,>F=B234X;*0>/=LB:9<V Q=*(*R45.H=G']W'XT(/
MUJW\QLQ__V@?WIFV_IP_Z!T\?ZB&<HQP$(;O)IT*LX2( (U*"R()OKC6LDX&
M^*O)_$D;NS;MIE1::\K18AF86R0#Z<(%6BV6?5.ZCB<$^S+Y$^@]EDI,ME^_
MSXM7G>YO=Q6!&%_7H2E.VF*-)[5-*L\Z]N&O_O.AE$Y &2I7DE.&"HL$ 5GG
M8:>CMIT(.=G4+KUD5G#/"&?=>-;W7ZL/IFDE%/N(J?PPNX>LA)QU0R6JK/2=
M^6.VH!'R1B_ 1;N9D/  D*C_^^W'7Y5FM5SJ]6]I E(JFUVKBR8D;=J76B(R
M90RY;5^JA#JS.HH@JQZOW<'1\^&!+L# KE\OB<S(CN&:26%)/22$^8K*QZ5L
M)YCPO,R&;I6R\TDZPWZ.34Q 0A6+A4^>I!X;)C#==%_OK8>#TL'K?EU=(?$O
M\K-+86IE)ZWL6_HM<W;3^I@Y5)INZ>6\W+I3[QJM=S<<>2^H7BX&J!Y@*@P*
MC<'E[U]/KWX:VSI!]0);=%NX*<N-I]/C6BEV"M8?!K=76@9NCW#<;>=RY';O
M.I61GB#<7K[I_KZX/LC6G/[^@6]@?0JX/6ADJ0U_G;5[/:OT;CCPC^['>&[*
MY#(S'=6^M61%K1H*%C->^\B[B['618?<2N,UW>N16=;D4?MB^&Y<6 ]+G1*V
MP(L=PE'5R6735SK')_)QXSZC?^,8@;;DSS@)Y/2D0-*C2I5F$96I2MX6NE]#
ML08MLB#"=C-E%GQ>R##(.H1A6%-,H^MOP7O*)?9#RR66_G+3/3Q0G[5._;'T
M7)Y;]A#"0EZ%PS;5,42[WJ8+'+)-]VQR?CEZNWIL%'R-;+K 89;)$JIEV!<J
M&(HM._.D*#>-W,L65S#L"W4+F>/AW7CBJ*^#]<]X;74+J/Z,5;CAX25=B?!/
MKJN4(>1[833!D@;ZS7AU#2$C)U;JL!Z:Q:\FB$FSF 41"RGU&18:IY)B*98(
M#SMR4>=+>,PUJ=$>GCYT6%^N7E_6W..38M/-U^OM]+!RNW]12;J:(LP8"97.
MVY[P/Y_.H1@;H4ZSE7S"J7PYGE?X2]16K$#JM3FW\JE\IK*)2@JQ0 H0+<=0
M]GID6@?FL.5TAOHL$;PC+>#>0*C0/]=O1W+^E_WXN[M*H#!^4@"%P9'YI!'9
M5F'3]CJF?&QH>BF*QC^\24?H/BK.OR!@]GYJKC&C,9[S><E(V%$ E8JOK"4[
MZ"1P+*TU=$SK2%7!-KM6G:%E3*$4BN>P\/OR^OFD?=T;)W2_QHS8TX.J\ 6E
MR(6+2TK!S_BBI(ZJV@P?']?U!2._'$4KWL8F>YG3SD]KCN_^W:VDY$ULU6L=
M ?GT7,7^4G4\'>#6T^L=7^ZTCOKGJOF:4<O:&A6 B(#J_]>*[WQ!#Y_H8_S"
M(=MY^Y:XF9 N)1>:_;M?:Y8MV50Y7?QJH?3DXT2GO./@XG#082#!*?JUIGO=
MJET]#K7#P]Z[VU9-17V*\Z,^E:8K]_J/[L/M2[FM00H3G::F)M(G=\/1'F$U
M/,#S0?$=;_O9T5Y'<XR08,[\SQ ^N\L]&Z>&_/ X-W CTNUS!VQJ3;>1+IYH
M6NG7A96)"MB(S2VTD!.PWA#(D1"TZ4W:]7$F;3V42UL<M*D(09O]HVK5_FV[
M3^GVWZ#-WZ#-WZ#-YPC:5,)TD6MY?$&L6TLCNB+F<5ZKT#E-M<7 S>FEV[AM
M-]WSWQ>/XS?[4G]8);GZW6$;,E>ISR>[_5&$Q31.UAK+I(K9>-K]EPC:K$CN
M-3IJBC&K/]\9N,F'G>,C *DA*@R"#"T\R/7*U2!]D+?OY&R"@9H(H<JG*G5A
MKI_9?1B3(:/W)FD!D,ZMYH[YLH59R>S8^BI$8[8\6EO]>"%,EI %!_R[7&H4
M"\I9X2FM9W[ED[G^EW7T"D8J.GB_O&M7W**D7;G%8KQJY;^NW"7V9XVNVT+N
MB[;J"/</)N_6Q>1\YC6C .517MVL(#7GO-5TY8?G6K%5ZUQ-\N]UZD83R_?T
MEN9[>K--]^(^=U>4NU?'=@::$*L#65,D!OR&,?C='5R0Q%;$\.J3< 1_:*,6
MOG156+IDXLK;;.6LKP5S&N_N;-)KS-O2(7(HZZ(%O1_8M'DE"=V<\"C$LM[D
MH@@@\<[/-UWU[;SU\E0Z?<[-]3*'<: 4QH"?W =-3M[IZ;5U4<\-NJ^Q&BP/
MXC)H0A[JDN"AWA\\NY7#DR/W8/W-!=8WX[S@H1Y;G7JQ7K)_[:_?I_[70_W7
M0_W70YV(A_HHT#40!>"I0:X*R/STW%@?X7GF]Y3&9[/][M!I^B5K+I8*\;)B
MOX2G.19IUV;IE=)K)FWXV<O,GKU;@ Q]S[E; N9/?O-4'L>4+M0W\@4#('(D
M>>CT3 L;1'UL2K](E:2=+[E2O"3=C\K7?R>EUAAT*1=6;9V]^$P4I^U\MC!F
MKDR7N'UHJCVUFI8P&[ZJ$S]ZHY(]M,5L8K[[O]NT3O"HU=S:*X=82K,7*UMO
MT(^R!FD2==]&")M(%#NZ*-Y=?$T2Y5,[]F-L7++2)9<JY1-,U?Z[;<E(FUPJ
MFUFM>N>3AFGF +C=&O+]K]&%52Z5D@N&!*>T%)*5GBO7S'VS<?JKL'WS.VJZ
M:?-&3K^8F9OTNRL$YG2.CS6S>>!X^1C@>'DH44W?#YT[I?2J) R.1SYFV*?U
MV]_W]^E,*[9'[ \#QRLO XY'N%%1SNN/^U9UXB8)CE=JNE7W[$'.6\>W1;^6
M^5. XQ$B6?7V+UE]-EK&QTF4Y /G#0O0C9U)0Y<-Z)E^^#K4!M!+?7%]5#&@
M',<?INDZUV,B9<YNJR_E3836R_-#ZX1/>_7[@\YEY^;T&D/K="VH+7L+V6 8
M?:-%5H'5JGRU'P.H%\E%[PF.9^*PJ<"<#X7GB_[%RT7YM+L@_AW&)I\\V'U(
M+H=6^?%B7+_('G3C!;O#^&<#D>U.MO7T>V">/Y[DMCBR71 BV^ZO$_7XHIXN
MOE3^1K;_1K;_1K8_1V1;!%Z]D-L]S5"MB7AY(,"86*K1:%0/C]W;]G73O3YW
M]ANG=V>FH.IL,/A](1O#CMQVAA:A14K2Y59*< (*XGK;X[;1A$^Z#B,;$W/G
M2X3'ER3S&F.!F<T48!W&T0;1TQAQH,\N]\>C3G>_/4JR_.K;SWJGHQ$;?N:(
M?E14>!ZI$CZ"N7B8BML:3U^:<NL[5>EU4&XQC.S1T"+?)6818H^_P9_L>9?B
M:^--ZU^<ON6ZJS3;7B'N_NVG-T6\_CILDA_+&I%D2_@\I>-%-;;S/"U'M#6&
MGA,[26)%RKDJVVJ/**:G?6)8CU00%'./TN7X]>*N=U,HGJ\3M2UFWHHW6TD3
MIOMU\QZB=R?9$UM()Y;W\'>;U@C_7%XMRK^6#M*1>@:3'D)-L"\^J"BY=.N7
MHZ:;_W6^;V7>VMI83^96CGPRW >=DKHP]6VX=.83-^F$TG3N<R>4+DV[=::8
MKH5VBQU#U79[V!_JLJ,J!^K (I/#_HKDS[H*?R +K_9-<IA<_'DD4:9QH87S
M>7ATTB@^[E\-S,Y'7/4(V^ZODFR OTP\N+*POL]\N2S",U_33B?MMRIE_F)%
M;\.6KA--.F9EP3K0I&MQ=(MIM!%!6AT-[^U7)V^^W2=DXR^;&!NE9 C@TE\Z
MFS)Z"Q/.?ETQM_[/SGU=<K?6E_2Z(HK1UJ>\;@:;XF">4L3S\.&'0[*%RNZ.
M8TK_">9@5 (A"G&\J5NHV<;, JC^\[,B6/6!HSFPMKFS6<2#<SZ]6L?WE>Z\
M2),:\TMP43,$K"U!P+1'P,Q'$S"!;NO9;!2&'"4?-%^"[*Z)*ENVI!H*T>LQ
MTT(B9I,$&XFKABE!_Q=[H)+W1ZH^V?L:4#(;1"CBG0(:\@1D'_DK>4@YU^26
MIF.!+*]P$'[DYYMQ0/"(5,Q:2.N/]7RHZ;X\M?O'Q9N+4^5Y$\F:E?G)FH6F
M6WO(/$]>KYQ'N8W]0F!Y<W&0A(5^U2Q.3H8YE5ZZ3X7=G8^%TY]F42(<9[CT
MW1#[N;G]DN-_NND>'UQW9.OQZ>2LM*AA\@PO2I&L^,DS10^:[NG]\>'K<\FN
M:/DXF:+R4CR:4 9I0<@@[5YTQUK^H= :;S-Z?U'((#5_GXQR]OZ@K,A_,TC_
M9I#^S2#]'!FD8F>VP_Y -R>J>JVBOU&X$,*Z+C>J]:J;3Y-+R#TD:^O5CH>'
M'X+??R/K,C:4H;T>:0B@#1B#VY_4N)#DB4-Y%];<%?CK47M]D$OE>+#I[\PC
M+4S#R\RJD?//\TWQ5Z9PEJEU!KT$VRWZ\#*?.7P3 XTDDOP)8Z>5\W\S<Q+=
MJC5ZMA/KI[!81,R:G1&D"#9G]<7%X:3KOKZ.W:(F)W/]K]"H=2EK[HNC^\?>
MX*1UC7+^+_3_9C=OG44PA=6NDZV/O@6<H=S#&_#P)^^!/S>-[JUJ]0_45J0C
MO2SF8H<]WW2O!JW\*'.BE+L;\8=GT@O1"P97%Q<=6\F57UH0@6Q]?JP".+#0
M:THVP+$+SD,/L!5PY_O:L$^N%&W-'^0+6?>X:QTQ8A_JAG2DMJRA;$TD&KHC
M_P;7?LWL$UZ82.CH4 $&V3%W=V1RBSNJ)'<M%=.C,1(X$TA-!P*I+8=L CE8
M\/R1W%:K&,7VS1L:C\[D,LVF[WCOF9;C':+)0*V^:7:SV2;3-OO0MHCM*M_4
MS(7:;ZD6.65GMZ_EUDMUV%T<9@V?6)2LSA!!P2;0C/K^&E+V(PP#D'1X.,>:
MTY. VK@OMB-9Q%H&3I^?#B"N]92]>DW>/, *WP9A&%-I*@.^&=D"BVVO:5M:
M9]6^Y53O[>'S<OL2-=>H5(+,CVQA[?MU>GGD[=B/K+!EC:%%5-K\7J4<%2K_
M[^[.@*BVLD$&EW#O.D0\Z=) GN#Y(<NOMQV3S(4?OSWIMJ?9 #O.2""-9?)7
MVQ[B*81U&RHEG#<>%7<>4CD ..(R82P5C^SN#HPRH(H*#./TR!&67LG!)P36
M)_@]6=?Q@VQR-L7IT,CH S)E4-0]KB._F3GVQ4B.HWNFM1MTX,#!]_(H,NGT
M6GC-'%DO]SG[YD1>CM6F)CDO607_E$F3/R4O$3*5*"<@,EB*["RP 89C-8ML
MC;B3+97<  8P1Y5LI"[RF.HE%-G2F&RJA)"?9J<C*7C.O 2/T/R.]25R)'6%
MQK[PLN^_\*(Y/^K"R[Y3LF8YMY^EKXJ_6F\GEW)%2#]JD8F2+[,-7NM5F%T@
M6K/K8OQ2/JK>E"8AQ;X):RO?A%GO)ES;?MW>ZL9=*YT]NM:"^Q581H*79-:[
M)->[DPLOR6+T)2DMNB//9$,XL;EY=^3NSLJ7)!DA<$6JAM0G!.RM<CWN[LQ(
MB:,5[L=L.L?NQUPFNQX.[.1OU,,:D>;=O,>!#6\9WN+ZLK(D&\:Y0-'BQ@LT
M]R.3W8P<F9L*FI)B79_T]EO[Y?>Q68S:3[)5[9[:?@%4.H<=&/+'KB7WI7-3
M-C9Q(V]FL>3>OY"Y $D'KWQ+;:O:B-SY.EDR(-.U556Q49# 8_02#55Y"\%J
M%WP/.!UH9PO'.)W.LXLDG2X$U%SP%CF1IYCOC[\];'?88?;'86'3!M'G)[?D
M(-F4S>W]B?B;X.@W#OF%O2\;+Z=&U8&: 9D+B<&OXQ?SY#ACM0N"D* +E#ID
MA4BK&/4(09)$)S#CC43^5!"4ZD6K9X]%+F,=KM5<)JJP@6HA0Z(<TV3H>6?I
M.[CALNG_-1H-_%/F?_^D*!EKI@SR1J*+D& 5</>P=:2D8]4DS"WC);6[0]Y/
M2>2"(5<4[:>.1IWE)6363,LTY)%F#6VIJBDIB6R^IG8HUB0AO=G7VN34M(F2
MX$RD:MM)26QFM>KUX0W\A,TO!>=@I"ED3J#RPF[;T*:'6(PZ.5!$)N[NM(:V
M9JBVS9[AUL1P  ]F]PJ$<>#<LKG)(]4"0%U^I9*;QC)UW8\$L>?\+TC\ _2*
MIG/ ='H61.+W+='3+<A&)90:X>TM=QS *0,GOD1FELT3$T=]L8%<.CEP\%]1
M  SA\P[[A"< <%&$?ET-AAP,K8%I@]0A5Z4^!#\Z7T**7!2&VM$<FUACM#T"
MF>308=Y_"IW6E\ELR3^VMW!=':DZ6YLO8W *="DJK)W<3^39EDJDE#)LPZ([
M@;F#\"#:#>35J"R%@I#2@HG0YVV>@B/8=?)@H&MM)-4 ;^U-7VE1 ,JEIIN_
MN+L_2'<JY4$N(4>Y"/T<%]DYUW2URFWZK=ZJ7HVW:6*UIJL6JP7[0:O==A)K
M.?PN>/A"#'CX2M,U:G;A]_[1L';ITS<9>/ALT[W,I$\N)L=7ET?=V$F!?Q@\
M?&49>/A\T[T87@P?BH]#O>BG&JX?'OZPZ5HG^D7A9-QJ&4)"YSO@X0.G?**V
M!IFWW\;OB^<I+DP2.#[3=/OGA?3#P>&OV^O,!XB7I"NE$AH?[LXAT1Z(1L/T
M=V+0]31BJZ%_@%6I6'TL)-C=02M?P<N2.D2S%6X0$#T1,,' VS"MY9<B#?<+
M>(FH4@=DR*:BA-96;KVNW]!/\OK%9'#SJQAT2?79ZI!BW^+'UOW(>C*:/$P'
MM4A%GH"'6C5FFZE'[=*WGX&-S\XD$ @5HBTL;_2<.C+Y?Z23L?*.<-LGXY=R
M9_Q:W6\;3R^YCW%A;HC-5G5U9F+X.5.>HY&;0VVS3PA!\Q:XKV)WQXO64 =E
MG_RXI7H-VH CP00@8A,\D5"5:_JG%AU;ADF?IJY48FG).M@D=$QN0_2(/41L
M(,6W@9@](EI NSN^"60/B825[1D;+CAL7W5P1+*%BH8<%QX^B3X[!VK; E2V
M(]\>"@T>LLJLP_J).JG6K?9 ]CBS.@!#EEC8\&G!KEJ./T,FLKEJ]E(V*C>/
MRBHM:# R.QKV<4^J.F&5V1@%]'>[14Q$H^T##$AA^ *Y0(X3D2(L[0T"6VU_
M#_1G,_>6*2KG-3\@A8]SCE\(PR>,O9ZLQRF?3B2PR!QL@,,%BV>%=FFY=/KX
MNU<Z.7UY]S*7S@]<TG7UMS+_G7F!X/E2ZT2DRPZ1VH@>:<=*$)S[8M,]:-7J
M>>U(WF\G90@$,P4S"TOGL^G1LW[X^_YVHC#TUDU6Q&^&<X2+"RE1^A^1I'R/
MB%4N8[*Z!;=9G]RU-D0:R7_)T!JYO8G,[<AM</A-V+-[TCZ3JG9/54$YHN<8
M) $OA"-BU@GY+/L81"/)$551(K=4W1S_N['CD\1Q(8NJF;;SW@K]2F$:^'AV
MU*9[,AA5:KV<T:O.K;VGS.S5U).?Q-HUND/;7H'O;^M4$3XYTMWG[NF%^Y(Y
M_.6CMDZ5:B!ML%A3)$-"!?9Y08V[:Q3,X66]>W?@=^7<O@)[L453X^2Q.GSL
MWAR?Y]<^X^4+[.?R0LSZZOBEU,O4T4LA)?2KUX!OS1Q7J>A?GDVVMP;^;['_
M^XO]#Z=O-=O3$*LM8H82Y;VI[2=3Q+>  'X2Q90^]&_2$-$?(>'7.YOPS<Z+
M9> !0^ :/E7OW-DJMBQO:NG,*4>76UNY=Q1F0]1&4P+\,#L_AI UC+W4MQ]1
M8"YA$^Z\\"<A-RQ/Y_6A-A373.?%0"S!U?(BSXF'VO">\[IDBZ+(XRI44$O<
MK&?5U4G+R&5899IX"3=$*,2#J/VHVV7ME%L?'&A^'91;]B;TUGAI&NUUG*XX
MK0R6.E*$%C^V^5CYA$L8JGLM_>(^%_'6=K@*V;4VVV,)-&LJS5JSZY5A"LWW
MJB7J]YQ94CSGXY_D05QD:J^$,+2"51YF@J_9[^T-V_KYZ%4Z\I"&E-S'@A%9
M_L%WXS=M?CL"=&M9TO_[,QAMSG@ /LNS66RG6C).#RIC?1_X%CH70M%!W_G#
M]Y%]68<#ZUD\I6N)Y$[&[/4"^^5,I/X)4:5YS1+6;SK#%S>751(7V"RN[1R]
M%[$?^\_4$_XV19L)N$V!2JM 8P;WN-1SZY/"_EDN'/L8]\F_.B'+>BU[ED!;
MAGRN$+UC,<F?F%C=7A_LYQ&3(8&#*N9S32L,?VF\;E\:NXFFS9-MC'!L'ZT7
MP<K"$JC^//_Z;\MV3^H0@X_5F$[GWZRX&6'W?B7R0F'EZ_:=K3:U2[^I9FC&
M::Z@#7MM^[QV^AQ]NRQL)!@Y@<UI ]G('--%G/E/'%:+OMFC?>OS-F+FFK^[
M?KWX9;T,)@^9C6U$$IV7,G&N^+ 6C$D(R'CG]P$O+%7YP2M\+16*77U]'FH8
M/*?I3$[==XW!;-C_)"ULYR%R!+>>KZE*EW3-5X2_!-2-#&3^*LZ%F/ILG,N-
MNT?9=L^R7NIS/.+\F$N6N:4W<YRY/VRU_:\RM'"8Z7R\9==+>+.TEXLHETGZ
M_EIB3P_6M*=,KMB7@\&;\JH6^O,KH.:XA=>\#;G27FG>-FS=_3YS!!3-1N!<
M6DP5)1@V+0P.XS+. 9L^U"HU5*O-P/H]S"CDFYO*8]YX?KD<ETK1LB!(B%DA
ML)PINGB::P@#+:A]*NY%%QS\=XND1&$]F\V$1,]\>GYHM*M'[<I&MFPY=>/=
M6[9 HH@AIVFY)-1 5(^:KCE\L7JJEB]WWPNAD"FG]\ [G52@*LSNIJA!4+\'
MY61#J!>6^D0^]X=]=ID+T&"[.V&I_>:<L#*B,,HVZZIG)]E3+ZP$Q8M\\G+9
M=[?2.UA0]++@BTWWM5<[*M\T&NI^9<D8W 7;ECGTWL;86P@0Q&SJ_B0_*O4O
MKVY?7=^C.:=_7G\Q*1+*Z2\+AO+;L39)5YSKNW%OGGVVV03Y$'_;D6E)CUCW
M?6@H/O*;D!.^,*(VQQ,:7PU;UK,:$M%;G%D>(S\G&_<,<V/Y8*@"_6['IMC!
MZ+Q^?MYPNS>=IOOK\K!S\U8Y.3C/)9,BQTYB>1H.A7(.0 \F$5R:GZVY4G1H
M27HGG#Y7V4B#K/RJ_ 9XUA$<E]<R=Y=:Z;8X4A-*&_-8*_^QN4Q+4RQAGHFL
M0%Y>OL^OEXB_["-S:$7PR?5+;:*D#5TY[R2?O.NQ3.'SL S0+N%&1.DHM-;W
M<TQL=518=16 !''IVBA*O%PWQLI-KU&Y.,BN4;R$YL?<]HB-@."&[TX6VMIF
M;RMM3<)<F5BWOL7U!G')$>@ )W#GPZ/5<,[=UDVVLBFA=FLZBPSD% "G,F\'
MI-Q]!@F8+(\5L_'TJU7XJ1J7G^Z$33E\:Y-'>?."RU,_ .>^-3+V<^FQ8!;;
M"2I4$56?L(!_):T_&#H"!.QGEH<+@I(K[5C"S!K5FF$E@1@2S?1Y-SI&Y]'
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MN;'<0$UW>)Q]+69N'L?IQ+#L ^!W6?K?*/"[7-,MYFN5S*MSWGO6O_T4EH-
MD8$%??K^N7.N"HW875VBW5[(#I%)K(ON5\'^JQN2V6[+-M$B@YV!&-ZN9HQ,
M?43[;^I AMV=/J6#)%N:3?N*X8ODAM$,Z%1&3#++QO@K;V(B] WA+]-QL9.(
M90XL377@54=M]PQBG70G>V K T:P;!!9Q5I2Z9HZPG8ELK.[@T"\_EQ4#O-
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MA;60O22$I!83WP6^1)68.HH$W9#W))0;.!M^UE%8[.Y0J0#GWEL .EX"7S3
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MI\X>WT<C(*2]"8Z"V-ULZ,LG0H">@('54<+ R!QX"!:E!U6QI<&$2?HQ".Q
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M)=5Q*MW O.S^/42"KC7S53*=)*-O#US\?6C2.&YQ.&U!?*V*QZ!M,GB7LVY
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M2W'3_W%"19>"GW'R6Y&0GS8N(13EXE:=+)=,A[U T[?J2:0$7+#LG+KU6H,
M3Q=]K*9(-/M@F\N56CYMGE4RI8>(1[',\L_QPB%VV9'024!1JZU-Q?5ITAEY
MN$7)O6KU&=9EFX<;=_488M*IA61F=2*!CT DW)@M2<=VMJZI-]W,U\ESLQF_
M@G8$@0R13Y%DU<A?),/\*\0#)OV:_&RDN_AO:3'?J<1N3^22A=4)#Y?!3FPH
MXZ:!(Q,6=($,=,"BH23ES5KW14M7%\&JAXCP^\[;F;['!V+6@P@Q<#S.QA!9
M@U*F!"OGGN\3ZT"@I<WA:0>X)@'#94)[ETLPP?1NN'_[*<?O *5"AVRB.N0
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M4@98;8#$,2!PN[^';SSP:1%/$_2(1OCQD88<3A(_01Z#"=Q)?V,/;,5>,TE
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MRQ-\[U93; GA409R:1V:MJQ+"G+(0)PTNCH.5TRZ1XA<)-")PPS(KI#K.*2
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MWR+,F%XI,[(IMI#-YX 3@2\/-<P5[_G/ VF0XE/L!K$C-*8BX#LW:Y(B7*Z
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M)IAJLIA$Q\Z4DD^$>XNJJ:DRS"C0F^@_1=WLZAISC+L&UZ41\R0HDCKJ2HK
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M'<F:*2&OZ]:4,.Q@ ON2=H0506GY22RRFF4-=?N=A7F%UC9<@+AD(I_:]KO
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M>1L^Y[5N3^Q<?CV>Z^+=[=M+]7IT:MSF6DU>OVRVK^_:RNV341X=]ECM]\5
MR-]U7[H7Y</J0W?T]/LX=_V;%2YSAY5ZY[%XIEZDTQ>?RFOIJ=;4<]K;U?%]
M^_:EIGREWGB5-P;7H[9V>G?9;;=ZSUF#O\M?]216ZISWWQZRPDNZ6U.ONL<O
MUVE55A_9+U'DOMI7A]77U[O12?=5>.!_5[G?-XUAF7U6<L6Z+/S^Y-Z*+T^7
M)VSSNE.2VX?*:U_)_GY22\W1VU5]I+U<CMZJ)W=77Z=BZ2OUR@];)^UR1E6+
M%WE-S!>%QWZN_5$X/A1>\_<J47W_/U!+ 0(4 Q0    ( .^![52FS:H+B@P
M &L-   &              "  0    !A,2YJ<&=02P$"% ,4    " #O@>U4
M@M?V;X59  #47@  !P              @ &N#   83$P+FIP9U!+ 0(4 Q0
M   ( .^![53\](JZ(2T  .\Q   '              "  5AF  !A,3$N:G!G
M4$L! A0#%     @ [X'M5-:VQ3U,%   ;!4   8              ( !GI,
M &$R+FIP9U!+ 0(4 Q0    ( .^![52&M&RPMA4  -,6   &
M  "  0ZH  !A,RYJ<&=02P$"% ,4    " #O@>U4X3U=%-D,  #$#0  !@
M            @ 'HO0  830N:G!G4$L! A0#%     @ [X'M5#DY/;.$"P
M1 P   8              ( !Y<H  &$U+FIP9U!+ 0(4 Q0    ( .^![51(
M/A36!B\  *TQ   &              "  8W6  !A-BYJ<&=02P$"% ,4
M" #O@>U4-\,R2P80   %$0  #0              @ &W!0$ :6UA9V5?,# Q
M+FIP9U!+ 0(4 Q0    ( .^![53LMOF@61   $X1   -              "
M >@5 0!I;6%G95\P,#(N:G!G4$L! A0#%     @ [X'M5$T6MKPI%0  V14
M  T              ( !;"8! &EM86=E7S P-"YJ<&=02P$"% ,4    " #O
M@>U4'^XU/7</  "TJ   $0              @ ' .P$ <VYO82TR,#(R,#,S
M,2YX<V102P$"% ,4    " #O@>U4=5+IMSD8   420$ %0
M@ %F2P$ <VYO82TR,#(R,#,S,5]C86PN>&UL4$L! A0#%     @ [X'M5$KQ
MV[2&)   J&L" !4              ( !TF,! '-N;V$M,C R,C S,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( .^![506"&A%0&@  'H@!@ 5              "
M 8N( 0!S;F]A+3(P,C(P,S,Q7VQA8BYX;6Q02P$"% ,4    " #O@>U4910B
M'S!(  "P\00 %0              @ '^\ $ <VYO82TR,#(R,#,S,5]P<F4N
M>&UL4$L! A0#%     @ [X'M5&'B$>GT @  L@H  !$              ( !
M83D" '-O;F]M85]E>#(S,#$N:'1M4$L! A0#%     @ [X'M5(3A94'G @
M\@H  !$              ( !A#P" '-O;F]M85]E>#(S,#(N:'1M4$L! A0#
M%     @ [X'M5&@?:C44!P  HB   !$              ( !FC\" '-O;F]M
M85]E>#,Q,#$N:'1M4$L! A0#%     @ [X'M5-%4?<@9!P  \A\  !$
M         ( !W48" '-O;F]M85]E>#,Q,#(N:'1M4$L! A0#%     @ [X'M
M5%K.! K7 P  +Q(  !$              ( !)4X" '-O;F]M85]E>#,R,#$N
M:'1M4$L! A0#%     @ [X'M5/:D5K.:( ( \O,1 !8              ( !
M*U(" '-O;F]M85]I,3!K+3 S,S$R,BYH=&U02P4&     !8 %@ =!0  ^7($
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
